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Abstract 
 
Cell-mediated immunity (CMI) is central to the host response to intracellular pathogens 
such as Mycobacterium tuberculosis (Mtb). The function of CMI can be modulated by 
human immunodeficiency virus (HIV)-1 via its pleiotropic effects on the immune 
response, including modulation of macrophages, which are parasitized by both HIV-1 
and Mtb. HIV-1 infection is associated with increased risk of tuberculosis (TB), and so 
in this thesis I sought to explore the host/pathogen interactions through which HIV-1 
dysregulates CMI, and thus changes the natural history of TB. 
Using an in vitro model of human monocyte-derived macrophages (MDMs), I 
characterise a phenotype wherein HIV-1 specifically attenuates production of the 
immunoregulatory cytokine interleukin (IL)-10 in response to Mtb and other innate 
immune stimuli. I show that this phenotype requires HIV-1 integration and gene 
expression, and may result from a function of the HIV-1 accessory proteins. I identify 
that the phosphoinositide 3-kinase (PI3K) pathway specifically regulates IL-10 
production in human MDMs, and thus may be a target for HIV-1 to mediate IL-10 
attenuation. I show that HIV-1 may attenuate IL-10 to maximise its own replication, and 
identify potential consequences of IL-10 attenuation for CMI. 
By using the tuberculin skin test (TST) as a human challenge model, I evaluate HIV-1 
modulation of CMI in vivo in active TB patients, and demonstrate IL-10 attenuation in 
this context. I identify a role for type I inteferons (IFNs) in HIV-1 anergy, and observe 
exaggerated T helper 2 responses associated with the immune reconstitution 
inflammatory syndrome (IRIS). To fully explore CMI in vivo by transcriptional profiling, I 
utilize the transcriptional heterogeneity of stimulated macrophages to develop a 
modular analysis strategy for transcriptional profiles, and apply this in the TST model. 
My results delineate novel modulatory effects of HIV-1 on the function of CMI, and thus 
provide insights into immunopathogenesis in HIV-1/TB co-infection. 
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Chapter 1. Introduction 
1.1 The cell-mediated immune system 
1.1.1 Overview: the delayed-type hypersensitivity and cell-mediated immunity 
paradigm 
The delayed-type hypersensitivity (DTH) reaction was first described in 1798 by 
Edward Jenner in his seminal studies of vaccination against smallpox, when he 
reported that individuals previously infected with cowpox had an accelerated reaction 
to injection with variolous matter derived from smallpox lesions (Allison, 1967). These 
reactions were evident as redness and induration at the injection site over 24–48 
hours, and subsequently were found to occur in response to a range of pathogens or 
their products (Wing and Remington, 1977; Zinsser, 1921). Histological 
characterisation of the DTH reaction site showed capillary dilatation, endothelial 
swelling, and a perivascular infiltrate composed chiefly of lymphocytes and histiocytes, 
suggesting a cellular basis to this response (Allison, 1967). 
By the 1960s, key criteria for defining a DTH reaction had been described 
(Humphrey, 1967). A gradual inflammatory response to a locally introduced antigen 
was typical, which did not resemble allergic hypersensitivity in terms of its gross or 
histopathological appearance. It was a distinct phenomenon from antibody-mediated 
immunity, as transfer of lymphoid cells, but not serum, from sensitized to unsensitised 
animals could render them hypersensitive (Chase, 1946). Importantly, the reaction was 
mediated locally by lymphocytes and activated macrophages, and was associated with 
resistance to pathogens that induced it (Wing and Remington, 1977). These 
observations led to its re-definition as cell-mediated immunity (CMI), to reflect more 
appropriately the functional importance of the phenomenon (Humphrey, 1967).  
However, in the pre-pattern recognition and pre-lymphocyte subset era, many 
questions remained regarding what was described as a “complex, ill-defined and 
sometimes rather tiresome aspect of immunology” (Humphrey, 1967). Which 
“inherently hypersensitive” cells initiated the DTH reaction – the lymphocytes or the 
macrophages, or both (Dumonde, 1967)? Did lymphocytes make any antibody in the 
reaction (Gell, 1967), and did they secrete factors to activate the macrophages 
(Humphrey, 1967)? And what precisely were its relative contributions to pathology and 
protection (Humphrey, 1967)? 
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As a result of investigations in the intervening decades, CMI is now well-
characterised at the cellular and molecular levels (Figure 1.1). A canonical primary 
CMI response is known to be initiated by phagocytes such as macrophages, which 
detect pathogens via pattern recognition receptors (Lemaitre et al., 1996; Medzhitov 
and Horng, 2009; Medzhitov et al., 1997) and become activated. These macrophages 
go on to present antigen and secrete cytokines such as interleukin (IL)-12 and IL-18 
(Gracie et al., 2003; Hsieh et al., 1993), in order to activate CD4+ T cells, the main 
lymphocyte effectors of CMI (Cher and Mosmann, 1987). Macrophage-derived IL-12 
drives a polarised T-helper 1 (Th1) phenotype in CD4+ T cells (Hsieh et al., 1993; 
Mosmann et al., 1986), inducing them to secrete interferon (IFN)γ and other cytokines, 
which then signal to macrophages in return, promoting their effector functions (Celada 
et al., 1984; Nathan et al., 1983; Pace et al., 1983). Macrophages and CD4+ T cells 
may also co-ordinate with other effector cells of CMI, such as CD8+ T cells and natural 
killer (NK) cells, which perform various cytotoxic functions and secrete further IFNγ 
(Kaufmann, 1995; Moretta et al., 2002). Activation of specific CD4+ T cells via 
presentation of their cognate antigen leads to establishment of immunological memory 
for that antigen, the basis of the accelerated CMI response observed upon re-
challenge in CMI (Bell et al., 1998). Together, these effector functions are thought to be 
critical in effective responses to many pathogens, as well as playing roles in the 
immune response to tumours, in transplant rejection and in chronic inflammatory 
conditions.  
Thus, the clinical phenomenon of the DTH redness reaction first described by 
Jenner over 200 years ago is now known to result from a complex interplay of cells and 
secreted factors, which act together to cause inflammation and to co-ordinate a key 
arm of effective immunity. 
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Figure 1.1: The cell-mediated immune response. 
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1.1.2 CMI and infectious diseases 
CMI is central to the immune response to intracellular pathogens (Kaufmann, 
1995). Classic experiments showed that transfer of lymphocytes from immunised to 
unimmunised animals could essentially vaccinate the latter (Lefford et al., 1973), 
demonstrating that cellular immunity was sufficient for protection against infection in 
some contexts. During early DTH research, it was noted that pathogens which were 
facultative intracellular parasites of macrophages, such as Mycobacterium tuberculosis 
(Mtb), Brucella abortus, Listeria monocytogenes and Salmonella typhimurium, were 
potent inducers of DTH responses (Mackaness, 1967). These pathogens induced a 
highly activated anti-bacterial phenotype in macrophages, termed “acquired cellular 
resistance”, which conferred time-limited non-specific protection against other 
intracellular infections (Mackaness, 1964). 
 Subsequent characterisation of CMI (Figure 1.1) has elucidated the effector 
functions which confer this potent restrictive ability. For bacterial or fungal pathogens, 
key responses may be direct macrophage-mediated killing, and anti-microbial peptide 
secretion (Flannagan et al., 2009; Izadpanah and Gallo, 2005). For viruses, cytotoxic 
activity and induction of anti-viral type I IFN responses are thought to be critical 
(Stetson and Medzhitov, 2006). In chronic infections, pathogens may be contained in a 
granuloma, which is essentially a mature focus of CMI made up of activated 
macrophages, CD4+ T cells and other effector cells (Ulrichs and Kaufmann, 2006).  
Deficiencies in components of the CMI response can lead to uncontrolled 
infections by intracellular pathogens in mouse models and in humans, and so CMI is 
suggested to be essential for protection against these pathogens (Table 1.1). In 
humans, CMI is observed to be particularly important in protection against 
mycobacteria, as a range of genetic deficiencies in CMI components such as IL-12 and 
IFNγ signalling cause Mendelian susceptibility to mycobacterial diseases (MSMD), in 
which patients present with severe infections caused by both weakly virulent 
mycobacteria and virulent mycobacteria such as Mtb (Al-Muhsen and Casanova, 
2008). 
The importance of CMI in the immune response to Mtb is also highlighted by 
the increased risk of tuberculosis (TB) in HIV-1+ patients, who for a number of reasons 
may have compromised CMI responses. Both Mtb and HIV-1 are pathogens which 
directly parasitize macrophages, a central cellular effector of CMI. The interaction 
between macrophages, HIV-1, Mtb and the other immune mediators of CMI therefore 
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represents a complex set of host/pathogen interactions, which is likely to play a 
significant role in the diseases caused by these two critical global pathogens.  
In the introduction to this thesis, I will explore this set of host-pathogen 
interactions, by introducing the role of macrophages in CMI, exploring HIV-1 and TB 
pathogenesis, and then examining the potential role of macrophages in CMI 
dysregulation in HIV-1/TB co-infection. I will also describe the function of the 
immunoregulatory cytokine IL-10, which has been shown to be dysregulated in the 
responses of HIV-1-infected macrophages to TB (Tomlinson et al., 2014). I will lastly 
discuss the use of transcriptional profiling for exploring immune responses to 
tuberculosis in vivo, and novel methods which could be utilized in this context to further 
understand the function of CMI in the host response to Mtb. 
Chapter 1 Introduction 
 
28 
CMI component Mouse Reference Human Reference
IFNγ IFNγ or IFNγ receptor 
−/−: increased 
suscepibility to Mtb, BCG 
and Salmonella 
typhimurium
Dalton et al. (1993); 
Hess et al. (1996); 
Flynn et al. (1993); 
Cooper et al. (1993)
Autoantibodies to IFNγ 
associated with increased risk 
of mycobacterial disease
Browne et al. (2012)
IFNγ receptor genetic 
deficiency in children with 
disseminated mycobacterial 
infections
Jouanguy et al. ( 1995); 
Newport et al. ( 1995); 
Dorman & Holland 
(1998)
TNFα TNFR p55−/−: increased 
suscepibility to Listeria 
monocytogenes
Pfeffer et al. (1993) Patients treated with 
monoclonal antibodies to 
TNFα for auto-inflammatory 
conditions have increased risk 
of tuberculosis
Keane et al. (2001)
IL-12 IL-12 −/−: increased 
susceptibility to BCG
Wakeham et al. 
(1998)
IL-12 receptor genetic 
deficiency in patients with 
mycobacterial infections
Altare et al. (1998)
IL-12 p40 deficiency in a child 
with disseminated BCG and 
Salmonella infection
Altare et al. (1998)
STAT1 (IFNγ 
signalling)
STAT1 −/−: increased 
susceptibility to L. 
monocytogenes and 
vesicular stomatitis virus
Meraz et al. (1996) Heterozygous STAT1 
mutation associated with 
mycobacterial disease
Dupuis et al. (2001)
CD4
+
 T cells Mice depleted of CD4+ T 
cells succumb more 
rapidly to Mtb infection
Leveton et al. (1989) CD4+  T cell depletion in HIV-
1 infection associated with 
increased risk of 
mycobacterial disease, 
cryptococcosis, herpesvirus 
infections
Moore et al. (1996)
T-bet (Th1 
signature 
transcription 
factor)
T-bet −/−: increased 
susceptibility to Mtb and 
S. typhimurium
Sullivan et al. (2005); 
Ravindran et al. 
(2005)
Table 1.1: Deficiencies in components of CMI and risk of intracellular infections in 
mouse models and human disease. 
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1.2 The role of macrophages in CMI 
1.2.1 The mononuclear phagocyte system 
CMI responses are mediated via the co-ordinated function of CD4+ T cells and 
macrophages (Figure 1.1). Macrophages are a member of the mononuclear phagocyte 
system (MPS), which also includes monocytes and dendritic cells. To explore the 
functions of macrophages in mediating CMI, it is critical to understand their 
relationships with the other MPS cell types, as a group of phagocytic sentinel cells with 
diverse roles in homeostasis, inflammation and immunity (Chow et al., 2011a) 
The first description of phagocytic cells was made by Elie Metchnikoff in 1892, 
and his work subsequently provided many insights into their functions: that 
phagocytosis is an active defence mechanism; that phagocytes could provide “natural 
immunity” via their responses to pathogens; that phagocytes could actively move 
towards inflammatory foci; and that phagocyte activation could enhance their 
microbicidal capabilities (Gordon, 2008). Subsequent work demonstrated shared 
characteristics of different tissue-resident phagocyte populations, leading to their 
common classification as macrophages (Guilliams et al., 2014), and also showed that 
peripheral blood monocytes could differentiate into macrophages in vitro and in vivo 
(Carrel and Ebeling, 1926; Ebert and Florey, 1939; van Furth and Cohn, 1968). 
Monocytes and macrophages were thus classified together as the MPS (van Furth et 
al., 1972), along with dendritic cells (DCs) once identified (Steinman and Witmer, 1978; 
Steinman et al., 1974).  
This original classification of the MPS was based on distinct functional 
characteristics of monocytes, macrophages or DCs, wherein monocytes were 
circulating precursor cells; macrophages were large vacuolar cells specialised for 
phagocytosis and clearance; and DCs were stellate cells optimised for activating T 
cells (Guilliams et al., 2014).  As such, this MPS classification was also based on the 
premise that macrophages and DCs were primarily derived from monocytes, and that 
recruitment of blood monocytes replenished tissue populations of these cells in the 
steady state (Ginhoux and Jung, 2014), but the ontogeny of mononuclear phagocytes 
(MPs) is now no longer considered to be interrelated in this manner.  
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Mononuclear phagocytes (MPs) are now thought to be derived from three 
sources (Ginhoux and Jung, 2014). Most tissue macrophages are thought to be self-
renewing via proliferation, and to have embryological origins (Ginhoux et al., 2010; 
Guilliams et al., 2013; Hashimoto et al., 2013; Hoeffel et al., 2012; Schulz et al., 2012; 
Yona et al., 2013). DCs are derived from a common DC precursor in the bone marrow 
(the cDP; Naik et al., 2013; Schraml et al., 2013), and monocytes from a distinct 
common monocyte precursor (the cMoP; Hettinger et al., 2013), although both cells 
originate from the clonotypic source of all haematopoietic MPs, the macrophage 
dendritic cell precursor (MDP; Fogg et al., 2006). Cells derived from monocytes are 
found in tissues under some inflammatory conditions, but do not substantially 
contribute to tissue populations in homeostasis (Ginhoux and Jung, 2014). A new 
ontogeny-based classification for the MPS has been proposed in light of these findings, 
based on these three origins (embryologic, the cDP, or the cMoP; Guilliams et al., 
2014). The current consensus on the ontogeny of the MPS is shown in Figure 1.3. 
The majority of the evidence for MPS ontogeny is derived from mouse models 
(Guilliams et al., 2014), and so its relevance in humans is unconfirmed. Some evidence 
exists to support its application. Comparative gene expression analyses have 
demonstrated substantial homology between murine and human monocyte and DC 
subsets, indicating that there are cross-species phenotypic similarities in the MPS 
(Crozat et al., 2010; Ingersoll et al., 2010; Robbins et al., 2008). Some observations 
also support the concept of macrophage self-renewal in humans. After haematopoietic 
stem cell (HSC) transplant, recipient macrophages persist longer in the skin than 
recipient DCs which are rapidly replaced with donor cells (Haniffa et al., 2009); 
conversely, in a limb transplant, the donor macrophages persisted in the skin and were 
not replaced with recipient-derived cells (Kanitakis et al., 2011). Additionally, genetic 
conditions affecting haematopoiesis exist wherein there are deficiencies in monocytes 
and DCs but tissue macrophage populations are unaffected, suggesting that 
macrophages do not require mature haematopoiesis for maintenance (Bigley et al., 
2011). 
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Figure 1.2: Ontogeny of mononuclear phagocytes. 
Schematic of the development and ontogeny of the MPS based on current 
understanding. Adapted from diagrams in Guilliams et al. (2014) and Ginhoux and 
Jung (2014). Tissue macrophage ontogeny is purely embryological, while monocytes 
and DCs are derived from distinct mature haematopoietic precursor cells. Monocytes 
can differentiate into cells which infiltrate tissues and display macrophage- or DC-like 
properties. Macrophages and some monocyte-derived cells are capable of self-
renewal. HSC, haematopoietic stem cell; GMP, granulocyte-macrophage precursor; 
MDP, macrophage and dendritic cell precursor; cMoP; common monocyte precurscor; 
cDP, common dendritic cell precursor; cDC, classical dendritic cell; pDC, plasmacytoid 
dendritic cell.  
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1.2.2  Monocytes and monocyte-derived cells 
Monocytes are a short-lived cell population, with an estimated half-life of hours 
to days, which make up approximately 10% of the peripheral blood mononuclear cell 
(PBMC) population in humans (Ginhoux and Jung, 2014). Two major circulating 
subsets of monocytes have been identified in human (Ziegler-Heitbrock et al., 2010) 
and in mouse (Geissmann et al., 2003). Pro-inflammatory or classical monocytes 
(Ly6Chi in mouse and CD14hi in human) are rapidly recruited to tissues during 
inflammation, wherein they differentiate and perform effector functions (Shi and Pamer, 
2011). Patrolling or non-classical monocytes (Ly6Clow in mouse and CD14low in human) 
adhere and migrate along endothelial surfaces, from where they may also be recruited 
into tissues and undergo differentiation (Auffray et al., 2007); these cells have been 
described as “luminal blood macrophages” (Ginhoux and Jung, 2014). A third 
intermediate monocyte subset exists in humans, which may have inflammatory 
functions (Belge et al., 2002). The existence of these specialized subsets 
demonstrates that monocytes have specific functions beyond differentiation into 
macrophage and DC-like cells, such as patrolling of blood vessels (Auffray et al., 
2007). They may also mediate specific functions in the tissues without further 
differentiating, such as carriage and presentation of antigen, and promoting 
angiogenesis (Avraham-Davidi et al., 2013; Jakubzick et al., 2013; Leirião et al., 2012)  
Monocytes are no longer thought to contribute substantially to tissue 
macrophage populations in the steady-state (Ginhoux and Jung, 2014). However, after 
recruitment into tissues in inflammation, they can differentiate into cells with a spectrum 
of properties characteristic of macrophages and DCs, leading to the designations of 
monocyte-derived macrophages (MDMs) and monocyte-derived dendritic cells 
(MDDCs) (Shi and Pamer, 2011). Many in vitro evaluations of macrophages and DCs 
utilize this capacity of monocytes to differentiate, as the factors necessary to induce 
MDMs and MDDCs from monocytes in vitro have been established as macrophage 
colony stimulating factor (M-CSF; CSF1), or granulocyte-macrophage colony 
stimulating factor (GM-CSF; CSF2) and IL-4, respectively (Geissmann et al., 2010). 
Monocyte-derived cells may contribute to tissue MP populations in homeostasis in 
some tissues, for example in the gut and skin (Bogunovic et al., 2009; Tamoutounour 
et al., 2013; Varol et al., 2007) wherein inflammatory encounters may be more frequent 
(Ginhoux and Jung, 2014; Zigmond and Jung, 2013). At inflammatory foci, monocyte-
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derived cells are postulated to mediate a range of DC and macrophage functions 
(Mildner and Jung, 2014; Wynn et al., 2013). It has been shown that MDDCs in murine 
skin are transcriptionally similar to resident classical DCs, supporting the hypothesis 
that they become phenotypically similar to resident cells – although this observation 
was made in steady-state rather than inflammatory conditions (Tamoutounour et al., 
2013). The temporal nature of the contributions of MDMs and MDDCs have been 
investigated, and in some contexts, such as in the central nervous system, their 
seeding of tissues has been shown to be transient and resolve after inflammation 
(Ajami et al., 2011). In other contexts, such as MDM infiltration of atherosclerotic 
lesions, and MDDCs in a murine model of skin herpes simplex virus infection, they 
have been shown to persist and in some cases to proliferate in situ (Eidsmo et al., 
2009; Robbins et al., 2008). It is suggested that the severity and nature of 
inflammation, and how it has affected resident MPs, may determine the persistence of 
monocyte-derived cells (Ginhoux and Jung, 2014). 
Many effector functions of MPs have been elucidated using in vitro MDM and 
MDDC models. It is cognizant to consider how accurately these cells replicate in vivo 
tissue MPs. Early work noted that MDMs generated in whole blood cultures were 
“indistinguishable from tissue macrophages”  (Carrel and Ebeling, 1926), and the 
morphological similarity of in vitro M-CSF-differentiated MDMs and ex vivo alveolar 
macrophages (AMs) has been noted (Tomlinson et al., 2012). Comparative gene 
expression profiling of M-CSF-differentiated MDMs and AMs showed that they were 
more similar to each other than to monocytes, DCs or macrophage-like cell lines, but 
were still transcriptionally distinct (Li et al., 2007; Tomlinson et al., 2012). As AMs are 
dependent on GM-CSF signalling for their development in addition to M-CSF (Guilliams 
et al., 2013; Shibata et al., 2001), and are phenotypically more similar to MDMs 
differentiated used GM-CSF (Akagawa et al., 2006), the described functional 
distinctions between MDMs and AMs may be predicated on inherent development 
differences, as opposed to global incongruities between MDMs and tissue 
macrophages. The substantial heterogeneity of tissue macrophage phenotypes 
(Davies et al., 2013) suggests it is unlikely that in vitro MDMs can precisely model all 
their highly specialised phenotypes. However, evidence for shared morphological and 
functional features, as well as a common developmental requirement for M-CSF, 
suggests MDMs are a reasonable reductionist model to study often inaccessible tissue 
macrophages in vitro (as well as presumably modelling in vivo MDMs), with the clear 
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caveat of any in vitro study, that the absence of the tissue microenvironment may 
influence functional insights. 
1.2.3  Dendritic cells 
DCs were identified by Steinman in 1972 as the critical accessory cell for 
initiating adaptive immune responses (Steinman and Witmer, 1978; Steinman et al., 
1974). They are now known to be a distinct haematopoietic lineage derived from a 
dedicated precursor, the cDP (Naik et al., 2007; Figure 1.3) under the control of the 
cytokine Flt3L, with some input from M-CSF and GM-CSF for specific DC subsets 
(Schmid et al., 2010). 
Several DCs subsets exist with specific phenotypes and functions (Satpathy et 
al., 2012). The original DC phenotype identified by Steinman is now held to be that of a 
classical DC (cDC), which are highly phagocytic and specialised for processing and 
presentation of antigen (Satpathy et al., 2012). A defining feature of cDCs is their ability 
to migrate from the periphery to secondary lymphoid organs wherein they present 
antigen and activate adaptive immune responses (Randolph et al., 2005), during which 
process they differentiate from an immature phagocytic phenotype to a mature 
phenotype specialised for antigen presentation (Pierre et al., 1997). A second subset, 
plasmacytoid DCs (pDCs), also arise from the cDP in the bone marrow, after which 
they are phenotypically and functionally divergent from cDCs (Satpathy et al., 2012). 
They are spherical rather than stellate, are not phagocytic, and do not efficiently 
present antigen; instead their primary function appears to be the ultra-fast production of 
type I IFN (Siegal et al., 1999). 
Some controversy exists regarding the purpose behind classifying some cells 
as macrophages and some as DCs based on functional properties (Hume, 2008). The 
recent proposal that classification should be based on ontogeny may dispel these 
issues (Guilliams et al., 2014), but a key point is highlighted, which is that the 
functionality of different MPs clearly overlaps, with consequences for considering their 
specific roles in a CMI response. For example, although mature cDCs are specialised 
for antigen presentation, macrophages are also known to present antigen and prime T 
cells (Hume, 2008). Classical activation of macrophages via inflammatory stimuli may 
induce cDC-like characteristics, and differentiated inflammatory monocytes may also 
share similar phenotypic features (Mildner and Jung, 2014; Mosser and Edwards, 
2008). Although mature cDCs, classically activated macrophages and mature 
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inflammatory monocytes do have key differences - such as their ontogeny, and their 
tendency to migrate (Murray and Wynn, 2011) – this functional convergence of 
different MPs upon an inflammatory T cell-priming phenotype suggests that they all 
may contribute to CMI responses. As macrophages are the primary targets for many of 
the intracellular pathogens which induce CMI responses, it seems likely that they are 
the critical MP functioning at the site of inflammation in this arm of immunity. 
1.2.4  Embryologically-derived tissue macrophages 
Macrophages are resident in tissues throughout the body and perform essential 
protective and homeostatic functions, including clearance of debris, immune 
surveillance, and co-ordination and resolution of inflammation (Davies et al., 2013). 
They are relatively long-lived cells with lifespans which may be in the region of months 
(Murphy et al., 2008). It is now known that the majority of tissue macrophages have 
embryological origins and are maintained by self-renewal throughout adult life 
(Ginhoux and Jung, 2014). This has been demonstrated by a range of studies in 
mouse models (Ginhoux et al., 2010; Guilliams et al., 2013; Hashimoto et al., 2013; 
Hoeffel et al., 2012; Naito et al., 1997; Schulz et al., 2012; Yona et al., 2013). Although 
there are some inconsistencies in these reports, the resultant consensus is that all 
tissue macrophages derive from fetal monocytes generated during early definitive 
haematopoiesis in the fetal liver, except microglia and some Langerhans cells, which 
derive from yolk sac macrophages generated during primitive haematopoiesis in the 
yolk sac (Ginhoux and Jung, 2014). As discussed in section 1.2.2, a minority of tissue 
macrophages are monocyte-derived. 
Tissue macrophage development depends on CSFR1 signalling (Wynn et al., 
2013). Many tissue macrophage populations are deficient in the M-CSF deficient 
mouse model (Witmer-Pack et al., 1993), but the phenotype of this mouse is less 
severe than that of the CSFR1-deficient mouse, which has additional deficiencies in 
microglia and Langerhans cells (Dai et al., 2002; Wynn et al., 2013) – indicating that a 
second CSFR1 ligand was involved in macrophage development. This was identified to 
be IL-34 (Greter et al., 2012; Wang et al., 2012). GM-CSF also contributes to 
macrophage development, specifically in terminal differentiation of AMs; the GM-CSF-
deficient mouse has grossly normal haematopoiesis, but specific defects in lung 
homeostasis due to disrupted AM development (Dranoff et al., 1994; Guilliams et al., 
2013; Shibata et al., 2001; Stanley et al., 1994), and human genetic defects in GM-
CSF recapitulate this phenotype (Carey and Trapnell, 2010). Both M-CSF and GM-
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CSF regulate macrophage biology post-developmentally; M-CSF, which is present in 
tissues under homeostasis, may influence macrophage survival and self-renewal, while 
GM-CSF, which is produced as part of the immune response, may induce inflammatory 
macrophage phenotypes (Wynn et al., 2013). 
Populations of tissue macrophages (Table 1.3) display striking phenotypic 
diversity both between and within tissues, despite shared fetal origins and common 
growth factor requirements; this may result from differing interactions of populations 
with their tissue microenvironments (Davies et al., 2013; Hume, 2008; Wynn et al., 
2013). Some macrophage functions are developmental or homeostatic, such those of 
osteoclasts, which co-ordinate bone remodelling, and liver Kupffer cells, which clear 
cell debris from the blood (Davies et al., 2013). However, many of their functions are 
those involved in immune responses and inflammation which are most integral to their 
role in CMI, which are discussed subsequently in section 1.2.5.  
The diversity of macrophages has led to consideration of what fundamentally 
determines macrophage function. M-CSF-induced monocyte to MDM differentiation 
involves substantial changes in gene expression (Dong et al., 2013; Lehtonen et al., 
2007; Liu et al., 2008), suggesting that transcriptional adaptations may partly determine 
macrophage cell state. The transcription factor (TF) PU.1 is a key regulator of myeloid 
cell fate (Mak et al., 2011), and PU.1 deficient mice have no macrophages from the 
yolk sac stage (Schulz et al., 2012), indicating that it is necessary for macrophage 
development. It is found to be associated with active transcriptional enhancers and 
may initiate nucleosome remodelling, suggesting that it may determine cell identity by 
instructing transcription (Ghisletti et al., 2010; Heinz et al., 2010). However, the PU.1-
deficient mouse has multi-lineage defects in haematopoiesis (Anderson et al., 1998; 
Scott et al., 1994), and PU.1 expression also contributes to DC identity, so it cannot be 
considereda classic “lineage-specific” TF for macrophages (Bakri et al., 2005). A recent 
study confirmed that the substantial heterogeneity of tissue macrophages was evident 
at the transcriptional level, but also defined a core macrophage transcriptomic 
signature which distinguished macrophages from DCs (Gautier et al., 2012). This 
included genes classically involved in macrophage function such as MR1, CD64 and 
TLR4, and up-regulated in monocytes in vivo during MDM differentiation. The TF 
C/EBPα was identified as a potential regulator of these genes, and has been 
suggested in other studies as an instructor of macrophage identity (Liu et al., 2008). 
Much remains to be clarified with regards to determinants of macrophage phenotype. 
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A recently defined tissue macrophage function is proliferation in order to self-
renew in homeostasis (Davies et al., 2013). Macrophage proliferation may also occur in 
inflammation (Jenkins et al., 2011), where it may assist in replenishing tissue 
macrophage populations after inflammatory depletion (Davies et al., 2011). M-CSF is 
suggested to drive steady-state self-renewal, whereas proliferation in inflammation may 
require IL-4 (Jenkins et al., 2013, 2011). It has also been shown that proliferative 
capacity is controlled as part of an specific in vivo macrophage phenotype, which is lost 
when cells are cultured ex vivo (Rosas et al., 2014); highlighting the substantial 
contribution of the tissue microenvironment to macrophage function. Understanding the 
mechanisms by which tissue-specific signals control macrophage phenotypes may 
assist in developing tissue-specific in vitro models to study tissue macrophage function 
(Okabe and Medzhitov, 2014; Rosas et al., 2014). 
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Tissue Macrophage type Functions References
Lung Alveolar macrophages Immune surveillance & 
homeostatic regulation, such as 
clearance of surfactant
Carey & Trapnell 
(2010); Westphalen et 
al. (2014) 
Interstitial macrophages Regulation of DCs Bedorot et al. (2009)
Liver Kupffer cells Clearance of debris from the 
blood - microorganisms, cells, 
RBCs
Bilzer et al. (2006)
Motile liver macrophages Immune surveillance Klein et al. (2007)
CNS Microglia Immune surveillance & neuronal 
maintenance & remodelling
London et al. (2013)
Perivascular and 
meningeal macrophages
Immune surveillance Prinz et al. (2011)
Skin Dermal macrophages Immune surveillance Chorro & Geissmann 
(2010)
Langerhans cells Immune surveillance & activation 
of T cells
Chorro & Geissmann 
(2010)
Bone Osteoclasts Bone resorption Pollard (2009)
Bone marrow macrophages Support erythropoiesis & provide 
stem cell niche
Nagata (2007); Chow 
et al. (2011)
Gut Intestinal macrophages Regulation of gut homeostasis 
and inflammatory responses
Zigmond & Jung 
(2013)
Serosal surfaces Peritoneal macrophages Immune surveillance & 
homeostatic regulation
Cailhier et al. (2005)
Pleural macrophages Immune surveillance Cailhier et al. (2006)
Spleen Marginal zone 
macrophages
Immune surveillance den Han & Kraal 
(2012)
Metallophilic macrophages Immune surveillance den Han & Kraal 
(2012)
Red pulp macrophages Erythrocyte clearance & iron 
metabolism
Kohyama et al. (2009)
Lymph nodes Subcapsular sinusoidal 
macrophages
Processing & presentation of 
antigen to B cells
Junt et al. (2007)
Medullary macrophages Induction of immune tolerance Albacker et al. ( 2013)
Blood CD14
lo
 monocytes 
("luminal macrophages")
Surveillance & homeostasis of 
endothelial surfaces
Auffray et al. (2007); 
Ginhoux & Jung (2014)
Inflamed tissues Monocyte-derived 
macrophages
Inflammatory & regulatory 
responses
Murray and Wynn 
(2013)
Table 1.2: Hetereogeneity and functions of tissue macrophages. 
Adapted from Davies et al. (2013) and Murray & Wynn (2011). CNS, central nervous 
system. 
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1.2.5 Functions of macrophages in CMI 
Tissue macrophages and MDMs perform key functions in mediating CMI. These 
range from initiation of the immune response via pattern recognition, to microbicidal 
effector functions and resolution of inflammation. Importantly, they also interact with the 
adaptive immune response (Davies et al., 2013; Murray and Wynn, 2011). The striking 
plasticity of macrophages is critical for their ability to carry out this array of roles, and 
both innate activation by microbes and adaptive modulation can contribute to their 
responsive functional heterogeneity.  
1.2.6  Innate immune recognition by macrophages 
The pattern recognition hypothesis for pathogen detection by sentinel cells was 
proposed by Janeway in 1989 and within ten years was proven by the discovery of toll-
like receptors (TLRs; Lemaitre et al., 1996; Medzhitov et al., 1997), transmembrane 
proteins which bind conserved pathogen components designated as pathogen-
associated molecular patterns (PAMPs). The function of germline-encoded pattern 
recognition receptors (PRRs) is now known to fundamentally underlie the initiation of 
the immune response to microbial infection in invertebrates and vertebrates (Medzhitov, 
2009). In macrophages, PRR activation stimulates intracellular signalling cascades, 
which converge on transcriptional and non-transcriptional outputs manifest as 
macrophage activation and inflammatory responses (Taylor et al., 2005). 
Ten TLRs have been characterised in mammals (Takeda et al., 2003). These 
are membrane-bound receptors found on the cell surface or in endosomes; the former 
mainly recognise microorganism membrane components, while the latter recognise 
pathogen-associated nucleic acid forms (Kawai and Akira, 2010). Many other PRR 
families are now also recognised. The C-lectin type receptors (CLRs) are also 
membrane-localised and recognise carbohydrate PAMPS; an archetypal CLR is dectin-
1, which is important in fungal and mycobacterial recognition (Reid et al., 2009). 
Pattern recognition also occurs in the cytoplasm, where it is mediated by nucleotide 
oligomerization domain (NOD)-like receptors (NLRs; Chen et al., 2009), RIG-1-like 
receptors (RLRs; Loo and Gale, 2011) and a range of DNA sensors (Paludan and 
Bowie, 2013). The NLRs are divided into three sub-families: the NODs, the NLRPs 
(NLR, leucine-rich repeat and pyrin-domain-containing) and the IPAFs (ice protease-
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activating factors). The NODs, which recognise bacterial peptidoglycans, mediate 
classical transcription-activating innate immune signalling, while the NLRPs and IPAFs 
recognise a range of substrates and form inflammasomes, discussed subsequently 
(Schroder and Tschopp, 2010). The RLRs are sensors for pathogen-associated RNA 
motifs, and along with sensors which sense pathogenic DNA, such as IFI16 and cyclic 
GMP-AMP synthase (cGAS), activate anti-viral responses primarily mediated by type I 
IFNs (Loo and Gale, 2011; Paludan and Bowie, 2013). In view of the focus on Mtb in 
this thesis, I have summarized the contributions of PRRs from several families to 
recognition of mycobacteria (Table 1.3). This example demonstrates the ability of 
macrophages, which express most known PRRs, to initiate immune responses to 
pathogens encountered extracellularly, in endosomes or in the cytoplasm. 
Family PRR Location Mycobacterial ligand References
TLR-2                   
or TLR-1/TLR-2
Cell surface Phosphatidylmyoinositol 
mannosides (PIMs); cell wall
Gilleron et al. (2003)
Lipoproteins; membrane and 
secreted
Ferwerda et al. (2005); 
Jung et al. (2006)
Lipoarabinomannan (LAM); cell 
wall
Quesniaux et al. (2004)
TLR-4 Cell surface Lipoproteins; membrane and 
secreted
Jung et al. (2006)
Heat shock proteins; 
cytoplasmic
Bulut et al. (2005)
TLR-9 Endosomal DNA Kiemer et al. (2009)
TLR-3 Endosomal RNA Bai et al. (2014)
Mannose 
receptor (MR)
Cell surface Mannosylated (man)-LAM; cell 
wall
Kang et al. (2005)
PIMs; cell wall Torrelles et al. (2006)
DC-SIGN Cell surface Alpha-glucan; cell wall Geurtsen et al. (2009)
Man-LAM; cell wall Maeda et al. (2003)
PIMs; cell wall Torrelles et al. (2006)
Dectin-1 Beta-glucan; cell wall Yadav & Schorey 
(2006); Rothfuchs et al. 
(2007)
NOD2 Cytoplasm Muramyl dipeptide; 
peptidoglycan; cell wall
Ferwerda et al. (2005); 
Coulombe et al. (2009)
NLRP3 Cytoplasm ESAT6; secreted Mishra et al. (2010)
TLRs
CLRs
NLRs
Table 1.3: Pattern recognition of Mtb. 
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Ligation of most membrane-bound PRRs, such as TLRs, causes intracellular 
domain conformational changes leading to recruitment of adaptor proteins such as 
MyD88, which activate intracellular signalling via enzymatic functions (Takeuchi and 
Akira, 2010). The archetypal pathways which are activated in this manner downstream 
of TLRs include the NFκB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) pathway, the MAPK (mitogen-activated protein kinase) cascades, and interferon 
response factor 3 (IRF3) signalling (Takeuchi and Akira, 2010). TLR-induced NFκB 
pathway activation causes degradation of the inhibitor of κB (IκB), which retains NFκB 
TFs in the cytoplasm in the steady state, thus leading to their release and translocation 
to the nucleus where they induce innate inflammatory gene expression (Takeuchi and 
Akira, 2010). Concomitant activation of the MAPK cascade also leads to transcription 
factor activity, such as that of AP-1 and CREB (Dong et al., 2002).  
Other PRRs stimulate similar signalling pathways to TLRs; e.g. the RLR RIG-1 
(retinoic acid-inducible gene 1) activates NFκB via the adaptor IPS-1 (interferon-beta 
promoter stimulator 1) (Kawai and Akira, 2006), and CLRs recruit the tyrosine kinase 
Syk via which MAP kinases are activated, as well as stimulating calcium-signaling 
pathways to activate the TFs CREB and NFAT (Kelly et al., 2010). A major DNA 
sensing pathway is activated by the inherent enzymatic activity of the sensor, cGAS, 
which produces cyclic dinucleotides that act as second messengers to activate STING 
(stimulator of IFN genes), leading to IRF activation (Li et al., 2013). IRF3, which is also 
activated downstream of TLRs, then induces type I IFN transcription and thus 
stimulates innate antiviral responses (Burdette and Vance, 2013). 
It has also been established that some innate immune responses are not 
powered by transcription, such as inflammasome activation (Strowig et al., 2012). 
Activation of the NLRP or IPAF NLRs causes their oligomerization via their NACHT 
domains, forming complexes termed inflammasomes which can activate caspase-1. 
Caspase-1 then enzymatically cleaves the pro-forms of two pro-inflammatory cytokines, 
pro-IL-1β and pro-IL-18, into their active forms which can be secreted. This process 
can also induce a form of inflammatory cell death termed pyroptosis (Rathinam et al., 
2012). Many stimuli have been shown to activate inflammasomes, including microbial 
PAMPs, and also signals that communicate tissue damage termed danger-associated 
molecular patterns (DAMPs), such as urate crystals, β-amyloid and extracellular ATP 
(Schroder and Tschopp, 2010). The mechanisms by which these signals activate 
Chapter 1 Introduction 
 
42 
inflammasomes are unclear, but may involve effects on membrane integrity, or the 
recently favoured hypothesis of mitrochondrial dysfunction and reactive oxygen 
species (ROS) generation (Schroder and Tschopp, 2010).  
Other non-transcriptional innate immune signalling outputs have been 
described, which modulate the outcome of inflammatory gene expression programmes 
via mechanisms such as altering splicing, mRNA stability and translation (Carpenter et 
al., 2014). One example involves the phosphoinositide (PI)-3-kinase (PI3K)–
mammalian target of rapamycin (mTOR) pathway, the activity of which was shown to 
be modulated in macrophages after bacterial infection, leading to alterations in the 
efficiency of translation of cytokine mRNAs, and resultant biasing of pro- or anti-
inflammatory responses (Ivanov and Roy, 2013).  
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1.2.7 Macrophage effector functions 
It has been long been established that during interactions with pathogens, 
macrophages assume a pro-inflammatory phenotype involving an increased 
microbicidal capacity (Unanue, 1976). It is now known that this is primarily induced by 
pattern recognition, which primes the macrophage for physiological adaptation to 
inflammation, and directs active anti-microbial functions. One potent macrophage 
effector function is secretion of cytokines: pleiotropic secreted proteins which act in an 
autocrine, paracrine and endocrine fashion. They signal via receptors on both immune 
and non-immune cells to stimulate outcomes such as leukocyte activation, increased 
vascular permeability and tissue adaptation to inflammation. It was first shown in the 
1970s that factors secreted by macrophages could alter lymphocyte activity (Hoffmann 
and Dutton, 1971) and that macrophage activation modulated this secretion (Unanue, 
1976). A range of macrophage-produced cytokines have now been characterised 
(Table 1.4). Macrophages are also able to secrete chemokines, molecules which are 
able to control the migration and positioning of leukocytes (Griffith et al., 2014), and so 
they also modulate inflammation by controlling the recruitment of other immune cells 
(Mantovani et al., 2004). Via the action of cytokines and chemokines, macrophages 
exert powerful effects on the quality of inflammation and the immune response. 
Table 1.4: Cytokines secreted by macrophages. 
Cytokine Ascribed functions References
TNFα Broad range of inflammatory bioactivites, including co-
ordination of the acute phase response, induction of 
intracellular killing in macrophages and induction of 
apoptosis
Wajant et al. (2003)
IL-6 Broad range of inflammatory bioactivities, including co-
ordination of the acute phase response, stimulation of 
neutrophil production, and induction of monocyte 
recruitment
Scheller et al. (2011)
IL-1β Broad range of inflammatory bioactivities, including 
increasing vascular adhesion, co-ordination of the acute 
phase response, activating and inducing survival of  
innate immune cells such as neutrophils, influencing 
polarisation of Th17 cells, 
Dinarello (2009)
IL-12 Influences polarisation of Th1 cells Hsieh et al. (1993)
IL-18 Influences polarisation of Th1 cells Gracie et al. (2003)
IL-10 Immunomodulatory functions; contributes to resolution 
of inflammation
See section 1.5
IFNβ Antiviral responses and immunosuppressive functions Stetson & Medzhitov (2006); 
Gonzalez-Navajas et al. 
(2012)
IL-23 Influences polarisation of Th17 cells Iwakura & Ishigame (2006)
TGFβ Promotes resolution of inflammation and fibrosis; 
influences polarisation of Treg and Th17 cells
Lee et al. (2001); Murray & 
Wynn (2013)
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In addition to regulating other cells, macrophages display direct anti-microbial 
activity via their potent phagocytic function and capacity for intracellular killing. 
Phagocytosis is initiated by binding of pathogens by receptors which can mediate 
ingestion, including scavenger receptors, complement receptors, lectins, integrins and 
Fc receptors (Stuart and Ezekowitz, 2005). The initiation of phagocytosis triggers a 
range of intracellular processes, including cytoskeletal rearrangements and membrane 
trafficking events involved in uptake, but also pro-inflammatory signalling, microbial 
killing pathways and in some cases apoptosis (Stuart and Ezekowitz, 2005). 
Phagocytosis essentially co-operates with pattern recognition to trigger anti-microbial 
defences (Underhill and Ozinsky, 2002); this is evidenced by observations that PRRs 
such as dectin-1 can mediate phagocytic uptake (Herre et al., 2004), but also in the 
recruitment of PRRs such as TLRs to phagosomes to facilitate microbial detection 
(Ozinsky et al., 2000; Underhill et al., 1999). Macrophages can also phagocytose 
fragments of apoptotic cells as a result of pro-phagocytic signals on the apoptotic cell 
surface (Flannagan et al., 2012). 
Phagocytosis internalises micro-organisms in an early phagosome, which then 
undergoes a maturation process to mediate microbial killing (Stuart and Ezekowitz, 
2005). This involves acidification and a series of fusion and fission events with other 
endosomal compartments, most importantly lysosomes, to form the phagolysosome 
(Flannagan et al., 2009). The phagolysosome is optimised for pathogen degradation, 
containing degradative enzymes such as hydrolases and proteases (Stuart and 
Ezekowitz, 2005). ROS are also generated to mediate killing, via the NADPH oxidase 
and mitochondrial pathways (Sakata et al., 1987; West et al., 2011). In humans, 
mutations in the genes encoding the subunits of the NADPH oxidase are associated 
with chronic granulomatous disease (CGD), a primary immunodeficiency characterised 
by recurrent bacterial and fungal infections, demonstrating the importance of this 
phagocytic killing pathway in pathogen control (Heyworth et al., 2003).  Generation of 
reactive nitrogen species (RNS) by the action of inducible nitric oxide synthase (iNOS) 
is an accepted event in murine macrophages which contributes to host protection but 
evidence for this pathway in human macrophages is less clear (Aberdein et al., 2013). 
The importance of phagolysosomal killing is evident in the range of pathogens which 
have evolved to inhibit phagosomal maturation and function (Flannagan et al., 2009); 
as a result, alternative pathways of killing may be utilized, such as autophagic killing of 
Mtb (Gutierrez et al., 2004). In some contexts wherein the macrophage capacity for 
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phagolysosomal killing is exhausted, it has been shown that macrophage apoptosis 
may be utilized as an alternative microbial killing mechanism, for example in the 
response to Streptococcus pneumonie (Aberdein et al., 2013; Ali et al., 2003; Bewley 
et al., 2011; Dockrell et al., 2003, 2001). 
Macrophages also co-ordinate tissue repair and resolution of inflammation. Acute 
inflammatory macrophage responses can be inherently tissue-damaging and contribute 
to disease, in addition to damage which may be caused directly by pathogens (Wynn et 
al., 2013). Chronic inflammation, which arises when the acute response is not 
appropriately resolved, is also a major driver of pathology in which macrophage 
function is implicated (Nathan and Ding, 2010). Therefore, the resolving functions of 
macrophages represent an important feedback mechanism by which they regulate 
immunopathogenic outcomes of their own function. Two specialised macrophage 
phenotypes mediate resolution, described as either pro-fibrotic macrophages, which 
are involved in wound-healing, or regulatory macrophages, which are involved in 
suppression of inflammation (Wynn and Ramalingam, 2012). The latter have also been 
referred to as “M2” or alternatively activated macrophages, and are proposed to 
represent a polarised macrophage phenotype in contrast to pro-inflammatory “M1” 
macrophages; however, the utility of these designations is a matter of debate, and is 
discussed subsequently in section 1.2.9.  
The factors which induce these resolution phenotypes include the Th2 cytokines IL-
4 and IL-13, IL-10, glucocorticoids, prostaglandins and apoptotic cells (Wynn et al., 
2013). Pro-fibrotic macrophages secrete factors such as platelet-derived growth factor 
(PDGF) and transforming growth factor β (TGFβ), which mediate repair by inducing 
fibroblasts to synthesise collagen (Wynn and Ramalingam, 2012). They also secrete 
tissue inhibitors of metalloproteinases (TIMPs), which inhibit matrix metalloproteinase 
(MMP)-mediated degradation of the extra-cellular matrix (ECM) (Murray and Wynn, 
2011). Although depletion studies have demonstrated the necessity of pro-fibrotic 
macrophages in repair (Duffield et al., 2005; Lucas et al., 2010), they have also alluded 
to their potentially pathogenic functions in causing fibrosis and scar formation in 
chronic inflammation (Wynn and Ramalingam, 2012). Regulatory macrophages 
contribute to the resolution of inflammation by producing factors which suppress pro-
inflammatory responses, such as IL-10, which is discussed subsequently in section 
1.5. Another suppressive factor produced is resistin-like molecule alpha (RELMα), 
which may contribute to the regulation of Th2-polarised immune responses (Nair et al., 
2009). 
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1.2.8  Interactions of macrophages with the adaptive immune system 
The crux of the CMI response is the collaboration between macrophages and CD4+ 
T cells in the control of intracellular pathogens (Figure 1.1). Macrophages are thought 
to be less migratory than DC, and to persist in tissues after initiating inflammation 
(Murray and Wynn, 2011). Thus, their interactions with adaptive immune cells are 
subject to lymphocyte recruitment to the site of inflammation. The chemokine milieu 
produced by macrophages in acute inflammation may drive this, including factors such 
as CXCL9 and CXCL10, which are chemotactic for CD4+ Th1 cells, CD8+ cytotoxic 
cells and natural killer (NK) cells, and CCL17, which is chemotactic for Th2 cells 
(Griffith et al., 2014; Hardison et al., 2006; Katakura et al., 2004). 
Once macrophages and adaptive immune cells are closely spatially related, several 
interactions may occur. The first set of interactions stem from the macrophage, and the 
most classic interaction in this regard is macrophage-driven activation of CD4+ T cells. 
This is suggested to involve three signals from the macrophage or antigen presenting 
cell (APC): antigen presentation is signal 1, ligation of co-stimulatory receptors is signal 
2, and secretion of modulatory cytokines is signal 3 (Curtsinger et al., 1999; 
Kapsenberg, 2003). The ability of macrophages to provide signal 3 is clear, as they 
secrete a range of cytokines which can modulate T cells (Table 1.5). They are also 
able to provide signal 1 and signal 2, as although they are not considered to be 
professional APCs like DCs, they do express major histocompatibility class (MHC) II 
and co-stimulatory molecules, and have the appropriate phagocytic and antigen 
processing capabilities to facilitate class II-restricted presentation to CD4+ T cells 
(Hume, 2008). Investigations have demonstrated that macrophage-mediated antigen 
presentation to CD4+ T cells can occur in vitro (Desmedt et al., 1998) and in vivo 
(Moser, 2001). 
The cytokine-driven signal 3 produced by macrophages can alter the polarisation of 
the subsequent CD4+ T cell response. Associations of different macrophage-derived 
cytokines with different polarised CD4+ T cell responses are shown in Table 1.6. 
Polarised CD4+ T cell responses are can then feedback to macrophages to modulate 
their effector functions and hence produce further immune response adaptation, which 
again mainly occurs via cytokine signalling. IFNγ was the first lymphocyte-produced 
factor described which modulated macrophage function (Celada et al., 1984; Fowles et 
al., 1973; Mackaness, 1964; Nathan et al., 1983, 1973; Pace et al., 1983), and was 
found to induce a potently pro-inflammatory, microbicidal activated macrophage 
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response. Subsequently, the Th2-produced cytokines IL-4 and IL-13 were shown to 
induce a divergent form of macrophage activation: promoting endocytosis via mannose 
receptors, inducing expression of MHC class II molecules, and downregulating pro-
inflammatory cytokine secretion (Doyle et al., 1994; Stein et al., 1992). These two 
macrophage phenotypes were respectively designated as classical and alternative 
activation of macrophages, and led to the development of the M1 vs. M2 macrophage 
polarisation concept, discussed subsequently in section 1.2.9. In addition to 
responding to IFNγ, IL-4 and IL-13, macrophages have been reported to alter their 
functions in response to other cytokines produced by CD4+ T cells, demonstrating the 
diverse ways in which T cells and macrophages interact to mediate CMI. These are 
summarised in Table 1.5. 
 
Polarised CD4
+
 T 
cell response
Immune response
Macrophage-
derived cytokines
References
Th1 CMI; IFNγ-producing; 
intracellular pathogens
IL-12, IL-18 Hsieh et al. (1993); 
Gracie et al. (2003)
Th2 Humoral immunity; IL-4/IL-13 
producing; extracellular 
pathogens
IL-4 Pouliot et al. (2005); 
Mukhurjee et al. (2009)
Th17 IL-17 producing; extracellular 
bacteria and fungi
IL-23, IL-6, IL-1β, 
TGFβ
Langrish et al. (2005); 
Scheller (2011); Chung 
et al. (2009); Mangan et 
al. (2006)
Treg Immunoregulation IL-10, TGFβ Horwitz et al. (2003); 
Chen et al. (2003)
Th9 IL-9 producing; immunity to 
nematodes
TGFβ, IL-4 Veldhoen et al. (2008)
Th22 IL-22 producing; skin immune 
responses
IL-6, TNFα Duhen et al. (2009); 
Trifari et al. (2009)
Table 1.5: Induction of polarised CD4+ T cell responses by macrophage-derived 
cytokines. 
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Table 1.6: Modulation of macrophages by different CD4+ T cell subset-derived cytokines. 
T-cell derived 
cytokine
T cell subset 
association
Reported effects on macrophages References
IFNγ Th1, Th17 Classical macrophage activation; 
induction of microbicidal killing and 
inflammation
Fowles et al. (1973); 
Nathan et al. (1983); 
Pace et al. (1983); 
TNFα Th1 Induction of microbicidal killing, 
effects on apoptosis pathways; 
regulation of cytokine secretion
Rojas et al. (1999); 
Munoz-Fernandez et al. 
(1992); Hodge-Dufour et 
al. (1998)
IL-4 Th2 Alternative macrophage activation; 
enhancement of phagocytosis & 
antigen presentation pathways, 
suppression of killing pathways
Stein et al. (1992); 
Martinez et al. (2009)
IL-13 Th2 Similar effects to IL-4 Doyle et al. (1994)
IL-17 Th17 Reported to induce an anti-apoptotic 
phenotype involved in resolution; 
other reports suggest induction of pro-
inflammatory cytokines
Zizzo & Cohen (2013); 
Jovanovic et al. (1998)
IL-10 Tregs; most 
subsets under 
some conditions
Outlined in section 1.5.3
TGFβ Tregs Activation of a specific gene 
expression programme which may be 
involved in Th2 responses and lipid 
metabolism
Gratchev et al. (2008)
IL-22 Th22, Th17 Induction of microbial killing; however 
also reported that macrophages may 
not express the IL-22R
Wolk et al. (2004); 
Dhiman et al. (2009)
IL-9 Th9 May induce inflammatory phenotypes Nowak et al. (2009)
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1.2.9  Macrophage functional plasticity 
Macrophages are able to appropriately adapt their function in response to 
detection of a wide range of extracellular signals (Mosser and Edwards, 2008). As 
such, macrophages display substantial functional plasticity, in addition to phenotypic 
heterogeneity in different tissues. This plasticity of activation states has been a subject 
of intensive research, mainly using in vitro MDM models, and has provided many 
insights into the diverse ways in which macrophages may function during the immune 
response.  
Stimulation of macrophages with either IFNγ or IL-4 and IL-13 produces distinct 
macrophage phenotypes which have been strongly associated with Th1 and Th2 
immune responses, with demonstrations in vitro and in vivo that they are both 
provoked by these immune responses and played key roles in their outcomes (Mills et 
al., 2000). A macrophage subset nomenclature was proposed to formalise this parallel 
with the type I vs. type II immune response paradigm, in which classically activated 
macrophages, which could also be induced by innate stimulation, became known as 
M1 macrophages and alternatively activated macrophages became known as M2 
macrophages (Mills et al., 2000). However, many other stimuli could clearly modulate 
macrophage biology, including cytokines such as IL-10 and TNFα, and other factors 
such as glucocorticoids and immune complexes (Mantovani et al., 2004). Modifications 
of the nomenclature were proposed to incorporate this, such as division of 
macrophages into three functional subsets of host defence, wound healing and 
immune regulation (Mosser and Edwards, 2008), or sub-division of the M2 category 
into M2A, B and C sub-subsets, depending on which input stimuli were used to induce 
alternative activation (Mantovani et al., 2004). Formulation of this classification was 
accompanied by research into the molecular mechanisms by which a macrophage 
becomes classically or alternatively activated, for example at the transcriptomic level 
(Martinez et al., 2006) or by identification of what are postulated to be subset signature 
transcription factors, such as IRF5 in M1 polarisation (Krausgruber et al., 2011) and 
IRF4 (Satoh et al., 2010) and PPAR-γ (Bouhlel et al., 2007; Odegaard et al., 2007) in 
M2 polarisation. 
Throughout the characterisation of macrophage activation within the M1 vs. M2 
framework, there was recognition that these phenotypes were an oversimplification, 
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and were actually likely to represent polarised extremes of a spectrum of phenotypes 
(Mantovani et al., 2004; Biswas and Mantovani, 2010). Their existence in vivo as pure 
polarized subsets was questioned (Lawrence and Natoli, 2011), with the suggestion 
that it was more likely that mixed phenotypic populations were driven by multiple 
signals (Martinez and Gordon, 2014). It was also reported that activated macrophage 
phenotypes were in fact more labile and prone to temporal re-adaptations than a 
system describing polarised subsets might indicate (Biswas and Lopez-Collazo, 2009; 
Stout and Suttles, 2004; Stout et al., 2005). Subsequently, a report evaluating human 
macrophages in vitro using a wide range of stimulation conditions, and transcriptional 
profiling of the activation states produced, showed that the M1 vs. M2 bipolarization 
model could be replaced with a complex spectral range of heterogeneous macrophage 
activation states (Xue et al., 2014).  
As a result, the concept of macrophage plasticity as a binary polarised system of 
classically and alternatively activated macrophages has been superseded by a 
paradigm in which macrophages are understood to be functionally dynamic, long-lived 
cells which are capable of switching their function between a complex array of 
“metastable” activation states appropriate to their microenvironment (Wynn et al., 2013; 
Xue et al., 2014). This plasticity is assumed to be primarily controlled at the 
transcriptional level, wherein the extracellular mediators inducing phenotypic 
adaptation activate intracellular signalling cascades via receptor ligation, converging on 
transcriptional outputs which reprogram the function of the cell (Lawrence and Natoli, 
2011; Natoli and Monticelli, 2014).  
Overall, it is clear that both autocrine and paracrine signals in CMI, generated by 
macrophages and T cells, can substantially affect the phenotype of both of these cell 
types as well co-ordinating other effector functions. Hence, the outcomes of CMI 
responses are likely to be determined stochastically by these signals, and an 
understanding of both macrophage biology and how it is modulated by these signals, 
and by pathogens such as HIV-1 and Mtb which can parasitize macrophages, is central 
to understanding the function of CMI. 
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1.3 HIV-1 infection and CMI 
1.3.1 The human immunodeficiency virus 
In the early 1980s, the first reports were made of a condition characterised by 
severe opportunistic infections, tumours and reduced CD4+ T cell counts. Within four 
years this condition had been formalized in name as the acquired immunodeficiency 
syndrome (AIDS), and its causative agent identified: a retrovirus able to infect and 
cause cytopathic effect in T cells, now called human immunodeficiency virus 1 (HIV-1) 
(Barré-Sinoussi et al., 1983; Popovic et al., 1984). In the subsequent three decades, 
research has extensively characterised this infection and its pathogenesis. The cellular 
receptors for HIV-1 have been identified – the co-stimulatory molecule CD4 (Dalgleish 
et al., 1984; Maddon et al., 1986) in combination with a chemokine co-receptor 
(Alkhatib et al., 1996; Feng et al., 1996; Deng et al., 1996), which allows the virus to 
infect a range of cell types in vivo, including CD4+ T cells and macrophages. The ability 
of HIV-1 to infect both of these central cellular players in CMI highlights the propensity 
of the virus to modulate this arm of immunity. CMI modulation represents a major 
pathway of viral pathogenesis, which is mediated through the direct effects of the virus 
on these cells and through its pleiotropic effects on the immune system more broadly. 
The aberrant effects of HIV-1 on CMI are evident in the increased risk of infection by 
intracellular pathogens in HIV-1+ individuals, of which one the most striking examples is 
mycobacterial disease including TB. 
1.3.2  Epidemiology, clinical course and treatment of HIV-1 disease 
The global burden of the HIV-1 pandemic is substantial. In 2012, 35.3 million 
people globally were HIV-1+, 2.3 million new HIV-1 infections occurred, and 1.6 million 
deaths were attributed to the virus (UNAIDS, 2013). This burden of infection is 
disproportionately found in sub-Saharan Africa, where more than 70% of new HIV-1 
infections occurred in 2012 (UNAIDS, 2013). Two distinct epidemiological patterns of 
HIV-1 infection exist; firstly, countries in which infection is primarily found in particular 
at-risk groups, such as men who have sex with men (MSMs) or injecting drug users 
(Cohen et al., 2008). This is the primary pattern of disease in countries outside sub-
Saharan Africa. Therein, the second epidemiological pattern is observed, in 
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generalised epidemics of HIV-1 infection which are self-sustaining throughout the 
whole population (Cohen et al., 2008). 
The natural history and clinical manifestations of HIV-1 disease result from the 
immunopathogenic processes driven by the virus discussed subsequently in section 
1.3.6). Many individuals (estimates range from 40–90%) experience an acute retroviral 
syndrome or seroconversion illness within 2–6 weeks of infection, due to the initial 
immune response to the virus, with archetypal symptoms of viral infection, such as 
fever, myalgia, rash, lymphadenopathy and headache (Kassutto and Rosenberg, 
2004). The infection soon enters a phase of clinical latency, in which most individuals 
are asymptomatic and the plasma HIV-1 viral load (VL) is maintained at a lower set 
point (Levy, 2009). After approximately 5–10 years of untreated infection, late-stage 
HIV-1 disease is manifest in substantial loss of peripheral blood CD4+ T cells and 
increased incidence of opportunistic infections, recognized clinically as AIDS (Cohen et 
al., 2008). Progression to AIDS can be prevented by effective anti-retroviral therapy 
(ART); however, it is now recognized that even treated HIV-1+ individuals are at 
increased risk of non-AIDS-related chronic health complications, including 
cardiovascular disease, neurocognitive disease, liver and kidney disease, some 
cancers, and frailty (Deeks et al., 2013). 
 Notwithstanding non-AIDS related morbidity, the development of ART and the 
global expansion of access to anti-retrovirals (ARVs) is coincident with substantial 
reductions in HIV-1-associated mortality. The central principal of ART is the use of 
several ARVs in combination, to avoid the rapid development of drug resistance to 
single agents that occurs due to the rapid HIV-1 replication rate; this is termed highly 
active anti-retroviral therapy (HAART) (Cohen et al., 2008). Due to the robust efficacy 
of HAART in preventing progression to AIDS and reducing HIV-1-related mortality (The 
HIV-CAUSAL Collaboration, 2010), and recent demonstrations that it can also reduce 
transmission (Cohen et al., 2011a), it is now recommended that ART is initiated in all 
HIV-1+ individuals with a CD4+ T cell count of less than 500/mm3 (WHO, 2013a).  
1.3.3 HIV-1 virology 
HIV-1 is spherical enveloped virus which is a member of the genus Lentivirus, 
part of the family Retroviridae (Fields Virology, 2007). It is a single-stranded positive-
sense RNA virus, with genome of approximately 10kB (Ratner et al., 1985; Wain-
Hobson et al., 1985) containing nine genes flanked by two long terminal repeats (LTR) 
Chapter 1 Introduction 
 
53 
(Morrow et al., 1994). The gag gene encodes a polyprotein containing structural 
components of the virus; the pol gene encodes a polyprotein containing the viral 
enzymes, reverse transcriptase, integrase and protease; and the env gene encodes 
the viral glycoproteins gp120 and gp41 (Morrow et al., 1994). The six remaining genes 
– tat, rev, vpr, vpu, vif and nef – encode the viral accessory proteins which have a 
range of functions in replication and host cell manipulation (Morrow et al., 1994; Strebel, 
2013). In the virion, two copies of the RNA genome are packaged in diploid form inside 
the viral core which has a characteristic conical structure in mature virions (Morrow et 
al., 1994). This is surrounded by the viral matrix, and lastly the lipid envelope, which 
contains the glycoproteins which determine the cellular tropism of the virus (Shioda et 
al., 1991). The virion also contains viral enzymes and various host factors which are 
either packaged or derived from the host membrane during the budding process 
(Morrow et al., 1994; Ott, 2008). 
Phylogenetic analyses have determined that the closest ancestor of HIV-1 is 
simian immunodeficiency virus (SIV) cpz, a pathogenic lentivirus of chimpanzees, and 
HIV-1 is estimated to have transmitted to humans zoonotically within the last century 
(Gao et al., 1999; Keele et al., 2009; Korber et al., 2000). HIV-1 is formed of four 
genetic groups; M (major), O (outlier), N (non-M, non-O) and P; group M is the 
pandemic HIV-1 which accounts for ≥ 90% of infections globally (Hemelaar, 2012). 
Within group M, there is great genetic diversity, as a result of the inherent replicative 
properties of HIV-1 that confer a rapid evolutionary rate upon the virus (Rambaut et al., 
2004). There are nine group M clades; clade B viruses predominate in Europe and the 
Americas, whereas clade C viruses are most common in sub-Saharan Africa 
(Hemelaar, 2012). 
HIV-2, despite also being an aetiological agent of AIDS in humans, is less 
closely related to HIV-1 than SIVcpz, and its genome is only partially homologous to 
HIV-1 (de Silva et al., 2008). Its closest relation in the lentivirus family is the sootey 
mangabey virus SIVsm, from which a separate zoonotic transmission event is thought 
to have occurred (Gao et al., 1992). HIV-2 is less pathogenic than HIV-1, causing 
slower progression to AIDS and exhibiting reduced rates of transmission; its global 
distribution is mostly limited to west Africa (Gilbert et al., 2003; Marlink et al., 1994).  
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1.3.4 Interactions of HIV-1 with host cells: the viral lifecycle, host restriction 
and immune evasion 
The HIV-1 replication strategy in host cells is described as follows (Fields 
Virology, 2007). HIV-1 enters cells by interaction of the viral envelope glycoproteins 
with the host glycoprotein CD4 and a chemokine receptor, leading to fusion of the viral 
and host membranes and release of the viral core into the cell. This core is made of 
capsid proteins and contains the HIV-1 RNA genome and the viral enzymes reverse 
transcriptase (RT), protease and integrase (IN), as well as tRNA primers for the 
process of reverse transcription, which takes place rapidly after entry to produce a 
double stranded DNA (dsDNA) copy of the viral genome. This initial RT complex then 
reassembles around the dsDNA genome to form the pre-integration complex (PIC), 
made up of both viral and host proteins, which is trafficked into the host cell nucleus for 
the process of integration into chromosomal DNA, facilitated by IN. The transport of the 
PIC through nuclear pores allows HIV-1 to effectively infect non-dividing cells, such as 
tissue macrophages, a feature shared with other lentiviruses. The integrated viral 
genome, termed the provirus, is used as the template for viral transcription under the 
control of the viral LTR and mediated by host RNA polymerase II and the viral 
transactivator protein Tat, along with cellular transcription factors. Viral transcripts are 
transported to the cytoplasm using both the host nuclear export systems and the viral 
protein Rev, and are translated into the polyproteins Gag and Gag-Pol, as well as 
accessory proteins and envelope proteins, or alternatively become nascent viral 
genomes. Viral proteins and genomic RNA dimers assemble at the plasma membrane 
and bud as an immature virion, which matures throughout the budding process as the 
protease enzyme cleaves the polyproteins to form a mature virion which is competent 
for infection of new host cells.   
This strategy is broadly similar to most retroviruses, although the six HIV-1 
accessory proteins provide additional functions which aid replication, infectivity and 
transmission. The transactivator protein Tat increases the efficiency of viral 
transcription by promoting the formation of a highly efficient RNA polymerase II 
complex, and the export protein Rev allows efficient shuttling of viral transcripts in 
spliced and unspliced forms. These two proteins are essential for viral infectivity, and 
deletion or mutation of their genes renders the virus non-infectious (Dayton et al., 
1986; Terwilliger et al,. 1988). The remaining four accessory proteins - Vif, Vpr, Vpu 
and Nef - perform functions which maximise the efficiency of viral replication, but 
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deletion of these genes in many studied cell systems is not fully deleterious for viral 
replication. Vif interacts with the host restriction factor APOBEC3G to counteract the 
effects of this protein on the virus (Conticello et al., 2003). A range of functions have 
been ascribed to Vpr; it is suggested to be most important for replication in 
macrophage-lineage cells (Balliet et al,. 1994), and has been reported to influence viral 
and host gene expression, enhance nuclear import of the PIC, and interfere with the 
host cell cycle and apoptotic processes (Andersen & Planelles, 2005). It is not clear 
which, if any, of these is the dominant function of Vpr. The Vpu protein is unique to 
HIV-1 among lentiviruses, and has been implicated in enhancing release of virus by 
countering the host restriction factor tetherin (Neil et al., 2008), and causing 
degradation of CD4 in infected cells, the latter in order to prevent retention of the 
envelope glycoproteins in the cell (Dubé et al., 2010). The final accessory protein, Nef, 
has been shown to be important for pathogenesis in vivo, as individuals infected with 
Nef-mutated viruses progressing more slowly to AIDS (Kirchhoff et al., 1995). Several 
functions have been ascribed to Nef in vitro: altering cellular activation states, 
downregulating a range of cell surface molecules, and interacting with autophagy 
pathways, although exactly how these functions link to enhancement of infectivity in 
vivo is not understood (Roeth & Collins, 2006). 
A common theme emerges that many HIV-1 accessory proteins act to 
antagonise or degrade host proteins which can inhibit viral replication; these proteins 
are termed restriction factors, and represent a cell-autonomous part of the innate 
immune system which acts to inhibit viral replication (Towers and Noursadeghi, 2014). 
These factors include APOBEC3G, which introduces mutations in viral DNA (Mangeat 
et al., 2003); TRIM5α, which mediates restriction by binding to the viral capsid 
(Stremlau et al., 2004); tetherin, which physically prevents viral budding from the 
plasma membrane (Neil et al., 2008); SAMHD1, which reduces intracellular nucleotide 
pools to reduce reverse transcription efficacy (Hrecka et al., 2011; Laguette et al., 
2011), and Mx2, which restricts viral nuclear entry (Goujon et al., 2013; Kane et al., 
2013). This system of cell-autonomous HIV-1 restriction is inducible by IFN responses, 
and so HIV-1 has evolved to avoid triggering IFN responses, by evading innate 
immune detection in the immune sentinel cells it infects, such as macrophages 
(Rasaiyaah et al., 2013; Tsang et al., 2009). The main step in the HIV-1 lifecycle at 
which pattern recognition might occur is after reverse transcription of viral RNA in the 
cytoplasm, as the resultant viral DNA could potentially trigger cytoplasmic DNA 
sensors such as cGAS and IFI16 (D. Gao et al., 2013; Towers and Noursadeghi, 2014). 
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HIV-1 utilizes cellular co-factors to prevent DNA sensor triggering and hence prevent 
restrictive IFN responses. These cofactors include TREX1, which degrades excess 
viral DNA products (Yan 2010), and cyclophilin A and CPSF6, both of which are 
recruited to the viral capsid and are necessary for evasion of IFN triggering (Rasaiyaah 
et al., 2013). 
1.3.5 HIV-1 pathogenesis and antiviral immune responses 
The pathogenesis of HIV-1 infection, and subsequent progression to AIDS, has 
been characterised via clinical observations and studies of SIV infection in primate 
models. The first event post-transmission is establishment of infection in small 
populations of founder cells – indicated from animal models to primarily be resting 
CD4+ T cells, although myeloid cells may also be affected - in the mucosa, wherein 
virus infection and replication expands locally for the first week of infection. This is 
known as the “eclipse phase”, during which viraemia is not detectable (Cohen et al., 
2011b). Infection then disseminates systemically to secondary lymphoid organs, 
manifesting within the second week post-infection as a high viraemia, as large 
numbers of target cells in these cell-rich tissues are infected (Haase, 2005). 
Pathological processes, including CD4+ T cell depletion, start in secondary lymphoid 
organs during the initial first four weeks or “fast phase” of infection: memory CD4+ T 
cells, and those in the gut-associated lymphoid tissue (GALT), are particularly affected 
(Cohen et al., 2011b). By week four, viraemia starts to decline as the infection enters 
its “slow phase”, as a result of the development of some immunity to the virus and 
potentially depletion of target cells for infection (Haase, 2010). The slow phase, 
characterised by a low steady state level of viral replication and resulting low set-point 
VL, continues for a number of years, which is clinically manifest as the latent phase 
until virus-driven depletion of the CD4+ T cell population becomes profound and 
progression to AIDS occurs (Levy, 2009). 
Throughout this process, an immune response is mounted, which may confer some 
control of the virus, but which also contributes to pathogenesis. An innate anti-viral 
immune response is evident early post-infection, in production of acute-phase proteins 
(Kramer et al., 2010) and an inflammatory cytokine storm (Stacey et al., 2009). This 
response is thought to be generated by the responses of cells such as pDCs, which 
may be able to detect HIV-1, unlike macrophages (Lepelley et al., 2011; Towers and 
Noursadeghi, 2014). This innate response importantly includes production of type I 
IFNs, which may confer some control of the virus in the acute phase (Towers and 
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Noursadeghi, 2014). This is evident in the observation that successful founder viruses 
have low propensity to trigger type I IFN responses (Salazar-Gonzalez et al., 2009). 
However, prolonged IFN signalling in HIV-1 infection is thought to contribute to disease 
pathogenesis as a part of chronic immune activation (discussed subsequently in 
section 1.3.6), as well as potentially contributing to immunosuppression and tolerance 
of the virus (González-Navajas et al., 2012; Towers and Noursadeghi, 2014). Strong 
evidence for this bimodal role of type I IFNs in mediating both protection and 
pathogenesis in lentiviral disease is provided in the macaque model of SIV infection 
(Sandler et al., 2014). HIV-1 specific T and B cell responses can also be measured in 
vivo, with a particularly strong CD8+ T cell response evident (Cohen et al., 2011b). This 
adaptive response contributes to the decline in viral load after the initial fast phase 
(Haase, 2005), but fails to clear the virus. The replicative properties of HIV-1 make it 
unusually adapted for immune escape, and so these responses are ineffectual in the 
face of the constantly mutating viral quasispecies (Rambaut et al., 2004). Additionally, 
like the innate response, they may contribute to disease progression, via contributing to 
CD4+ depletion via cytotoxicity, and potential involvement in chronic immune activation 
phenotypes (Levy, 2009).  
1.3.6  Immune dysfunction in HIV-1 infection 
 The most apparent immune dysfunction in HIV-1 infection is the progressive loss 
of CD4+ T cells. Several mechanisms have been suggested for how depletion occurs, 
and concomitantly why and when AIDS develops as a result of this (Levy, 2009). Early 
studies suggested that increased apoptosis was a major mechanism, and that 
reduction in thymic output might also contribute to the decrease in circulating numbers 
(Douek et al., 1998; Finkel et al., 1995; Meyaard et al., 1992). Recent investigations 
have demonstrated that pyroptosis of abortively infected CD4+ T cells may account for 
the majority of cell death caused by the virus, and that apoptosis may only occur in a 
minority of productively infected cells (Doitsh et al., 2013, 2010). Pyroptosis is an 
inherently inflammatory form of cell death driven by the inflammasome, which in this 
case is triggered by the DNA sensor IFI16 detecting defective RT products in the T cell 
cytosol (Monroe et al., 2014). This leads to IL-1β release as well as cell death, and so 
the process may be propagated as inflammation attracts new target cells for infection 
and depletion (Doitsh et al., 2013). In terms of how depletion leads to progression to 
AIDS, a critical event may be loss of central memory CD4+ T cells which normally act 
as a self-renewing source for effector memory CD4+ T cells, as has been shown in the 
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macaque SIV model (Okoye et al., 2007). As well as depletion, HIV-1 infection is 
associated with changes in T cell function. These include gross alterations in the make-
up of T cell subsets and increased basal rates of T cell activation (Douek et al., 2009). 
As ART can reverse these phenotypes, ongoing viral replication is implicated in their 
mechanism; however, they have not been shown to correlate with disease progression, 
and their contribution to pathogenesis is unclear (Douek et al., 2009). 
In addition to its effects on the T cell compartment, HIV-1 is associated with other 
aberrant immune phenotypes, which may contribute to pathogenesis and impact on the 
function of CMI. The most striking of these is a state of chronic immune activation 
present in HIV-1+ individuals throughout the slow phase of disease, characterised by 
ongoing leukocyte activation and hypercytokinaemia (Douek et al., 2009). This process 
correlates with disease progression and does not occur in long-term non progessors 
(individuals who remain chronically infected without progression to AIDS) and so is 
thought to be critical in pathogenesis (Deeks et al., 2004; Douek et al., 2009; Forsman 
and Weiss, 2008). This is supported by the observation that pathogenic lentiviruses are 
more likely to cause immune activation in their hosts than non-pathogenic lentiviruses 
(Evans and Silvestri, 2013; Forsman and Weiss, 2008). The inflammatory processes 
surrounding CD4+ depletion, as well as anti-HIV-1 immune responses, may contribute 
to chronic immune activation (Douek et al., 2009). However, a specific mechanism 
involving HIV-1-mediated disruption of the gut mucosa has been suggested to play a 
role. The postulated process is as follows (Douek et al., 2009): massive loss of CD4+ T 
cells in the GALT soon after infection causes immunodeficiency and inflammation 
within the mucosa. This causes fibrosis and structural abnormalities, along with 
dysbiosis of gut commensals. These combined immunological and structural insults to 
this important barrier tissue allow the translocation of microbial products from the gut 
flora into the bloodstream, activating innate immune cells and causing chronic immune 
activation. Evidence for this model comes from high levels of circulating LPS measured 
in HIV-1+ individuals and in the SIV macaque model, which correlate with measures of 
immune activation (Brenchley et al., 2006).  
Two consequences of chronic immune activation are suggested. Firstly, it may 
contribute to CD4+ depletion, T cell dysfunction and viral replication (i.e. the processes 
which drive progression to AIDS) by providing a source of activated T cells for the virus 
to infect. This essentially establishes a vicious cycle, wherein viral replication leads to 
gut pathology, which drives immune activation, which then potentiates viral replication, 
etc (Douek et al., 2009). The second aberrant outcome is suggested to be the non-
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AIDS-related chronic health complications observed in HIV-1+ individuals. Chronic 
inflammation itself, and a hypercoagulable state produced by effects on the liver (Shen 
and Frenkel, 2004), are both drivers of tissue damage which may cause these 
conditions (Deeks et al., 2013). Immune activation may therefore be a major cause of 
HIV-1-related disease which is not reversible by ART, as although ART does effectively 
reduce immune activation, tissue damage as a result of chronic inflammation may have 
already occurred (Douek et al., 2009). 
Another aberrant HIV-1-associated immune phenotype is the immune reconstitution 
inflammatory syndrome (IRIS), wherein after the commencement of ART there is a 
severe inflammatory exacerbation or unmasking of an underlying condition, most 
commonly TB, Cryptococcus neoformans infection or cytomegalovirus (CMV) retinitis, 
but also other herpesvirus infections and neoplastic syndromes (Lai et al., 2013).  IRIS 
has a high incidence and mortality, which were estimated as 16% and 4.5% 
respectively in a meta-analysis (Müller et al., 2010). The mechanisms which underlie 
this pathology are not well understood. Although the term IRIS suggests that it results 
from reconstitution of the immune system and a recovered CD4+ T cell count mediating 
exacerbated inflammation, it is accepted that this explanation is too simple. Most 
investigations exploring IRIS immunopathology have focussed on TB IRIS, which is 
either considered to be paradoxical (worsening of TB symptoms after commencing 
ARVs) or unmasking (presentation of TB after commencing ARVs) (Lai et al., 2013).  In 
these studies, various phenotypes have been associated with IRIS, such as T cell 
expansions, hypercytokinaemia, innate dysfunctions and high rates of NK cell 
activation (Table 1.7). A common mechanism for IRIS in different infections was 
proposed by one study, in which expansions of polyfunctional (TNFα and IFNγ 
secreting) memory CD4+ T cells were observed which were specific to the underlying 
co-infection (Mahnke et al., 2012). Altogether, these observations may assist in 
explaining the pathogenesis of IRIS, but they may also be phenomena resulting from 
the disease process rather than precipitating it, and the underlying cause-and-effect 
behind the syndrome is not yet clear (Chahroudi and Silvestri, 2012).  
One suggested mechanism for IRIS, as well as for immune activation processes, 
involves HIV-1-triggered dysfunction of innate inflammatory cells such as macrophages 
(Lai et al., 2013). As macrophages are target cells for HIV-1, modulation of their 
function by the virus represents another potential aberrant immune phenotype 
associated with HIV-1. This is discussed subsequently in section 1.3.9.  
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The range of dysfunctional immune phenotypes found in HIV-1 infection are 
summarised in Table 1.8, including observed dysfunction of B cells, NK cells, 
neutrophils and pDCs (Fauci et al., 2005; Fitzgerald-Bocarsly and Jacobs, 2010; 
Kuritzkes, 2000; Moir and Fauci, 2008). HIV-1 has been associated with dysfunction of 
almost all components of the immune system in some context; however, cause-and-
effect for these phenotypes are not clear, and whilst some of these are likely to be 
secondary to T cell dysfunction or chronic immune activation, conclusive evidence is 
lacking for their mechanisms. It is clear that the disease caused by HIV-1 is not only an 
immunodeficiency, but also an immunopathology, involving aberrant inflammatory 
phenotypes which may contribute substantially to pathogenesis. Dysregulated CMI 
responses could potentially result from many of these phenotypes; HIV-1 dyregulation 
of macrophages, as key CMI effector cells, may be a major contributor in this regard. 
TB IRIS-associated phenotype Reference
T cell-based
Expansions of PPD//Mtb-specific Th1 cells Bourgarit et al. (2006); 
Elliott et al. (2008)
Increased activation of circulating T cells Antonelli et al. (2010)
Impaired T-regulatory cells Seddiki et al. (2009)
Increased numbers of TCR+ γδ T cells Bourgarit et al. (2009)
Cytokine dysregulation
Increased cytokine release in heat-killed Mtb-stimulated 
IRIS patient PBMC & concomitant increased cytokines 
in serum
Takodera et al. (2011)
Innate responses
Dysregulated complement component expression Tran et al. (2013)
High CRP expression Haddow et al. (2011)
High TLR-2 expression Tan et al. (2011)
High rates of NK cell activation Conradie et al. (2011)
High neutrophil counts and TNF at site of inflammation Marais et al. (2013)
Humoral responses
High expression of TB-specific anti-phenolic glycolipid 
antibody
Simonney et al. (2008)
Table 1.7: Immune phenotypes associated with TB-IRIS. 
Table produced from the mechanisms for TB IRIS reviewed in Lai et al. (2013). In the studies 
presented, the comparator groups for TB IRIS patients include a range of controls (HIV-1 
negative TB, HIV-1 non-IRIS TB, etc) and include both paradoxical and unmasking IRIS 
presentations. 
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Immune phenotype Description Suggested mechanisms
CD4
+
 T cell depletion Depletion of CD4
+
 T cells, which occurs 
first in primary infection but then 
recovers, then progressively decreases 
over the clinically latent phase until 
progression to AIDS.
Pyroptosis & apoptosis of infected 
cells or bystander cells; killing by 
HIV-1-specific CD8+ T cells; 
impaired thymic function leading to 
reduced T cell production
T cell dysfunction Gross alterations in T cell subset 
makeup; high basal rates of activation
Driven by viral replication; may be 
due to anti-HIV immune response, 
or be part of immune activation
Gut pathology Preferential depletion of CD4+ T cells 
in the GALT, inflammatory damage to 
the gut epithelium, dysbiosis. 
Commences early post-transmission
Depletion of CD4
+
 T cells as above, 
which leads to inflammation, 
damage & compromised immunity.
Chronic immune 
activation
Chronic lymphocyte activation & 
hypercytokinaemia throughout the 
clinically latent phase of infection.
Translocation of microbial 
components across the gut wall 
leading to dysregulated innate 
immune cell responses, as well as 
anti-HIV immune responses and 
inflammation resulting from CD4
+ 
cytotoxicity
Chronic IFN signalling Elevated levels of type I IFN evidence 
systemically throughout disease which 
may be broadly immunosuppressive
Chronic anti-viral immune response
Macrophage 
dysfunction
B cell dysfunction Hyperactivation and alterations in 
subpopulation frequencies, and 
decreases in memory B cell pools
Associated with chronic immune 
activation and effects on T cell 
compartment
NK cell dysfunction Increased expression of inhibitory 
receptors, along with decreased 
capacity for cytotoxic responses and 
cytokine & chemokine production
Direct interactions of the virus with 
NK cells, or resulting from chronic 
immune activation
Neutrophil dysfunction Reduced numbers, increased 
apoptosis, and deceased microbicidal 
abilities
Bone marrow dysfunction, 
treatment-related, aberrant cytokine 
regulation
pDC dysfunction Chronic activation combined with 
reductions in numbers and altered 
functionality
Direct interactions of the virus with 
pDCs, or resulting from chronic 
immune activation
IRIS Clinical exacerbation or unmasking of 
an infection or neoplasm after 
commencement of HAART
See Table 1.7
See section 1.3.8
Table 1.8: Immune dysfunctions in HIV-1 infection 
Table produced from mechanisms and references cited throughout section 1.3.6. 
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1.3.7  HIV-1-associated co-infections 
The most apparent clinical manifestation of HIV-1 and AIDS are the co-
infections which result from immunodeficiency. In the early era of AIDS, fungal 
Pneumocystis pneumonia (PCP) and neoplastic herpesvirus infection with Kaposi’s 
sarcoma herpes virus (KSHV) were the most commonly observed conditions in the 
USA (Jaffe et al., 1983). Other fungal co-infections are caused by C. neoformans 
(Harrison, 2009) and Candida albicans (Imam et al., 1990), while infections with 
herpesviruses other than KSHV, such as CMV and herpes simplex virus (HSV) are 
also common (Jacobson et al., 1997; Siegal et al., 1981). Protozal co-infections are 
caused by Cryptosporidium and Toxoplasma (Antinori et al., 2004; Pozio et al., 1997), 
and invasive bacterial co-infections by non-typhoidal Salmonella spp. and S. 
pneumoniae, among others (Noursadeghi et al., 2006a). Finally, mycobacterial 
infections caused by both Mtb and non-tuberculous mycobacteria such as 
Mycobacterium avium complex (MAC) organisms contribute a significant burden of co-
infections (De Cock et al., 1992; Karakousis et al., 2004). 
Co-infections can be divided into two categories; those caused by pathogens 
which do not commonly cause disease in immunocompetent hosts, such as 
Pneumocystis, KSHV and Cryptococcus (typically designated as opportunistic 
infections), and those caused by pathogens which cause a burden of disease in 
healthy individuals, such as Mtb, HSV & CMV and bacterial infections. In the latter 
category, HIV-1+ individuals may experience disease more frequently, more severely or 
in atypical presentations compared to healthy individuals. The risk of different co-
infections varies with the degree of immunosuppression (shown in Table 1.7); typically, 
infections termed opportunistic only present at very low CD4+ counts; this may be 
because these infections are directly controlled by CD4+ T cells, or simply indicate that 
CD4+ count is a powerful marker of disease progression. Risk of other conditions, such 
as TB (non-disseminated) and invasive bacterial infection, are higher in all HIV-1+ 
individuals regardless of CD4+ count (Noursadeghi et al., 2006a; Sonnenberg et al., 
2005). This suggests that some inherent consequence of HIV-1 infection which is not 
necessarily involved in disease progression may contribute to risk in these settings. 
This is supported by the observation that risk of opportunistic infections decreases with 
HAART (Kaplan et al., 2000), whereas increased risk of TB and invasive bacterial 
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infections persists in ARV-treated individuals (Gupta et al., 2012; Noursadeghi et al., 
2006a). 
 TB co-infection, in particular, causes a substantial burden of morbidity and 
mortality in HIV-1+ individuals. Mtb is thought to be controlled by CMI (discussed in 
section 1.4.3), and like HIV-1, parasitizes macrophages. The interaction between Mtb, 
HIV-1 and macrophages may therefore be a key example of where dysregulation of 
CMI contributes to risk of co-infection in HIV-1+ individuals, and this is discussed in the 
following sections describing HIV-1 infection of macrophages, tuberculosis, and HIV-1-
associated TB. 
 
Table 1.9: HIV-1 associated co-infections. 
HIV-1
+
 group at risk Infections References
All HIV-1
+
 individuals Pulmonary TB, invasive bacterial 
infections
Gupta et al. (2012); 
Noursadeghi et al. (2006); 
Sonnenberg et al. (2005); 
Zumla et al. (2013)
CD4<200/mm
3 KSHV, cryptosporidium, PCP, atypical 
pulmonary or extrapulmonary TB
Crowe et al. (1994); Phair et 
al. (1990); Zumla et al. (2013)
CD4<100/mm
3 Disseminated MAC, HSV, 
toxoplasmosis, cryptococcosis, 
oesophageal candidiasis
Crowe et al. (1994); Chaisson 
et al. (1992)
CD4<50/mm
3 CMV retinitis, disseminated TB Crowe et al. (1994); von Reyn 
et al. (2011); Zumla et al. 
(2013)
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1.3.8 HIV-1 infection of macrophages 
All lentiviruses can infect cells of the macrophage lineage (Chapter 57, Fields 
Virology, 5th ed, Knipe 2007), and HIV-1 is no exception. It was determined soon after 
the isolation of HIV-1 that the virus could infect macrophages in vitro and in vivo 
(Gartner et al., 1986a; Ho et al., 1986), an infection which is permissible due to 
macrophage expression of CD4 and the chemokine receptor CCR5, as well as the 
ability of HIV-1 to evade innate immune detection in these cells (Towers and 
Noursadeghi, 2014). HIV-1 infection of macrophages is productive but not cytopathic 
(Cassol et al., 2006), and has been shown to occur in vivo in tissue macrophages (Cao 
et al., 1992; Jambo et al., 2014; Jarry et al., 1990; Koenig et al., 1986). Infection of 
monocytes in vivo is shown to be much less frequent (Spear et al., 1990) reflecting 
their lower expression of the CCR5 co-receptor (Naif et al., 1998; Tuttle et al., 1998). 
DCs are thought to be resistant to infection by HIV-1 in vivo, in part because of their 
lower expression of CD4 and CCR5 (Luban, 2012), but also due to expression of the 
restriction factor SAMHD1 (Laguette et al., 2011). Macrophage tropism may also be 
modulated by SAMHD1 restriction to some extent (Sunseri et al., 2011), and it is 
possible that macrophage-tropic HIV-1 strains have evolved to specifically avoid this 
restriction pathway (Towers and Noursadeghi, 2014). 
 Infection of macrophages by HIV-1 may be important for a number of reasons. 
Production of virus by macrophages may contribute considerably to viral production 
and burden, even if they are only infected at low levels (Eckstein et al., 2001). 
Macrophages may be infected early post-transmission, due to the fact that they are 
present at the initial site of infection in the mucosa (Margolis and Shattock, 2006) 
coupled with the preferential transmission of R5-tropic virus, which can infect 
macrophages (Zhu et al., 1993), although the observation that MDMs are poorly 
permissive in vitro to founder viruses means their role in early infection is not yet 
clarified (Li et al., 2010; Salazar-Gonzalez et al., 2009). Later in disease, macrophages 
form a long-lived reservoir of virus, capable of infecting CD4+ T cells (Groot et al., 
2008). This reservoir might be a privileged site in which the virus evades the immune 
system, in light of findings that virions are protected from neutralizing antibodies in 
macrophage intracellular compartments (Koppensteiner et al., 2012). Due to their 
relatively long life-spans, any consequences of macrophage infection are likely to be 
prolonged, and this covert reservoir may persist after HAART (Stevenson, 2003). It has 
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recently been reported that cell-to-cell spread of virus can continue after HAART (Sigal 
et al., 2011), which highlights the potential significance of this reservoir in HIV-1 
persistence. Infection of macrophages might also contribute to HIV-1 pathology by 
causing bystander apoptosis of T cells (Badley et al., 2000) and neurons (Kaul et al., 
2001), which may be due to increased expression of death receptor ligands such as 
Fas ligand on infected macrophages (Dockrell et al., 1998). Furthermore, it has been 
reported that macrophages harboring HIV-1 infection have altered functionality in a 
number of ways which may contribute to immunopathogenesis, discussed 
subsequently in section 1.3.9.  
In addition to evidence demonstrating that HIV-1 infection of macrophages 
occurs in vivo and has functional consequences, a broader perspective on the 
significance of HIV-1 macrophage tropism exists. It is clear that infection of CD4+ T 
cells is a central feature of HIV-1 pathogenesis, as this is the compartment wherein the 
vast majority of viral replication takes place in vivo (Towers and Noursadeghi, 2014). 
However, this infection is often abortive and cytopathic (Doitsh et al., 2013, 2010), 
whereas the virus appears to be more highly adapted to macrophages as a host cell, in 
which it does not trigger cell death or an IFN response and establishes a productive 
infection (Cassol et al., 2006; Tsang et al., 2009). As such, it has been proposed that 
the virus has specifically evolved to establish this quiet but productive infection in 
macrophages, suggesting that they may be a critical host cell for HIV-1 to maximise its 
own replication or persistence in some context (Towers and Noursadeghi, 2014). 
 Evidence from other animals also indicates that macrophages can drive 
lentiviral pathogenesis. Visna-maedi virus (VMV), which infects sheep, and caprine 
arthritis encephalitis virus (CAEV), which infects goats, are both retroviruses of the 
genus Lentivirus, like HIV-1 (Blacklaws, 2012). They present clinically as slowly 
progressing inflammatory conditions: VMV is characterised by chronic pulmonary 
inflammation, a wasting syndrome and neurological disease (Sigurdardottir and 
Thormar, 1964; Thormar, 2013), while CAEV presents with inflammatory arthritis and 
neurological disease (Narayan and Cork, 1985). Importantly, VMV and CAEV do not 
infect lymphocytes, but only cells of the monocyte/macrophage lineage (Anderson et 
al., 1983; Blacklaws, 2012; Narayan et al., 1982), suggesting that the inflammatory 
disease processes are purely driven by infection of these cells. Although their clinical 
courses are clearly distinct from HIV-1, it is speculated that shared clinical features 
(wasting and neurological involvement) may also be driven by macrophage infection in 
HIV-1 infection (Forsman and Weiss, 2008). These conditions also provide a proof of 
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principal, in terms of infected macrophages contributing to disease in lentiviral 
pathogenesis. 
1.3.9  Modulation of macrophages by HIV-1 
Due to the role of macrophages as key immune sentinel and effector cells 
(section 1.2.5–1.2.9), there has been considerable interest in assessing whether these 
functions are disrupted by HIV-1 infection, as this has the potential to contribute to HIV-
1-associated immunopathogenesis (Noursadeghi et al., 2006a). Various investigations 
have been made into the function of MDMs and ex vivo tissue macrophages from HIV-
1+ individuals, reporting a range of phenotypes, such as impaired phagocytosis 
(Chaturvedi et al., 1995; Koziel et al., 1998; Torre et al., 2002; Wehle et al., 1993); 
conserved phagocytosis (Elssner et al., 2004; Gordon et al., 2001); impaired cytokine 
release (Gordon et al., 2005; Nicol et al., 2008; Tachado et al., 2005); increased 
cytokine release (Gordon et al., 2007; Millar et al., 1991; Trentin et al., 1992); and 
impaired apoptosis (Patel et al., 2009). However, as the burden of infection in 
monocytes and macrophages in vivo is not uniform, it is likely that many of the cells in 
these studies were not actually HIV-1-infected, and so it is difficult to assess whether 
these phenotypes are directly caused by the virus or result from indirect effects of the 
virus on the host immune response (Noursadeghi et al., 2006a). 
Other studies have used in vitro models of HIV-1 infection in MDMs, ex vivo 
AMs or macrophage cell lines, to establish more conclusively that observed 
phenotypes result from HIV-1 infection. The range of described phenotypes is 
summarised in Table 1.10, and include effects on phagocytosis, microbicidal killing, 
autophagy, inflammatory responses and apoptosis. These phenotypes have the 
potential to contribute to disease, particularly in the context of opportunistic infections. 
However, due to the range of models used (different time-points, methods of MDM 
differentiation, HIV-1 strains used, etc), it is challenging to draw many overarching 
conclusions from this body of work. Identifying mechanisms for phenotypes in terms of 
their HIV-1 determinants may lend confidence; for example, it is reported that some 
inhibitory effects on phagocytosis are Nef-dependent (Mazzolini et al., 2010). 
Corroboration of phenotypes in vivo is also likely to be an important step in determining 
whether they contribute to disease, and recently developed methods for quantifying 
HIV-1 infection in ex vivo AMs from HIV-1+ individuals has allowed specific assessment 
of their phagocytic function (Jambo et al., 2014). 
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Effects of HIV-1 accessory proteins in modulating signalling pathways involved 
in innate immunity have also been described, which could potentially contribute to HIV-
1 dysregulation of macrophages; these include inhibition of NFκB signalling by Vpu and 
Vpr (Bour et al., 2001; Muthumani et al., 2005), and multifaceted effects on signalling 
and receptor expression by Nef (Aiken et al., 1994; Tachado et al., 2005; Vigerust et al., 
2005). However, these effects have mainly been described in cell lines or in T cells, 
and their relevance to macrophage function, innate immune responses and particular 
HIV-1-dysregulated phenotypes remains to be assessed.  
As it has been shown in two independent assessments that HIV-1 does not 
modulate the baseline transcriptome of macrophages (Maddocks et al., 2009; 
Noursadeghi et al., 2009), and it is known that it does not trigger innate immunity or 
cause baseline cytotoxicity in these cells (Cassol et al., 2006; Rasaiyaah et al., 2013), 
effects of the virus are likely to be evident in altered innate immune responses, rather 
than in changes in resting activity. A hypothesis for why the virus might act to alter 
innate immune signalling in macrophages is presented by the observation that these 
pathways can modulate HIV-1 replication via effects on viral transcription (Chen et al., 
1997; Perkins et al., 1994, 1993; Williams et al., 2007). Therefore, it is possible that 
HIV-1 may have evolved to modulate inflammatory pathways to maximise its own 
replication; further evidence for this comes from studies using HIV-1/Mtb co-infected 
macrophages, discussed subsequently in section 1.4.5. 
 Clearly, if HIV-1 modulates macrophage function in vivo in the ways it has been 
described to in vitro, this may contribute to immune dysfunction in HIV-1 infection, and 
in particular affect CMI pathways in which macrophage function is integral. One 
scenario in which this would be likely to contribute is in TB, as CMI is critical in control 
and pathogenesis of Mtb, for which macrophages also act as host cells. 
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Phenotype Experimental model Reference
Uptake and microbicidal killing
Increased intracellular growth of 
Mycobacterium avium
MDM infected with full-length HIV-1 Kallenius et al. (1992)
Impaired phagocytosis of Candida 
albicans
MDM infected with full-length HIV-1 Crowe et al. (1994)
Impaired phagocytosis and killing of 
Toxoplasma gondii
MDM infected with full-length HIV-1 Biggs et al. (1995)
Impaired phagosome-lysosome fusion MDM infected with full-length HIV-1 
or treated with gp120
Moorjani et al. (1996)
Impaired killing of Cryptococcus 
neoformans
Ex vivo AMs infected with full-length 
HIV-1
Ieong et al. (2000)
Increased intracellular growth of Mtb MDM infected with full-length HIV-1 Imperiali et al. (2001)
Impaired complement-mediated 
phagocytosis
MDM infected with full-length HIV-1 Azzam et al. (2006)
Impaired intracellular killing of Leishmania MDM infected with full-length HIV-1 Barreto-de-Souza et al. 
(2006)
Impaired FcR-mediated phagocytosis MDM infected with full-length HIV-1 Leeansyah et al. (2007)
Interaction with autophagy pathways MDM infected with full-length HIV-1 Kyei et al. (2009)
Impaired phagocytosis due to 
perturbations in endosomal remodelling
MDM infected with full-length HIV-1 Mazzolini et al. (2010)
Increased intracellular growth of 
mycobacteria
MDM infected with full-length HIV-1 Pathak et al. (2010)
Impaired phagocytosis Ex vivo small AMs from HIV-1+ 
individuals confirmed to be infected 
with HIV-1 by FiSH
Jambo et al. (2014)
Inflammatory responses
Impaired LPS-induced MAP kinase 
activation, NFκB binding to the IL-12p40 
promoter & IL-12 production
Macrophage cell line infected with 
full-length HIV-1
Chambers et al. (2004)
Reduction in co-stimulatory molecule 
expression
MDM treated with HIV-1 Vpr Muthumani et al. (2005)
Reduction in mannose receptor expression MDM expressing HIV-1 Nef Vigerust et al. (2005)
Impaired LPS-induced TNFα release Macrophage cell line harbouring HIV-
1 provirus
Tachado et al. (2005); 
Nicol et al. (2008)
Impairment of TNFα release and apoptosis 
in response to Mtb
Macrophage cell line harbouring HIV-
1 provirus and ex vivo AMs infected 
with HIV-1
Patel et al. (2007)
Attenuation of classical NFκB signalling 
but broadly preserved downstream 
transcriptional response
MDM infected with full-length HIV-1 Noursadeghi et al. (2009)
Increased pro-inflammatory cytokine 
production in response to Mtb
MDM infected with full-length HIV-1 Pathak et al. (2010)
Activation of the inflammasome leading to 
IL-1β and IL-18 production
MDM cultured with plasma from 
viraemic HIV-1+ patients
Chattergoon et al. (2014)
Table 1.10: Reported effects of HIV-1 on macrophage innate immune responses. 
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1.4 Tuberculosis 
1.4.1  Epidemiology, clinical course and treatment of TB 
TB, the disease caused by Mtb, has been present in human populations for at 
least 2000 years (Russell, 2007; Zink et al., 2003). Advances in public health and 
antibiotic therapy throughout the 20th century reduced the mortality attributed to TB 
(Lawn and Zumla, 2011), but the global burden of TB disease remains substantial. In 
2012, 8.6 million new cases of TB occurred worldwide, and 1.3 million deaths were 
attributed to the disease (WHO, 2013b). This burden is disproportionately found in low- 
and middle-income countries, but high TB incidence is also observed in urban centres 
in some high-income countries, including the UK (Abubakar et al., 2011; Hayward et al., 
2003). The global distribution of the TB pandemic is co-incident with the HIV-1 
pandemic, leading to a huge burden of morbidity and mortality associated with TB/HIV-
1 co-infection in sub-Saharan Africa (Lawn and Churchyard, 2009). 
Current estimates suggest that approximately 10% of individuals exposed to 
Mtb will develop active TB in their lifetime, whereas the remaining 90% either contain 
the pathogen as a latent infection, or potentially clear the infection, although the latter 
scenario may be difficult to conclusively prove (O’Garra et al., 2013). Two billion 
individuals worldwide are estimated to have latent TB (Zumla et al., 2013). Within the 
10% of exposed individuals who develop active TB, half are estimated to do so within 
18 months of exposure; designated as primary progressive disease (Zumla et al., 
2013). The remainder initially contain the infection latently, and then go on to develop 
active disease due to reactivation (Zumla et al., 2013).  
Mtb transmission occurs via the respiratory route, and the majority of TB 
disease is pulmonary, with archetypal symptoms including cough, increased sputum 
production, fever, weight loss, night sweats and haemoptysis (Zumla et al., 2013), 
along with pulmonary features evident on chest X-ray such as lung lesion cavitation 
and thoracic lymphadenopathy (O’Garra et al., 2013). Extra-pulmonary presentations 
of TB are also relatively common, enumerating 10-42% of patients depending on the 
at-risk group. The manifestations of extra-pulmonary disease can be extremely varied 
and preclude simple diagnosis; in fact, diagnosis of TB is often challenging, due to 
sharing of cardinal clinical features with other diseases such as sarcoidosis and cancer 
(O’Garra et al., 2013). Microbiological confirmation forms the backbone of diagnosis, 
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although the challenges inherent in culturing the bacterium also present difficulties 
(Lawn and Zumla, 2011; Zumla et al., 2013). 
Current standard care for drug-sensitive active TB is quadruple antibiotic 
therapy with isoniazid, rifampin, ethambutol, and pyrazinamide (Zumla et al., 2013). 
The emergence of multi-drug resistant (MDR)-TB, enumerating approximately 5% of 
cases annually (WHO, 2013b), has meant that an additional 17 anti-microbial agents 
are used therapeutically (Zumla et al., 2013). Immunotherapy for TB has previously 
been evaluated, but has not been cemented as a therapeutic option, with a need for 
further assessment in randomised controlled trials (Uhlin et al., 2012). Treatment 
targeting active TB immunopathology is commonly used in one context, wherein 
corticosteroids are used as adjunctive treatment for TB meningitis (Thwaites et al., 
2004). Increasing interest in host-directed immunotherapy exists, after it was 
demonstrated that the outcome of corticosteroid therapy in TB meningitis was 
dependent on host genotype (Tobin et al., 2012). 
The bacilli Calmette-Guerin (BCG) vaccine for TB has been available for nearly 
100 years, but its efficacy varies between groups and wanes over time (Lawn & Zumla 
2011). It may be effective in preventing disseminated disease in infants, but its value is 
limited in preventing adult pulmonary infection (Colditz et al., 1994; Trunz et al., 2006). 
The first TB vaccine efficacy trial since BCG, which tested the vaccine-modified 
Vaccinia virus Ankara expressing antigen 85A (MVA85A), reported no protective effect 
after promising results in pre-clinical studies (Tameris et al., 2013). When considering 
the complexity of the immune response to Mtb, in that immunocompetent individuals 
with latent TB develop an immune response which is protective in preventing active 
disease, but the development of active TB in other individuals involves an immune 
response which causes immunopathology (discussed in section 1.4.3), the challenges 
are clear for developing a vaccine which can induce an immune response with this 
critical balance between protection and pathogenesis (Andersen and Woodworth, 
2014). 
Chapter 1 Introduction 
 
71 
 
1.4.2 Mtb and parasitism of macrophages 
In 1882, Robert Koch identified the infective aetiological agent of tuberculosis, the 
tubercle bacillus, by staining fine rod-like bacilli in tuberculous material from infected 
animals (Sakula, 1982). This agent, known now as Mycobacterium tuberculosis, is an 
aerobic, acid-fast, non-motile, unencapsulated bacterium which replicates slowly and 
has a lipid-rich cell wall characteristic of mycobacteria (Lawn and Zumla, 2011). Mtb is 
a facultative intracellular pathogen, and its primary host cell is the macrophage 
(Russell et al., 2010). Macrophage uptake of Mtb is the initial host-pathogen interaction 
that occurs after aerosol Mtb transmission, when alveolar macrophages internalise 
inhaled bacilli (Russell et al., 2010). This occurs by phagocytosis mediated via 
receptors such as scavenger, complement and mannose receptors (Schäfer et al., 
2009). This host-driven process is rapidly hijacked by the pathogen: Mtb arrests 
maturation of the phagosome, hence preventing early macrophage-mediated killing 
and limiting the hostility of the intracellular environment (Russell, 2007).  
Mtb then persists within the early endosomal system in macrophages, wherein it 
can access nutrients for growth (Russell et al., 2010). Despite phagosome arrest, 
macrophage activation can deliver Mtb to bactericidal environments and lead to killing 
(Russell, 2007). In humans, autophagy pathways may be critical for this process, in 
which arrested phagosomes are targeted via the autophagosome to acidified 
lysosomes, wherein the bacterium can be degraded by acidification, antimicrobial 
peptides and hydrolases (Alonso et al., 2007; Gutierrez et al., 2004; Russell et al., 
2010). Activation of macrophages by TLR ligands and IFNγ may activate or enhance 
autophagy (Delgado et al., 2008; Singh et al., 2006). The importance of intracellular 
killing of Mtb in human macrophages is also demonstrated by the association of CGD 
(in which NADPH oxidase mutations lead to impaired respiratory burst killing in 
phagocytes) and predisposition to TB (Bustamante et al., 2011; Lee et al., 2008). 
Mtb parasitism of macrophages may cause cell death, and it is apparent that 
macrophage cell death occurs in TB pathogenesis, as dead or dying macrophages are 
observed in vivo within granulomata (Ramakrishnan, 2012). However, the contribution 
of different cell death pathways to this remains ill-defined. Some evidence indicates 
that Mtb is anti-apoptotic in macrophages, diverting the cell to death by necrosis (Gan 
et al., 2008), and that this process is associated with virulence (Velmurugan et al., 
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2007). Mtb may also directly induce necrosis (Divangahi et al., 2009). Conversely, 
some reports show that Mtb and other mycobacteria promote macrophage apoptosis 
(Davis and Ramakrishnan, 2009; Keane et al., 1997). Which of these pathways is more 
advantageous for the bacterium is not clear. Necrosis may confer more benefit, as 
uncontrolled intracellular replication followed by cell lysis promotes extracellular 
propagation of high bacillary loads, whereas apoptosis may be a form of innate 
defence and reduce Mtb viability (Behar et al., 2011; Keane et al., 2000). However, 
apoptosis has been shown to facilitate transmission to new host macrophages as a 
result of phagocytosis of apoptotic fragments containing viable bacilli (Davis and 
Ramakrishnan, 2009). The association between active TB and necrotic phenotypes in 
granulomata (Ramakrishnan, 2012) suggests that necrosis may be a particularly host-
detrimental process. 
1.4.3 TB pathogenesis and the immune response 
It is known that the immune system, and in particular CMI, is important in 
protection against TB. Many known TB risk factors demonstrate the importance of CMI 
in protecting against TB disease. Firstly, the existence of MSMD conditions, in which 
patients have genetic mutations in CMI effectors such as IFNγ, the IFNγ receptor and 
IL-12 (see table 1.1). Although these conditions have mainly been described to confer 
susceptibility to less virulent non-tuberculous mycobacteria, they have also been 
shown to be associated with severe tuberculosis in some patients with mutations in IL-
12p40, IL-12Rβ1 and IFNGR1 (Abel et al., 2014; Boisson-Dupuis et al., 2011; de 
Beaucoudrey et al., 2010; Dorman et al., 2004; Picard et al., 2002; Sasaki et al., 2002). 
Thus, MSDM highlights the importance of these effectors of CMI in the response to TB. 
Further evidence is provided by some polymorphisms in genes related to CMI 
components which are associated with increased TB risk, such as IL12B1, IFNG and 
MBL (Lawn and Zumla, 2011; Maartens and Wilkinson, 2007). 
Some iatrogenic TB risk factors also demonstrate the protective role of the 
immune response in TB, such as the increased risk of active TB in patients on anti-
TNFα antibody therapy (Keane et al., 2001) or corticosteroids (Lawn and Zumla, 2011). 
However, the most clear example of immune dysfunction increasing TB risk is 
observed in HIV-1 infection, which is the strongest single risk factor for active TB 
(Walker et al., 2013). As HIV-1 is characterised by immune defects, this strongly 
indicates that alterations in the immune response impact on both TB risk and the 
natural history of the condition, and so in some capacity the immune response must be 
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protective. However, it is also clear that we do not yet understand the correlates of 
immune protection in TB, and precisely what components of immunity mediate 
protection (O’Garra et al., 2013). This is complicated by the fact that the pathogenesis 
of TB disease is driven by the immune response; the hallmark of disease is the 
caseating granuloma, a classic focus of CMI (Dannenberg, 1994; Dannenberg et al., 
1968), and immune-mediated tissue destruction is strongly implicated in active disease 
(Elkington et al., 2011).  
The archetypal drivers of CMI, Th1-polarised CD4+ T cells, are suggested to be 
necessary for protection against Mtb, due to studies of their deficiency in mouse 
models (Leveton et al., 1989) and their depletion in HIV-1+ individuals. However, 
whether they are sufficient for protection is unclear, and the effector functions they 
utilise to mediate this protection are not defined (Sakai et al., 2014). For example, the 
contribution of IFNγ production by CD4+ T cells is unclear, as it has not been found to 
correlate with BCG-induced immune protection against Mtb (Kagina et al., 2010), and 
protection mediated by CD4+ T cells was independent of IFNγ in a mouse model 
(Gallegos et al., 2011). IFNγ may also be produced by cytotoxic CD8+ T cells, and this 
may contribute to protection (Tascon et al., 1998). Overall, the relative contributions of 
CD4+ and CD8+ T cells to anti-mycobacterial immunity via CMI remain unclear. The 
fact that most individuals exposed to TB, including those with active disease, develop a 
TB-specific Th1 response as evidenced by positive IFNγ release assays (IGRAs) and 
tuberculin skin tests (TSTs) also demonstrates that although a Th1 response is 
necessary for protection against TB due to risk factors as discussed above, it is not 
sufficient for protection, as active disease occurs in its presence.  
This has raised the question of what other immune components contribute to 
protection. A range of cytokine signalling axes which can modulate the function of CMI 
have been implicated in this. An overarching theme is observed with regard to these 
cytokines modulating CMI to produce a balanced inflammatory response which can 
induce protection without immunopathogenesis. This is exemplified by investigations 
into the role of TNFα in the zebrafish M. marinum model, in which it is demonstrated 
that either too little or too much production of TNFα can drive disease, whereas the 
“just-right” amount of TNFα is protective (Roca and Ramakrishnan, 2013; Tobin et al., 
2012)  – a so-called “Goldilocks effect” (Andersen and Woodworth, 2014). The 
downstream effects of either low or high TNFα result in macrophage necrosis and 
uncontrolled extracellular replication of bacteria (Roca and Ramakrishnan, 2013), and 
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the potential relevance of this phenotype to human TB has been confirmed via genetic 
studies of homologues of implicated factors (Tobin et al., 2012).  
TNFα dysregulation in this zebrafish model is caused by various eicosanoid lipid 
mediators (Tobin et al., 2012). The anti-mycobacterial functions of the cytokine IL-1β 
(Fremond et al., 2007) have also been shown to be mediated by eicosanoid induction. 
Again, counter-regulation of pro- and anti-inflammatory pathways is found to be key in 
this mechanism, as these lipid mediators act by limiting the anti-inflammatory effects of 
another group of cytokines, type I IFNs (Mayer-Barber et al., 2014). Signatures of type 
I IFN responses, and by implication their immunosuppressive functions (Guarda et al., 
2011; Reboldi et al., 2014), have been described to distinguish active TB from latent 
controlled infection in peripheral blood gene expression profiles (Berry et al., 2010), 
lending support to the hypothesis that they are host-detrimental in mycobacterial 
infection (Teles et al., 2013). In this regard, they have been strongly associated with 
the anti-inflammatory cytokine IL-10 and are suggested to induce its expression (Teles 
et al., 2013), although this is yet to be conclusively demonstrated. The role of IL-10 in 
the response to tuberculosis is a matter of some investigation and is discussed 
subsequently in section 1.5.4. 
Overall, these investigations have begun to describe a system in which the 
protective immune response to Mtb involves a CMI response driven by CD4+ T cells 
and IFNγ, in the context of a cytokine and lipid mediator mileu which appropriately 
regulates the burden of inflammation caused by this response, while also ensuring it 
can mediate protection against the pathogen – a balanced inflammatory response. 
Dysfunction of CMI, due to deficiency or aberrant immunoregulation, is then suggested 
to lead to active TB, by disrupting this balance with consequences for bacterial growth 
and immunopathology. 
Studies of the site of TB disease in granulomata have lent support to this 
concept. The granuloma is driven by CMI, and is implicated in both containment of Mtb 
and in immunopathology (Russell et al., 2009). Contexts in which well-formed 
granuloma are not generated are associated with severe disseminated TB, such as in 
immunosuppressed HIV-1+ individuals (Lawn and Zumla, 2011), or TNFα-deficient 
mouse models (Bean et al., 1999), showing that the CMI response in TB granuloma 
can contribute to protection. However, inappropriate inflammation, such as that causing 
macrophage cell death by necrosis (Roca and Ramakrishnan, 2013) may lead to 
instability of the granuloma and thus compromise protection; clinical observations 
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indicate that necrosis and liquefaction in granulomata are associated with active TB 
(Ramakrishnan, 2012). Dysregulated inflammation at the site of disease may also 
contribute to tissue destruction and cavitation, for example by production of matrix 
metalloproteinases (Elkington et al., 2011).  
Studies in the macaque Mtb infection model have also demonstrated that the 
CMI response in granulomata can contribute to active disease, by demonstrating the 
heterogeneity of granulomata in vivo. Animals with both latent and active infection were 
shown to have a spectrum of lesion types, from healed fibrous sterile lesions, to 
caseating lesions with high bacillary burdens (Lin et al., 2014, 2009). However, in 
animals with active disease, there were more caseating granulomata with extensive 
tissue pathology (Lin et al., 2014). This indicated that the granulomatous CMI response 
had the potential to contain bacteria and sterilize sites of disease in all animals, but that 
stochastic degenerative events in individual granulomata caused some animals to 
develop active disease.  
It can be assumed that the nature of the immune response contributes to these 
stochastic determinants of granuloma degeneration, and resulting active disease, and 
that risk factors such as HIV-1 which dysregulate CMI increase the likelihood that the 
immune response at the site of TB disease will not be appropriately balanced to 
mediate microbial killing without exacerbated inflammation. Considering the nature of 
TB disease in HIV-1+ individuals lends support to this, as the natural history of TB is 
drastically altered by HIV-1 co-infection. 
1.4.4  HIV-1 and TB 
TB co-infection is the leading cause of death in HIV-1+ individuals (UNAIDS, 
2013). Globally, the incidence of active TB in HIV-1+ individuals is approximately twenty 
times greater than in HIV-1− individuals (Lawn and Churchyard, 2009), and risk is 
increased in all HIV-1+ patients, including those with preserved CD4+ counts 
(Sonnenberg et al., 2005). HIV-1 co-infection severely alters the natural history of TB. 
Although HIV-1+ individuals with preserved CD4+ counts may present with typical 
pulmonary TB, those with CD4+ counts of less than 200/mm3 often have atypical 
presentations of pulmonary TB and extra-pulmonary manifestations (Zumla et al., 
2013). Individuals with severely depleted CD4+ counts (<50/mm3) often present with 
disseminated TB disease, characterised by a non-specific febrile illness with 
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widespread organ involvement and mycobacteraemia (Domoua et al., 1995; Elliott et 
al., 1993; Gilks et al., 1990; von Reyn et al., 2011). 
In addition to aberrant clinical phenotypes, the underlying pathology of TB may 
be altered in HIV-1+ individuals. Radiological features of pulmonary TB have been 
reported to be different, with less consolidation, apical involvement and 
bronchopulmonary spread, but higher rates of pleural effusions and lymphadenopathy 
(Lawn et al., 1999). Tissue pathology studies have also described altered phenotypes, 
particularly in severely immunosuppressed patients where granulomata are often 
absent or poorly formed (Lawn and Zumla, 2011). Other observations from the site of 
disease in HIV-1+ individuals, when compared to HIV-1− individuals, have shown 
increased granuloma necrosis and polymorphonuclear cell infiltration (de Noronha et 
al., 2008); increased TNFα levels and necrosis in pleural granulomata (Bezuidenhout 
et al., 2009); increased rates of apoptosis in cells from pleural fluid (Hirsch et al., 
2001); and a paucity of inflammation accompanied by many extracellular bacilli in 
tuberculous lymphadenitis biopsies (Nambuya et al., 1988). Although TB tissue 
pathology may not be atypical in relatively immunocompetent HIV-1+ individuals 
(Walker et al., 2013), there is clearly a spectrum of pathology associated with HIV-1 
that illustrates potent dysregulation of anti-mycobacterial immune responses by the 
virus. 
This poses the question of which of the immune responses that are affected by 
HIV-1 mediate these effects on TB natural history? CD4+ depletion does correlate with 
increased rates of atypical TB presentation (Zumla et al., 2013), and the extent of initial 
CD4+ depletion by SIV correlates with the time to TB reactivation in the macaque 
model of SIV/TB co-infection (Diedrich et al., 2010; Mattila et al., 2011). Low numbers 
of CD4+ cells are observed at the site of disease in HIV-1+ patients, indicating that 
systemic depletion does translate into differences in in situ CMI responses (Law et al., 
1996). Additionally, Mtb-specific T cells may be preferentially depleted by HIV-1 due to 
their higher CCR5 expression, meaning that TB risk would be hypersensitive to CD4+ 
loss (Geldmacher et al., 2012, 2010).  
However, the increased risk of TB in HIV-1+ individuals before CD4+ depletion 
has strongly indicated that other changes in immune function may also contribute to 
disease risk. One hypothesis is that T cell function is altered in a way that 
compromises TB protection (O’Garra et al., 2013), and investigations have shown that 
the frequency of polyfunctional mycobacteria-specific T cells (i.e. those producing 
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IFNγ, TNFα and IL-2) are lower in the lungs of HIV-1+ individuals compared to healthy 
individuals, although this study was not performed in patients with active TB (Kalsdorf 
et al., 2009). Another report in HIV-1+ individuals with ongoing active TB showed 
increased numbers of polyfunctional T cells at the site of disease (Matthews et al., 
2012), and no consensus has yet emerged about the contribution of T cell functionality.  
An alternative hypothesis is that dysfunction of HIV-1-infected macrophages 
contributes to increased TB risk, and this is further discussed in section 1.4.5. Other 
proposed mechanisms include dysregulation of MMPs in HIV-1+ individuals causing 
tissue damage, although observations that MMP levels are lower in the sputum of HIV-
1+ active TB patients do not support this suggestion (Walker et al., 2012). Finally, the 
increased rates of HIV-1 replication which are observed at the site of TB disease (Lawn 
et al., 2001; Nakata et al., 1997) has suggested that a direct effect of viral replication in 
situ may exacerbate immunopathology (Diedrich and Flynn, 2011), although the 
mechanisms by which this would compromise control are unclear. 
No all-encompassing theory of how HIV increases TB risk has yet emerged. It is 
likely that several factors contribute to this interaction (Diedrich and Flynn, 2011), and 
the diversity of clinical presentations & pathology observed in HIV-1/TB co-infection 
may reflect the diverse effects of HIV-1 on the immune response (Walker et al., 2013). 
The fact that HIV-1 is the strongest known risk factor for TB suggests that the parts of 
the immune system which are dysregulated by HIV-1, including those involved in 
mediating CMI, are essential for protection against active TB. Increased understanding 
of how HIV-1 modulates CMI is therefore critical for understanding HIV-1/TB co-
infection pathogenesis. The role of macrophages, as a host cell for both HIV-1 and Mtb 
infection, may be critical in this. 
1.4.5  Macrophages, HIV-1 and Mtb 
 Both HIV-1 and Mtb parasitize macrophages in vivo as a niche for growth and 
persistence which may contribute to disease. It is possible that co-infection of 
macrophages by both pathogens may take place in vivo, particularly in the respiratory 
tract wherein both may infect AMs. This has posed the question of whether the 
increased risk of TB in HIV-1+ individuals may result from dysregulation of 
macrophage/Mtb interactions by HIV-1 co-infection. As discussed in section 1.3.9, 
HIV-1 infection of macrophages may result in a range of dysregulated phenotypes, 
including some involving Mtb. These include increased intracellular growth of Mtb in 
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HIV-1 infected MDMs (Imperiali et al., 2001; Pathak et al., 2010), which may be due to 
effects of HIV-1 on autophagic pathways which are critical in macrophage control of TB 
(Gutierrez et al., 2004; Kyei et al., 2009). Exaggerated pro-inflammatory responses and 
dysregulation of apoptosis have also been reported in HIV-1/Mtb co-infected 
macrophages (Patel et al., 2007; Pathak et al., 2010).  
HIV-1 replication is also reported to be modulated in co-infected macrophages, 
although there has been some controversy about whether Mtb promotes viral 
replication (Honda et al., 1998; Hoshino et al., 2004, 2002; Toossi et al., 1997) or 
inhibits it (Goletti et al., 2004; Weiden et al., 2000). Reports from sites of TB disease in 
vivo in co-infected individuals have shown high levels of HIV-1 (Collins et al., 2002b; 
Lawn et al., 2001; Nakata et al., 1997), and a mechanism involving Mtb activation of 
the transcription factor NFAT and subsequent transactivation of the HIV-1 LTR has 
been described (Ranjbar et al., 2012); these observations support the concept that 
HIV-1 replication increases in co-infected macrophages, although this is likely to vary 
with temporal and Mtb-strain-specific conditions (Ranjbar et al., 2009). 
Previous work in our group has investigated the consequences of HIV-1/Mtb 
co-infection of macrophages, using a well-characterised in vitro MDM model in which 
confluent HIV-1 infection can be established (Noursadeghi et al., 2009). This work has 
found that expression of the anti-inflammatory cytokine IL-10 in response to Mtb is 
attenuated in HIV-1 infected macrophages, potentially as a result of attenuated 
signalling through MAP kinase pathways (Tomlinson et al., 2014) – a previously 
unreported phenotype. This deficiency in IL-10 was associated with exaggerated and 
sustained pro-inflammatory macrophage responses to Mtb. These in vitro data were 
mirrored by identification of lower levels of IL-10 and higher levels of pro-inflammatory 
IL1 in respiratory samples from HIV-1 infected patients with pulmonary TB in 
comparison to non-tuberculous respiratory infections, suggesting that the same 
immunological phenotype may occur in vivo.  
Attenuation of IL-10 by HIV-1 might be caused by a novel host/virus interaction 
affecting common macrophage IL-10 induction pathways, and so this observation 
might also be applicable in responses to other co-infecting pathogens. IL-10 is known 
to have a range of potent immunomodulatory functions (described further in section 
1.5), and so this phenotype may have consequences which contribute to dysregulation 
of CMI and immunopathogenesis in HIV-1/TB co-infection. Therefore, further 
characterisation of this phenotype and its consequences, and identifying the 
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mechanism by which HIV-1 causes IL-10 attenuation merits further investigation, which 
may also provide insight into the regulation of IL-10 responses in macrophages. 
1.5 Interleukin-10 
1.5.1 The IL-10 and IL-10 receptor family 
Although most cytokines induce pro-inflammatory or immune-activating 
processes, several have been identified that have anti-inflammatory activities which are 
essential for producing a balanced immune response capable of pathogen clearance 
with limited immunopathology. Among these, interleukin-10 (IL-10) is considered to be 
non-redundant in the initial anti-inflammatory component of the immune response (Iyer 
and Cheng, 2012). IL-10 is a homodimeric secreted protein produced by immune cells, 
which mediates potent negative regulation of immune responses by gene-specific 
transcriptional repression and up-regulation of factors that modulate immune signalling 
pathways (Iyer and Cheng, 2012; Moore et al., 2001). It was first identified as a factor 
produced by Th2 CD4+ T cells, which was capable of suppressing Th1 responses, and 
was subsequently found to be produced by other cells including B cells, mast cells and 
macrophages, and to be broadly suppressive with regard to many cell types (O’Garra & 
Murphy, 2009). 
The human IL-10 protein is relatively highly conserved, with 73% homology to 
mouse IL-10, and has an α-helical bundle structure classic of many cytokines including 
IFNs (Moore et al., 2001). The secreted IL-10 homodimer signals via a receptor 
complex made up of IL-10R1 and IL-10R2, of which IL-10R1 is the ligand-binding 
subunit with some signalling activity, and IL-10R2 purely functions in signalling (Moore 
et al., 2001). As IL-10R2 is constitutively expressed in most cells, IL-10R1 expression 
determines IL-10 responsiveness (Moore et al., 2001). IL-10R1 is expressed on most 
haematopoietic cells at relatively low levels, but most highly on macrophages and DCs, 
and its expression can be regulated by cellular activation (Murray, 2006; Tan et al., 
1993). Expression on fibroblasts and in intestinal epithelium has also been observed 
(Denning et al., 2000; Weber-Nordt et al., 1994). Binding of IL-10 to its receptor 
complex initiates a cascade of signalling: the receptor-associated kinases JAK1 and 
TYK2 are phosphorylated and activated, leading to recruitment and phosphorylation of 
STAT3 (Carey et al., 2012; Finbloom and Winestock, 1995; Riley et al., 1999; Rodig et 
al., 1998; Weber-Nordt et al., 1996). Activated STAT3 homodimerises and translocates 
to the nucleus (Pranada et al., 2004) wherein initiates transcription to mediate the 
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downstream functions of IL-10 (described subsequently in section 1.5.3). It should 
also be noted that seven other cytokines, along with IL-10, form the IL-10 cytokine 
superfamily; these cytokines generally signal via other receptors and have a range of 
divergent effects on immunity and inflammation (Commins et al., 2008). 
1.5.2 Regulation of IL-10 production 
IL-10 can be produced by many immune cells in vivo, but T cell subsets and 
MPs such as monocytes, macrophages and cDCs are the main cell types involved 
(Murray, 2006). Most CD4+ T helper subsets can produce IL-10 in some contexts, and 
this is thought to be partly regulated by subset-specific signals (Cretney et al., 2011; 
Saraiva and O’Garra, 2010; Saraiva et al., 2009; Shoemaker et al., 2006). A central 
role for ERK signalling has been suggested (Saraiva et al., 2009), but the mechanisms 
controlling production in T cells are not well delineated (Iyer and Cheng, 2012). 
However, IL-10 induction pathways in macrophages and other MPs downstream of 
pattern recognition have been extensively described, and are thought to involve an 
array of transcriptional and post-transcriptional regulatory mechanisms (summarised in 
Figure 1.3).  
TLR-2 and dectin-1 are central PRRs in IL-10 induction (Kelly et al., 2010; Moreira 
et al., 2008; Netea et al., 2004), and have been shown to be synergistic in this regard 
(Ferwerda et al., 2008). TLR-3, TLR-4, TLR-9 and NOD2 stimulation have also been 
shown to induce macrophage IL-10 production (Boonstra et al., 2006; Moreira et al., 
2008). PRR stimulation activates complex arrays of signalling pathways (section 1.2.6), 
and accordingly IL-10 is regulated via several axes. The MAPK cascades via p38 and 
ERK are thought to be critical (Chanteux et al., 2007; Elcombe et al., 2013; Ma et al., 
2001; Yi et al., 2002), and both signalling strength through this pathway and negative 
regulation of its activity contribute to fine-tuning of IL-10 production (Chi et al., 2006; 
Kaiser et al., 2009; Saraiva and O’Garra, 2010). MAPKs, along with NFκB signalling 
(Banerjee et al., 2006; Gringhuis et al., 2007), calcium-burst signalling downstream of 
dectin-1, CaM kinase II and Pyk2 (Kelly et al., 2010), and some PI3K-stimulated 
pathways (Hu et al., 2006), activate a range of transcription factors which may 
influence IL-10 transcription. These include Sp1, IRFs, CREB, C/EBP, c-MAF and 
NFκB; which of these are necessary and sufficient for IL-10 transcription is still not 
clarified, although Sp1 is suggested to have a critical role (Brightbill et al., 2000). 
Regulation at this level may be highly stimulus-specific (Saraiva and O’Garra, 2010). 
Chromatin remodelling at the IL-10 locus may also influence IL-10 transcription; this 
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has been shown to occur at the IL-10 locus downstream of LPS stimulation of 
macrophages (Saraiva et al., 2005), and histone modifications of the locus also 
contribute to control of expression (Cheng et al., 2014; Villagra et al., 2009). Active 
negative regulation of IL-10 transcription has been demonstrated: suppression by 
factors including CIITA, STAT1 and BCL-6 has been demonstrated, but whether all 
these pathways operate in macrophages is not clear (Saraiva and O’Garra, 2010). The 
IκB protein BCL-3 has been shown to negative regulate IL-10 expression in murine 
macrophages, via regulation of the initiation of IL-10 transcription (Riemann et al., 
2005). 
Post-transcriptional mechanisms also contribute to regulation of macrophage IL-10 
production. Like many other cytokines, IL-10 mRNA has destabilizing motifs in the 3’ 
untranslated region (Powell et al., 2000) and is a target for the RNA-degradation 
mediator, tristetraprolin (Stoecklin et al., 2008). IL-10 regulation by miRNAs, which act 
on mRNA to increase degradation or prevent translation, has also been demonstrated 
downstream of TLR-2 and TLR-4 signalling (Xie et al., 2014). Finally, mechanisms 
acting on translation have been described. The activity of the PI3K pathway, mediated 
by Akt and ultimately through mTOR, has been reported to determine the magnitude of 
IL-10 production via global effects on the efficiency of translation; this allows distinct 
regulation of anti-inflammatory IL-10 production vs. pro-inflammatory cytokine 
production in a phenomenon termed “cytokine biasing” (Ivanov and Roy, 2013; 
Weichhart et al., 2008). 
Another line of evidence suggests that there may be indirect control of IL-10 
production in the innate immune response, via PRR-induced type I IFN production 
which feeds back to induce IL-10 in a circuit which may also involve the production of 
IL-27 (Chang et al., 2007; Iyer and Cheng, 2012). However, other reports suggest that 
type I IFNs can inhibit IL-10 production (Lin et al., 2013), and so this mechanism is not 
yet clarified. However, it is representative of the complex molecular mechanisms which 
control IL-10 expression in macrophages. This complexity is likely to be linked to the 
fine balance which is required in its expression, owing to the potency of its suppressive 
functions.  
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Figure 1.3: Regulation of IL-10 expression in macrophages. 
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1.5.3 Functions of IL-10 
IL-10 signalling activates the transcription factor STAT3, which has been shown to 
be essential for all described functions of IL-10 (Williams et al., 2004; Williams et al., 
2007). The main targets for IL-10 signalling are the MPs: macrophages, DCs and 
monocytes, which express the highest amounts of IL10R1 (Murray, 2006), although 
most other immune cells may respond to IL-10 in some context (Iyer and Cheng, 
2012). IL-10 signalling may occur in a paracrine or an autocrine fashion; autocrine 
signalling in macrophages downstream of PRR activation has suggested to be an 
important auto-regulatory axis (Lang et al., 2002c; Murray, 2006). 
The downstream functions of IL-10/STAT3 signalling have been termed the “anti-
inflammatory response” (AIR), and it has been shown in macrophages that the overall 
outcome of the AIR is selective inhibition of transcription of components of the 
inflammatory response (Murray, 2005). However, STAT3 is a positive transcriptional 
regulator, and mediates the AIR in macrophages indirectly by inducing the transcription 
of “AIR factors”: various transcription factors and signalling modulators which then 
exert the AIR (Hutchins et al., 2012). Some AIR factors have been identified via gene 
expression studies of IL-10 stimulated cells (Antoniv et al., 2005; Hutchins et al., 2012; 
Park-Min et al., 2005; Stumpo et al., 2003), and include molecules such as SOCS3, 
which regulates pro-inflammatory cytokine signalling (Berlato et al., 2002; Niemand et 
al., 2003; Yasukawa et al., 2003); BCL3, which limits the production of TNFα via NFκB 
signalling suppression (Kuwata et al., 2003; Wessells et al., 2004); Zfp36, which 
targets TNFα mRNA for degradation (Gaba et al., 2012; Schaljo et al., 2009); and Nfil3, 
while regulates IL-12 expression (Kobayashi et al., 2011). Suppression of NFκB 
signalling and potent inhibitory effects on TNFα production are common themes of the 
AIR (Chan et al., 2012; Driessler et al., 2004; Smallie et al., 2010). However, the 
suppressive effects of IL-10 are not uniform across the entire pro-inflammatory 
response; a study in mouse macrophages showed that IL-10 negatively regulated 
approximately 15–20% of the response to LPS (Lang et al., 2002a). The significance of 
which components of the inflammatory response are regulated by IL-10, and which are 
not, is not yet clarified (Murray, 2006), and limited data exists investigating the 
intricacies of this pathway in human macrophages. 
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Various cellular phenotypes have been described which result from these 
molecular mechanisms of IL-10 signalling. Macrophages and other APCs, as well as 
being subject to inflammatory response auto-regulation, are suggested to take on an 
anti-inflammatory phenotype (variously described as M2, alternatively activated or 
regulatory; Mantovani et al., 2004). These effects of IL-10 on APCs lead to inhibition of 
Th1-polarised responses (Fiorentino et al., 1991, 1991) and may act to promote 
resolution of inflammation (Ogawa et al., 2008). In T cells, IL-10 signalling may directly 
suppress Th1 effector functions such as IFNγ production, but this mechanism is less 
clear than its indirect modulation of Th1 responses via APCs (Del Prete et al., 1993; 
Redford et al., 2011). Despite its original description as a Th2 factor, IL-10 has also 
been shown to suppress Th2-driven responses in some contexts (Grunig et al., 1997). 
Induction of a Treg phenotype is another described function of IL-10 (Horwitz et al., 
2003), which may potentiate regulatory function via the production of further IL-10. The 
overall effects of IL-10 on B cells and NK cells are less clear; it has been shown to 
modulate activation of these cells in some reports (Go et al., 1990; Itoh and Hirohata, 
1995; Shibata et al., 1998; Stacey et al., 2011). Another key cellular phenotype 
controlled by IL-10 is apoptosis. Its anti-apoptotic functions have been described both 
in vitro and in vivo (Eslick et al., 2004; Geng et al., 2000; Penttilä et al., 2008; Zhou et 
al., 2001), and it may act either directly, or indirectly via TNFα regulation, to mediate 
these (Cyktor and Turner, 2011). 
The potent effects of IL-10 on a range of immune cells suggest its signalling may 
have significant consequences for disease and inflammation. Many studies of 
physiological IL-10 function have been performed in mouse models of IL-10 deficiency, 
signalling blockade, or supplementation, and examples of phenotypes observed in 
these models are presented in Table 1.11. The baseline phenotype of the IL-10 
deficient mouse model is severe spontaneous enterocolitis, and the important role of 
IL-10 in maintaining gut homeostasis has recently been attributed to its effects on gut-
resident macrophages (Kühn et al., 1993; Shouval et al., 2014; Zigmond et al., 2014). 
Various models using inflammatory and infectious challenges have elucidated the 
importance of IL-10 in limiting immunopathology, as deficient mice are 
hypersusceptible to endotoxin-induced shock, contact hypersensitivity, and succumb 
rapidly in some infections due to exacerbated inflammation in the absence of IL-10 
regulation (Berg et al., 1995a, 1995b; Gazzinelli et al., 1996; Hunter et al., 1997; Li et 
al., 1999). However, in some contexts IL-10 is shown to limit control of infections due to 
its suppressive effects on microbicidal functions; this is most clear in the context of 
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persistant viral infections (Brooks et al., 2006; Ejrnaes et al., 2006), but also in bacterial 
infections such as Salmonella enterica serotype Typhimurium and Yersinia pestis 
(Lokken et al., 2014; Sing et al., 2002). The discovery of functional viral IL10 
homologues supports the concept that IL10 expression may confer an evolutionary 
advantage to pathogens in some contexts (Ouyang et al., 2013). An overall picture of 
the role of IL-10 in infections has emerged wherein IL-10 exerts regulation which must 
be limited to allow pathogen clearance, but sufficient to prevent immunopathology 
(Couper et al., 2008). It is suggested that features of particular infections determine the 
net outcome of its signalling; for pathogens which induce lots of inflammation, IL-10 
signalling may be critical in preventing disease, but for persistent pathogens which 
have adapted to avoid killing, IL-10 signalling may exacerbate disease by further 
preventing microbicidal functions (Cyktor and Turner, 2011). 
In humans, the precise role of IL-10 in regulating inflammation is not as well 
elucidated as in mice. Its homeostatic role in the gut is clear, as IL-10 receptor 
mutations have been found in patients with spontaneous severe inflammatory bowel 
disease (Glocker et al., 2009). IL-10 polymorphisms, including promoter haplotypes 
which influence levels of gene expression, have been described which contribute to the 
risk or severitiy of inflammatory and infectious diseases such as graft vs. host disease, 
hepatitis C virus and community-acquired pneumonia (Edwards-Smith et al., 1999; 
Gallagher et al., 2003; Lin et al., 2003; Paladino et al., 2006), and treatment of patients 
with HCV with recombinant IL-10 was shown to limit the tissue damage caused by 
chronic inflammation (Nelson et al., 2000) – again suggesting that IL-10 limits 
damaging immunopathology in humans as well as in mice. 
The potential role of IL-10 in regulating CMI is clear from its described effects in 
modulating macrophage and T cell function, and this is supported by the observation 
that infections by intracellular pathogens such as Listeria monocytogenes, Salmonella 
enterica serotype Typhimurium, Toxoplasma gondii and Toxoplasma cruzii have 
altered phenotypes in mouse models in the context of IL-10 deficiency (Table 1.11). 
Inhibition of macrophage IL-10 production by HIV-1 (section 1.3.9) may therefore have 
substantial consequences for the regulation of CMI, and pathology caused by 
intracellular pathogens such as Mtb. 
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Mouse model Phenotype Reference
IL-10 −/− Spontaneous chronic enterocolitis Kuhn et al. (1993)
Excessive inflammation & death after 
Trypanosoma cruzi infection, but 
improved parasite clearance
Hunter et al. (1997); Holscher et al. 
(2000)
Excessive inflammation & death after 
Toxoplasma gondii infection
Gazzinelli et al. (1996)
Excessive inflammation & death after 
Listeria monocytogenes 
meningoencephalitis
Deckert et al. (2001)
Increased morbidity and mortality in 
malaria infection but improved 
parasite clearance
Li et al. (1999)
Protection against Yersinia pestis 
infection
Sing et al. (2002)
Hypersensitive to endotoxin-induced 
shock
Berg et al. (1995a)
Exaggerated contact hypersensitivity 
response
Berg et al. (1995b)
Impaired resolution of lung 
inflammation
Aggarwal et al. (2014)
Neutralization of IL-10 via 
antibody
Improved control of Salmonella 
typhimurium co-infection during 
malaria infection
Lokken et al. (2014)
Blockade of IL-10 signalling 
by neutralising antibody to IL-
10R
Increased inflammation but improved 
parasite control in Leishmania 
infection
Gonzalez-Lombana et al. (2013)
Resolution of chronic viral infections Ejrnaes et al. (2006); Brooks et al. 
(2006)
IL-10 −/−: 
macrophage/neutrophil-
specific
Enhanced inflammatory response to 
LPS
Siewe et al. (2006)
IL-10 −/−: T cell-specific Excessive inflammation & death after 
Trypanosoma cruzi infection, but 
protected from LPS and skin irritant 
hypersensitivity
Roers et al. (2004)
IL-10 supplementation to 
WT
Protection from endotoxin-induced 
shock
Howard et al. (1993)
Protection from acute induced 
pancreatitis
Kusske et al. (1996)
Table 1.11: Effects of IL-10 on infection and inflammation in mouse models. 
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1.5.4 The role of IL-10 in tuberculosis 
The role of IL-10 in regulating TB disease has been extensively researched 
(Redford et al., 2011). The known functions of IL-10 in regulating Th1 responses and 
macrophage microbicidal functions could clearly impact on control of Mtb; however, it 
also regulates the inflammation associated with TB immunopathology, suggesting that 
the contribution of IL-10 to TB disease may be dichotomous.  Accordingly, 
investigations of TB in mouse models have described a spectrum of phenotypes, from 
those in which IL-10 deficiency improves control of TB with reduced bacterial loads in 
deficient mice (Beamer et al., 2008; Redford et al., 2010; Turner et al., 2002), to those 
in which it is unaffected (Jung et al., 2003; North, 1998), to those in which it 
exacerbates immunopathology (Higgins et al., 2009). Different inbred mouse strains 
are known to have different inherent susceptibilities to Mtb, which may somewhat 
account for this range of observations (Redford et al., 2011). As such it is difficult to 
draw any overall conclusions from this body of work, except from the broad observation 
that dysregulation of IL-10 can compromise TB control or cause immunopathology in a 
context-dependent manner. Differences between human and mouse TB, such as the 
inability to establish latent infection also make it difficult to extrapolate from this model 
to human disease (Flynn, 2006). 
IL-10 is thought to contribute to human TB, as it can be measured at the site of 
disease in active TB patients (Barnes et al., 1993). Studies of IL-10 function in active 
TB patient PBMC have shown that it can inhibit proliferation and IFNγ production by T 
cells (Gong et al., 1996; Zhang et al., 1994). Although this demonstrates the potentially 
suppressive role of IL-10 in TB, it does not provide insight into the potential function of 
IL-10 at the site of disease, in which its roles in regulating resolution, tissue damage 
and apoptosis could be critical. One study has reported that a polymorphism that 
increases the risk of pulmonary TB also increases IL-10 levels, providing some 
indication that it may compromise protection (Awomoyi et al., 2002); however, a 
metaanalysis of the contribution of IL-10 polymorphisms to risk of TB showed no 
overall effect (Pacheco et al., 2008). 
Overall, the postulated function of IL-10 in human TB is mainly still derived from 
knowledge about its functions and how these impact on the immune response to TB. 
As described above, its inhibitory effects on the Th1 axis of immunity have the potential 
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to compromise protection. However, as IL-10 is a potent regulator of TNFα responses 
and apoptosis (Cyktor and Turner, 2011), it seems likely that it may also feed into the 
TNFα-balance and cell death determinants of TB immunopathology (as discussed in 
section 1.4.3), and again may be subject to a “Goldilocks effect” in terms of too much 
or too little IL-10 being damaging. However, this hypothesis has not been formally 
demonstrated. It has also been shown that IL-10 may inhibit phagolysosome 
maturation in Mtb-infected human macrophages (O’Leary et al., 2011), suggesting that 
it may also impact on macrophage parasitism by the pathogen.  
The role of IL-10 in regulating the immune response to TB is clearly complex. 
This is a scenario in which there is substantial host-damaging inflammation, which IL-
10 can regulate, but also in which the pathogen persists and subverts killing, which IL-
10 may compromise. In terms of the effects of HIV-1-mediated IL-10 attenuation for 
HIV-1-associated mycobacterial disease, existing knowledge about the role of IL-10 
mainly indicates that this phenotype has the potential to dysregulate host immunity, but 
the precise downstream consequences are not clear and merit further investigation. It 
should also be noted that due to systemic immune dysfunction in HIV-1 infection, the 
consequences of IL-10 inhibition may have context-specific effects, as the normal role 
of IL-10 in the immune system is likely to be altered by concurrent HIV-1 infection. 
Notwithstanding the complexity of these interactions, investigation of the 
consequences of this potent mechanism of CMI dysregulation by HIV-1 is likely to 
provide valuable insights into pathogenesis in HIV-1/TB co-infection. 
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1.6 Investigating immune responses using transcriptional 
profiling 
1.6.1 Using transcriptional profiling to understand immune responses in 
tuberculosis in vivo 
Of the various –omics technologies, transcriptomics or transcriptional profiling, 
in which the expression of thousands of transcripts is measured simultaneously in one 
sample, has perhaps been used most widely to gain biological insights. The main 
advantage of transcriptional profiling, as with other –omics technologies, is that it can 
provide systems-level insights into biology, with resolution of these systems at the 
molecular level. For investigating cells, transcriptional profiling can provide a broad 
impression of cell state; at the tissue level, it can be used to assess the overall activity 
of tissues in homeostasis and disease. Key insights using transcriptional profiling of 
tissues have been made in a range of human diseases, including cancer and 
autoimmune conditions (Chaussabel et al., 2008; Rhodes et al., 2005). 
As a major human disease in which the immune response remains poorly understood, 
TB is a clear candidate for systems-level analysis via transcriptional profiling. To date, 
this has mainly been performed using peripheral blood samples from active TB patients 
and appropriate comparator groups (latent TB, healthy individuals, etc). Evaluating the 
blood is suggested to be a suitable method, as it contains immune effector cells which 
may traffic from the site of disease (Berry et al., 2013), and various insights have 
indeed been gained from these studies. Dominant IFN signatures driven by neutrophil 
and monocyte activity in the peripheral blood have been identified, which are 
specifically associated with active TB as opposed to latent disease (Berry et al., 2010; 
Maertzdorf et al., 2012; Ottenhoff et al., 2012).  These signatures may have diagnostic 
and therapeutic utility, as they can differentiate TB from some other conditions, and 
may correlate with the resolution of disease throughout chemotherapy (Bloom et al., 
2013, 2012; Cliff et al., 2013). 
However, there are arguably major limitations in studying TB in the peripheral blood. 
The site of disease is known to be crucial in determining disease outcome in TB (Lin et 
al., 2014), and although the blood transcriptome may reflect activity at the disease site 
(as the signatures seen resolve with recovery from active disease; Berry et al., 2013), it 
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clearly has a very different cellular and structural milieu. Regardless of whether the 
blood is an appropriate tissue to study, transcriptional profiling of the site of disease 
would certainly provide further insights into mechanisms of pathogenesis, as it has in 
other settings such as leprosy and transplantation (Cantu et al., 2013; Teles et al., 
2013). However, the site of disease in TB usually has limited accessibility, and so 
collecting appropriate samples for this purpose may be challenging. It may be even 
more challenging to obtain samples which can be robustly evaluated comparatively 
(i.e. to assess the effect of HIV-1 co-infection on TB) which are appropriately controlled 
in terms of time of disease, site of disease and other aspects of disease heterogeneity.  
An approach recently developed by our group to assess anti-mycobacterial immune 
responses in vivo in humans may assist in overcoming these various limitations, by 
using the TST, a classic model of CMI/DTH, as a standardised human challenge 
model, from which RNA samples can be collected and assessed by transcriptional 
profiling. Using this method in healthy individuals has provided a proof-of-concept that 
it can characterise CMI in vivo in an inflamed site, and provide molecular-level insights 
into the anti-mycobacterial immune response (Tomlinson et al., 2011). As a tissue 
model which contains macrophages and infiltrating T cells, it is arguable that it provides 
a stronger surrogate for the site of TB disease than the peripheral blood, although 
clearly aspects of pulmonary inflammation may not be replicated here. However, this 
method provides an attractive option for performing comparative studies of immune 
responses to tuberculosis in vivo in particular groups of patients, for example those 
with HIV-1 co-infection. 
1.6.2 Transcriptional profiling analysis 
To gain reliable insights into biological systems by using transcriptional 
profiling, it is clear that robust analysis methods are required. Traditional methods 
include feature selection analysis, in which statistical testing and fold-change difference 
cut-offs are used to identify differences in transcript levels across gene expression 
profiles. This method is crucial for generating lists of differentially expressed 
transcripts, but does not provide any inherent systems-level insights.  These are 
generally gained by further downstream assessments using bioinformatics methods 
such as pathway, gene ontology or transcription factor binding site enrichment 
analyses.  
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In addition to these supervised methods of exploring transcriptomic data, 
unsupervised clustering methods, such as principal component analysis (PCA), can 
provide powerful insights. PCA is a unsupervised exploratory statistical method which 
can be used to assess variance across a large data set in such a way that retains more 
information than simple hierarchical clustering (Chain et al., 2010; Ringnér, 2008). It 
identifies directions (components) across which the variation in the data is maximal. 
Each sequential principal component (PC) identified by the PCA algorithm describes 
variation in a new direction, which is uncorrelated to the previous components 
identified. PCA can thus be used to gain an impression of the overarching patterns of 
variation within a set of gene expression datasets, by describing multiple distinct 
relationships between samples. The PCA algorithm output assigns each sample a 
numerical value within each identified component (a PC score). This simplifies 
visualisation of the highly multidimensional data, as each sample can be represented 
by a single PC score for each component, rather than by using the many thousands of 
expression values which contribute to this (Ringnér, 2008).  
The power of PCA lies in its ability to deconvolute highly multidimensional gene 
expression data into a restricted set of components which can be used for simple 
cross-sample comparisons. Another method of gene expression data deconvolution is 
modular analysis, which is a powerful method for assessing the activation of pathways 
of biological interest in gene expression profiles. 
1.6.3 Modular analysis of transcriptomic data 
Modular analysis, in which the expression of defined sets of genes of interest is 
measured as a unified variable, has been widely used in recent years for analysis of 
transcriptomic data, initially in the fields of cancer biology and diabetes, and 
subsequently in immunology (Chaussabel et al., 2008; Li  et al., 2014; Rhodes et al., 
2005; Segal et al., 2003). It is postulated to be an intuitive systems-based approach for 
exploring gene expression datasets (Chaussabel and Baldwin, 2014), and may be 
superior to traditional methods such feature selection for a number of reasons. It does 
not rely as heavily on user-selected cut-offs or ranking methods (Chaussabel and 
Baldwin, 2014), and by defining a priori gene sets of interest, it may be less subject to 
bias than post hoc assessments of functional enrichment (Mootha et al., 2003). It may 
also be less susceptible to confounding by multiple testing (Subramanian et al., 2005) 
or cross-platform transcriptomic comparisons – i.e. those in which compared datasets 
are generated using different platforms – as measuring sets of genes is presumably 
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less likely to be affected by statistical noise or technological differences than 
assessment of a single transcript (Chaussabel and Baldwin, 2014). The overarching 
advantage of modular analysis may be the increased power of assessing gene 
expression changes at the level of sets of genes, rather than at the level of single 
genes, which seems plausible when biological systems are considered at the pathway 
level (Subramanian et al., 2005).  
Two principal methods of generating modules have been employed. Firstly, data-
driven modules, which use the expression values in a collection of transcriptome 
datasets of interest to build co-clustering networks of transcript correlations. Sets of 
transcripts which behave in a similar way in that particular setting are extracted from 
the network in an unsupervised manner to construct repertoire of modules, which can 
then be functionally explored and defined as being associated with particular functional 
axes – relying on the premise that co-clustering will be driven by functional 
associations (Chaussabel and Baldwin, 2014). The activity of these modules can then 
be assessed in similar types of datasets to those used to generate the module. 
Limitations of this method lie in the ability of the investigator to associate a given 
module with a plausible function, which is somewhat reliant on individual expertise 
and/or the availability of appropriate bioinformatics tools, and also the assumption that 
co-correlation of transcriptomic data will provide superior functional insight than purely 
providing an assessment of differential cell numbers within the source dataset. Data-
driven modules have been employed extensively for analysis of peripheral blood 
transcriptomic data, where they have provided valuable insights into disease 
phenotypes, including in TB (Berry et al., 2010; Bloom et al., 2013). 
The second method of module generation can be described as hypothesis-driven. 
In this method, the modular activity that the user wishes to assess is defined a priori – 
for example, the activity of a particular cytokine or the phenotype of a specific cell. 
There are two options for deriving such a module; (a) to use a curated gene list from a 
bioinformatics source which pertains to the module of interest, or (b) to use 
experimental transcriptomic data, either from curated gene expression data 
repositories or generated independently, to build a stimulus/cell-specific gene list. Both 
methods have been used successfully to gain specific biological insights (Cantu et al., 
2013; Mootha et al., 2003; Rhodes et al., 2005; Teles et al., 2013). As this is a 
supervised method, there is a considerable degree of user determination in setting the 
parameters for what genes should make up a module. For the bioinformatics approach, 
this relates to the resources selected to obtain gene lists. For the transcriptome-derived 
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approach, there is firstly the question of what experimental setup will provide the most 
appropriate data for module derivation. There are then multiple options for extracting a 
gene list from the dataset, pertaining to statistical or fold-change thresholds, correlation 
analyses and specificity filters. For testing specific hypotheses, this module generation 
approach is arguably superior to data-driven modules, as it provides an increased 
degree of confidence that a module is strongly associated with the context of interest, 
rather than requiring external verification of the module’s nature. Furthermore, although 
data-driven modules can provide valuable insight into a particular system, the 
unsupervised approach used may mean that a desired module is not generated and so 
that particular pathway cannot be assessed in that system. 
A reliable modular analysis method also relies on selecting an appropriate 
measurement for evaluation of whether expression of a module is enriched in a dataset 
of interest in comparison to control or other datasets. Similarly to generating modules, 
multiple strategies have been developed to do this. The simplest of these are the most 
intuitive methods, in which the mean or median expression value of the genes making 
up the module is calculated in the sample of interest, which is then used as a module 
score which can be used for between-group comparisons (Chaussabel and Baldwin, 
2014). This strategy has been used most often for assessing data-driven module 
expression within the framework of the system used to generate the modules, with the 
assumption that the inherently co-correlated nature of the sets of genes within each 
module mean that assessing them as essentially a single variable is justified 
(Chaussabel and Baldwin, 2014).  
Assessing the expression of hypothesis-driven modules has generally been 
performed using more complex techniques, perhaps owing to a lower level of prior 
confidence that a module which is generated entirely independently from the system in 
which it is to be assayed will have specificity for phenotypes within that system. One of 
the most widely used methods in this regard is gene set enrichment analysis (GSEA), 
the development of which helped to pioneer the concept of assessing hypothesis-
driven modules (Mootha et al., 2003; Subramanian et al., 2005). GSEA uses an 
algorithm which determines a list of ranked gene expression differences between the 
transcriptomes of two phenotypes of interest, e.g. a disease state and a control, and 
then assesses where the members of the module gene set lie in this ranked list; if they 
tend to occur towards one or other end of the list, then the module is assessed as 
significantly enriched in that phenotype in comparison to the other (Subramanian et al., 
2005).  
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This approach essentially produces a gene-set level statistic by the sum of the 
gene-level statistics (Alavi-Majd et al., 2014), and variations on this univariate testing 
approach have been developed using different statistical tests and assumptions about 
dataset distribution (Dinu et al., 2007; Luo et al., 2009; Irizarry et al., 2009). Multivariate 
approaches which incorporate the correlation structures of gene sets into the testing 
algorithm have also been developed (Tsai and Chen, 2009). A gold standard for 
hypothesis-driven module enrichment analysis is yet to emerge (Hung et al., 2012), 
and it is suggested that the most appropriate analysis method to use depends on the 
distribution of the dataset to be assessed (Alavi-Majd et al., 2014), or that use of 
multiple methods to widely explore datasets and confirm enrichment may be most 
appropriate (Glazko and Emmert-Streib, 2009). 
As macrophages are highly responsive to many different signals and stimuli, 
and their plasticity is evident transcriptionally (discussed in section 1.2.9), they may be 
an appropriate cell type to use as a barometer for different functional axes in 
transcriptional profiles, by deriving hypothesis-driven modules from gene expression 
profiles of differentially stimulated macrophages. Data-driven modules derived from 
macrophage gene expression profiles have already been successfully used to gain 
insights in macrophage heterogeneity and in vivo disease processes (Xue et al., 2014), 
indicating that they may indeed be an appropriate source of gene expression data for 
modular assessments. Modules derived from macrophages may be particularly 
appropriate for the analysis of CMI in vivo, due to the central role of macrophages in 
CMI, and assessment of immune responses in TB may be one example of where such 
modules might have utility. 
 
1.7 Summary and research objectives 
Macrophages are critical effector cells of CMI, the function of which is central to 
determining protection and pathogenesis in active TB. HIV-1 infection is associated 
with aberrant immune phenotypes which modulate the function of CMI, and also 
significantly alters the natural history of TB. HIV-1 infection and modulation of 
macrophages, which are also the host cell for Mtb, may be a major contributor to these 
complex host/pathogen interactions. Recent observations in our group have shown that 
production of the critical immunomodulatory cytokine IL-10 is attenuated in HIV-1 
infected macrophages in the response to Mtb. As IL-10 has potent modulatory effects 
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on CMI, this phenotype is highly likely to have consequences for TB control and 
pathogenesis, which may contribute to the increased risk of TB in HIV-1 infection. As 
such, investigation of the mechanism and consequences of this phenotype are merited. 
A central feature of macrophage function, which is likely to impact on CMI, is 
their responsive plasticity to different stimuli.  In particular, their responses to different 
T cell subset cytokines may determine the quality of a CMI response. As their plasticity 
is controlled transcriptionally, macrophage heterogeneity represents an opportunity for 
development of modular tools for transcriptional profiling analysis, by using gene 
expression profiles from differentially stimulated macrophages to derive specific 
modules of interest. Such tools would clearly have potential applications for gaining 
insights into the function of CMI in HIV-1/TB co-infection at the systems level, wherein 
transcriptional profiling may assist in elucidating complex immune phenotypes in this 
host/pathogen interaction. Using the TST as a human challenge model in HIV-1− and 
HIV-1+ patients represents an opportunity to do this in a controlled and highly 
comparative manner. 
My broad research objectives for this thesis are as follows, with specific 
objectives expanded upon in each chapter. 
1. To investigate the mechanisms and consequences of attenuation of IL10 
responses by HIV-1 in monocyte derived macrophages (Chapter 3 and Chapter 4). 
2. To investigate MDM molecular heterogeneity in response to differentially 
polarised T cell responses and cytokines, and to use this data to develop modular tools 
for investigation of in vivo gene expression datasets (Chapter 5). 
3. To investigate CMI responses in vivo in HIV-1 infected patients with TB by 
using the TST as a human challenge model (Chapter 6).
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Chapter 2. Materials & Methods 
2.1 Buffers, solutions and media 
2.1.1 Buffers and solutions 
Buffer or solution Composition 
Phosphate buffered saline 
(PBS) 
10×: 80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g 
KH2PO4, pH adjusted to 7.4 and made up to 1l with 
deionised H2O (dH2O) 
  1×: 10× diluted 1 in 10 with dH2O 
PBS-Tween 1× PBS with 0.05% vol/vol Tween-20 (Fisher 
Scientific) 
Tris buffered saline (TBS) 10×: 24.23g Tris-base, 80.06g NaCl, pH adjusted 
to 7.6 and made up to 1l with dH2O 
  1×: 10× diluted 1 in 10 with dH2O 
TBS-Tween 1× TBS with 0.05% vol/vol Tween-20 
Tris/borate/EDTA (TBE) 10×: 108g of Tris-base, 55g of boric acid, 7.5 g of 
EDTA disodium salt, made up to 1l with dH2O 
  1×: 10× diluted 1 in 10 with dH2O 
SDS-PAGE MES running buffer Proprietary (Novex; Life Technologies) 
Western blotting transfer buffer Proprietary (Novex; Life Technologies) with 10% 
methanol (Sigma-Aldrich) 
Western blotting blocking buffer TBS-Tween, 5% weight/vol bovine serum albumin 
(BSA), 0.45μM filtered 
Western blotting antibody buffer TBS-Tween, 5% weight/vol BSA, 0.45μM filtered 
ELISA blocking buffer PBS-Tween, 1% weight/vol BSA, 0.45μM filtered 
Cell freezing buffer FCS, 10% dimethyl sulfoxide (DMSO) 
25% sucrose buffer for 
ultracentrifugation 
25% weight/vol sucrose in sterile DBPS, 0.22μM 
filtered 
Magnetic-activated cell sorting 
(MACS) buffer 
1x PBS with 0.5%BSA and 2mM EDTA 
Table 2.1: Buffers and solutions. 
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2.1.2 Cell culture media 
Cell type Medium 
Primary human PBMC Roswell Park Memorial Institute (RPMI)-
1640 with L-glutamine (GIBCO, Invitrogen), 
supplemented with 5% heat-inactivated 
(56°C, 30 minutes) filtered (0.45μM filter 
units; Corning) pooled human type AB 
serum (ABS) (Sigma-Aldrich) 
Primary human monocytes RPMI-1640 with L-glutamine supplemented 
with 10% heat-inactivated autologous 
serum 
Primary human MDMs   
Differentiation media RPMI-1640 with L-glutamine supplemented 
with 10% heat-inactivated autologous 
serum and M-CSF (20ng/ml; R&D Systems)  
Maintenance media RPMI-1640 with L-glutamine supplemented 
with 5% heat-inactivated filtered pooled 
human ABS 
Primary human MDDCs   
Differentiation media RPMI-1640 with L-glutamine supplemented 
with 10% heat-inactivated autologous 
serum, IL-4 (50ng/ml; Peprotech) and GM-
CSF (100ng/ml; Peprotech) 
Maintenance media RPMI-1640 with L-glutamine supplemented 
with 5% heat-inactivated filtered pooled 
human ABS 
HEK293T cells Dulbecco's Modified Eagle's Medium 
(DMEM) with 2 mM L-glutamine (Invitrogen) 
supplemented with 10% foetal calf serum 
(FCS) (Biosera) 
NP-2 cells DMEM (Invitrogen) supplemented with 5% 
FCS, puromycin (1μg/ml; Sigma-Aldrich) 
and geneticin (G418; 100μg/ml; Sigma-
Aldrich) 
Table 2.2: Cell culture media. 
All plastic used for tissue culture was obtained from TPP. All cultures were incubated at 
37°C, 5% CO2 except where stated otherwise. 
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2.2 Isolation and culture of primary human cells 
This healthy volunteer study was approved by the joint University College 
London/University College London Hospitals National Health Service Trust Human 
Research Ethics Committee, and written informed consent was obtained from all 
participants. 
2.2.1 Isolation of PBMC 
Blood samples of up to 120ml were obtained from healthy volunteers. Blood 
was collected into heparinised syringes, mixed in a 1:1 ratio with sterile Dulbecco’s 
phosphate buffered saline containing Ca and Mg - DPBS with Ca, Mg - (Gibco, Life 
Technologies), layered in a 2:1 ratio over density gradient media (Lymphoprep, Axis-
Shield), and centrifuged at 800g for 20 minutes with minimum brake, in order to 
separate the peripheral blood mononuclear cell fraction (PBMC) from erythrocytes and 
granulocytes. The PBMC layer was removed using a Pasteur pipette and centrifuged 
for 10 minutes at 800g. PBMC were subsequently washed three times in DPBS with 
Ca, Mg, for 5 minutes at 400g. PBMC were counted and resuspended at 6.25 x 105/ml 
in PBMC medium (see Table 2.2).  
Blood samples for autologous serum were collected concurrently with blood 
samples for cell isolation, into unheparinised syringes. Serum was isolated from whole 
blood using serum separation tubes (Starstedt) which were centrifuged for 10 minutes 
at 1000g. Serum was aspirated using a Pasteur pipette and heat-inactivated at 56° for 
30 minutes. 
2.2.2 Differentiation and culture of monocyte-derived macrophages 
For differentiation of MDMs, monocytes were selected by adhesion as follows. 
PBMC were seeded at 2×106/cm2 in appropriate tissue culture plates and incubated for 
1 hour at 37°C, 5% CO2, to allow the monocytic fraction to adhere. Non-adherent cells, 
which were peripheral blood lymphocytes (PBLs), were then removed and adherent 
peripheral blood monocytes were washed 3 times with DPBS with Ca, Mg.  Adherent 
monocytes were cultured for 3 days in MDM differentiation medium (see Table 2.2), 
after which they were washed to remove remaining non-adherent cells, followed by 3 
further days of culture in MDM differentiation medium without M-CSF supplementation. 
This method typically yields 1×105 MDM/cm2 with less than 5% lymphocyte 
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contamination (Noursadeghi et al., 2009). From 6 days post-isolation, MDMs were 
used for experiments, and were maintained in culture for up to 4 weeks in macrophage 
maintenance medium (see Table 2.2). Media was replaced every 3–4 days. 
In this MDM model, M-CSF was selected as the macrophage differentiation 
factor as opposed to GM-CSF, for several reasons. M-CSF has been shown in vivo to 
be necessary for the development and homeostatic maintenance of many tissue 
macrophage populations, whereas GM-CSF primarily plays a role in terminal 
differentiation of AMs and under inflammatory conditions (Wynn et al., 2013). Hence, 
M-CSF differentiated MDMs may be a reasonable in vitro model for a resting tissue 
macrophage. Additionally, in the experience of our laboratory, M-CSF differentiated 
MDMs are much more permissive for infection by full-length HIV-1 (without VSV-G 
pseudotyping or Vpx-mediated relief of SAMHD1 restriction), meaning that this MDM 
model is practically more suited for some of the experiments conducted using these 
viruses.  
For some experiments wherein MDMs were to be compared to monocytes and 
monocyte-derived DCs, monocytes isolated by MACS (section 2.2.3) were used for 
MDM differentiation as above. MDMs were also differentiated by this method using 
GM-CSF (20ng/ml; Peprotech) instead of M-CSF. 
2.2.3 Isolation and culture of monocytes 
Periphal blood monocytes were isolated from PBMC by MACS using a CD14 
positive selection kit (Miltenyi Biotec) according to the manufacturer’s instructions. 
Monocytes were resuspended in monocyte medium (see Table 2.2) at 1×106 cells/ml 
and seeded in appropriate tissue culture plates. Monocytes were used for experiments 
within 48 hours of isolation. 
2.2.4 Differentiation and culture of monocyte-derived DCs 
Peripheral blood monocytes, isolated by CD14 positive selection MACS, were 
differentiated into MDDCs by resuspension at 1×106 cells/ml in MDDC differentiation 
media (see Table 2.2). Cells were differentiated over 4 days, after which they were 
used for experiments, and were maintained in MDDC maintenance media (see Table 
2.2). 
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2.3 Cell line culture 
2.3.1 HEK293T cell culture 
Human embryonic kidney 293T (HEK-239T) cells, which were used for virus 
production, were cultured at 37°C, 10% CO2 in HEK293T media (see Table 2.2), and 
were passaged 1:4 three times per week using trypsin/EDTA (GIBCO, Invitrogen). 
Frozen stocks were maintained in cell freezing buffer stored in liquid nitrogen.  
2.3.2 NP2 cell culture 
NP2 cells are an astrocytoma cell line stably transduced to express the HIV-1 co-
receptors CD4 and CXCR4 (NP2-X4) or CD4 and CCR5 (NP2-R5), which were used 
for HIV-1 titrations. NP2 cells were cultured in NP2 media, which is DMEM 
supplemented with 5% FCS and antibiotic selection (100μg/ml G418 and 1μg/ml 
puromycin) to maintain expression of the HIV-1 co-receptors. The cells were passaged 
1:10 once a week. 
2.4 HIV-1 strains and HIV-1 based vectors 
All full-length HIV-1 strains were used in Category 3 laboratories using 
appropriate safety precautions. VSV-G-pseudotyped HIV-1 strains with env deletions, 
VLPs and lentiviral vectors were used in Category 2 laboratories using appropriate 
safety precautions. 
2.4.1 Production of HIV-1 Ba-L 
The CCR5- and thus macrophage-tropic HIV-1 strain Ba-L (Gartner et al., 
1986b) was produced by propagation of infectious stocks in PBL and MDM cultures. 
Non-adherent PBLs from MDM preparations were cultured for 3 days in RPMI-1640 
with 20% FCS and 0.5g/ml phytohaemagglutinin (PHA; Sigma-Aldrich) to generate 
activated T cells. These cells were then inoculated with HIV-1 Ba-L, using a multiplicity 
of infection (MOI) of 1, and subsequently cultured in RPMI 1640 with 20% FCS and 20 
U/ml IL-2 (PeproTech). At 3- to 4-day intervals, the cell culture supernatants were 
collected and additional PHA-stimulated PBMC were added to maintain the cell density 
at 1x106/ml. Cell culture supernatants containing PBMC-derived HIV-1 were filtered 
through 0.45μm filters (Millipore) and used to inoculate 6-day-old MDM cultures 
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overnight (MOI of 1), refreshing the medium on the following day. Culture supernatants 
from infected MDM, containing MDM-derived HIV-1 Ba-L, were collected at weekly 
intervals, centrifuged at 400g for 5 min and 0.45μm filtered to remove cellular debris. 
Virus was purified and concentrated from supernatants as below (section 2.4.4). 
2.4.2 Production of HIV-1 and lentiviral vectors from molecular clones 
Full-length, and Env-deleted single-round HIV-1 strains with a range of 
mutations, were generated by transfection of producer cells with molecular clones. The 
range of molecular clones used in this thesis, and details of their derivations, are listed 
in Table 2.3. 
To generate the R9ΔenvΔvif and R9ΔenvΔvpr molecular clones as described in 
Table 2.3, I performed molecular cloning. All enzymes and buffers used in this process 
were obtained from Promega, and plasmid preparation and transformations were as 
detailed below. Ligations were performed at 4°C overnight. Clones were verified by 
sequencing (performed by the Wolfson Institute for Biomedical Research Scientific 
Support Services) using primers obtained from Sigma-Aldrich. All plasmids were 
prepared for transfections by transformation of HB101 competent Escherichia coli with 
1μl of plasmid DNA at 42°C for 45 seconds, followed by plating of bacteria onto 
lysogeny broth (LB) agar (Invitrogen) plates with the appropriate selection antibiotic. 
Plates were incubated overnight at 37°C. Single colonies were picked and inoculated 
into starter cultures of 5ml LB (Invitrogen) with appropriate selection antibiotic, which 
were incubated for 8 hours at 37°C on a shaker. One millilitre of starter culture was 
inoculated into 100ml of media as above and incubated on a shaker overnight at 37°C 
to grow bacteria for plasmid purification, which was performed using a Qiagen Plasmid 
Midikit (Qiagen). Plasmid concentration and purity was determined using a NanoDrop 
spectrophotomer. All plasmids were routinely checked by restriction digests and TBE 
agarose gel electrophoresis. 
Transient transfection of plasmids into subconfluent HEK-239T producer cells 
was performed to produce viruses, using Fugene-6 transfection reagent (Roche) and 
OptiMEM media (GIBCO, Life Technologies). Fugene-6 (18μl per 10cm2 tissue culture 
dish) was mixed with OptiMEM (200μl per dish) and left for 5 minutes, followed by 
addition of plasmid DNA as detailed below. This mixture was incubated for 20 minutes 
after which it was added dropwise to cells. Media was changed the following day, and 
supernatants were collected to harvest virus on the subsequent 2 days.  
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Full-length HIV-1 clones were generated by transfection of 3.5μg of plasmid 
DNA per 10cm2 dish of HEK293T cells. Env-deleted viruses were vesicular stomatitis 
virus G protein (VSV-G) pseudotyped, and so were co-transfected with pMDG, a VSV-
G expression vector (Naldini et al., 1996). Three micrograms of Env-deleted virus 
plasmids and 1ug of pMDG were used for these transfections per 10cm2 dish of 
HEK293T cells. Gag-Luc-GFP and HR’-based lentiviral vector were co-transfected with 
the packaging plasmid p8.91 (Zufferey et al., 1997) and pMDG. 1.5ug of virus/vector 
plasmid, 1ug of p8.91 and 1ug of pMDG were used for these transfections per 10cm2 
dish of HEK293T cells. 
2.4.3 Production of Vpx virus-like particles (Vpx VLPs) 
To express the SIV and HIV-2 protein Vpx, which can increase the efficiency of 
macrophage lentiviral transduction by overcoming SAMHD1-medated restriction 
(Berger et al., 2011; Hrecka et al., 2011; Laguette et al., 2011), VSV-pseudotyped Vpx 
virus-like particles (Vpx VLPs) were produced as follows. The plasmid pSIV3+, a 
SIVmac Gag-Pol expression vector which includes the gene for Vpx (Nègre et al., 
2000), was co-transfected with pMDG, without any genome plasmid, into HEK293T 
cells as above. pSIV3+ was used at 3μg, and pMDG at 1μg, per 10cm2 dish of 
HEK293T cells. 
2.4.4 Virus purification by ultracentrifugation 
To purify and concentrate virus, filtered culture supernatants were layered over 
25% sucrose buffer cushions and ultracentrifuged in sterilised ultracentrifuge tubes 
(Beckman-Coulter) for 2 hours at 23000 rpm, 4°C, to remove soluble contaminants. 
Ultracentrifugation was performed using a Sorvall Sure-Spin 630 rotor. Viral pellets 
were resuspended in MDM maintenance media, aliquoted and stored in liquid nitrogen. 
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Virus Details and references 
Full-length HIV-1   
NL4.3 BaL NL4.3 BaL was provided by Dr Jane Rasaiyaah (UCL). The full-
length X4-tropic HIV-1 clone NL4.3 was modified by cloning in 
the Env gene from R5-tropic HIV-1 BaL, to render NL4.3 R5-
tropic in order to infect MDMs (Rasaiyaah et al., 2013). 
NL43 BaL ΔIN NL4.3 BaL ΔIN was provided by Dr Jane Rasaiyaah (UCL). A 
mutation in integrase, D116N, was introduced to NL4.3 BaL by 
site-directed mutagenesis (Rasaiyaah et al., 2013). 
Env-deleted HIV-1   
R9Δenv The R9Δenv molecular clone was provided by Dr Elspeth 
Potton (UCL). This virus is a derivative of the R9 BaL full-length 
HIV-1 clone (Saphire et al., 2002) with a 445bp deletion in Env. 
R9ΔenvΔnef The R9ΔenvΔnef molecular clone was provided by Dr Elspeth 
Potton (UCL). A fragment from a full-length HIV-1 NL4.3 clone 
with a premature stop codon in Nef (Schindler et al., 2006) 
provided by Professor Frank Kirchoff (University of Ulm) was 
cloned into R9Δenv to produce R9ΔenvΔnef. 
R9ΔenvΔvif To create a Vif-defective virus in the R9 background, a 
fragment from the Vif-defective virus VH17 (Simon et al., 1995) 
which has nonsense mutations in Vif (provided by Professor 
Mike Malim, KCL) was cloned into R9Δenv using the SpeI and 
SalI restriction sites. 
R9ΔenvΔvpr To create a Vpr-defective virus in the R9 background, a full-
length HIV-1 NL4.3 molecular clone with a mutation in the start 
codon of Vpr (provided by Dr Jane Rasaiyaah, UCL) was used. 
NL4.3 and R9 are essentially equivalent, as although R9 was 
based on an NL4.3/HXB2 hybrid, all HXB2 sequence has been 
removed in subsequent modifications (Saphire et al., 2002). 
Accordingly, the NL4.3Δvpr clone was modified by cloning in 
the R9Δenv BamHI–SalI fragment which contains the truncated 
Env sequence, to produce R9ΔenvΔvpr. 
Gag-Luc-GFP The Gag-Luc-GFP molecular clone was provided by Professor 
Greg Towers (UCL). This clone is a derivative of pLAI (Peden 
et al., 1991), a HIV-1 clone with a 500bp deletion in Env, based 
on the original LAI HIV-1 isolate. The gene for luciferase is 
cloned in frame in Gag and GFP is cloned in place of Nef. This 
construct therefore encodes the accessory genes Tat, Rev, 
Vpu, Vpr and Vif and a gag luciferase fusion protein. The Gag-
Pol sequence downstream of luciferase is out of frame. 
Lentiviral vector   
HR'-based The pHR' vector plasmid (Naldini et al., 1996), expressing 
eGFP under the control of the CMV promoter, was used to 
generate lentiviral vector particles expressing GFP only as a 
transgene. 
Table 2.3: HIV-1 molecular clones and lentiviral vectors. 
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2.4.5 Virus titrations 
HIV-1 strains were titrated on the NP2 cell line (section 2.3.2) as previously 
described (Noursadeghi et al., 2009). NP2/CD4/CCR5 cells were seeded 24 hours 
prior to titrations, to allow for attachment to the tissue culture plastic as well as for 
expression of the receptors required for HIV-1 infection. Cells were inoculated for 2 
hours at 37°C with serial log-fold dilutions of viral stocks, using duplicate wells. The 
inoculum was then removed and the media replaced. Infection was detected after 72 
hours by p24 immunostaining (section 2.8.1). P24-positive cells were counted using 
an AID Viruspot reader, and titres calculated from the lowest dilution with positive cells, 
in which the number of positive cells was verified by manual counting using the light 
microscope. Titration values were calculated as infectious units per ml. 
Integrase-deficient HIV-1, Gag-LucGFP, lentiviral vectors and Vpx VLPs, which 
could not be titrated by p24-gag staining, were titrated by measuring the amount of 
reverse transcriptase in the viral sample a reverse transcriptase (RT) assay 
colorimetric kit (Roche) according to the manufacturer’s instructions. One nanogram of 
RT correlates to 1×106 infectious units in this assay. 
2.5 Cryptococcus neoformans strains and culture 
2.5.1 C. neoformans strains 
C. neoformans strains used are shown in Table 2.4. All strains were provided by 
Professor Robin May, University of Birmingham. 
2.5.2 C. neoformans culture 
All strains were propagated on yeast-peptone-dextrose (YPD) agar (Sigma-
Aldrich) plates. Stocks of C. neoformans were stored at −80° in glycerol stocks, using a 
microbank bacterial and fungal preservation system (Fisher Scientific). Beads from 
microbanks were added to agar plates and incubated for up to 48 hours at 25–30°C. 
Fungal lawns were re-streaked onto a fresh plate to give stock plates for experiments, 
which were incubated similarly. Stock plates were stored at 4°C for up to 2 weeks 
before re-streaking. For experiments, YPD broth (Sigma-Aldrich) was inoculated from 
fungal lawns, and C. neoformans yeasts were cultured in suspension for 16–24 hours 
at 20rpm in a microbial incubator at 25–30°C. These cultures were centrifuged at 
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6000g for 2 minutes to pellet yeast cells, which were then resuspended in sterile DPBS 
for counting by haemocytometer. 
 
C. neoformans 
strain 
Details Serotype Reference 
H99 WT laboratory-propagated 
strain; C. neoformans type 
strain 
A 
Perfect et al. (1980); 
Perfect et al. (1993) 
Cap59  Unencapsulated derivative of 
H99 
A Nelson et al. (2001) 
B3501 WT laboratory-propagated 
strain 
D Kwon-Chung (1976) 
Cap67 Unencapsulated derivative of 
B3501 
D Jacobson et al. 
(1982) 
H99-GFP5 H99 expressing GFP A Voelz et al. (2010) 
Table 2.4: Cryptococcus neoformans strains. 
 
 
2.6 Cell culture infections and stimulations 
2.6.1 Infection with HIV-1 and viral vectors 
MDMs were inoculated with Ba-L at an MOI of 3–5 in a minimal cell culture 
volume, followed by an overnight incubation, after which inoculums were removed and 
maintenance media refreshed. Infected MDMs were kept in culture for a further seven 
days, to allow spreading propagation of virus to establish uniform infection of the 
culture, before use in experiments.  
MDMs were inoculated with NL4.3 Ba-L WT or ΔIN at an MOI of 15 in a minimal 
cell culture volume, followed by an overnight incubation, after which inoculums were 
removed and maintenance media refreshed. Infected MDMs were kept in culture for a 
further 14 days, to allow spreading propagation of virus to establish uniform infection of 
the culture, before use in experiments.  
MDMs, MDDCs and monocytes were inoculated with VSV-G pseudotyped HIV-
1 strains at an MOI of 3–5 in a minimal cell culture volume, and were co-transduced 
with Vpx VLPs at 2ng RT/ml. Inoculums were removed after an overnight incubation 
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and normal maintenance media was refreshed. Infected cells were kept in culture for at 
least 24 hours before use in experiments. 
MDMs were inoculated with the lentiviral vector HR’ and HIV-1 GagLucGFP at 
7ng RT/ml in a minimal cell culture volume, and were co-transduced with Vpx VLPs at 
2ng RT/ml. Inoculums were removed after an overnight incubation and normal 
maintenance media was refreshed. Infected cells were kept in culture for at least 24 
hours before use in experiments. 
For all experiments in which Vpx VLPs were used, uninfected wells were also 
transduced with Vpx VLPs at 2ng RT/ml as a control. Success of HIV-1 infection was 
routinely verified in experiments using p24 immunostaining of paired wells (see 
section 2.8.1). 
 
2.6.2 C. neoformans infection 
C. neoformans yeasts from liquid cultures were resuspended at the appropriate 
MOI (10–100; indicated in figure legends) in MDM maintenance media, and incubated 
with MDMs for 4 hours, after which MDMs were washed thoroughly using DPBS to 
eliminate extracellular yeasts. Infected MDMs were maintained for up to 24 hours. 
 
2.6.3 Innate immune stimuli and cytokines 
MDMs were incubated with innate immune stimuli and recombinant human 
cytokines as shown in Table 2.5. 
MDMs were also stimulated with Mtb culture supernatant. To generate this, 
M.tuberculosis H37Rv was cultured in Middlebrook 7H9 medium (BD Biosciences) 
supplemented with 10% ADC enrichment medium, 0.2% glycerol (AnalaR, VWR) and 
0.02% Tween-80 (Sigma-Aldrich). Mtb culture filtrate was generated by centrifugation 
of cultures at an OD600nm of 0.6 at 15000g for five minutes followed by filtration through 
a 0.2µm Anopore filter (Whatman), and this was used to stimulate MDMs. 
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Reagent 
Concentration for 
use 
Manufacturer 
Innate immune stimuli     
Ultrapure lipopolysaccharide (LPS) 
from Escherichia coli O111:B4 
100ng/ml Invivogen 
Pam3-Cys-Ser-Lys4 (Pam3CSK4) 100ng/ml Axis-Shield 
Zymosan from Saccharomyces 
cerevisiae cell wall 
0.4mg/ml Invivogen 
Curdlan (β-1,3-glucan from 
Alcaligenes faecalis) 
0.1mg/ml Wako Chemicals 
Recombinant human cytokines     
IL-10 10ng/ml eBioscience 
TNFα 10ng/ml eBioscience 
IFNγ 10ng/ml Peprotech 
IFNα (clinical grade) 200IU/ml Teva 
IFNβ (clinical grade) 200IU/ml Merck Serono 
IL-4 10ng/ml Peprotech 
IL-13 10ng/ml eBioscience 
TGFβ 10ng/ml Peprotech 
Table 2.5: Innate immune stimuli and cytokines. 
2.6.4 Blockade of cytokine signalling 
To block IL-10 signalling in innate immune responses, MDMs were 
preincubated with neutralising antibodies to IL-10 (clone JES3-9D7, 5ug/ml, 
eBioscience) and the IL-10 receptor (clone 3F9, 10ug/ml, BD Biosciences) for 2 hours 
prior to innate immune stimulation, and throughout the stimulation conditions. 
To block type I IFN signalling in innate immune responses, MDMs were 
preincubated with neutralising antibody to the type I IFN receptor IFNBAR2 (clone 
MMHAR-2, 1ug/ml, PBL Assay Science) for 2 hours prior to innate immune stimulation, 
and throughout the stimulation conditions. 
2.6.5 Chemical inhibitors and drugs 
MDMs were incubated with chemical inhibitors and drugs as detailed in Table 2.6. 
Cells were pre-incubated with inhibitors for 2 hours before experiments, and throughout 
the experiment as appropriate. Conditions without inhibitors were controlled by the 
addition of the appropriate carrier. For experiments using indinivir sulphate, MDMs 
were pre-incubated for 3 days prior to assays. 
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Inhibitor/drug Target Carrier 
Concentration 
for use 
Manufacturer 
SB203580 p38 MAP kinase DMSO 10µM Calbiochem 
PD98059 MEK (and 
downstream 
ERK1/2 MAP 
kinase) 
DMSO 10µM Calbiochem 
UO126 MEK1 (and 
downstream 
ERK1/2 MAP 
kinase) 
DMSO 10µM Calbiochem 
AG17 Pyk2 DMSO 10µM Calbiochem 
KN93 CaM kinase II DMSO 10µM Calbiochem 
LY294002 PI3K DMSO 10µM Calbiochem 
Triciribine Akt DMSO 20µM Calbiochem 
Rapamycin mTOR DMSO 200nM Sigma-Aldrich 
Actinomycin D RNA polymerase II DMSO 10ug/ml Sigma-Aldrich 
Indinivir 
sulphate 
HIV-1 protease H2O 10µM Centre for AIDS 
reagents, NIBSC 
Table 2.6: Chemical inhibitors and drugs. 
2.7 PBMC migration assays 
PBMC were isolated from healthy donor blood samples as above, and 
resuspended at 5×106 cells/ml in PBMC media. Five hundred microliters of MDM-
conditioned media (described below) or control media was placed into the lower 
chamber of 5μm-pore polycarbonate transwells (Costar). One hundred microliters of 
the PBMC suspension was transferred into the top chamber of transwells, and 
incubated for 3 hours at 37°C for migration to occur. Transwells were gently lifted out of 
the lower chamber and the undersurface was rinsed twice with trypsin-EDTA and 
incubated for a further 10 minutes to remove adherent cells. Transwells were removed 
and the migrated cells were fixed by addition of PFA to the lower chamber suspension 
to a final concentration of 1% and incubation for 15 minutes. Cells were then stained 
with fluorochrome-conjugated antibodies to CD14 and CD3, to delineate monocytes 
and T cells respectively (both antibodies from BD Biosciences) and acquired on a 
FACS Calibur flow cytometer to quantify migrated cells. Fluorescent beads (Flow-
Check Fluorospheres; Beckman Coulter) were added to all samples to standardise 
acquisition. Migration indices were calculated as follows to quantify the migration of 
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different cell populations: the absolute numbers of cells recruited, for the cell population 
of interest, were normalised as a ratio to the absolute number of that cell population in 
an input PBMC sample. 
MDM-conditioned media, which was generated by stimulation of MDMs in 
conditions described in figure legends, was pooled from 4 donors, diluted 1 in 10 in 
macrophage maintenance media and 0.45μM filtered before use. 
2.8 Quantification of HIV-1 p24 
2.8.1 Intracellular HIV-1 p24 staining 
Immunostaining of cells for HIV-1 p24 was performed as follows. Cells were 
fixed with ice cold acetone (Sigma-Aldrich) and methanol (Sigma-Aldrich) in a 1:1 ratio 
for 30 minutes at room temperature, followed by three washes with PBS. The primary 
antibody (mouse anti-p24, clone EVA365/366, NIBSC) diluted 1 in 50 in PBS with 1% 
FCS was added. After incubation for 2 hours at room temperature, cells were washed 3 
times with PBS and the secondary antibody, goat anti-mouse Ig β-galactosidase 
conjugate (Southern Biotechnology Associates) diluted 1 in 40 in PBS with 1% FCS 
was applied and incubated for 1 hour at room temperature. Cells were washed three 
times in PBS, and pre-mixed β-galactosidase substrate, X-gal, at 20mg/ml (Fermentas) 
was added in X-gal solution (PBS containing 3 mmol/l potassium ferricyanide, 3 mmol/l 
potassium ferrocyanide and 1 mmol/l magnesium chloride), followed by incubation 
overnight at 37°C. p24-positive cells, stained blue, were quantified as infected cells per 
field using an AID Viruspot reader. 
2.8.2 HIV-1 p24 ELISA 
HIV-1 p24 enzyme-linked immunosorbant assay (ELISA) was used to quantify 
HIV-1 in cell culture supernatants. Plates, antibodies and standards were from the p24 
ELISA kit version 9.2, AIDS and Cancer Virus Programme, National Cancer Institute, 
Frederick. Cell culture supernatants were diluted 1 in 10 in RPMI-1640 with 1% BSA 
and 0.2% Tween-20. Lysing solution, which was 10% Triton-X-100 (Sigma-Aldrich) in 
Milli-Q H2O (Millipore UltraPure Water Purification System), was added in a 1:10 ratio. 
Samples were incubated for 1 hour at 37°C for HIV-1 lysis. Recombinant protein 
standards were prepared by making two-fold dilutions in the appropriate cell culture 
medium. Standards and samples were added in duplicate or triplicate to pre-blocked 
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plates coated with anti-p24 capture antibody and incubated at 37°C for 2 hours, 
followed by washing three times with PBS-Tween (see Table 2.1). The biotinylated 
detection antibody was prepared 1 in 150, in 0.45μm filtered RPMI-1640 with 10%FCS 
and 2% normal mouse serum (NMS) (Sigma-Aldrich), added to wells and incubated for 
1 hour at 37°C. Wells were washed as above and the avidin-horseradish peroxidase 
(HRP) conjugate, diluted 1 in 100 in 0.45μm filtered RPMI-1640 with 2% NMS, 5% 
normal goat serum (NGS) (Sigma-Aldrich) and 0.01% Tween-20, was added to wells 
and incubated for 1 hour at 37°C. Wells were washed as above, the HRP substrate, 
3,3',5,5'-tetramethylbenzidine (TMB) in solution was applied and the reaction was 
allowed to develop in the dark. When the reaction had reached an appropriate stage, it 
was stopped using 1N hydrochloric acid (Sigma-Aldrich). The resulting colorimetric 
product was quantified at OD450nm using a Thermo Scientific Multiskan FC, and the 
standard values used to construct a standard curve, from which p24 concentrations in 
the samples were calculated. Co-efficients of variation (CV) were calculated for 
replicate wells and samples with %CV greater than 20% were re-assayed. 
2.9 RNA isolation from cultured cells 
RNA was isolated by lysis of cells using RLT buffer (Qiagen) as per the 
manufacturer’s instructions. Extraction was performed using a Qiagen RNeasy Kit 
(Qiagen) as per the manufacturer’s instructions. For downstream processing, RNA was 
subject to DNase treatment using a TURBO DNA-free kit (Ambion, Life Technologies) 
as per the manufacturer’s instructions to remove contaminating genomic DNA. When 
RNA was used for microarray analysis, RNA quality and quantity was checked using 
RNA Nanochips (Agilent) and an Agilent 2100 Bioanalyzer. 
2.10 Quantitative real-time PCR measurements of gene 
expression 
DNase-treated RNA was used as the template to make first strand cDNA, using 
qScript cDNA Mastermix (Quanta Biosciences), which contains appropriate buffer, 
dNTPs, MgCl2, primers, RNase inhibitor protein, qScript reverse transcriptase and 
stabilizers. Quantitative real-time PCR (qRT-PCR) for genes of interest was performed 
using TaqMan inventoried assays (Applied Biosystems, Invitrogen), shown in Table 2.7, 
and 2× TaqMan Gene Expression Mastermix (Applied Biosystems, Invitrogen), using 
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an AB7500 Fast RT-PCR System. Expression levels of target genes were normalised 
using a Δ cycle threshold (Ct) calculation, to that of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which was amplified and detected using primer and probe 
sequences (Table 2.8) as previously reported (Tsang et al., 2009). GAPDH primers 
and probes were obtained from Sigma-Aldrich. TaqMan assays use FAM as the dye, 
and GAPDH probes were also used with FAM.  
 
Gene Applied Biosystems Assay ID 
IL10 Hs00961622_m1 
IL6 Hs00985639_m1 
TNFA Hs00174128_m1 
IL1B Hs01555410_m1 
IFI16 Hs00194261_m1 
HIV-1 LTR Pa03453409_s1 
Table 2.7: Applied Biosystems Taqman qRT-PCR assays. 
 
  Sequence (5'–3') 
GAPDH forward primer GGC TGA GAA CGG GAA GCT T 
GAPDH reverse primer AGG GAT CTC GCT CCT GGA A 
GAPDH probe TCA TCA ATG GAA ATC CCA TCA CCA 
Table 2.8: GAPDH primer and probe sequences. 
 
2.11 Cytokine ELISAs 
To measure cytokine secretion from cells, ELISAs were performed as follows. 
Cell culture supernatants were collected during experiments, centrifuged for 2 minutes 
at 12000g to remove cell debris, and stored at −80°C. Antibodies, standards and 
detection reagents from Ready-Set-Go ELISA kits (eBioscience) were used, and 100μl 
volumes of all reagents was used per well. Antibodies, sample dilution factors and 
upper concentrations of standards are summarised in Table 2.9 and buffers used are 
shown in Table 2.1. Flat-bottomed polystyrene 96-well plates (Nunc) were coated with 
the primary capture antibody at 1μg/ml in PBS and incubated overnight at 4°C. The 
capture antibody was flicked out, and blocking buffer was applied for 2 hours at room 
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temperature. A range of standards were prepared from recombinant proteins by 
doubling dilutions in sample buffer, which was the appropriate cell culture medium. 
Sample dilutions were also made in sample buffer. The blocking buffer was flicked out 
and the plate was washed three times with PBS-Tween and blotted dry. Standards and 
samples were applied to wells, in duplicate or triplicate as appropriate, leaving 
duplicate blank wells. This was incubated at room temperature for 2 hours or at 4°C 
overnight. Samples and standards were flicked out and the plate washed as above. 
The biotinylated secondary detection antibody was applied at 1μg/ml in PBS-Tween, 
incubated for 1 hour at room temperature, flicked out, and washed as above. The 
avidin-HRP conjugate was applied at 1μg/ml in PBS-Tween, for 30 minutes at room 
temperature, flicked out, and washed as above. TMB was added and the reaction was 
developed and assessed as detailed in section 2.8.2, pg. 27. 
 
Cytokine 
Capture 
antibody clone 
Detection 
antibody clone 
Highest 
standard used 
(pg/ml) 
MDM culture 
supernatant 
dilution factor 
IL-10 JES3-9D7 ES3-12G8 4000 1:2 
IL-6 MQ2-13A5 MQ2-39C3 4000 1:5 
TNFα MAb1 MAb11 4000 1:5 
Table 2.9: ELISA antibodies, standards and dilutions. 
 
2.12  SDS-PAGE and western blotting 
Cell lysates were collected in sodium dodecyl sulfate (SDS) sample buffer 
(Novex, Life Technologies), containing protease and phosphatase inhibitor cocktails 
(Pierce), and were homogenised by boiling at 103°C for 5 minutes and subsequent 
sonication at 40 Hz using an ultrasonic processor (Jencons Scientific). Proteins were 
separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) using 4−12% Bis-
Tris polyacrylamide gels (Novex, Life Technologies) in MES running buffer (Novex, Life 
Technologies) using an XCell SureLock electrophoresis system (Novex, Life 
Technologies). PageRuler protein marker (Fermentas) was used as a size reference. 
Protein transfer onto Hybond nitrocellulose membranes (Amersham, GE Healthcare) 
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was performed in transfer buffer (Novex, Life Technologies), also using the XCell 
SureLock electrophoresis system with the blot module.  
Buffers used for western blotting are shown in Table 2.1 and antibodies are 
shown in Table 2.10. Membranes were blocked on a shaker for 1 hour at room 
temperature, and washed three times in TBS-Tween for five minutes on a shaker. 
Membranes were sequentially immunoblotted with primary antibodies overnight at 4°C, 
and HRP-conjugated secondary antibodies for one hour at room temperature, with 
washing as above between each step. Immediately before detection, membranes were 
washed twice in TBS without Tween. Detection was performed using ECL Prime 
(Amersham, GE Healthcare) according to the the manufacturer’s instructions, and 
chemiluminescence was visualized using the FluorChem FC2 imaging system (Alpha 
Innotech). Images were acquired and analysed for densitometry using AlphaView 
software v3.03 (Alpha Innotech). 
 
 
Table 2.10: Western immunoblotting antibodies. 
Target Species Clone Dilution Manufacturer 
Primary antibodies         
HIV-1 gag/p24 Mouse E365/366 1:1000 NIBSC 
HIV-1 Vif Mouse #319 1:500 
NIH AIDS Reagent 
Program 
HIV-1 Nef Rabbit Polyclonal 1:200 
NIH AIDS Reagent 
Program 
β-actin Mouse AC-15 1:10000 Abcam 
Akt Rabbit C67E7 1:1000 Cell Signaling 
Phospho Akt (Ser473) Rabbit 9271 1:1000 Cell Signaling 
Secondary 
antibodies         
Anti-rabbit HRP 
conjugate Swine Polyclonal 1:3000 DAKO 
Anti-mouse HRP 
conjugate Goat Polyclonal 1:3000 DAKO 
Chapter 2 Materials and Methods 
 
 
114 
2.13 Microscopy 
2.13.1 C. neoformans uptake assay 
Confocal immunofluorescence microscopy was used to analyse MDM uptake of 
C. neoformans. For this purpose, MDMs were cultured in 96-well tissue culture-treated 
confocal plates (Perkin-Elmer). Three replicate wells were used per condition. After 
experiments, MDMs were fixed using 4% paraformaldehyde (Sigma-Aldrich) for 30 
minutes at 4°C, and washed with ice-cold PBS. Cells were blocked using 10% normal 
goat serum (Sigma-Aldrich) in PBS for 1 hour at room temperature. Intracellular C. 
neoformans was visualised by use of a GFP-expressing strain (H99-GFP5). 
Extracellular C. neoformans was counterstained using a monoclonal antibody to 
glucuronoxylomannan, a component of the C. neoformans capsule (mouse; clone 
18B7; used at 1.98 μg/ml; provided by Arturo Casadevall, Albert Einstein School of 
Medicine, New York) and goat anti-mouse conjugated to Alexa Fluor 555 (Molecular 
Probes; Life Technologies), both applied for 1 hour at room temperature with 3 washes 
in PBS between incubations. MDM nuclei were stained for 5 minutes at room 
temperature with 4',6-diamidino-2-phenylindole (DAPI; Cell Signaling) at 2 μg/ml in 
PBS. Confocal microscopy was performed using the PerkinElmer Opera LX 
microscope and images were analysed using IMAGEJ, in collaboration with Dr Janos 
Kristin-Vizi, Laboratory for Molecular and Cellular Biology, University College London. 
2.13.2 NFκB translocation assay 
Confocal immunofluorescence microscopy was used to quantify nuclear 
translocation of NFkB RelA as previously described (Tsang et al., 2009). For this 
purpose, MDMs were cultured in 96-well tissue culture-treated confocal plates (Perkin-
Elmer). Three replicate wells were used per condition. Cells were fixed and blocked as 
above (section 2.13.1). Cells were permeablised using 0.1% Triton-X-100 (Sigma-
Aldrich) in PBS. The primary antibody NFκB p65 (RelA) (rabbit; clone C-20; Santa Cruz 
Biotechnology) was applied at 1 in 100 in blocking buffer for 1 hour at room 
temperature. Wells were washed 3 times with PBS, and the secondary antibody (goat 
anti-rabbit conjugated to Alexa Fluor 488; Molecular Probes, Life Technologies) was 
applied at 1 in 250 in 1 in 100 in blocking buffer for 1 hour at room temperature. Wells 
were washed as above, and then stained with CellMask HCS Orange reagent for 30 
minutes at room temperature to delineate the cytoplasm (1 in 20000 of stock in PBS; 
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Molecular Probes, Life Technologies) and DAPI to delineate the nucleus, as above. 
Cells were imaged using a Hermes WiScan Cell Imaging System (IDEA Biomedical) on 
the 10× objective, with 100% coverage and 100% density of each well imaged to 
acquire images of approximately 5×104 cells/well. Images were analysed using Wiscan 
software (IDEA Biomedical), to quantify the nuclear:cytoplasmic ratio of average RelA 
fluorescence intensity, per well. Ratios were compared over time-courses to analyse 
nuclear translocation. 
2.14 Tuberculin skin tests 
The study was approved by the research ethics committees of all sites and 
institutions involved, and informed written consent was obtained from all participants. 
2.14.1 TST injection and sample collection 
TSTs were performed by intradermal injection of 2U purified protein derivative 
(PPD) (Serum Stratens Institute) into the proximal third of the volar aspect of the 
forearm. A subset of patients received saline injections (clinical grade saline, from local 
clinical sites) as a control cohort. TSTs were assessed at 48 hours and two 3mm 
punch skin biopsies were collected from the marked injection site which were collected 
into either RNAlater reagent (Sigma-Aldrich) for RNA isolation, or 4% neutral buffered 
formalin (NBF; LabSource) for adjunctive histological analysis. All TSTs and biopsies 
were performed by trained clinical staff. Until processing, samples in RNAlater were 
stored at −80°C and samples in 4%NBF were stored at room temperature. 
2.14.2 Histological assessment of TST biopsy samples 
After fixation in 4%NBF, biopsies were embedded in paraffin (performed by the 
Department of Pathology, Groote Schuur Hospital, Cape Town, South Africa), 
sectioned and mounted on slides, and stained with haemotoxylin and eosin (performed 
by the University College London Hospital histopathology department). Digital images 
were acquired with an AxioScan Z1 slide scanner (Zeiss) and are presented without 
any subsequent processing. All histological assessments were performed by a 
histopathologist blinded to concomitant clinical information. 
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2.14.3 RNA isolation from TST biopsy samples 
Biopsy samples were transferred into QIAzol reagent (Qiagen) and were 
disrupted using a homogeniser (Omni International). RNA was purified from 
homogenised samples using the Lipid Tissue RNeasy kit (Qiagen) according to the 
manufacturer’s instructions. RNA was subject to DNase treatment using a TURBO 
DNA-free kit (Ambion, Life Technologies) as per the manufacturer’s instructions to 
remove contaminating genomic DNA. RNA quality and quantity was checked using 
RNA Nanochips (Agilent) and an Agilent 2100 Bioanalyzer. 
2.15 RNA isolation from peripheral blood samples 
Blood samples for RNA isolation were collected into Tempus RNA blood tubes 
(Life Technologies) and were stored at −80°C until processing. RNA processing of 
blood samples was performed by Dr Jennifer Roe and Dr Gabriele Pollara, UCL 
Division of Infection and Immunity. RNA was purified using a Tempus Spin RNA 
Isolation Kit (Ambion; Life Technologies) and globin mRNA was eliminated using a 
GlobinClear kit (Life Technologies) both according to the manufacturer’s instructions. 
RNA was subject to DNase treatment using a TURBO DNA-free kit (Ambion, Life 
Technologies) as per the manufacturer’s instructions to remove contaminating genomic 
DNA. RNA quality and quantity was checked using RNA Nanochips (Agilent) and an 
Agilent 2100 Bioanalyzer. 
2.16 QuantiFERON-TB Gold assays 
Blood samples for QuantiFERON-TB Gold (QFT) assays were collected into QFT 
assay blood tubes (Qiagen) and processed according to the manufacturer’s 
instructions to isolate plasma samples. Plasma samples were stored at −80°C until 
processing. IFNγ in plasma samples was measured using the QFT ELISA kit according 
to the manufacturer’s instructions. 
2.17 Transcriptional profiling by cDNA microarray 
2.17.1 Microarray methodology  
The quantity and quality of all RNA samples was checked using RNA Nanochips 
(Agilent) and the Agilent 2100 Bioanalyzer prior to processing for microarray analysis. 
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Only RNA samples with an RNA integrity value (Rin) of greater than 6 were used for 
microarrays. The Agilent Low RNA Input Linear Amplification Kit was used to generate 
amplified cDNA and subsequently labelled cRNA, according to the manufacturer’s 
instructions. Successful purification, labelling and intensity and cRNA concentration 
were verified using a NanoDrop ND-1000 UV-VIS Spectrophotometer (Thermo 
Scientific). Equal concentrations of Cy5-labelled and Cy3-labelled cRNA samples were 
mixed and hybrised to Agilent 8×60k whole genome cDNA microarrays, according to 
the manufacturer’s instructions. Array images were acquired with a dual-laser 
G2565BA microarray scanner (Agilent) and signal data was collected and processed 
using Agilent Feature Extraction software (v10.7.1.1). 
2.17.2 Microarray data analysis 
Raw microarray signal data were processed, log2 transformed, and subjected to 
local regression (LOESS) normalisation to a baseline derived from gene expression 
data of the appropriate cell type or tissue, using the agilp R package (Chain, 2012; 
Chain et al., 2010; available at 
http://www.bioconductor.org/packages/release/bioc/html/agilp.html) in R v3.0.2 
(http://www.r-project.org/). This process also averages duplicate probe signal data. 
Normalised log2 transformed gene expression data was used for all subsequent 
analyses. Within datasets, data cleaning was performed before clustering, statistical 
and bioinformatics analyses, by removing data from any microarray probe for which 
signal never exceeded the baseline background signal in any sample, and for which 
signal never varied by more than two-fold between any two samples.  
Euclidean distance hierarchical clustering and statistical analyses of microarray 
data were performed using MultiExperiment Viewer (MeV) v4.9.0 
(http://www.tm4.org/mev.html). For experimental MDM gene expression data, 
significant differences in gene expression between groups were assessed by paired t-
tests with a Welch’s correction for unequal variance, or unpaired tests where samples 
were not derived from shared paired healthy donors. For clinical sample data, I 
assumed data were not normally distributed, so elected to use non-paramteric tests 
and thus assessed significant differences in gene expression between groups by 
Wilcoxon rank sum tests. For both tests, a P value of <0.05 was considered significant. 
The generated lists of significantly differently expressed genes were then subject to a 
two-fold change cut-off between groups to produce gene lists for downstream 
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bioinformatics analyses. These approaches have been used extensively in published 
data from our group (Chain et al., 2010; Le Bert et al., 2011; Rasaiyaah et al., 2013; 
Tomlinson et al., 2014, 2012, 2011; Tsang et al., 2009).  
Bioinformatic analyses were performed using publicly available online tools. All 
gene lists submitted for bioinformatics analyses were restricted to genes for which 
annotation with a RefSeq accession number was available, and any duplicate genes 
(by Gene Symbol) were removed. InnateDB (www.innatedb.com; Breuer et al., 2013) 
was used to perform gene ontology (GO) and pathway enrichment analyses, using the 
recommended default settings to identify significantly enriched GO terms and pathways 
(a hypergeometric algorithm with a significance level of Benjamini-Hochberg 
correction-adjusted P<0.05). InnateDB integrates GO term and pathway annotation 
information from several publicly available databases, and the databases used for 
particular analyses are indicated in the relevant figure legends. GO and pathway 
enrichment analysis results are presented as network visualisations which were 
generated using Gephi v0.8.2 (https://gephi.github.io/). Transcription factor binding site 
(TFBS) enrichment analysis was performed using oPOSSUM-3 human single site 
analysis (Kwon et al., 2012; http://opossum.cisreg.ca), which compares the rate of 
occurrence of a TFBS in the submitted set of genes to the expected rate estimated 
from the pre-computed background set, by describing the normal approximation to the 
binomial distribution and determining how many standard deviations away from this the 
gene-list rate of occurrence lies: the Z-score is equal to this number of standard 
deviations. A Z score of greater than 10 is commonly accepted as significant. 
Clustering analysis of microarray gene expression data was also performed by 
principal component analysis (PCA), in R v3.0.2 using a package provided by 
Professor Benjamin Chain. Modular analysis strategies were also used for microarray 
data analysis purposes, and are discussed and outlined in Chapter 4. 
2.18 Statistical analysis of experimental data 
Statistical tests used for analyses of experimental data are indicated in the 
relevant figure legends, and were performed using GraphPad Prism v6.0. = 
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Chapter 3. Results 1. Attenuation of IL-10 responses 
by HIV-1 in human monocyte-derived macrophages 
3.1 Background 
Previous work has shown that HIV-1-infected MDMs display attenuated IL-10 
responses to Mtb, which are associated with downstream exacerbated pro-
inflammatory responses to Mtb (Tomlinson et al., 2014). IL-10 is a critical 
immunomodulatory cytokine, and so this phenotype may represent a novel host-virus 
interaction with physiologically significant consequences. Elucidation of the mechanism 
behind IL-10 attenuation is therefore merited, to characterize HIV-1 modulation of 
macrophage function, and to further understand CMI dysfunction in HIV-1 infection. 
The initial observation, that full-length replication-competent HIV-1 can attenuate 
the MDM IL-10 response to Mtb, poses several questions. Is this phenotype Mtb-
specific, or can HIV-1 also attenuate IL-10 expression induced by other innate immune 
stimuli? Does the phenotype require ongoing viral propagation with replicative virus, or 
can it result from macrophage-autonomous infection? As HIV-1 has been shown to 
modulate macrophage function in a number of ways (Introduction, section 1.3.8), it is 
possible that IL-10 attenuation represents further direct modulation by the virus; 
therefore, what are the viral determinants of the phenotype? 
The pathways regulating IL-10 production in mononuclear phagocytes are complex 
and highly context-specific (Introduction, section 1.5.2). Exploring which host 
pathways are modulated by HIV-1 to produce specific attenuation of IL-10 while not 
affecting pro-inflammatory cytokines may assist in elucidating the mechanism behind 
the phenotype, and also provide insight into specific regulation of IL-10 responses. 
I aimed to characterise the specificity of IL-10 attenuation, and the viral and host 
determinants of this phenotype, by evaluating the following questions: 
1) Does HIV-1 attenuate IL-10 responses to innate immune stimuli other than Mtb 
in MDMs? 
2) Is IL-10 attenuation by HIV-1 evident over the time-course of the innate immune 
IL-10 response in MDMs? 
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3) If IL-10 attenuation represents direct modulation of macrophage function by 
HIV-1, specific components of the viral lifecycle will be necessary and/or 
sufficient for the phenotype. 
a. Is viral entry necessary or sufficient to cause IL-10 attenuation? 
b. Is HIV-1 integration necessary or sufficient to cause IL-10 attenuation? 
c. Which expressed components of HIV-1 are necessary or sufficient to 
cause IL-10 attenuation? 
4) Type I IFNs have been shown to be involved in regulating IL-10 responses. Is 
this evident in this MDM model, and does HIV-1 modulate this pathway? 
5) Monocytes and DCs can also mount innate immune IL-10 responses. Are these 
affected by HIV-1? 
6) IL-10 can be regulated by post-transcriptional mechanisms. Does HIV-1 alter 
IL-10 mRNA stability? 
7) A range of innate immune signalling pathways have been implicated in 
regulating IL-10 transcription in macrophages. 
a. Which of these signalling pathways are important in MDM IL-10 
responses? 
b. Are any of these signalling pathways modulated by HIV-1 infection? 
 
Chapter 3 Results 
 
 
121 
 
3.2 Results 
3.2.1 IL-10 attenuation by HIV-1 is not Mtb-specific 
The effect of infection with full-length HIV-1 Ba-L on MDM IL-10 responses was 
assessed following stimulation with Mtb culture filtrate and a range of alternative innate 
immune stimuli, including those which have previously been reported to induce IL-10, 
or which share innate immune receptors for Mtb (Table 3.1). The primary cellular 
response to stimulation was initially assessed at four hours. In these experiments, IL10 
mRNA expression and IL-10 protein secretion were reduced in HIV-1 infected MDMs 
compared to uninfected MDMs in response to all stimuli (Figure 3.1). Mtbfiltrate, 
zymosan and curdlan induced the IL10 mRNA responses of the greatest magnitude, 
which were statistically significantly attenuated by HIV-1 (Figure 3.1a). Pam2CSK4 and 
LPS induced smaller IL-10 responses, which were attenuated by HIV-1, but this did not 
reach statistical significance (Figure 3.1a, b).  
These data suggest that HIV-1 inhibits IL-10 induction pathways which are 
conserved in the innate immune responses to different stimuli, and so this phenotype is 
not specific to Mtb. For further experiments evaluating the phenotype of IL-10 
attenuation by HIV-1, I employed zymosan as a model inducer of IL-10 expression, 
which stimulates similar PRRs to Mtb (TLR-2 and dectin-1; Table 3.1). 
Stimulus Description Receptor Reference
Mtbfiltrate
Filtrate from M. tuberculosis 7H9 
cultures
TLR-2, dectin-1, 
TLR-4, others
Tomlinson et al. 2014
Zymosan
Derivative of the cell wall of the 
fungus Saccharomyces cerevisiae
TLR-2, dectin-1 Gantner et al. 2004
Pam2CSK4 Synthetic diacylated lipopeptide TLR-2/6 Long et al. 2009
Curdlan
β-1,3-glucan from Alcaligenes 
faecalis
Dectin-1 Goodridge et al. 2009
LPS
Ultra-pure lipopolysaccharide from 
E. coli  O111:B4
TLR-4 Poltorak et al. 1998
Table 3.1: Innate immune stimuli used to induce IL-10 expression in MDMs. 
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Figure 3.1: IL-10 attenuation by HIV-1 is not Mtb-specific. 
MDMs were infected with HIV-1 (full-length strain Ba-L at an MOI of 3-5) for 1 week, 
and then stimulated for 4 hours with Mtb culture filtrate, zymosan (0.4mg/ml), 
Pam2CSK4 (100ng/ml), curdlan (0.1mg/ml) or LPS (100ng/ml). (a) IL10 mRNA was 
measured 4 hours post-stimulation by qRT-PCR. HIV-1 infected MDMs expressed 
lower levels of IL10 mRNA in comparison to uninfected MDMs in response to all 
stimuli, and a significantly lower level in response to Mtb filtrate, zymosan and curdlan 
(b) IL-10 protein secretion at 4 hours was measured by ELISA of culture supernatants. 
HIV-1 infected MDMs secreted lower levels of IL-10 in comparison to uninfected MDMs 
in response to all stimuli, and significantly lower levels in response to zymosan. * = 
P<0.05, paired t-test. Paired data points from the same experiment are indicated. Bars 
represent the mean result +/- SEM of 4 experiments. Each experiment employed 
MDMs from a single healthy blood donor, and a different donor was used for each 
experiment. Both IL10 mRNA and IL-10 protein production varied up to fourfold 
between different healthy donors; this magnitude of variation was seen consistently 
across experiments. 
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3.2.2 A single-round model of HIV-1 infection can attenuate IL-10 
Next, I investigated whether a single-round model of HIV-1 infection in MDM 
was sufficient to attenuate IL-10 responses. On one hand, this experiment would 
establish whether on-going viral propagation is necessary for the phenotype. More 
importantly, using this approach would also allow further experiments to investigate the 
virological determinants of IL-10 attenuation, as establishing confluent infection in a 
single round mitigates the deleterious effects of viral mutations or deletions in a 
spreading infection. 
For this purpose, I used a HIV-1 clone (R9 Δenv) with a deletion in envelope 
which is produced as a VSV-G pseudotyped virus, and so can infect cells but is not 
capable of assembly, budding or propagation of infection (see Methods section 2.4.2 
for all details of viruses). It should be noted that VSV-G pseudotyped viruses use 
different receptors and potentially routes of entry to WT virus, and so the dynamics of 
this infection may differ from the full-length model. 
Vpx VLPs were used to maximise infection efficiency in this model (described in 
Methods section 2.4.3). As use of Vpx VLPs involves entry of viral components into 
the cell, which are functional and mediate cellular modulation such as degradation of 
SAMHD1, it was possible that they had autonomous effects on IL-10 production, and 
so MDMs were transduced with Vpx VLPs alone and IL-10 transcription was measured. 
Vpx VLPs did not have any effect on IL-10 transcription autonomously, and so their use 
should not alter the phenotype of IL-10 attenuation (Figure 3.2a).  
Confluent infection of MDMs was achieved using the single-round model of 
infection (Figure 3.2b, c). R9Δenv attenuated zymosan-induced IL10 mRNA 
expression in MDMs at 4 hours post-stimulation, while IL6 mRNA expression was 
unaffected (Figure 3.2d). Secretion of IL-10 at 4 hours was similarly attenuated while 
IL-6 was again unaffected (Figure 3.2e).  
These results demonstrate that a single-round infection by HIV-1 can lead to IL-
10 attenuation, similarly to full-length HIV-1. This suggests that ongoing viral 
propagation is not required for IL-10 attenuation, nor are the Env-derived proteins. This 
model was used to further investigate the virological determinants of IL-10 attenuation. 
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In all subsequent experiments using this model, control uninfected MDMs were 
transduced with Vpx VLPs. 
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Figure 3.2: Single round infection by HIV-1 attenuates IL-10. 
(a) MDMs were transduced with Vpx VLPs at 2ng RT/ml and stimulated 1 week  
subsequently with zymosan (0.4mg/ml) for 4 hours. Vpx-transduced MDMs and control 
MDMs expressed similar amounts of IL10 mRNA. (b) HIV-1 p24 staining of Vpx-only 
transduced or single-round HIV-1 (R9Δenv, MOI of 3–5) plus Vpx transduced MDMs. 
(c) Representative images of p24 stains. (d, e) MDMs were infected and stimulated 
with zymosan as in (b). IL10 mRNA expression and protein secretion were significantly 
attenuated in comparison to Vpx-only transduced MDMs. IL6 mRNA expression and 
protein secretion were unaffected. mRNA expression was measured by qRT-PCR, and 
cytokine secretion was measured by ELISA of cell culture supernatants. * = P<0.05, 
n.s. = non-significant, paired t-test. Bars represent the mean result −/+ SEM of at least 
3 experiments.  
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3.2.3 The time-course of the zymosan-induced IL-10 response and HIV-1 
attenuation 
To further evaluate the phenotype of IL-10 attenuation by HIV-1, I characterised 
the time-course of the zymosan-induced IL-10 response, and for comparison, the pro-
inflammatory IL-6 and TNFα responses, and the effects of HIV-1 infection on these 
responses over a time-course of 1–72 hours. Induction of IL10 mRNA expression in 
response to zymosan was evident from 3 hours and peaked at 6 hours, before 
returning to baseline levels by 24 hours (Figure 3.3a). Attenuation of this response by 
HIV-1 was evident across the time-course, and was statistically significant at 3–6 
hours. It was also clear that although HIV-1 attenuated IL10 mRNA expression, it did 
not entirely inhibit it, as some IL10 mRNA expression was induced in HIV-1 infected 
MDMs over a similar time-course to uninfected MDMs (Figure 3.3a). IL6 and TNFA 
mRNA expression in response to zymosan was not attenuated by HIV-1 at any time-
point (Figure 3.3b, c). 
Similar observations were made when measuring zymosan-induced cytokine 
secretion over this time-course. IL-10 protein secretion was detected from 3 hours, at 
which time IL-10 attenuation was already evident (Figure 3.4a). Peak levels of IL-10 
were measurable in the MDM culture supernatants at 12 hours, and these then 
declined over the following 60 hours (Figure 3.4a). HIV-1 attenuation was evident 
across the time-course and was statistically significant at 3, 12 and 72 hours (Figure 
3.4a). IL-6 and TNFα protein secretion was measured at 6, 24 and 72 hours, and was 
evident across the time-course for both cytokines, with no clear diminution of these 
responses over 72 hours, or as a result of HIV-1 infection (Figure 3.4b, c). 
These results demonstrated that HIV-1 attenuated the innate immune IL-10 
response to zymosan across the time-course of IL-10 production. They also confirmed 
that attenuation was specific to the IL-10 response and did not similarly affect pro-
inflammatory cytokines.  
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Figure 3.3: The time-course of zymosan-induced cytokine mRNA expression. 
 MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml) for 1 week and then stimulated with zymosan (0.4mg/ml) for 1–72 hours. 
Cytokine mRNA expression was measured by qRT-PCR. (a) IL10 mRNA expression 
was significantly attenuated by HIV-1 at 3 and 6 hours post-stimulation. (b) IL6 mRNA 
expression was not altered by HIV-1 at any time-point. (c) TNFA mRNA expression was 
not altered by HIV-1 at any time-point. * indicates P<0.05, paired t-test. Bars represent 
the mean −/+ SEM of at least 3 experiments. 
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Figure 3.4: The time-course of zymosan-induced cytokine secretion. 
 MDMs were infected with HIV-1 and stimulated with zymosan as in Figure 3.3. 
Cytokine secretion was measured by ELISA of cell culture supernatants. (a) IL-10 
secretion was significantly attenuated by HIV-1 at 3, 12 and 72 hours. (b) IL-6 
secretion was not altered by HIV-1 at any time-point assessed. (c) TNFα secretion was 
not altered by HIV-1 at any time-point assessed. * indicates P<0.05, paired t-test. Bars 
represent the mean −/+ SEM of at least 3 experiments. 
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3.2.4 IL-10 attenuation is not affected by protease inhibitors 
Infection with a single-round model of HIV-1 infection demonstrated that viral 
propagation is not necessary for IL-10 attenuation. Viral propagation can be also be 
prevented by ARVs, which inhibit parts of the viral lifecycle. To test whether IL-10 
attenuation could persist in the context of ART, the protease inhibitor indinavir was 
supplemented into confluently HIV-1-infected MDM cultures, and IL-10 secretion in 
response to zymosan was measured. 
The mechanism of action of protease inhibitors is shown in Figure 3.5a. Briefly, 
during budding, the HIV-1 particle undergoes a maturation process mediated by the 
viral protease, which is necessary for infection of new cells (Flexner, 1998). HIV-1 
clones lacking the protease gene produce only immature non-infectious viral particles 
(Kohl et al., 1988), and protease inhibitors are understood to exert the same effect. 
Addition of indinavir to infected MDMs led to a near-complete reduction in HIV-1 
p24 measurable in the culture supernatant (Figure 3.5b), indicating that release of 
mature virus was abrogated. IL-10 protein secretion in response to zymosan was 
attenuated in infected MDMs supplemented with indinavir (Figure 3.5c). Indinavir 
alone had no effect on cytokine secretion, and secretion of IL-6, assessed for 
comparison, was unaffected in all conditions (Figure 3.5d). This supports conclusions 
made based on the single-round virus experiments; that viral propagation is not 
necessary for attenuation to occur. It also indicates that HIV-1 attenuation of 
macrophage IL-10 responses might persist in the context of anti-retroviral therapy, 
while a reservoir of non-productively infected macrophages remains. 
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Figure 3.5: Inhibition of HIV-1 protease does not alter IL-10 attenuation by HIV-1. 
(a) Schematic of the protease inhibitor mechanism of action. (b) MDMs were infected 
with HIV-1 for one week of spreading infection (full-length strain Ba-L, at an MOI of 3–
5) and then were treated with the protease inhibitor indinavir sulphate at 10µM for 3 
days prior to zymosan stimulation.  Inhibition of mature virion production was assessed 
by p24 ELISA of cell culture supernatants. Indinavir sulphate treatment reduced p24 
levels by 2 logs. (c, d) MDMs were stimulated with zymosan (0.4mg/ml) for 4 hours. IL-
10 and IL-6 secretion were assessed by ELISA of cell culture supernatants. HIV-1 
significantly attenuated IL-10 secretion, and this was not altered by indinavir treatment. 
Indinavir alone had no effect on IL-10 production. IL-6 secretion was not altered by 
HIV-1 infection or indinavir treatment. * indicates P<0.05, paired t-test. Bars represent 
the mean +/- SEM of 4 experiments.   
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3.2.5 HIV-1 entry is not sufficient for IL-10 attenuation 
Treatment of viral particles with ultra-violet (UV) radiation dimerises viral nucleic 
acids, which are then non-replicable, rendering the virus non-infectious (Mohr et al., 
2009). The consequences of UV treatment for HIV-1 are that the virus can enter the 
cell, but is unable to reverse transcribe or integrate its genome, and thus is unable to 
establish infection. UV-inactivated HIV-1 was used to assess whether viral entry was 
sufficient to cause IL-10 attenuation, or whether the presence of viable viral nucleic 
acid was necessary for the phenotype. No HIV-1 LTR transcript was detected in MDMs 
infected with UV-treated virus after 1 week (Figure 3.6a), and there was no attenuation 
of IL10 mRNA expression in response to zymosan (Figure 3.6b). IL-10 protein 
secretion in response to zymosan was also reduced by HIV-1 but not by UV-treated 
HIV-1, although these differences did not reach statistical significance (Figure 3.6d). 
IL-6 responses were not affected (Figure 3.6c, e). 
These data indicated that HIV-1 entry alone is not sufficient for IL-10 
attenuation, but that carriage of viable viral genomes is required. I explored this 
observation further, by assessing the relationship between the timing of HIV-1 infection 
and the presence of the IL-10 attenuation phenotype (Figure 3.7). MDMs were infected 
with HIV-1 at 1 week, 24 hours or 4 hours before zymosan stimulation, or were infected 
at the same time as stimulation. MDMs which had been infected for 1 week or 24 hours 
pre-stimulation displayed statistically significantly attenuated IL10 mRNA expression, 
whereas those which had been infected for 4 hours or simultaneously with stimulation 
did not (Figure 3.7a).  The MDMs that were infected for 4 hours prior to stimulation, or 
that were simultaneously infected with stimulation, were within the first 8 hours of viral 
infection when they were assessed. Previous reports suggest that integration of the 
HIV-1 pro-virus will not have occurred in this timeframe (Mohammadi et al., 2013), and 
thus that nascent viral production will not have commenced. In-keeping with this 
hypothesis, detectable HIV-1 RNA levels decreased over this time-frame (4–8 hours) 
post-infection (Figure 3.7b), suggesting that de novo viral transcription from an 
integrated provirus had not yet occurred. These results indicated that early post-entry 
events are not sufficient for HIV-1 to attenuate IL-10 responses, but that subsequent 
steps in the viral life-cycle involving the viral genome may be necessary, such as 
integration of the HIV-1 provirus. 
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Figure 3.6: UV-inactivated HIV-1 does not attenuate IL-10. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml), or an equivalent inoculum in which HIV-1 was UV-inactivated (UV-C, 254nm, 
for 10 min). MDMs were stimulated with zymosan (0.4mg/ml) for 4 hours at 1 week 
post-infection. mRNA expression was measured by qRT-PCR and secretion was 
measured by ELISA of cell culture supernatants. (a) HIV-1 RNA was measured by qRT-
PCR for the HIV-1 LTR. No HIV-1 RNA was detectable in MDMs infected with UV-
inactivated HIV-1. (b) HIV-1, but not UV-inactivated HIV-1, significantly attenuated IL10 
mRNA expression in response to zymosan. (c) IL6 mRNA expression was not altered 
by HIV-1 infection. (c) HIV-1, but not UV-inactivated HIV-1, reduced IL-10 secretion in 
response to zymosan. (d) IL-6 secretion was not altered by HIV-1 infection. * indicates 
P<0.05, paired t-test. n.d., not detectable. Bars represent the mean −/+ SEM of 4 
experiments. 
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Figure 3.7: The timing of IL-10 attenuation post-infection indicates that early 
post-entry events are not sufficient. 
 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml) and then stimulated for 4 hours with zymosan (0.4mg/ml) at the indicated times 
(0h, 4h, 24h, 1 week) post-HIV-1 infection (a) IL10 mRNA expression was measured by 
qRT-PCR. Expression was significantly attenuated at 24h and 1 week post-HIV-1 
infection, but not 4h post-infection or when zymosan and HIV-1 were added 
simultaneously. (b) HIV-1 transcript in MDMs measured by qRT-PCR for the HIV-1 
LTR. Viral RNA was detectable at 4 hours post-infection (the 0h HIV-1 condition, as all 
conditions have 4 hours of zymosan stimulation after the infection), which dropped 
approximately fourfold after 8 hours of infection, before rising >100-fold 28 hours post-
infection and remaining stable at this level for 1 week. * indicates P<0.05, paired t-test. 
n.d., not detectable. Bars represent the mean −/+ SEM of 4 experiments. 
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3.2.6 Integration by HIV-1 is necessary but not sufficient for IL-10 attenuation 
Once HIV-1 enters the cell, the RNA viral genome is reverse transcribed into a 
DNA copy by the viral reverse transcriptase. This DNA is then integrated into the host 
cell genome to form the HIV-1 provirus by the action of the viral integrase. To establish 
if these events in the viral lifecycle are necessary for IL-10 attenuation, a full-length 
HIV-1 clone with a mutation in the integrase active site was employed (Rasaiyaah et al., 
2013), which is capable of cell entry and reverse transcription but not integration (see 
Methods section 2.4.2 for details of this virus). MDMs were infected with this virus 
(HIV-1ΔIN) or its WT parent virus. Confluent infection with the WT virus was confirmed 
at 2 weeks post-infection by HIV-1 p24 staining of MDM cultures (Figure 3.8a, b). 
MDMs infected with HIV-1ΔIN were negative for HIV-1 p24, confirming that this virus 
could not establish replicative infection (Figure 3.8a, b). IL-10 secretion in response to 
zymosan was statistically significantly attenuated by WT HIV-1 but not by HIV-1ΔIN 
(Figure 3.8c), suggesting that integration is necessary for IL-10 attenuation to occur. 
Insertion of viral DNA into the host genome has an inherent mutagenic potential, 
and can lead to dysregulation of expression of host genes (Cavazza et al., 2013). 
Proviral integration itself may thus have consequences for cell function, irrespective of 
the transcription and production of new viral components. IL-10 attenuation may 
therefore be a consequence of integration itself. To assess whether integration was 
sufficient to cause IL-10 attenuation, I employed a HIV-1 based viral vector (HR’) 
carrying a genome with just the GFP gene, and no HIV-1 components other than the 
viral LTRs (see Methods section 2.4.2 for details). The absence of mature HIV-1 
proteins expressed after infection with this virus was confirmed by negative HIV-1 p24 
staining of transduced cells (Figure 3.9a, c). Successful integration of the sequence 
carried by HR’ was confirmed by measuring transcription from the HIV-1 LTR, which 
was present, albeit at lower levels than with single-round HIV-1 (Figure 3.9b). 
HR’-transduced cells did not exhibit attenuated IL-10 responses at the level of 
mRNA expression or protein secretion, in comparison to single-round HIV-1, which 
statistically significantly attenuated both (Figure 3.9c, e). IL6 mRNA expression was 
not affected by either virus (Figure 3.9d). This suggests that integration alone is not 
sufficient for IL-10 attenuation, but that it is necessary for the provirus to express HIV-1 
genes.
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Figure 3.8: An integrase mutant of HIV-1 does not attenuate IL-10. 
 
MDMs were infected with HIV-1 (full length strain NL4.3 BaL, MOI of 15) or an integrase 
deficient (ΔIN) mutant (NL4.3 BaLΔIN – D116N) for 2 weeks of spreading infection. (a) Cultures 
were stained for HIV-1 p24 to enumerate infected cells. HIV-1 p24 staining of cells infected with 
the ΔIN mutant did not significantly exceed background levels. (b) Representative images of 
HIV-1 p24 staining (blue). (c) MDMs were stimulated with zymosan (0.4mg/ml) and IL-10 
secretion was measured by ELISA of cell culture supernatants. HIV-1 significantly attenuated 
IL-10 secretion in comparison to uninfected MDMs or MDMs infected with the ΔIN mutant. HIV-
1ΔIN did not attenuate IL-10 secretion. * indicates P<0.05, paired t-test. n.s., not significant. 
Bars represent the mean −/+ SEM of 4 experiments. 
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Figure 3.9: A HIV-1-based lentiviral vector does not attenuate IL-10. 
 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng RT/ml), or a 
HIV-1-based viral vector (HR’) carrying only the eGFP gene under the control of the CMV 
promoter (7ng RT/ml with Vpx VLPs at 2ng RT/ml). MDMs were stimulated with zymosan 
(0.4mg/ml) for 4 hours at 1 week post-infection. mRNA expression was measured by qRT-PCR 
and secretion was measured by ELISA of cell culture supernatants. (a) Cultures were stained 
for HIV-1 p24 to enumerate infected cells. Staining of cells infected with HR’ did not significantly 
exceed background levels. (b) HIV-1 transcript was measured by qRT-PCR for the HIV-1 LTR, 
and was detectable in cells infected with HIV-1 or HR’, but was significantly less in those 
infected with HR’. (c) Representative images of HIV-1 p24 staining (blue). (d) HIV-1, but not 
HR’, significantly attenuated IL10 mRNA expression in response to zymosan. (e) IL6 mRNA 
expression was not affected. (f) HIV-1, but not HR’, reduced IL-10 secretion in response to 
zymosan. * indicates P<0.05, paired t-test. n.d., not detectable. Bars represent the mean −/+ 
SEM of 3 experiments. 
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3.2.7 HIV-1 Gag-Pol is not necessary for IL-10 attenuation 
As integration of a provirus containing HIV-1 genetic material was necessary for 
IL-10 attenuation, I next investigated which HIV-1 gene products were necessary for 
this phenotype. The single-round virus, deleted in env, suggested that the Env-derived 
viral glycoproteins gp120 and gp41 were not necessary for attenuation. To assess 
whether components of the HIV-1 gagpol coding region, wherein the viral capsid and 
enzymes are encoded, were necessary for IL-10 attenuation, a mutant clone of HIV-1 
(GagLucGFP) was used. In this virus, Gag-Pol expression is disrupted by cloning of 
the luciferase gene into this region (see Methods section 2.4.2 for details). Infectious 
particles are produced using a separate Gag-pol expressor packaging plasmid. 
Deficiency of HIV-1 capsid protein expression using GagLucGFP was 
confirmed by the absence of HIV-1 p24 staining in infected MDMs (Figure 3.10a, c), 
which also confirms the absence of immature HIV-1 gag p55. Transcription from the 
integrated provirus was confirmed by measurement of HIV-1 LTR transcript (Figure 
3.10b). Expression of viral accessory proteins in the absence of HIV-1 capsid 
expression in GagLucGFP infection was confirmed by western immunoblotting for HIV-
1 gag p55 and p24 and the accessory protein Vif (Figure 3.10d). The absence of viral 
enzymes was confirmed by an RT-ELISA of concentrated supernatants from HEK293T 
cells transfected with GagLucGFP plasmid with or without a Gag-Pol expressor 
plasmid. This showed that no RT was detectable in the latter condition (Figure 3.10e).  
IL10 mRNA expression in response to zymosan was reduced in MDMs infected 
with both WT HIV-1 and GagLucGFP, but this did not reach statistical significance in 
either condition (Figure 3.11a). However, IL-10 secretion was statistically significantly 
reduced by both WT HIV-1 and GagLucGFP (Figure 3.11c). IL6 mRNA expression 
was not affected by either virus (Figure 3.11b). These results suggest that Gag-Pol 
expression is not necessary for IL-10 attenuation, and thus that the viral components 
encoded in this region – capsid proteins, integrase, reverse transcriptase and protease 
– are not necessary for this phenotype.  
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Figure 3.10: Infection using GagLucGFP, a HIV-1 mutant which does not express Gag-
Pol. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng RT/ml), or a 
HIV-1 mutant with the luciferase gene cloned into the GagPol coding sequence to disrupt it 
(GagLucGFP; at 7ng RT/ml with Vpx VLPs at 2ng RT/ml). Assessments were made 1 week 
post-infection. (a) Cultures were stained for HIV-1 p24 to enumerate infected cells. Staining of 
cells infected with GagLucGFP did not significantly exceed background levels. (b) HIV-1 RNA 
was measured by qRT-PCR for the HIV-1 LTR, and was detectable in cells infected with HIV-1 
or GagLucGFP, but was less in those infected with GagLucGFP. (c) Representative images of 
HIV-1 p24 staining (blue). (d) Western immunoblotting for HIV-1 proteins. Capsid proteins p55 
gag and p24 were detectable in cells infected with HIV-1, but not GagLucGFP. The HIV-1 
accessory protein Vif was detectable in both infections. β-actin was used as a loading control. 
(e) Supernatants from HEK293T cells transiently transfected with the indicated plasmids were 
concentrated by ultracentrifugation and HIV-1 RT was measured by an RT ELISA. RT was not 
detectable in supernatants derived from GagLucGFP transfection unless a Gag-Pol expression 
plasmid (p8.91) was also transfected, indicating lack of functional RT in GagLucGFP. n.d., not 
detectable. Bars represent the mean −/+ SEM of 3 experiments. 
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Figure 3.11: The HIV-1 mutant GagLucGFP attenuates IL-10. 
MDMs infected as in Figure 3.10 were stimulated with zymosan (0.4mg/ml) for 4 hours. 
(a) IL10 mRNA expression was measured by qRT-PCR, and was significantly induced 
by zymosan. HIV-1 and GagLucGFP both reduced IL10 mRNA expression but this was 
not significant. (b) IL6 mRNA expression was not altered by either virus. (c) IL-10 
secreted by MDMs was measured by ELISA of cell culture supernatants. HIV-1 and 
GagLucGFP significantly attenuated IL-10 secretion in response to zymosan. There 
was no significant difference between levels of IL-10 secreted by HIV-1 infected or 
GagLucGFP infected MDMs. * indicates P<0.05, paired t-test. Bars represent the mean 
−/+ SEM of 3 experiments. 
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3.2.8 The HIV-1 accessory proteins Nef, Vif and Vpr are not individually 
necessary for IL-10 attenuation 
HIV-1 Gag-Pol and Env expression were shown not to be necessary for IL-10 
attenuation but the role of the other six HIV-1 proteins in the mechanism of this 
phenotype remained to be explored. The viral regulatory proteins are Tat and Rev, 
which transactivate viral transcription and co-ordinate viral RNA transport respectively. 
As a result, Tat and Rev are difficult to assess in isolation via deletion, as their function 
is necessary for expression of all HIV-1 genes. The other four accessory proteins are 
non-essential for infection of cells by HIV-1, but provide functions which enhance 
replication such as counteracting host restriction factors (Strebel, 2013). The 
consequences of their loss-of-function can thus be assessed using a high-efficiency 
single-round model of infection such as the one presented in Figure 3.2. Using this 
model, the consequences of the loss-of-function of these proteins for propagation of 
infection are mitigated by achieving confluent infection of the culture in a single 
transduction. 
To assess the role of accessory proteins in IL-10 attenuation, deleterious 
mutations in the genes encoding for the accessory proteins Vif, Nef and Vpr were 
cloned into the R9Δenv single-round infection background (see Methods section 2.4.2 
for details of mutants). Establishment of confluent infection in MDM cultures using 
these mutants was confirmed by HIV-1 p24 staining (Figure 3.12a, c), and they also 
displayed similar levels of viral transcript as the WT virus (Figure 3.12b). Deletions of 
Vif and Nef were confirmed by western blotting (Figure 3.13); suitable antibody 
reagents to confirm the Vpr deletion were not identified. 
All mutants tested statistically significantly attenuated IL10 mRNA expression in 
response to zymosan (Figure 3.14a), while IL6 mRNA expression was unaffected 
(Figure 3.14b). IL-10 protein secretion was also significantly attenuated by all mutants 
(Figure 3.14c), excepting the HIV-1Δvif mutant, which non-statistically significantly 
attenuated IL-10 secretion. This suggests that the HIV-1 accessory proteins Nef, Vif 
and Vpr are not necessary for IL-10 attenuation.  
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Figure 3.12: Infection with HIV-1 clones with mutations in the accessory 
genes Nef, Vif and Vpr. 
 
MDMs were infected with HIV-1 clones with mutations in the accessory genes Nef, Vif 
and Vpr. These mutants were all in the single-round infection R9Δenv background and 
were used at an MOI of 3–5, with Vpx VLPs at 2ng RT/ml. Assessments were made 1 
week post-infection. (a) Cultures were stained for HIV-1 p24 to enumerate infected 
cells. Staining of cells infected with deletion mutants was equivalent to that with WT 
virus. (b) HIV-1 RNA was measured by qRT-PCR for the HIV-1 LTR, and was 
equivalent in cells infected with deletion mutants to that with WT virus. (c) 
Representative images of HIV-1 p24 staining (blue). Bars represent the mean −/+ SEM 
of at least 3 experiments. 
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Figure 3.13: Confirmation of HIV-1 accessory protein deletions by western 
blotting. 
MDMs were infected with HIV-1 clones with mutations in the accessory genes Nef, Vif 
and Vpr as in Figure 3.12. Western immunoblotting for Nef and Vif was performed to 
confirm deletions. Immunoblotting for HIV-1 p55 gag and p24 was performed to confirm 
HIV-1 infection, and β-actin was used as a loading control.  
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Figure 3.14: HIV-1 clones with mutations in the accessory genes Nef, Vif and Vpr 
attenuate IL-10. 
 
MDMs infected as in Figure 3.12 were stimulated with zymosan (0.4mg/ml) for 4 hours. 
mRNA expression was measured by qRT-PCR and secretion was measured by ELISA 
of cell culture supernatants. (a) IL10 mRNA expression was significantly attenuated by 
WT HIV-1 and all mutants. (b) IL6 mRNA expression was not affected by any virus 
used. (c) IL-10 secreted by MDMs was significantly attenuated by WT HIV-1 and all 
mutants tested, except HIV-1Δvif, in which secretion was non-significantly reduced 
(P=0.054). * indicates P<0.05, paired t-test. Bars represent the mean −/+ SEM of at 
least 3 experiments. 
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3.2.9 Type I IFN does not induce IL-10 in human MDMs 
Recently, investigations of type I IFN responses in mycobacterial infection have 
suggested that they may exert an immunosuppressive effect by inducing IL-10 
expression in monocytes and macrophages (Mayer-Barber et al., 2011; McNab et al., 
2013; Teles et al., 2013). Corroboration of this observation in human MDMs, and 
investigation of whether HIV-1 could attenuate such a pathway, may provide insight 
into both the mechanism and the stimulus-specificity of IL-10 attenuation. Therefore, I 
sought to test whether induction of IL-10 expression by type I IFNs in human MDMs 
occurs, and if so, whether this can be attenuated by HIV-1 infection.  
Stimulation of MDMs for 24 hours with either IFNα or IFNβ did not induce IL-10 
mRNA expression or protein secretion (Figure 3.15a, b). This phenotype was not 
affected by HIV-1 infection. Type I IFN responses in MDMs at this time-point were 
confirmed by measuring mRNA of a prototypic IFN responsive gene, IFI16 (Trapani et 
al., 1994), which was induced by both IFNα and IFNβ (Figure 3.15c). These data 
suggest that type I IFNs do not induce IL-10 responses over this time-course in M-CSF 
differentiated human MDMs, although they do induce other gene expression changes. 
In mouse models, it has been reported that type I IFNs may be involved in 
inducing IL-10 expression in the context of innate immune stimulation, wherein LPS-
induced IFNβ acts on macrophages in an autocrine fashion to mediate the LPS-
induced IL-10 response (Chang et al., 2007).  To test whether this mechanism played a 
role in zymosan-induced IL-10 responses and attenuation of these by HIV-1, MDMs 
were stimulated with zymosan in the presence of neutralising antibody to the β chain of 
the IFNα/β receptor (anti-IFNAR2), a method which has been shown to effectively 
neutralise type I IFN responses in MDM cultures (Rasaiyaah et al., 2009). Anti-IFNAR2 
supplementation had no effect on zymosan-induced IL-10 mRNA expression or protein 
secretion, or HIV-1 attenuation thereof (Figure 3.16), suggesting that type I IFN does 
not contribute to this phenotype. 
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Figure 3.15: Type I IFNs do not induce IL-10 production in human MDMs. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml) for 1 week, and stimulated with zymosan (Zym., 0.4mg/ml) for 4 hours, or either 
IFNα or IFNβ (200IU/ml) for 24 hours. (a) IL10 mRNA expression was measured by 
qRT-PCR. Zymosan induced IL10 mRNA expression, which was attenuated in HIV-1 
infected MDMs. IFNα and IFNβ did not induce IL10 mRNA expression. (b) IL10 protein 
secretion was measured by ELISA of cell culture supernatants. Zymosan induced IL10 
secretion, which was attenuated in HIV-1 infected MDMs. IFNα and IFNβ did not 
induce IL-10 secretion. (c) IFI16 mRNA expression was measured by qRT-PCR. Both 
IFNα and IFNβ induced IFI16 mRNA expression. * indicates P<0.05, paired t-test. Bars 
indicate the mean +/- SEM of at least 3 experiments. 
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Figure 3.16: Type I IFNs do not contribute to zymosan-induced IL-10 
responses. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng RT/ml) 
for 1 week, and stimulated with zymosan (Zym., 0.4mg/ml) for 4 hours, with or without 
neutralising antibody to the β chain of the IFNα/β receptor (anti-IFNAR2, 1μg/ml). (a) IL-10 
mRNA expression was measured by qPCR. Zymosan induced IL-10 mRNA expression, 
and this was attenuated by HIV-1. This phenotype was not altered by anti-IFNAR2 
supplementation. (b) IL-10 secretion was measured by ELISA of cell culture supernatants. 
Zymosan induced IL-10 secretion, and this was attenuated by HIV-1. This phenotype was 
not altered by anti-IFNAR2 supplementation. * indicates P<0.05, paired t-test. Bars 
indicate the mean +/- SEM of at least 3 experiments. 
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3.2.10 IL-10 attenuation by HIV-1 is context-specific 
IL-10 can be produced by cells of the mononuclear phagocyte system other 
than macrophages, such as monocytes and DCs (Saraiva and O’Garra, 2010). 
Therefore, in order to assess the cell specificity of IL-10 attenuation by HIV-1, I tested 
the effect of HIV-1 infection on innate immune IL-10 responses in peripheral blood 
monocytes, MDMs differentiated with GM-CSF rather than M-CSF, and MDDCs 
differentiated with IL-4 and GM-CSF. This may provide insight into the mechanism of 
IL-10 attenuation, as different signalling pathways are thought to be involved in the 
induction of IL-10 responses in different myeloid cells (Saraiva and O’Garra, 2010), as 
well as determining the context-specificity of this phenotype. 
All cell types were infected using the single-round (R9Δenv with Vpx VLPs) 
model of HIV-1 infection, thus overcoming post-entry restrictions that have previously 
been reported in monocytes, GM-CSF differentiated MDM or MDDC. After 24 hours of 
infection, cells were stimulated with either zymosan, as an innate immune inducer of 
IL-10, or IFNβ, to assess whether type I IFNs induce IL-10 in cell types other than 
macrophages. HIV-1 transcription could be measured in all cell types 24 hours post-
infection, suggesting that the virus had successfully integrated and was transcribing in 
all contexts tested (Figure 3.17a). IL10 mRNA expression was induced by zymosan in 
monocytes, M-CSF MDMs and MDDCs, but not in GM-CSF MDMs (Figure 3.17b). 
HIV-1 statistically significantly attenuated this response in M-CSF MDMs only (Figure 
3.17b). Significant induction of IL10 mRNA expression by IFNβ was not observed in 
any cell type. TNFA mRNA expression was measured to assess pro-inflammatory 
responses, and occurred in response to zymosan in all cell types. This was unaffected 
by HIV-1 infection (Figure 3.17b). 
Zymosan induced IL-10 protein secretion in monocytes and M-CSF MDMs 
(Figure 3.18a). IL-10 protein secretion was also evident in MDDCs, but this experiment 
was not adequately powered to reach statistical significance, and GM-CSF MDMs did 
not secrete IL-10 under any condition (Figure 3.18a).  HIV-1 infection significantly 
attenuated IL-10 protein secretion in M-CSF MDMs (Figure 3.18a), in-keeping with 
previous data (Figure 3.1). In monocytes, HIV-1 infection was associated with reduced 
zymosan-induced IL-10 secretion, but this did not reach statistical significance (Figure 
3.18a). 
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Induction of IL-10 by type I IFN was only observed in MDDCs, which secreted 
IL-10 after stimulation with IFNβ; however, this failed to reach statistical significance 
(Figure 3.18a). Cellular responses to IFNβ were confirmed by measuring IFI16 mRNA 
expression, which was induced by IFNβ in all cell types (Figure 3.18b). 
These results demonstrate striking cell-type specificity, in both the magnitude of 
IL-10 responses to zymosan and in the effect of HIV-1 infection on these. Considering 
the fact that equivalent levels of HIV-1 infection and pro-inflammatory cytokine 
responses are observed in all cell types tested, these results strongly suggest that 
innate immune IL-10 responses are differentially regulated in each cell, and 
consequently that there is a context-specific effect of the virus in exerting IL-10 
attenuation. 
Any role for type I IFN in inducing IL-10 responses is not demonstrated by 
these experiments. IFNβ does not induce IL-10 in human monocytes over 24 hours 
(Figure 3.17b, Figure 3.18a) as previously reported (Teles et al., 2013). The only 
context tested in which any IL-10 is produced in response to IFNβ is a secretory 
response in MDDCs, but that did not reach significance (Figure 3.18a), and IL10 gene 
expression is not induced by IFNβ in these cells (Figure 3.17b). 
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Figure 3.17: IL-10 transcription and HIV-1 attenuation in mononuclear phagocytes. 
Monocytes were isolated from peripheral blood by CD14+ positive selection, and either infected 
with HIV-1 directly ex vivo (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng RT/ml), or 
differentiated into MDMs with either M-CSF (20ng/ml) or GM-CSF (20ng/ml), or into MDDCs 
with IL-4 (50ng/ml) and GM-CSF (100ng/ml). MDMs and MDDCs were differentiated for 6 days 
and then infected with HIV-1 as above. (a) HIV-1 transcription in different cell types was 
measured by qRT-PCR for the HIV-1 LTR. No HIV-1 transcript was detectable in uninfected 
cells. (b) After 24 hours of HIV-1 infection, each cell type was stimulated with zymosan (Zym., 
0.4mg/ml) for 4 hours or IFNβ (200IU/ml) for 24 hours. IL10 and TNFA mRNA expression were 
measured by qRT-PCR. IL10 mRNA expression in response to zymosan occurred in 
monocytes, MDDCs and M-CSF differentiated MDMs, and this was attenuated by HIV-1 
infection in the latter. TNFA mRNA expression in response to zymosan occurred in all cell 
types. IFNβ did not induce IL10 or TNFA mRNA expression in any cell type. * indicates P<0.05, 
paired t-test; * above bars indicates difference from unstimulated cells, and * above brackets 
indicates difference between the relevant bars. 
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Figure 3.18: IL-10 secretion, HIV-1 attenuation and IFN responses in 
mononuclear phagocytes. 
For details of cell differentiation, HIV-1 infection and stimulation, please see Figure 
3.17 legend. (a) IL-10 protein secretion was measured by ELISA of cell culture 
supernatants. Secretion of IL-10 in response to zymosan occurred in monocytes and 
M-CSF differentiated MDMs, and this was attenuated by HIV-1 infection in the latter. 
Significant induction of IL-10 secretion did not occur in HIV-1 infected monocytes.  
IL-10 secretion was observed in response to zymosan and IFNβ in MDDCs, but this 
was not significant in comparison to unstimulated MDDCs. (b) IFI16 mRNA expression 
was measured by qRT-PCR, and occurred in response to IFNβ in all cell types. * 
indicates P<0.05, paired t-test.  Bars indicate the mean +/- SEM of at least 3 
experiments. 
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3.2.11 HIV-1 does not accelerate IL-10 mRNA decay 
In addition to being controlled transcriptionally, inflammatory responses can 
also be regulated by effects on mRNA stability and decay (Hao and Baltimore, 2009), 
for example by the activity of RNA-degrading enzymes, or via the action of micro-
RNAs. The molecular details of some of these mechanisms have been elucidated for 
pro-inflammatory cytokines such as IL-6 (Iwasaki et al., 2011) and TNFα (Carballo et 
al., 1998) and also for IL-10 (Stoecklin et al., 2008; Teixeira-Coelho et al., 2013). I 
therefore sought to test the hypothesis that reduction of IL10 mRNA levels observed in 
the context of HIV-1 infection could be due to accelerated IL10 mRNA decay. This 
hypothesis might underpin the observation that some induction of IL10 mRNA by 
zymosan was still evident in HIV-1 infected MDM. 
To measure cytokine mRNA decay rates, an inhibitor of transcription, 
actinomycin D, was employed. Actinomycin D prevents any new transcription by 
inhibiting RNA polymerase II (Sobell, 1985), and so sequential measurements of 
mRNA levels after its addition can be used to plot the rate of mRNA decay. MDMs with 
and without HIV-1 infection were stimulated with zymosan for 3 hours, after which 
actinomycin D was added. Measurements of mRNA levels were then made over the 
following 3 hours. 
As expected, less IL10 mRNA was induced by zymosan in HIV-1 infected 
MDMs (Figure 3.19a). Decay of IL10 mRNA clearly occurred over 3 hours in both 
unstimulated and zymosan-stimulated cells, and this was shown to be statistically 
significant by two-way ANOVA (Figure 3.19a). IL10 mRNA decay rates appeared 
similar in HIV-1 infected MDMs (Figure 3.19a). Decay rates were quantified by fitting a 
one-phase decay curve and measuring the mRNA half-life (Table 3.2). The half-lives 
calculated for IL10 mRNA were longer in HIV-1 infected MDMs, suggesting that the 
mRNA was in fact more stable in this context, rather than less stable.  This suggests 
that HIV-1 does not attenuate IL-10 by accelerating the rate of IL10 mRNA decay. 
The effects of HIV-1 on pro-inflammatory cytokine mRNAs were also measured. 
Statistically significant decay over this time-course was detected for TNFA mRNA in 
unstimulated and zymosan-stimulated MDMs, and for IL1B mRNA in unstimulated 
MDMs (Figure 3.19b, c). IL1B and IL6 mRNA in zymosan-stimulated MDMs did not 
show statistically significant decay rates, potentially reflecting increased stability of 
these mRNAs due to activation of inflammatory signalling (Figure 3.19c, d, Hao and 
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Baltimore, 2009)). HIV-1 did not accelerate any cytokine mRNA decay rates, but in fact 
stabilised all cytokine mRNAs measured, as quantified by one-phase decay half-lives. 
These were increased for all mRNAs measured, or in some cases could no longer be 
calculated as decay curves could no longer be fitted to the data (Table 3.2). 
These results demonstrate that HIV-1 does not attenuate IL-10 responses by 
modulating cytokine mRNA decay pathways. However, they do strongly suggest that 
cytokine mRNA is differentially regulated in HIV-1 infected MDMs, as all cytokine 
mRNAs tested were found to be more stable in this context. 
 
 
Table 3.2: Cytokine mRNA half-lives calculated from one phase decay curves. 
Half-lives for cytokine mRNAs were calculated from fitted one-phase decay curves 
using GraphPad Prism 6. Where significant decay curves could not be fitted, 
suggesting that mRNA did not decay, half-lives are not presented (indicated by n/a). 
Zymosan stimulation increased the half-life of TNFA mRNA and prevented decay of 
IL1B mRNA. HIV-1 infection increased half-lives or prevented decay for all cytokine 
mRNAs measured. Data are derived from the results of 3 experiments. 
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Figure 3.19: HIV-1 does not accelerate cytokine mRNA decay. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng RT/ml) for 1 
week and then stimulated with zymosan (0.4mg/ml) for 3 hours, at which time actinomycin D 
(an RNA polymerase II inhibitor) was added to cultures at 10ug/ml to inhibit further transcription. 
RNA samples were collected at 0, 30, 60, 120 and 180 minutes post-actinomycin D addition. 
Levels of cytokine mRNA at each time-point were measured by qRT-PCR. One-phase decay 
curves were fitted to data using GraphPad Prism 6. Symbols show mean mRNA level −/+ SEM 
at each time-point and lines show one-phase decay curves. The X-axis shows time post-
actinomycin D addition. Statistical assessment was performed by two-way ANOVA, with P<0.05 
used to determine significance. (a) IL10 mRNA measurements and decay curves. Significant 
decay of IL10 mRNA was observed across this time-course in all conditions. (b) TNFA mRNA 
measurements and decay curves. Significant decay of TNFA mRNA was observed across this 
time-course in all conditions. (c) IL1B mRNA measurements and decay curves. Significant 
decay of IL1B mRNA was observed across this time-course in unstimulated MDMs, with and 
without HIV-1 infection. (d) IL6 RNA mRNA measurements and decay curves. No significant 
decay of IL6 mRNA was detected across this time-course in any condition. IL6 RNA was not 
detected in unstmulated MDMs. RNA half-lives, calculated from one-phase decay curves, are 
presented in Table 3.2. Data are derived from the results of 3 experiments.  
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3.2.12 HIV-1 does not attenuate zymosan-induced NFκB translocation 
HIV-1 did not modulate IL-10 mRNA post-transcriptionally by accelerating its 
decay. It also did not act at the level of receptor signalling, as attenuation was 
observed downstream of multiple PRRs (Figure 3.1). This indicates that that the 
mechanism of attenuation involves the signalling pathways controlling IL-10 
transcription downstream of PRR signalling.  
Diminution of the activity of a signalling pathway, rather than complete 
inhibition, would account for the observed incomplete inhibition of IL-10 transcription. 
Previous investigations have shown that LPS-induced NFκB pathway activation is 
attenuated in HIV-1 infected MDMs (Noursadeghi et al., 2009). The NFkB pathway has 
been implicated in the control of IL-10 responses in macrophages (Saraiva and 
O’Garra, 2010), but NFkB attenuation was not previously observed to be associated 
with IL-10 attenuation (Noursadeghi et al., 2009). However, LPS is not a strong inducer 
of IL-10 responses in M-CSF differentiated MDMs (Figure 3.1b), and so significant IL-
10 attenuation may simply not have been evident in that context. I investigated NFκB 
activation in response to zymosan, which does induce substantial IL-10 responses in 
MDMs. 
NFκB activation was measured by assessing nuclear translocation of the RelA 
subunit of NFκB, quantified as a nuclear/cytoplasmic ratio of this protein. Induction of 
translocation by zymosan from 30−120 minutes was statistically significant by two-way 
ANOVA, and equivalent in uninfected and HIV-1 infected MDMs (Figure 3.20). This 
suggests that attenuation of NFκB signalling is not the mechanism of IL-10 attenuation 
in HIV-1 infected MDMs, as no clear attenuation occurs during stimulation with a strong 
inducer of IL-10.  
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Figure 3.20: HIV-1 does not alter zymosan-induced NFκB translocation. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml) for 1 week and then stimulated with zymosan (0.4mg/ml) for 0–120 minutes. (a) 
Activation of the NFκB pathway was measured by quantitative imaging analysis of 
nuclear translocation of NFκB (RelA), assessed as a ratio of nuclear:cytoplasmic 
intensity of RelA immunofluorescence staining. Nuclear localisation of RelA 
significantly increased with time (P=0.0054, two-way ANOVA) but this was not affected 
by HIV-1. Symbols represent mean values −/+ SEM from 4 experiments. Lines show 
linear regression, fitted using GraphPad Prism 6. (b) Representative images of the 
NFκB translocation assay. Nuclei are stained blue with DAPI and NFκB RelA is stained 
green. Nuclear NFκB is evident in the right-hand panels of zymosan-stimulated MDMs 
(green nuclear staining).  
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3.2.13 Inhibition of IL-10 induction pathways identifies the PI3K pathway as a 
specific regulator of anti-inflammatory cytokines 
In addition to the NFκB pathway, multiple other signalling pathways 
downstream of PRRs have been shown to contribute to IL-10 expression in 
mononuclear phagocytic cells. Activation of the MAP kinase cascades (Chanteux et al., 
2007; Ma et al., 2001b; Yi et al., 2002) and PI3K signalling (Bai et al., 2014; Hu et al., 
2006) are suggested to play critical roles. Calcium-burst stimulated signalling via CaM 
kinase II and Pyk2 is also thought to contribute, downstream of dectin-1 (Kelly et al. 
2010).  
I aimed to identify which of these pathways were involved in controlling IL-10 
production in M-CSF differentiated MDMs, in order to highlight candidate pathways on 
which HIV-1 might exert its effects. Small molecule inhibitors of these pathways were 
used to this effect. MDMs were pre-incubated with inhibitors of p38 and ERK MAP 
kinases, PI3K, CaM kinase II or Pyk2, prior to stimulation with Mtb culture filtrate or 
zymosan. Secretion of IL-10, and for comparison, IL-6, were measured at 4 hours. 
Inhibition of p38 MAP kinase, PI3K or Pyk2 reduced IL-10 secretion in response 
to Mtb culture filtrate (Figure 3.21a) or zymosan (Figure 3.21b). However, inhibiting 
p38 MAP kinase or Pyk2 also led to reduced IL-6 secretion in response to these stimuli 
(Figure 3.21c, d). As HIV-1 does not attenuate production of IL-6, this suggests that 
the virus does not act via these pathways to exert specific attenuation of IL-10. 
However, inhibition of PI3K did not reduce IL-6 secretion in response to these stimuli 
(Figure 3.21c, d), highlighting it as a candidate molecule involved in specific regulation 
of IL-10 but not of pro-inflammatory cytokines. 
Activation of the PI3K signalling pathway begins with recruitment of PI3K to the 
intracellular regions of activated receptors, including PRRs (Weichhart and Säemann, 
2008), where it is activated and catalyses the phosphorylation of phosphatidylinositol-
4,5-trisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Liu et al., 
2009). PIP3 then acts as a second messenger to activate downstream targets, the most 
critical of which is the serine/threonine kinase Akt (Liu et al., 2009). Akt acts as the 
main mediator of the functional effects of PI3K activation by phosphorylating a range of 
further targets (Liu et al., 2009). One key target of Akt is mTOR, a high molecular 
weight kinase which controls protein synthesis pathways (Liu et al., 2009). It has 
previously been highlighted that the PI3K-Akt-mTOR pathway might play a role in 
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differential regulation of the anti-inflammatory IL-10 response versus pro-inflammatory 
responses, in a review of the function of this pathway in innate immune cells 
(Weichhart and Säemann, 2008). A recent study further explored this mechanism in 
mouse bone marrow-derived macrophages (BMDMs), and showed that mTOR activity 
specifically controlled anti-inflammatory and pro-inflammatory responses (termed 
“cytokine biasing”) by controlling the efficiency of translation of cytokine mRNAs 
(Ivanov and Roy, 2013). 
I tested whether the PI3K-Akt-mTOR pathway was involved in differential 
control of anti-inflammatory and pro-inflammatory responses in M-CSF differentiated 
human MDMs, using specific inhibitors of PI3K, Akt and mTOR, and measuring 
cytokine mRNA and protein expression in response to zymosan. Inhibition of any of 
these molecules led to a statistically significant reduction in IL10 mRNA expression in 
response to zymosan (Figure 3.22a), while IL6 and TNFA mRNA expression were 
unaffected (Figure 3.22b, c). Similarly, at the level of protein expression, inhibition of 
PI3K or mTOR led to a statistically significant reduction in IL-10 secretion, and 
inhibition of Akt substantially reduced IL-10 secretion although this did not reach 
statistical significance (Figure 3.22d). Again, IL-6 and TNFα were unaffected (Figure 
3.22e, f). 
These results confirm that the PI3K-Akt-mTOR pathway specifically controls the 
anti-inflammatory IL-10 response, and not the pro-inflammatory cytokines TNFα and IL-
6, in human MDMs. The effects of inhibiting this pathway phenotypically copies the 
effect of HIV-1 on cytokine responses to zymosan, and thus highlights a strong 
candidate for where HIV-1 may exert its effects to mediate IL-10 attenuation. 
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Figure 3.21: Inhibition of innate immune signalling pathways inhibits IL-10 and 
IL-6 responses. 
 MDMs were pre-incubated with small molecule inhibitors of ERK1/2 MAP kinase (i: 
PD98059 or ii: U0126), p38 MAP kinase (SB203580), p38 and ERK1/2 combined 
(PD98059 and SB 203580), PI-3 kinase (LY294002), CaM kinase II (KN93) or Pyk2 
(AG17), all at 10μM, for 2 hours before stimulation with Mtb culture filtrate or zymosan 
(0.4mg/ml) for 4 hours. Cytokine secretion was measured by ELISA of cell culture 
supernatants. (a) IL-10 secretion in response to Mtbfiltrate was significantly reduced by 
inhibition of p38, p38 and ERK combined, PI-3 kinase or Pyk2. (b) IL-10 secretion in 
response to zymosan was significantly reduced by inhibition of p38, p38 and ERK 
combined, PI-3 kinase or Pyk2. (c) IL-6 secretion in response to Mtbfiltrate was 
significantly reduced by inhibition of ERK, p38, CaM kinase II or Pyk2. (d) IL-6 
secretion in response to zymosan was significantly reduced by inhibition of ERK, p38 
or Pyk2. * indicates P<0.05, paired t-test. Bars represent the mean −/+ SEM of 4 
experiments. 
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Figure 3.22: Inhibition of the PI3K pathway specifically inhibits IL-10 but not pro-
inflammatory cytokine responses. 
MDMs were pre-incubated with small molecule inhibitors of PI3K (LY294002, 10μM), 
Akt (triciribine, 20μM) or mTOR (rapamycin, 200nM), all at 10μM, for 2 hours before 
stimulation with zymosan (0.4mg/ml) for 4 hours. Cytokine mRNA expression was 
measured by qRT-PCR and secretion was measured by ELISA of cell culture 
supernatants. (a) IL10 mRNA expression in response to zymosan was significantly 
reduced by inhibition of PI-3 kinase, Akt or mTOR. (b, c) IL6 and TNFA mRNA 
expression in response to zymosan were not affected by any inhibitor. (d) IL-10 
secretion in response to zymosan was reduced by Akt inhibition and significantly 
reduced by PI-3 kinase and mTOR inhibition. (e, f) IL-6 and TNFα secretion were not 
affected by any inhibitor.  * indicates P<0.05, paired t-test. Bars represent the mean −/+ 
SEM of 3 experiments. 
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3.2.14 Levels of Akt and its phosphorylation are not altered by HIV-1 
As the PI3K-Akt-mTOR pathway was a strong candidate for where HIV-1 might 
act to exert IL-10 attenuation, I further investigated this pathway in HIV-1 infected 
MDMs. Akt is essentially the central hub of this signalling pathway: it is recruited to the 
membrane by PI3K-produced PIP3, where it undergoes a conformational change which 
facilitates its activation via phosphorylation, after which it phosphorylates a range of 
downstream targets (Liu et al., 2009). Assessment of Akt activation may therefore help 
identify if HIV-1 modulates the upstream membrane-proximal section of this signalling 
pathway involving PI3K, PIP3 and Akt, or the downstream components such as mTOR 
and other Akt targets. Control of total Akt levels by its ubiquitination and subsequent 
targeting for degradation has been reported as a regulatory mechanism for this 
pathway (Ivanov and Roy, 2013). It has also previously been reported that 
phosphorylation of Akt may be reduced in HIV-1 infected M-CSF differentiated human 
MDMs (Huang et al., 2006). 
I assessed total Akt levels and Akt phosphorylation in response to 5–120 
minutes of zymosan stimulation in uninfected and HIV-1 infected MDMs. Total levels of 
Akt were unaffected by HIV-1 infection, suggesting that ubiquitin-targeted degradation 
of Akt also does not play a role in this phenotype (Figure 3.23); however, the bands for 
total Akt for donors 2 and 3 were highly dense and may have been saturated, meaning 
that assessing the dynamic range of density of these bands may not have been 
optimal. Akt phosphorylation was present at baseline, and was increased by zymosan 
stimulation over this time-course, but this was not affected by HIV-1 infection (Figure 
3.23, 3.24). These results suggest that HIV-1 does not attenuate IL-10 by degrading 
Akt, or modulating its activation via phosphorylation at its Ser473 residue. This 
suggests that if HIV-1 does modulate the PI3K-Akt-mTOR pathway in order to 
attenuate IL-10, it may act downstream of Akt, potentially at the level of mTOR 
activation. It is also possible that an aspect of Akt activation which has not been 
assessed is affected, such as its localisation, or phosphorylation at its second 
activation residue, Tyr308.  
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Figure 3.23: Levels of total Akt and Akt phosphorylation in response to zymosan 
are not altered by HIV-1. 
 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml) for 1 week and then stimulated with zymosan (0.4mg/ml) for 0–120 minutes. 
Cell lysates were collected and Akt phosphorylation (Ser473) was assessed by 
Western immunoblotting. Total Akt levels were also measured for comparison. β-actin 
levels were measured to confirm equivalent loading. HIV-1 Gag p55 and p24 were 
measured to confirm HIV-1 infection. Western blots from 3 independent experiments 
are presented. 
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Figure 3.24: Densitometry of Akt phosphorylation in response to zymosan. 
Densitometry calculations were performed with AlphaViewer software on the Western 
blots presented in Figure 3.23. The average intensity of the phosphorylated (Ser473) 
Akt bands was normalised to the average intensity of the total Akt bands, to quantify 
relative levels of Akt phosphorylation. Akt phosphorylation was significantly induced 
over time (P= 0.0429, two-way ANOVA), but this was not altered in HIV-1 infection. 
Symbols represent mean values −/+ SEM from 3 experiments. 
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3.3 Chapter discussion 
In this body of work, I aimed to characterise HIV-1 mediated attenuation of 
macrophage IL-10 responses, in terms of viral and host determinants, and to identify a 
potential mechanism for this phenotype. I found that IL-10 attenuation was not limited 
to Mtb responses, but occurred downstream of other IL-10-inducing innate immune 
stimuli, and was evident across the time-course of the innate immune IL-10 response. 
Viral propagation was not required, as IL-10 was attenuated by a single-round HIV-1 
infection or in the presence of protease inhibitor inhibition of mature virion production. 
Viral entry was not sufficient for IL-10 attenuation to occur, nor was integration. My 
results indicate that transcription of HIV-1 genes, and specifically accessory proteins, 
were necessary for this phenotype.  
The host determinants of IL-10 attenuation were also delineated. Type I IFNs did 
not induce IL-10 responses in mononuclear phagocytes, and played no evident role in 
HIV-1 attenuation of IL-10. Attenuation was highly cell type-specific, as HIV-1-infected 
monocytes and DCs did mount innate immune IL-10 responses but these were not 
attenuated by HIV-1. Suppression of IL10 mRNA by HIV-1 was demonstrated to be 
due to modulation of pre-transcriptional regulatory pathways, as IL10 mRNA decay 
was not potentiated by the virus. Investigation of which signalling cascades controlled 
IL-10 production in MDMs highlighted the PI3K pathway as a key regulator of the anti-
inflammatory cytokine response. Exploration of the effects of HIV-1 on this pathway 
suggested that any modulation of its activity by the virus occurs downstream of the 
activation of the kinase Akt. 
HIV-1 attenuated IL-10 responses downstream of a range of innate immune 
stimuli, such as zymosan, curdlan and Pam2CSK4. This suggested that IL-10 
attenuation may be relevant to infection with pathogens other than Mtb which stimulate 
TLR-2 or dectin-1. To assess whether this phenotype is relevant in further contexts, 
challenge with ligands or pathogens which stimulate other PRRs may be informative. 
For example, IL-10 responses have been reported downstream of TLR-3 (Bai et al., 
2014). It is clear that the attenuating effect of HIV-1 is most apparent in the context of 
stimuli such as Mtb and zymosan, which induce the most substantial macrophage IL-
10 responses. When considering host immune adaptation to pathogens, it might be 
that when a large IL-10 response is requisite for an effective response, the attenuating 
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effect of HIV-1 is at its greatest and most subversive for normal host immunity. As such, 
the significance of this phenotype in vivo is likely to display pathogen specificity, in 
relation to their propensity to induce IL-10. 
These results also provide insight into the mechanism by which HIV-1 attenuates 
IL-10: it must act downstream of receptor ligation, as multiple receptors are implicated 
in this phenotype. Further mechanistic insight is provided by the demonstration that a 
single-round Env-deleted HIV-1 can attenuate IL-10 (Figure 3.2), as this shows that 
Env-derived proteins, viral assembly and budding are not causative in this phenotype. I 
further confirmed this observation via protease inhibitor supplementation of HIV-1 
infected MDM cultures, in which context IL-10 attenuation was still evident (Figure 3.5).  
These experiments demonstrate that non-productively infected MDMs exhibit 
attenuated IL-10 responses, and that ongoing viral propagation is not necessary for 
this phenotype. This is of particular significance when considering that macrophages 
may form a long-lived reservoir of HIV-1 infection during anti-retroviral therapy; these 
experiments suggest that IL-10 attenuation might persist in such a context, and that it 
might contribute to immune dysfunction which occurs during HAART, such as IRIS. It is 
interesting to note that some of the co-infections most commonly associated with IRIS 
are with Mtb or fungal pathogens (Lawn et al., 2008), which are indicated to be strong 
innate immune producers of IL-10 responses in macrophages, using Mtb culture filtrate, 
or the fungal cell wall derivative zymosan (Figure 3.1).  
Investigation of the viral determinants of IL-10 attenuation clearly showed that 
viral entry was not sufficient for attenuation to occur. This suggests that the component 
of HIV-1 which mediates attenuation is not present in the virion in sufficient quantities 
to mediate its effects. Viral integration was necessary for attenuation, but was not 
sufficient, as an empty viral vector did not cause attenuation. This experiment indicates 
that the various consequences of integration itself, such as insertional mutagenesis, do 
not cause IL-10 attenuation, but that HIV-1 genetic material is necessary for 
attenuation. It has not formally been demonstrated in this set of experiments that viral 
transcription from the integrated HIV-1 provirus is necessary for attenuation; it may be 
difficult to test this question specifically, as inhibitors of HIV-1 transcription generally 
also have off-target effects on host transcription (Baba, 2004). HIV-1 clones deleted for 
the viral transactivator Tat,  in which viral transcription is instead controlled by 
doxycycline responsive Tet-on elements, may be potential tools in this regard (Das et 
al., 2011). 
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It is difficult to envisage a viral function that results purely from the presence of 
HIV-1 genetic material without its transcription, out-with mutagenic consequences of 
the event of integration, which has already been eliminated as a sufficient mechanism. 
Consequently, the most likely hypothesis is that viral transcription, and production of 
new viral components, is necessary for IL-10 attenuation. I therefore investigated which 
components of the virus may be necessary. As previously discussed, Env-derived 
proteins and the viral protease have been shown not to be involved.   
I tested the role of the remaining Gag-Pol proteins by using a virus in which no 
mature Gag-Pol-derived proteins are expressed, as the luciferase gene is cloned in-
frame into Gag. This virus also lacks Env and expresses GFP in place of Nef. 
Resultingly, only the viral accessory proteins Tat, Rev, Vif, Vpr and Vpu are expressed. 
However, it was still capable of attenuating zymosan-induced IL-10 production – 
suggesting that one or more of the aforementioned accessory proteins are causative in 
this phenotype. It also remains possible that immature sections of Gag, which are still 
expressed as part of the Gag-Luciferase fusion protein expressed here, are involved. 
To clarify this, it may be necessary to construct and test a virus which expresses only 
Gag-Pol and no accessory proteins. 
The necessity of various HIV-1 accessory proteins was further investigated using 
deletion mutants, showing that Nef, Vif and Vpr are not autonomously necessary for IL-
10 attenuation. This leaves Vpu, Tat and Rev as candidates for this mechanism. 
Testing a Vpu deletion mutant in the same manner as Nef, Vif and Vpr is a simple 
subsequent experiment. However, Tat and Rev cannot be similarly assessed via 
deletion, as their functions are necessary for all efficient viral RNA production. As Tat in 
particular may be a strong candidate for mediating the phenotype, as it is a modulator 
of transcription, a priority for future experiments should be designing strategies for 
testing its role. The aforementioned doxycycline-inducible Tat mutants are an option for 
testing this, or expressing either Tat or Rev in isolation may demonstrate if either is 
sufficient to cause this phenotype. It also remains possible that IL-10 attenuation is a 
consequence of a redundant function of the accessory proteins, in which case single 
expression vectors should cause the phenotype. As the HIV-1 accessory proteins have 
a range of functions (see Introduction section 1.3.4), there is no single clear potential 
mechanism for how one of them might act to attenuate IL-10. However, the functions of 
Vpu and Vif in mediating host interactions are by degrading host proteins (Conticello et 
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al., 2003; Dubé et al., 2010) suggest that degradation of a host factor involved in IL-10 
regulation is a potential mechanism.  
A final potential mechanism to consider is that IL-10 attenuation does not involve 
viral proteins, but is due to a viral mRNA species, such as a microRNA. It has been 
shown that HIV-1 encodes microRNA species, and that these can regulate host gene 
expression (Narayanan et al., 2011; Ouellet et al., 2013; Schopman et al., 2012). 
MicroRNAs regulate gene expression post-transcriptionally by binding to mRNAs, 
preventing their translation or targeting them for degradation (Fabian et al., 2010). As 
the effect of HIV-1 on IL-10 is to reduce transcript levels, the former mechanism is 
unlikely, and the latter mechanism is refuted by later experiments showing that HIV-1 
does not accelerate IL-10 mRNA decay. This suggests the action of viral miRNAs is 
not likely to be causative in mediating attenuation. 
Further insights into the mechanism of IL-10 attenuation were made by 
investigating the host determinants of this phenotype. Various publications have 
described that induction of IL-10 by type I IFNs in macrophages and monocytes is a 
critical mechanism by which these cytokines exert immunosuppressive effects which 
may be relevant in protection against mycobacteria (Mayer-Barber et al., 2011; McNab 
et al., 2013; Teles et al., 2013). In my experiments, no significant IFN-mediated IL-10 
induction was evident in human MDMs, DCs or monocytes (Figure 3.15, Figure 3.18), 
nor was type I IFN found to contribute to zymosan-induced IL-10 (Figure 3.16), as has 
been reported for LPS-induced IL-10 (Chang et al., 2007). There may be several 
reasons for these discrepancies with published reports: substantial evidence is derived 
from mouse models of Mtb infection (Chang et al., 2007; Guarda et al., 2011; Mayer-
Barber et al., 2014, 2011; McNab et al., 2013), and so this may reflect differences 
between the murine and human immune systems. Additionally, several murine studies 
use surrogate methods to demonstrate induction of IL-10 by type I IFN, such as 
suppressed IL-10 responses in the context of IFNAR1 knock-out (Mayer-Barber et al., 
2011; McNab et al., 2013), or IL-10 production downstream of an inducer of type I IFN 
such as pICLC (Mayer-Barber et al., 2014, 2011), and do not show direct induction of 
IL-10 as a result of type I IFN signalling.  
Previous reports in the human system also have some key differences from the 
experiments presented here. These include showing induction of IL-10 by type I IFNs 
in whole PBMC (Aman et al., 1996; Rudick et al., 1996) rather than specifically in 
mononuclear phagocytic cells; induction in monocytes only during synergistic 
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stimulation with LPS (Aman et al., 1996); or drawing conclusions from increased serum 
IL-10 in multiple sclerosis patients treated with IFNβ (Rep et al., 1999; Rudick et al., 
1996). Additionally, the Interferome 3.0 database does not identify IL-10 as a type I IFN 
target gene (http://interferome.its.monash.edu.au/interferome; Rusinova et al., 2013).  
This review of the literature, in conjunction with the experimental data presented 
here, strongly suggests that although type I IFNs have clearly been shown to exert 
immunosuppressive functions (Mayer-Barber et al., 2014) and may indeed contribute 
to IL-10 responses in an indirect manner, they do not directly induce IL-10 production 
from resting human mononuclear phagocytes. Their well-characterised 
immunosuppressive effects on IL-1β production, via which pathway they have been 
postulated to regulate anti-mycobacterial responses, have recently been shown to be 
controlled by a pathway which does not implicate IL-10 (Reboldi et al., 2014). A single 
published report shows direct induction of IL-10 in human monocytes after stimulation 
with IFNβ (Teles et al., 2013), and there are no clear differences between that 
experimental setup and the one presented here. Reductionist experiments, such as 
using an IL-10 promoter-reporter system in an IFNAR-expressing cell line, may assist 
in further clarifying this issue. Overall, these experiments demonstrate that type I IFN 
does not directly induce macrophage IL-10 responses, and so further insights into HIV-
1 attenuation of IL-10 cannot be gained via investigation of this pathway. 
The cell type specificity of IL-10 responses and attenuation was also investigated. 
It was observed that HIV-1-mediated attenuation of zymosan-induced IL-10 specifically 
occurred in M-CSF differentiated MDMs and not in other IL-10-producing mononuclear 
phagocytes, such as monocytes or MDDCs (Figure 3.17, Figure 3.18). This suggests 
that IL-10 attenuation is a context-specific phenomenon. Macrophages differentiated 
with GM-CSF did not express IL-10 in response to zymosan, despite expressing a pro-
inflammatory cytokine, TNFα; it is possible that the IL10 locus is closed in these cells 
and as such IL10 expression is not inducible. This observation is interesting when 
considering that the major roles of GM-CSF in regulating macrophage biology are 
thought to be during inflammation or differentiation of alveolar macrophages. The 
absence of production of an anti-inflammatory cytokine may fit with the former scenario, 
but as AMs are suggested to produce IL-10 in vivo, the relevance to the latter scenario 
is less clear. 
The largest IL-10 responses evident in the different cell types tested were found 
in the cells in which HIV-1 significantly attenuated IL-10: the M-CSF differentiated 
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MDMs. This again suggests that the attenuating effect of HIV-1 is at its greatest and 
most potent in the context of large IL-10 responses which are generated by specific cell 
types in response to specific pathogens. If these responses are a host-evolved 
protective mechanism, then this suggests that modulation by HIV-1 may certainly have 
pathogenic consequences. This leads to consideration of how the demonstrated 
context-specificity of this phenotype might be relevant in vivo; which in vivo 
mononuclear phagocyte is the in vitro M-CSF differentiated MDM an appropriate model 
of? Are they an appropriate in vitro model of alveolar macrophages (AMs), which are 
presumably the most relevant cells for this phenotype in HIV-1/Mtb co-infection? A 
previous investigation showed that this MDM model is morphologically and 
transcriptionally more similar to AMs than to DCs and monocytes, but that AMs had a 
heightened pro-inflammatory bias compared to MDMs (Tomlinson et al., 2012). It is 
also clear that AM development is dependent on GM-CSF signalling (Bonfield et al., 
2003; Guilliams et al., 2013), which may suggest that GM-CSF differentiated MDMs 
are a more appropriate model of AM. AM, however, have been shown to produce IL-10, 
although less than M-CSF differentiated MDM (Hoppstädter et al., 2010). Further 
experiments assessing this phenotype using ex vivo isolated tissue mononuclear 
phagocytes, such as alveolar macrophages or Langerhans cells, including from HIV-1 
positive patients, may be informative. 
To establish the temporal dynamics of MDM cytokine responses and HIV-1 
modulation of these, I investigated zymosan-induced expression of IL-10 mRNA and 
IL-10 protein, and of pro-inflammatory cytokines for comparison, over a time-course in 
uninfected and HIV-1 infected MDMs (Figure 3.3, Figure 3.4). The dynamics of the IL-
10 response were clearly differentiated from that for the pro-inflammatory cytokines IL-
6 and pro IL-1β. IL10 mRNA expression took longer to develop, and this was also a 
self-limited response which returned to baseline after 24 hours, whereas the pro-
inflammatory cytokines were expressed rapidly after stimulation and these responses 
persisted to 72 hours. This raises two hypotheses about the specific regulation of IL-10 
responses in MDMs, which may provide insight into how HIV-1 attenuates these 
responses; firstly, is it a secondary response gene in the innate immune response 
(Medzhitov and Horng, 2009), as would be suggested by a delay in its transcription 
post-stimulation? Chromatin remodelling of the IL10 locus has been shown to play a 
role in LPS-induced IL-10 expression (Saraiva et al., 2005), which would support this 
suggestion. And secondly, do negative feedback loops exist to limit its expression? IL-
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10 is suggested to be negatively regulated by a range of transcription factors (Saraiva 
and O’Garra, 2010), and whether HIV-1 modulates these pathways merits investigation. 
Homeostatic control of IL-10 is also known to be mediated post-transcriptionally 
via destabilizing motifs in the 3’ untranslated region of the mRNA (Powell et al., 2000). 
It is also a target for the RNA-degrading enzyme tristetraprolin (Stoecklin et al., 2008). 
HIV-1 might attenuate IL-10 responses by accelerating decay of IL10 mRNA, leading to 
lower measurable levels of the cytokine mRNA at any single time-point. I investigated 
the rate of IL-10 mRNA decay, and found that it was not accelerated by HIV-1 infection. 
In fact, HIV-1 was associated with increased stability of all cytokine mRNAs measured; 
an interesting observation which may be informative when considering modulation of 
the PI3K-mTOR pathway by HIV-1 as a potential mechanism of attenuation, discussed 
subsequently. 
It is also possible that an effect of the virus on the IL-10 locus, e.g. in terms of its 
histone modifications and availability for transcription, is involved. However, as some 
IL-10 transcription is detectable in HIV-1 infected MDMs, this seems less likely, 
indicating that the virus acts pre-transcriptionally to attenuate IL-10. I therefore 
investigated the signalling pathways involved in inducing IL-10 transcription in 
macrophages. Although attenuation of the NFκB pathway has previously been 
demonstrated in HIV-1 infected MDMs (Noursadeghi et al., 2009), this was not evident 
downstream of zymosan stimulation, and so did not present a strong candidate for the 
host determinant of this phenotype. Investigation of which innate immune pathways 
were involved in specific regulation of IL-10 and not pro-inflammatory cytokine 
responses in MDMs identified the PI3K pathway as a clear candidate target for HIV-1, 
as inhibition of this pathway pheno-copied the effects of HIV-1 on IL-10.  
A number of previous reports have highlighted the PI3K pathway as a positive 
regulator of IL-10 in both human and murine macrophages, including in responses to 
mycobacteria (Bai et al., 2014; Fallah et al., 2011; Foey et al., 2001; Hu et al., 2006). 
One key report using mouse BMDMs demonstrated that this pathway was critical in 
establishing the phenomenon of “cytokine biasing”, wherein the cytokine response to 
pathogenic strains of Legionella was dominated by pro-inflammatory transcripts and 
displayed a lack of IL-10, while non-pathogenic strains did induce IL-10 (Ivanov and 
Roy, 2013). This was controlled by degradation of Akt during infection with the 
pathogenic bacteria, which led to lower levels of mTOR activity, thus reducing the 
efficiency of cellular translation. The mRNAs of pro-inflammatory cytokines, which were 
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in higher abundance, were then preferentially translated in comparison to low 
abundance IL-10 transcripts (Ivanov and Roy, 2013). 
If this mechanism also occurs in human macrophages, it is clearly a strong 
candidate for how HIV-1 might cause IL-10 attenuation; perhaps the virus essentially 
induces a “cytokine biasing” phenomenon, causing the macrophage to react to stimuli 
as though they had increased pathogenicity. The levels of IL-10 transcript which are 
induced in response to innate immune stimulation are generally of lower abundance 
than pro-inflammatory transcripts (Figure 3.19, Figure 3.22), which would support this 
possibility. However, these is clearly a discrepancy here, as the mechanism described 
by Ivanov and Roy (2013) takes place at the level of protein production, while the 
phenotype caused by HIV-1 attenuates IL-10 transcription. In addition, inhibiting mTOR 
in human MDMs inhibited IL-10 transcription as well as protein secretion (Figure 3.22), 
and as it is well-established that mTOR regulates proteins via translation and not 
transcription, this observation requires further exploration. It is possible that inhibitory 
effects on transcription due to mTOR inhibition represent negative feedback effects 
from its effects on translation, wherein reduced levels of IL-10 protein (or another anti-
inflammatory factor) feedback to impact on IL-10 transcription. The observation that 
HIV-1 increases all cytokine mRNA stability (Figure 3.19) is also interesting to consider 
in this regard; if the virus reduces mTOR activity and translational efficiency by 
affecting the PI3K pathway, perhaps mRNAs are more stable as a result due to less 
traffic through the translation pathway.  
 Although how the PI3K-Akt-mTOR pathway specifically regulates the IL-10 
response in human MDMs is not entirely clarified, I made preliminary assessments of 
its activity in HIV-1 infected MDMs. Previous reports linking HIV-1 to this pathway have 
suggested that Nef activates PI3K in order to downregulate MHC class I molecules and 
modulate apoptosis (Hung et al., 2007; Linnemann et al., 2002; Swann et al., 2001; 
Wolf et al., 2001). It has also been shown that Env-derived gp120 or Tat can activate 
this pathway (Deregibus et al., 2002; François and Klotman, 2003). An up-regulatory 
effect on this pathway would be unlikely to explain the IL-10 attenuation phenotype, 
and in any case the relevance of these reports to MDM biology is not entirely clear, as 
they are mainly made using T cells, or transformed cell lines which often have inherent 
PI3K pathway dysfunction (Astoul et al., 2001). Akt is a central hub of the PI3K 
pathway, and has been implicated in the phenomenon of cytokine biasing, and so it 
was selected as a focus for investigation. However, HIV-1 was not shown to have any 
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effect on its total levels or on Ser473 phosphorylation. This suggests that the virus 
does not modulate the activity of this pathway at this level, or further upstream; the 
most informative subsequent experiments, therefore, should be to investigate 
activation of mTOR and other downstream targets of Akt in HIV-1 infected MDMs. 
Localisation of Akt, which also plays a role in its activation, should also be assessed. 
In summary, I have shown that HIV-1 mediates innate immune IL-10 attenuation in 
macrophages in a highly context-specific manner, and that this is likely to be due to an 
as-yet unidentified function of a viral accessory protein.  The most promising candidate 
host pathway that might be affected by the virus is the PI3K-Akt-mTOR pathway, which 
appears to play a key role in specifically regulating IL-10, and hence potentially 
producing the phenomenon of cytokine biasing. HIV-1 might act downstream of Akt to 
modulate this pathway and hence dysregulate IL-10 production in macrophages. 
Further exploration of the activity of this pathway in MDMs, and of the virological 
determinants of this phenotype, may fully chararactise this novel host-virus interaction 
which has the potential to impact substantially on the function of the immune response.
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Chapter 4. Results 2. The consequences of IL-10 
attenuation for HIV-1 replication and the immune 
response 
4.1 Background 
HIV-1 attenuates macrophage IL-10 responses to Mtb and other innate immune 
stimuli. My investigation into the mechanism of this phenotype has shown that it is a 
consequence of integration by HIV-1 and is dependent on expression of viral 
accessory proteins. The host pathways affected by the virus may involve the specific 
regulation of the anti-inflammatory cytokine response differentially from the pro-
inflammatory cytokine response, and the PI3K pathway is a strong candidate in this 
regard. 
The ability of HIV-1 to specifically inhibit macrophage production of IL-10, which 
has well-established immunomodulatory and anti-inflammatory functions, raises 
several questions about the consequences of this phenotype. Firstly, does it have 
consequences for the virus? HIV-1 appears to have evolved to cause this phenotype, 
as it is indicated to be due to the function of viral proteins expressed in the 
macrophage. This raises the teleological question of whether IL-10 attenuation confers 
any advantage to the virus; can IL-10 modulate HIV-1 replication, or alter cellular 
permissivity to HIV-1 infection? 
The previously characterised potent functions of IL-10 suggest that its 
attenuation by HIV-1 is also likely to have consequences for the host immune response. 
The contexts in which this phenotype might play an immunopathological role must be 
considered. Mtb is clearly one example of a clinically important co-infecting pathogen 
that induces a strong macrophage IL-10 response which HIV-1 can attenuate. However, 
as this phenotype is not Mtb-specific, are there other pathogens which may be affected 
by it? Exploring whether other co-infecting pathogens induce IL-10 responses in MDMs 
may help elucidate the importance of this phenotype for immunopathology in vivo in 
HIV-1 positive patients.  
The potential mechanisms of immunopathology which IL-10 attenuation might 
trigger also clearly merit investigation. In a previous investigation within our group, IL-
10 attenuation was associated with exaggerated downstream pro-inflammatory 
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responses in HIV-1/Mtb co-infected macrophages (Tomlinson et al., 2014). This 
included exaggerated production of pro-inflammatory cytokines which IL-10 normally 
acts to suppress, such as TNFα, IL-1β and IL-23. These results indicated that autocrine 
IL-10 signalling in macrophage inflammatory responses could potently affect 
macrophage function. Further understanding of how IL-10 modulates macrophage 
function and macrophage-generated inflammatory processes may provide further 
insight into how HIV-1 might impact on inflammatory responses to co-infecting 
pathogens, and thus the prospective immunopathological consequences of this 
phenotype in vivo. 
I therefore aimed to explore the potential consequences of IL-10 attenuation for 
the virus and the host immune response, with the following objectives: 
1) To explore whether IL-10 modulates HIV-1 replication in human 
macrophages, in order to determine whether the virus might attenuate IL-10 
to promote its own replication. 
2) To identify whether IL-10 attenuation is present in macrophage responses to 
clinically important co-infecting pathogens other than Mtb, by evaluating the 
macrophage response to Cryptococcus neoformans and the effect of HIV-1 
on this. 
3) To explore how IL-10 modulates macrophage transcriptional responses, in 
the following contexts: 
a. The effects of IL-10 on gene expression in unstimulated MDMs. 
b. The effects of IL-10 on IFNγ-induced gene expression in MDMs. 
c. The role of IL-10 in modulating the pro-inflammatory transcriptional 
response to zymosan. 
4) To explore how attenuation of IL-10 modulates cell recruitment to 
inflammatory foci. 
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4.2 Results  
4.2.1 IL-10 inhibition may confer a replicative advantage on HIV-1 in 
inflammation 
I aimed to identify why HIV-1 attenuates IL-10 by exploring the consequences 
of this phenotype for the virus. The simplest hypothesis is that IL-10 is detrimental to 
viral replication, and so the virus has evolved to suppress IL-10 to avoid these 
detrimental effects. It has previously been shown that IL-10 can suppress HIV-1 
replication in macrophages (Tanaka et al., 2005; Wang and Rice, 2006). Conversely, 
innate immune signalling via the NFκB pathway (Pazin et al., 1996; Perkins et al., 
1993; Williams et al., 2004; Williams et al., 2007), and pro-inflammatory cytokines (Poli 
et al., 1994, 1990) can induce HIV-1 replication. The effect of IL-10 on HIV-1 replication 
in the context of an inflammatory response has not specifically been addressed.  To 
investigate this, I sought to supplement deficient IL-10 production in HIV-1-infected 
MDMs stimulated with zymosan, by addition of recombinant IL-10 four hours after 
zymosan stimulation.  
72 hours post-zymosan stimulation, HIV-1 release and transcription were 
measured, and were significantly increased above levels in unstimulated MDMs 
(Figure 4.1). Supplementation of IL-10 significantly suppressed zymosan-induced HIV-
1 transcription (Figure 4.1b) and showed a trend to suppression of zymosan-induced 
HIV-1 release at this time point (Figure 4.1a), although this effect fell short of statistical 
significance. The outcome of 72 hours of IL-10 supplementation on viral replication in 
unstimulated MDMs was also assessed, and no effect was seen on either viral 
transcription or release (Figure 4.2a, b). To investigate the effect of IL-10 on 
macrophage permissivity to HIV-1 infection, MDMs were pre-treated with IL-10 prior to 
HIV-1 infection. This had no impact on the number of cells which were infected by HIV-
1 when measured at 3 days post-infection (Figure 4.2c). These results indicate that IL-
10 can inhibit zymosan-induced viral replication in MDMs, but has no effect on the 
baseline level of HIV-1 replication in unstimulated MDMs, or on the permissivity of 
unstimulated MDMs to HIV-1 infection.  
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Figure 4.1: IL-10 suppresses zymosan-induced HIV-1 replication. 
MDMs were infected with HIV-1 (full-length strain Ba-L, at an MOI of 3–5) for 1 week of 
spreading infection, and then stimulated with zymosan (0.4mg/ml). 4 hours later, 
recombinant IL-10 (10ng/ml) was supplemented into the culture. Viral release and 
transcription were measured 72 hours post-supplementation. (a) Viral release was 
measured by HIV-1 p24 ELISA of cell culture supernatants. Zymosan induced 
significantly higher levels of HIV-1 release compared to unstimulated MDMs, and IL-10 
supplementation suppressed this. (b) Viral transcription was measured by qRT-PCR for 
the HIV-1 LTR. Zymosan induced significantly higher levels of HIV-1 transcript 
compared to unstimulated MDMs, and this was significantly suppressed by IL-10 
supplementation. * indicates P<0.05, paired t-test. Box-and-whisker plots indicate the 
median and range of at least 3 experiments.  
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Figure 4.2: IL-10 does not modulate HIV-1 replication in resting MDMs, or alter 
MDM permissivity to HIV-1. 
MDMs were infected with HIV-1 (full-length strain Ba-L, at an MOI of 3–5) for 1 week of 
spreading infection, and then supplemented with recombinant IL-10 (10ng/ml). (a) Viral 
release was measured at 72 hours by HIV-1 p24 ELISA of cell culture supernatants. 
IL-10 supplementation had no effect on HIV-1 release. (b) Viral transcription was 
measured at 72 hours by qRT-PCR for the HIV-1 LTR. IL-10 supplementation had no 
effect on HIV-1 transcription. (c) MDMs were pre-incubated with recombinant IL-10 
(10ng/ml) for 24 hours prior to infection with HIV-1 (full-length strain Ba-L, at an MOI of 
3-5). At 72 hours, MDMs were fixed and stained for HIV-1 p24 to measure the number 
of HIV-1 infected MDMs in the culture. IL-10 pre-treatment had no effect on the 
numbers of MDMs infected. Box-and-whisker plots indicate the median and range of at 
least 3 experiments. Bars indicate the mean +/- SEM of at least 3 experiments. 
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4.2.2 Macrophage responses to Cryptococcus neoformans 
Having shown that IL-10 attenuation was not Mtb-specific (section 3.2.1), I 
aimed to establish whether HIV-1 attenuation of IL-10 might have immunopathological 
consequences in the response to a pathogen other than Mtb. Zymosan, a particulate 
innate immune stimulus which is a derivative of the cell wall of the fungus 
Saccharomyces cerevisiae (Gantner et al., 2003), induced substantial IL-10 responses 
in human MDMs (Figure 3.1), as has been previously reported (Kelly et al., 2010). 
Therefore, I aimed to test if a clinically important fungal pathogen in HIV-1+ patients 
also induces IL-10 responses in human MDMs, and whether HIV-1 infection attenuates 
these responses. 
Cryptococcus neoformans is a fungal species which commonly causes 
disseminated infections associated with meningoencephalitis in HIV-1 positive patients 
with AIDS (Harrison, 2009). C. neoformans can be manipulated in culture (Sabiiti et al., 
2012), directly infects macrophages (Vecchiarelli et al., 1994), and the major 
component of its capsule, glucuronoxylomannan (GXM), has been shown to be a 
potent inducer of IL-10 expression (Monari et al., 2006; Vecchiarelli et al., 1996). 
Therefore, it provided an appropriate candidate pathogen with which to test IL-10 
attenuation by HIV-1 in the context of a fungal infection. To characterise infection by C. 
neoformans in this MDM model, MDM uptake of C. neoformans at 4 hours post-
infection was measured by confocal microscopy using a GFP-expressing C. 
neoformans WT strain, H99-GFP (Figure 4.3a). Using an MOI of 10, intracellular 
fungal burden at 4 hours was approximately 0.1 cryptococci per MDM (Figure 4.3b), 
indicating that approximately 10% of MDMs were infected, although heterogeneity in 
fungal burden may exist at the single cell level. Co-infection of MDMs with HIV-1 did 
not affect uptake of C. neoformans (Figure 4.3b). 
Macrophage inflammatory responses to C. neoformans, in the presence and 
absence of pre-existing HIV-1 infection, were assessed by measuring changes to 
selected cytokine mRNA expression in MDMs at 4h and 24h post-infection. In these 
experiments, zymosan was used as a positive control for induction of cytokine gene 
expression. Two WT laboratory-propagated strains of C. neoformans of different 
serotypes, H99 and B3501, did not induce IL-10, TNFα or IL-1β mRNA expression at 4 
or 24 hours post-infection, irrespective of co-existing HIV-1 infection (Figure 4.4). The 
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C. neoformans capsule is suggested to be its major virulence factor and may mask 
immunogenic PAMPs in the cell wall, or be directly immunosuppressive (Monari et al., 
2006; Vecchiarelli et al., 1996, 1995; Zaragoza et al., 2009). Isogenic unencapsulated 
mutants of the H99 and B3501 WT strains exist, which have mutations in enzymes 
involved in capsule production or trafficking (all C. neoformans strains used are 
detailed in Methods section 2.5). These mutants, Cap59 (H99) and Cap67 (B3501) 
were used to infect MDMs, to assess whether cytokine gene expression could be 
induced by C. neoformans when the capsule was absent. At 24 hours post-infection, 
these strains induced expression of mRNA for the pro-inflammatory cytokines IL-1β 
and TNFα (Figure 4.4). IL10 mRNA expression was not induced at any time-point, and 
consequently no modulation by HIV-1 was observed. 
To further assess whether C. neoformans could induce an IL-10 response in 
MDMs, secretion of IL-10 protein was measured at 4 and 24 hours post-infection with 
WT strains or unencapsulated mutants. No IL-10 secretion was evident at 4 hours in 
response to any C. neoformans strain (Figure 4.5a). At 24 hours post-infection with 
unencapsulated strains, IL-10 secretion was observed in 3 of 6 experiments, and this 
was reduced in paired HIV-1 co-infected MDMs, although these data were insufficient 
to reach statistical significance (Figure 4.5b). C. neoformans WT strains did not induce 
IL-10 secretion at 24 hours (Figure 4.5b). 
Previous investigators have reported that macrophages and monocytes can 
produce pro-inflammatory and IL-10 responses to C. neoformans in various in vitro 
models (Delfino et al., 1997; Levitz et al., 1994; Oliveira et al., 2010; Vecchiarelli et al., 
1996). The non-immunogenicity of C. neoformans in this MDM model was investigated. 
The MOI employed was not shown to be limiting, as an eight-fold increase in MOI did 
not induce IL-10 or IL-6 secretion (Figure 4.6a). In animal models of C. neoformans 
infection, the innate immune adaptor MyD88, which transduces TLR signals to activate 
the NFκB pathway, has been shown to be essential for protection against C. 
neoformans (Biondo et al., 2005; Yauch et al., 2004). Additionally, the C. neoformans 
capsule has been shown to induce NFκB activation, as assessed by nuclear 
translocation, in human PBMC (Shoham et al., 2001). I assessed NFκB nuclear 
translocation in response to a WT strain of C. neoformans in this MDM model. In 
comparison to LPS stimulation as a positive control, C. neoformans did not induce 
NFκB translocation (Figure 4.6b, c), suggesting that MDMs do not respond to C. 
neoformans via this archetypal innate immune signalling pathway. 
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Taken together, these data show that M-CSF-differentiated MDMs do not 
mount a classical transcriptional innate immune response to C. neoformans, despite 
internalising the pathogen. The absence of NFκB pathway activation suggests that they 
might not detect C. neoformans by classical pattern recognition. As such, whether HIV-
1 could attenuate IL-10 responses to C. neoformans could not be evaluated, and the 
effects of the phenotype of IL-10 attenuation in HIV-1/C. neoformans co-infection could 
not be explored using this experimental model. 
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Figure 4.3: Uptake of C. neoformans to human MDMs. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml) for 1 week, and then infected with GFP-expressing C. neoformans strain H99-
GFP at an MOI of 10. Four hours post-infection, MDMs were washed to remove 
extracellular yeasts. Cells were fixed and uptake was assessed by confocal 
microscopy. Non-internalised C. neoformans was excluded by counterstaining with an 
antibody (18B7) to the GXM component of the capsule. MDMs were enumerated by 
staining of nuclei with DAPI. (a) Representative images of the DAPI nuclear stain; 
GFP-expressing cryptococci; counterstaining of external cryptococci with 18B7; and a 
merged image demonstrating extracellular cryptococci (yellow) and intracellular 
cryptococci (green). (b) MDMs and intracellular cryptococci were enumerated, and 
expressed as a ratio of intracellular cryptococci per MDM over the whole culture. Bar 
represents the mean +/- SEM of 3 experiments. Confocal imaging and analysis was 
carried out in collaboration with Dr. Janos Kristin-Vizi, LMCB, UCL. 
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Figure 4.4: Expression of cytokine mRNA by MDMs in response to C. neoformans in HIV-
1 co-infection. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng RT/ml) for 1 
week, and then infected with WT C. neoformans strains H99 or B3501, their isogenic 
unencapsulated mutants Cap59 or Cap67 (all at an MOI of 10), or stimulated with zymosan 
(Zym.; 0.4mg/ml). Cytokine mRNA expression at 4 and 24h was measured by qRT-PCR. 
Significant (P<0.05, paired t-test) differences in mRNA expression from unstimulated MDMs are 
indicated by * above bars, and significant differences in mRNA expression between uninfected 
and HIV-1 infected cells are indicated by * above brackets. (a) IL10 mRNA was expressed at 4h 
in response to zymosan but not C. neoformans strains, and was not expressed at 24h in 
response to any stimulus. HIV-1 attenuated IL-10 mRNA expression. (b) TNFA mRNA was 
expressed at 4h and 24h in response to zymosan and at 24h in response to unencapsulated C. 
neoformans. (c) IL1B mRNA was expressed at 4h and 24h in response to zymosan and at 24h 
in response to unencapsulated C. neoformans. Bars represent mean -/+ SEM of at least 3 
experiments. 
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Figure 4.5: MDM secretion of IL-10 in response to C. neoformans in HIV-1 co-
infection. 
MDMs were infected with HIV-1 (R9Δenv at an MOI of 3–5, with Vpx VLPs at 2ng 
RT/ml) for 1 week, and then infected with WT C. neoformans strains H99 or B3501, 
their isogenic unencapsulated mutants Cap59 or Cap67 (all at an MOI of 10), or 
stimulated with zymosan (Zym., 0.4mg/ml). IL-10 secretion at 4h and 24h was 
measured by ELISA of cell culture supernatants. (a) IL-10 secretion at 4h. IL-10 was 
secreted in response to zymosan, but not in response to C. neoformans strains. IL-10 
secretion was reduced in HIV-1 infected MDMs, but this was non-significant. (b) IL-10 
secretion at 24h. In 3 of 6 experiments, IL-10 was secreted at 24h in response to 
unencapsulated mutants of C. neoformans, and this was attenuated by HIV-1 co-
infection. Significant differences between groups were not observed. Paired results 
from the same experiment are indicated. 
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Figure 4.6: Non-immunogenicity of C. neoformans. 
(a) MDMs were infected with C. neoformans WT strain H99 at an MOI of 10 or 80, or stimulated 
with zymosan (Zym., 0.4mg/ml). IL-10 and IL-6 secretion at 4h and 24h was measured by ELISA 
of cell culture supernatants. Both cytokines were secreted in response to zymosan at 4h and 24h, 
but not in response to C. neoformans at either MOI or timepoint. (b) MDMs infected with C. 
neoformans WT strain H99 at an MOI of 10 or 100, or stimulated with LPS at 10ng/ml. Activation 
of the NFκB pathway was measured by quantitative imaging analysis of nuclear translocation of 
NFκB (RelA), assessed as a ratio of nuclear: cytoplasmic intensity of RelA staining. LPS 
stimulation induced translocation of NFκB (P=<0.0001, 0 mins vs. 30 mins or 120 mins, two-way 
ANOVA). C. neoformans did not induce NFκB translocation at either MOI used at any time point 
(P>0.05, two-way ANOVA). Bars represent mean -/+ SEM of at least 3 experiments. (c) 
Representative images of the NFκB translocation assay. Nuclei are stained blue with DAPI and 
NFκB RelA is stained green. Nuclear NFκB is evident in the middle panel of LPS-stimulated 
MDMs (green nuclear staining).  
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4.2.3 The transcriptional response to IL-10 in human MDMs 
Previous investigations showed that attenuated IL-10 responses in HIV-1/Mtb 
co-infected macrophages were associated with exaggerated downstream pro-
inflammatory macrophage responses (Tomlinson et al., 2014), and it is well described 
that IL-10 induces an anti-inflammatory response in macrophages, which includes 
cytokine suppression (Murray, 2005). Accordingly, IL-10 supplementation of co-
infected MDM cultures reversed the HIV-1 associated exaggerated inflammatory 
phenotype (Tomlinson et al., 2014). Further understanding the function of IL-10 in 
macrophage-driven immune responses may delineate potential outcomes of HIV-1-
mediated IL-10 attenuation as well as the role of IL10 in the context of an inflammatory 
response. As macrophages express the IL-10 receptor (Moore et al., 2001), 
macrophage IL-10 production can lead to autocrine IL-10 signalling and modulation of 
macrophage function (Murray, 2006). To investigate this, MDMs were stimulated with 
recombinant IL-10 for 24 hours, and changes in gene expression were assessed by 
genome-wide transcriptional profiling. IL-10 induced the expression of 47 genes in 
resting MDMs (Figure 4.7a). TFBS enrichment analysis of these genes using 
oPOSSUM-3 (Kwon et al., 2012; http://opossum.cisreg.ca) corroborated that they could 
be regulated by IL-10. Binding sites for STAT3, the major downstream mediator of IL-
10 signalling (L. Williams et al., 2004), were highly enriched (Figure 4.7b). IL-10 did 
not cause any substantial suppression of gene expression in resting MDMs (Figure 
4.7a). 
The function of the IL-10-induced genes was investigated by GO enrichment 
analysis using the web-tool InnateDB (Breuer et al., 2013; http://www.innatedb.com). 
This analysis was visualised as a network of enriched GO terms and associated genes 
(Figure 4.7c). IL-10 induced expression of genes involved in the innate immune 
response, inflammation and apoptosis. Some of these encoded for molecules with the 
potential to alter macrophage function, including signalling molecules such as SOCS3 
and JAK3, and receptors such as IgG FC receptors and the IL-7 receptor. Secreted 
molecules were also highlighted, including the chemokine CCL18, and members of 
S100 protein family, which can be secreted and play immunomodulatory roles (Donato 
et al., 2013). IL-10 also induced expression of the genes encoding pro-IL-1β and the 
complement factor C1S. These results show that IL-10 modulates macrophages by 
inducing gene expression and thus potentially altering functionality, consistent with 
previous reports (Antoniv et al., 2005; Park-Min et al., 2005; Stumpo et al., 2003).
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Figure 4.7: The MDM transcriptional response to IL-10. 
MDMs were stimulated for 24h with recombinant IL-10 (10ng/ml). RNA was collected and genome-
wide transcriptional profiling by microarray was performed. Significant gene expression changes 
induced by IL-10 were identified by t-test (P<0.05) and a twofold change threshold in comparison to 
unstimulated MDMs. (a) Frequency distribution of IL-10-induced changes in gene expression, 
presented as fold-change increases/decreases. (b) Genes up-regulated by IL-10 were subjected to 
transcription factor binding site (TFBS) enrichment analysis using oPOSSUM-3. The sequence 
5000bp up/downstream of each gene was analysed. Significance of TFBS frequency compared to 
background was assessed by the Z-score statistic, which was considered significant when ≥10. The 
X axis lists the number of genes enriched for a TFBS, and the Y axis displays the Z score. (c) 
Network visualisation of InnateDB gene ontology (GO) enrichment analysis of IL-10-induced genes. 
Enrichment assessment was performed using a hypergeometric algorithm, and filtered to biological 
process GO terms with a significance level of P<0.05 (Benjamini-Hochberg correction-adjusted). 
The top 15 enriched GO terms by gene count are shown. GO terms are in blue and genes are in 
red. Node size is determined by number of connections. All data presented are derived from the 
mean results of 3 independent experiments. 
Chapter 4 Results 
 
 
187 
4.2.4 IL-10 pre-treatment does not inhibit the transcriptional response to IFNγ in 
human MDMs 
As well as negatively regulating the innate inflammatory response (Lang et al., 
2002b), IL-10 is also suggested to suppress functions of adaptive immunity (Hutchins 
et al., 2013). The ability of adaptive immune CD4+ Th1 cells to activate macrophages 
via IFNγ is a key interface of CMI. I tested whether IL-10 could modulate this interface 
by altering macrophage responses to IFNγ.  
MDMs were pre-treated with IL-10 for 24 hours prior to IFNγ stimulation. The 
response to IFNγ was assessed by genome-wide transcriptional profiling. In both the 
presence and absence of IL-10 pre-treatment, IFNγ up-regulated the expression of 
hundreds of genes in MDMs (Figure 4.8a, b). IL-10 modulation of this response was 
assessed by comparing gene expression in the two MDM conditions, and specifically 
testing for significant differences in gene expression in the IFNγ response gene list 
(Figure 4.8c). The IFNγ response was highly conserved in the presence of IL-10 pre-
treatment, with only four statistically significant changes of ≥two-fold in transcription 
(Figure 4.8c), which were either in genes independently inducible by IL-10 (JAK3, 
SOCS3), or were in uncharacterised loci.  
These results demonstrate that IL-10 priming of macrophages does not alter 
their transcriptional response to IFNγ.  
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Figure 4.8: IL-10 pre-treatment does not inhibit the MDM transcriptional response to IFNγ. 
MDMs were pre-treated for 24 hours with recombinant IL-10 (10ng/ml) and then stimulated for 
4 hours with recombinant IFNγ (10ng/ml). RNA was collected and genome-wide transcriptional 
profiling was performed by microarray. Significant gene expression differences were identified 
by t-test (P<0.05) and a twofold change threshold. (a) Frequency distribution of IFNγ-induced 
changes in gene expression in comparison to unstimulated MDMs, presented as fold-change 
increases or decreases. (b) Frequency distribution as in (a) but for IL-10 pre-treated MDMs. (c) 
XY plot comparing mean expression of all genes induced in MDMs stimulated with with IFNγ, or 
IFNγ with IL-10 pretreatment. Linear regression showed a significant positive correlation and 
covariance between the two conditions. Highlighted genes showed significantly higher 
expression in IL-10 pretreated MDMs. All data presented are the mean results of 3 independent 
experiments. 
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4.2.5 IL-10 deficiency in inflammation dysregulates macrophage gene 
expression 
As the primary function of IL-10 is thought to be regulation of immune and 
inflammatory responses, I assessed the role of IL-10 in the context of an inflammatory 
response. MDMs were stimulated with zymosan in the presence or absence of 
neutralising antibodies to IL-10 and the IL-10 receptor, in order to block zymosan-
induced autocrine IL-10 signalling, and thus assess the consequences of IL-10 
deficiency in the inflammatory response. A similar exercise has been carried out in 
LPS-stimulated murine BMDMs from IL-10 deficient mice (Lang et al., 2002a), but the 
role of IL-10 in regulating the inflammatory response of human macrophages to a 
strong IL-10 inducer, such as zymosan, has not previously been assessed. The MDM 
response to 24 hours of zymosan stimulation was measured by genome-wide 
expression profiling. Zymosan caused up- and down-regulation of the expression of 
hundreds of genes (Figure 4.9a), and IL-10 blockade magnified this response (Figure 
4.9b).  
These transcriptional response were explored using the unsupervised 
exploratory statistical method of PCA. PCA is described in Introduction section 1.6.2. 
Briefly, it can be used to assess variance across a large data set by identifying multiple 
directions (termed components) across which the variation in the data is maximal 
(Chain et al., 2010; Ringnér, 2008). Each sample in such a dataset can be represented 
by its value within each component (a PC score), rather than by using the many 
thousands of expression values which contribute to this (Ringnér, 2008), and thus 
these scores can be used to visualise relationships within the dataset in multiple 
different dimensions. PC scores for the major component describing the zymosan 
response were significantly increased in the presence of IL-10 neutralisation (PC1; 
Figure 4.9c). PC scores for components describing further aspects of the zymosan 
response were, conversely, attenuated by IL-10 neutralisation (PC2–4; Figure 4.9c). 
This suggests that blocking IL-10 function in the innate inflammatory response leads to 
both induction and suppression of components of gene expression.  
To identify which genes were involved in this dysregulated phenotype, the lists 
of genes up-regulated by zymosan were compared in the presence or absence of IL-10 
neutralisation (Figure 4.10a). As suggested by PCA, IL-10 blockade produced further 
increases in gene expression, while other gene expression increases were no longer 
evident (Figure 4.10a). Directly comparing the expression of all genes up-regulated in 
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either condition showed a significant positive correlation and covariance of the overall 
response. However, statistically significant differences in expression of ≥two-fold as a 
result of IL-10 neutralisation could be identified (Figure 4.10b): 117 genes were further 
increased in expression, while 45 genes were attenuated in expression, representing 
dysregulation of 17.4% of the response to zymosan.  
The 117 zymosan-induced genes which are further increased in expression as 
a result of IL-10 neutralisation (Figure 4.10b) are ostensibly negatively regulated by IL-
10 in the context of an innate immune inflammatory response, as IL-10 blockade leads 
to their up-regulation. The function of these genes was investigated by GO enrichment 
analysis using InnateDB, and the results of this were visualised as a network of 
enriched GO terms and associated genes (Figure 4.11). IL-10 exerted negative 
regulatory effects on genes encoding for innate immune signalling components, such 
as the NFκB pathway mediators RelA and IRAK1, and mediators and regulators of 
cytokine signalling such as JAK2, STAT5a and SOCS1. Regulation of apoptosis by IL-
10 was also highlighted, as well as negative regulation of cytokines and secreted 
factors, such as IL-12 p40, CCL22, M-CSF and GM-CSF.  
A similar analysis was performed for the 45 genes for which expression was 
attenuated as a result of IL-10 neutralisation (Figure 4.10b), which are postulated to be 
positively regulated by IL-10, as IL-10 blockade leads to their inhibition. A network for 
the GO enrichment analysis for these genes is presented in Figure 4.12. This analysis 
demonstrates that in the context of inflammation, IL-10 induced changes in gene 
expression with potential functions in modulating the innate immune response, in 
addition to suppressive effects. Many of the gene induction effects of IL-10 described in 
resting MDMS (Figure 4.7) were evident here, such as induction of JAK3 and SOCS3, 
S100 proteins, C1S and chemokines. 
A large component of the response to zymosan was not affected by autocrine 
IL-10 signalling as assessed by IL-10 blockade (Figure 4.10). To investigate the 
functional characteristics of the non-IL-10-regulated response, the most highly 
zymosan-upregulated genes (≥16-fold increase in expression) for which expression 
was not significantly altered by IL-10 blockade were selected, and assessed by GO 
enrichment analysis. The results of this analysis are presented in a network in Figure 
4.13. This analysis suggests that IL-10 does not regulate the expression of many 
molecules considered to be part of the type I IFN and antiviral responses, such as 
CXCL9 and members of the IFITM (IFN-induced transmembrane protein) and ISG (IFN 
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stimulated gene) families. Some genes which IL-10 had been shown to regulate in 
other contexts, such as IL23A and IL1B (Figure 4.7; Tomlinson et al., 2014), were not 
regulated by IL-10 in this setting, perhaps reflecting some context-specificity of the 
function of IL-10. 
To gain insight into the mechanisms by which IL-10 regulated gene expression 
in inflammation, TFBS enrichment analysis was performed on genes increased in 
expression (Figure 4.14a), attenuated in expression (Figure 4.14b) or conserved in 
expression (Figure 4.14c) in IL-10 blockade. It should be noted that identification of 
TFBS enrichment in this analysis does not definitively indicate that the TF in question is 
regulating the genes concerned in this particular experiment, as the majority of genes 
will be regulated by many TFs in different contexts, and hence will contain binding sites 
for many TFs. Additionally, the presence of a TFBS does not indicate whether the 
associated TF is positively or negatively regulating gene expression, both of which are 
possible. However, the analysis provides insight into the potential list of TFs which may 
regulate these groups of genes in either a positive or negative fashion. 
Many TFBSs were significantly enriched in the group of genes postulated to be 
negatively regulated by IL-10 (Figure 4.14a). This included binding sites for STAT3, 
the primary transcriptional mediator of IL-10 signalling; however, this was one of the 
least significantly enriched TFBSs identified, with sites in less than half of the genes 
assessed. However, many other TFs were identified in this analysis, and previous 
reports have described that the IL-10-induced AIR involves STAT3 inducing expression 
of a secondary wave of transcription factors, the AIR factors, which then co-ordinate 
the AIR by exerting inhibitory effects on transcription (Hutchins et al., 2012; Murray, 
2005). The multiplicity of TFBSs highlighted in this gene list, including many known 
innate immune mediators such as NFκB and MZFs, thus supports the suggestion that 
negative regulation by IL-10 may mainly be controlled indirectly by other TFs 
downstream of STAT3, which alter the outcome of innate immune signalling pathways. 
Assessment of the genes postulated to be positively regulated by IL-10 showed 
no significant TFBS enrichment (Figure 4.14b; no TFBS has a Z score ≥10). Stat3 
binding sites were identified in >50% of these genes, but this was not statistically 
significant. The presence of STAT3 binding sites nonetheless suggests that some of 
these genes may be directly positively regulated by IL-10 signalling. However, it may 
also be possible that these genes are indirectly regulated by IL-10. Overall, 
assessments of these gene lists are concordant with the hypothesis that IL-10 
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signalling involves a limited primary response mediated by STAT3, which then 
produces functional outcomes via secondary responses and feedback loops mediated 
via other TFs. TFBS enrichment analysis of the genes which were identified as not 
regulated by IL-10 (Figure 4.13) shows significant enrichment for NFκB binding sites 
only (Figure 4.14c). IRF1 and IRF2 binding sites are also identified in many of these 
genes, although are not enriched to a level of statistical significance; however, this 
lends support to the hypothesis that this gene list is highly enriched for features of type 
I IFN responses, further indicating that this axis of innate immunity is not regulated by 
IL-10. 
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Figure 4.9: Neutralisation of IL-10 alters the zymosan-induced inflammatory response in 
MDMs. 
MDMs were stimulated with zymosan (0.4mg/ml) for 24 hours in the presence of neutralising 
antibodies to IL-10 (5ug/ml) and to the IL-10 receptor (10ug/ml). RNA was collected and 
genome-wide transcriptional profiling was performed by microarray. Significant gene expression 
differences were identified by t-test (P<0.05) and a twofold change threshold. (a) Frequency 
distribution of zymosan-induced changes in gene expression in comparison to unstimulated 
MDMs, presented as fold-change increases or decreases. (b) Frequency distribution as in (a) 
but for MDMs stimulated with zymosan with IL-10 neutralisation. (c) PCA of zymosan-
stimulated MDMs −/+ IL-10 neutralisation. The first four principal components showed 
significant differences in PC score between unstimulated MDMs and zymosan-stimulated 
MDMs. PC1 scores were significantly increased by IL-10 neutralisation, while PC2–4 scores 
were significantly decreased by IL-10 neutralisation. * indicates P<0.05, paired t-test. Symbols 
represent mean −/+ SEM. All data presented are the mean results of 3 independent 
experiments. 
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Figure 4.10: Identification of zymosan-induced gene expression changes which 
are dysregulated by IL-10 neutralisation. 
(a) Venn diagram of genes which are upregulated in MDMs by zymosan stimulation −/+ 
IL-10 neutralisation. (b) XY plot comparing mean expression of all genes upregulated in 
MDMs stimulated with zymosan stimulation −/+ IL-10 neutralisation. Linear regression 
showed a significant positive correlation and covariance between the two conditions. 
Highlighted genes showed significantly different (≥two-fold higher or lower) expression in 
the presence of IL-10 neutralisation. Numbers in brackets indicate numbers of genes. All 
data presented are the mean of 3 independent experiments. 
 
Chapter 4 Results 
 
 
195 
 
Figure 4.11: Genes which are negatively regulated by IL-10 in zymosan 
stimulation of MDMs. 
IL-10 neutralisation significantly increased the expression of 117 genes which are 
usually upregulated in the MDM response to zymosan (Figure 4.10b), suggesting that 
these genes were negatively regulated by IL-10. InnateDB (Breuer et al., 2013; 
http://www.innatedb.com) GO enrichment analysis was performed for this gene list and 
the results of this analysis are visualised as a network. Enrichment assessment was 
performed using a hypergeometric algorithm, and filtered to biological process GO 
terms with a significance level of P<0.05 (Benjamini-Hochberg correction-adjusted). 
The top 20 enriched GO terms by gene count are shown. GO terms are in blue and 
genes are in red. Node size is determined by number of connections. All data 
presented are derived from the mean results of 3 independent experiments. 
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Figure 4.12: Genes which are positively regulated by IL-10 in zymosan 
stimulation of MDMs. 
IL-10 neutralisation significantly attenuated the expression of 45 genes which are 
usually upregulated in the MDM response to zymosan (Figure 4.10b), suggesting that 
these genes were positively regulated by IL-10. InnateDB (Breuer et al., 2013; 
http://www.innatedb.com) GO enrichment analysis was performed for this gene list and 
the results of this analysis are visualised as a network. Enrichment assessment was 
performed using a hypergeometric algorithm, and filtered to biological process GO 
terms with a significance level of P<0.05 (Benjamini-Hochberg correction-adjusted). All 
enriched GO terms are shown. GO terms are in blue and genes are in red. Node size is 
determined by number of connections. All data presented are derived from the mean 
results of 3 independent experiments. 
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Figure 4.13: Genes which are not regulated by IL-10 in zymosan-stimulated 
MDMs. 
A large proportion of the gene expression response to zymosan in MDMs was not 
affected by IL-10 neutralisation (769 of 915 genes; Figure 4.10b). To gain insight into 
the function of these non-IL-10 regulated components of the innate immune response, 
the most highly zymosan-inducible genes (≥16-fold increase in expression) were 
selected and InnateDB (Breuer et al., 2013; http://www.innatedb.com) GO enrichment 
analysis was performed for this gene list. Enrichment assessment was performed using 
a hypergeometric algorithm, and filtered to biological process GO terms with a 
significance level of P<0.05 (Benjamini-Hochberg correction-adjusted). The 10 most 
highly enriched GO terms are shown. GO terms are in blue and genes are in red. Node 
size is determined by number of connections. All data presented are derived from the 
mean results of 3 independent experiments. 
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Figure 4.14: TFBS enrichment analyses of IL-10 regulated genes in zymosan-
stimulated MDMs 
To gain insight into transcriptional regulation of the genes which were differentially 
expressed in zymosan stimulation −/+ IL-10 neutralisation, TFBS enrichment analysis 
was performed using oPOSSUM-3 (Kwon et al., 2012; http://opossum.cisreg.ca). The 
sequence 5000bp up/downstream of each gene was analysed. Significance of TFBS 
frequency compared to background was assessed by the Z-score statistic, which was 
considered significant when ≥10. The X axis lists the number of genes enriched for a 
TFBS, and the Y axis displays the Z score. (a) TFBS enrichment analysis for genes 
further up-regulated as a result of IL-10 neutralisation (Figure 4.10b; Figure 4.12). (b) 
TFBS enrichment analysis for genes which were attenuated in expression as a result 
of IL-10 neutralisation (Figure 4.10b; Figure 4.13). (c) TFBS enrichment analysis for 
genes which were conserved in IL-10 neutralisation (Figure 4.13). All data presented 
are derived from the mean results of 3 independent experiments. 
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4.2.6 IL-10 deficiency in inflammation modulates cell recruitment 
Neutralisation of IL-10 in the MDM response to zymosan dysregulated 
expression of a range of secreted factors, including cytokines and chemokines (Figure 
4.11, 4.12). This suggested that a deficiency in autocrine IL-10 signalling in 
macrophages might impact on the function of other cells which are responsive to these 
factors. One candidate pathway which may be affected is the recruitment of other 
leukocytes to an inflammatory focus generated by the macrophage. A previous 
investigation of dysregulated inflammatory responses in HIV-1/Mtb co-infected 
macrophages demonstrated that expression of the chemokines CCL20, CCL3, 
CCL3L3 and CCL5 in response to Mtb was potentiated by HIV-1 co-infection, and that 
this may be a result of IL-10 attenuation (Tomlinson et al., 2014).  
I aimed to investigate whether IL-10 deficiency in macrophage-generated 
inflammation altered cellular recruitment. A transwell experiment was used to model 
recruitment to an inflammatory focus (Figure 4.15a). Conditioned media generated by 
zymosan stimulation of macrophages in the presence or absence of IL-10 
neutralisation was placed in the lower chamber, and PBMC were placed in the upper 
chamber. After 3 hours of migration, cells in the lower chamber were collected and 
stained for CD3 and CD14 to quantify T cells and monocytes respectively, using flow 
cytometry. 
To quantify the migration of different cell populations, a migration index was 
used. The absolute numbers of cells recruited, for each cell population of interest, were 
normalised as a ratio to the absolute number of that cell population in an input PBMC 
sample. The acquisition of all samples, including the input sample, was standardised 
using beads spiked into equivalent volumes of fixed cell suspensions. Migration indices 
for conditioned media of interest were compared to the migration index for control non-
conditioned media, to identify differential recruitment generated by macrophage 
responses. 
The PBMC migration index was statistically significantly increased using 
conditioned media generated by MDMs with IL-10 neutralisation, regardless of 
zymosan stimulation (Figure 4.15b). The CD3+ migration index suggests that increased 
numbers of T cells are recruited using zymosan-stimulated conditions (Figure 4.15c), 
and this was significantly increased further by IL-10 neutralisation (Figure 4.15c). The 
CD14+ monocyte migration index was significantly increased by IL-10 neutralisation 
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alone (Figure 4.15d). Assessing modulation of CD14+ cell migration in the context of 
zymosan stimulation may be confounded by the fact that fewer monocytes migrated 
using zymosan-conditioned media (Figure 4.15d), which may be due to inflammatory 
mediator-induced increases in monocyte adhesion (Gerszten et al., 1999; Imhof and 
Aurrand-Lions, 2004; Jiang et al., 1992) meaning they adhere within the upper 
chamber and to the upper surface of the transwell, preventing migration. No differential 
recruitment was observed for the CD3−CD14− cell population (Figure 4.15e).  
These results suggest that deficiency of IL-10 can impact on cellular recruitment 
to a macrophage-generated inflammatory focus. Most strikingly, T cell recruitment is 
clearly potentiated by neutralisation of IL-10 in zymosan-stimulated MDMs. Monocyte 
recruitment may also be affected, as resting MDMs with IL-10 neutralisation appear to 
recruit increased numbers of monocytes; however, further assessment is merited to 
clarify whether this also occurs in the presence of inflammation. The CD3−CD14− 
population is made up of several cell types, including B cells, NK cells and CD14− 
mononuclear myeloid cells, and so although no gross differential recruitment was 
shown in this experiment, further assessment may be necessary to delineate any 
differential regulation as a result of IL-10 deficiency.  
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Figure 4.15: IL-10 neutralisation modulates recruitment of PBMC. 
 (a) Schematic of transwell experimental model. Conditioned media generated from stimulation of 
MDMs with zymosan −/+ IL-10 neutralisation (pooled from 4 donors) was placed in the lower 
chamber of the transwell. PBMC from a healthy donor were placed in the upper chamber and 
allowed to migrate for 3 hours. Recruited cells were stained and analysed by flow cytometry. 
Migration indices were calculated for each cell population by normalising the absolute number of 
recruited cells to the absolute number in an input PBMC sample. Sample acquisition was 
standardised using beads. Control (ctrl) indicates unconditioned media in the lower chamber. (b) 
PBMC migration was significantly increased by conditioned media generated with IL-10 
neutralisation −/+ zymosan stimulation. (c) CD3+ (T cell) migration was significantly increased by 
zymosan-stimulated conditioned media, and addition of IL-10 neutralisation significantly increased 
CD3+ migration above zymosan alone. (d) CD14+ (monocyte) migration was significantly increased 
by conditioned media generated with IL-10 neutralisation without zymosan stimulation. (e) CD3- 
CD14- cell migration index. No conditioned media altered migration. * indicates P<0.05, paired t-test. 
Bars show mean −/+ SEM of 4 independent experiments. 
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4.3 Chapter discussion 
I aimed to explore the consequences of IL-10 attenuation for viral replication, and 
for the host immune response, in terms of the pathogens affected and the functional 
outcomes of innate immune IL-10 deficiency. 
To understand the consequences of IL-10 attenuation by HIV-1 in MDMs, I 
assessed whether this phenotype provided the virus with a replicative advantage. IL-10 
supplementation inhibited zymosan-induced viral replication and release in MDMs 
(Figure 4.1), and did so at the level of virus transcription, corroborating previously 
published work suggesting this to be the case in other systems (Tanaka et al., 2005; 
Wang and Rice, 2006). This gives a strong indication of why restricting IL-10 
transcription might provide an advantage to the virus, and thus why HIV-1 has evolved 
this function. This enhancement of HIV-1 replication by zymosan, or other stimuli which 
activate dectin-1, has not previously been observed. Mtb has been shown to enhance 
HIV-1 replication in macrophages, but TLR-2 rather than dectin-1 stimulation has been 
the primary pathway implicated in this mechanism (Falvo et al., 2011; Ranjbar et al., 
2012). Establishing whether specific stimulation of dectin-1 can directly enhance HIV-1 
replication is of interest, as it would provide insight into the dynamics of viral replication 
during fungal co-infections in which dectin-1 is a major PRR.  Stimulation of MDMs with 
curdlan, a specific dectin-1 ligand, may provide insight into this interaction.  
IL-10 supplementation did not affect HIV-1 replication in non-stimulated 
macrophages, nor was IL-10 found to modulate macrophage permissivity to HIV-1 
infection (Figure 4.2). However, as IL-10 is less likely to be produced by macrophages 
in the resting state, and thus to elicit a response in these cells, this situation may be 
less relevant than the interplay between HIV-1, IL-10 and macrophages in the context 
of macrophage activation. In this model, macrophages are reservoirs of latent HIV-1 
infection, which begins to replicate during activation by a pathogen, at which time there 
is accumulation of other macrophages and T cells, i.e. an appropriate time for viral 
propagation between cells. IL-10 can suppress viral replication and limit the 
inflammatory response, so it is advantageous to the virus to inhibit IL-10 production in 
order to amplify the inflammatory environment and to maximise viral replication and 
transmission to new host cells. Importantly, several studies have identified increased 
HIV-1 replication in vivo at the site of TB disease, i.e. an inflammatory environment, 
indicating that these interactions may be relevant to co-infection pathogenesis (Collins 
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et al., 2002b; Garrait et al., 1997; Lawn et al., 2001; Nakata et al., 1997). Testing the 
effects of IL-10 supplementation on cell-to-cell spread of virus may provide further 
insight into this hypothesis, by determining if IL-10 attenuation by HIV-1 augments 
transmission between macrophages or from macrophages to T cells. 
To investigate whether HIV-1 attenuated IL-10 responses to a pathogen other 
than Mtb, the opportunistic pathogenic fungus C. neoformans was investigated. Uptake 
of C. neoformans to MDMs was confirmed, albeit at relatively low levels, and this was 
not affected by HIV-1 co-infection (Figure 4.3). However, inflammatory responses to C. 
neoformans were not evident, except in response to unencapsulated C. neoformans 
mutants, where some pro-inflammatory cytokine expression, and IL-10 secretion (non-
significantly in a subset of donors), was measured at 24 hours (Figure 4.4, Figure 4.5). 
The non-immunogenicity of C. neoformans was further confirmed by the lack of NFκB 
activation in response to this pathogen (Figure 4.6). As such, the existence or 
relevance of attenuated MDM IL-10 responses to C. neoformans could not be 
assessed.  
C. neoformans is known to be a relatively non-immunogenic organism 
(Vecchiarelli et al., 1995). However, as healthy individuals (who do not commonly 
experience cryptococcal disease) generate protective immune responses to C. 
neoformans, as evident by detectable antibody responses in most individuals by early 
childhood (Abadi and Pirofski, 1999; Goldman et al., 2001), presumably an innate 
response must occur in vivo in order for an adaptive response to be provoked. It is also 
clear that this innate response is likely to be generated by alveolar macrophages, as 
transmission of C. neoformans infection occurs via the respiratory tract, and so alveolar 
macrophages are assumed to be the primary host cell for the fungus (McQuiston and 
Williamson, 2011). It may be that this model of M-CSF differentiated MDMs does not 
effectively model the in vivo sentinel cell, alveolar macrophage or otherwise, which 
detects C. neoformans, and indeed other reports describing innate responses have 
used different cellular models, such as PBMC (Levitz et al., 1994; Walenkamp et al., 
1999) ex vivo alveolar macrophages (Vecchiarelli et al., 1994), DCs (Lupo et al., 2008; 
Vecchiarelli et al., 1995) or monocytes (Delfino et al., 1997; Vecchiarelli et al., 1995). 
Further experiments using these cells may allow assessment of whether HIV-1 
infection of the mononuclear phagocyte sentinel cell modulates the innate response to 
C. neoformans, as well as assessing other aspects of this host-pathogen interaction 
such as phagocytosis, killing and inflammasome activation. In terms of further 
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identification of pathogens for which HIV-1-mediated IL-10 attenuation may be relevant, 
the agents of other clinically important fungal co-infections are candidates, such as 
Candida albicans and Pneumocystic jirovecii. 
The consequences of IL-10 attenuation for the function of the immune response 
were explored in a set of experiments investigating regulation of macrophage function 
by IL-10 signalling. Stimulation of resting MDMs with recombinant IL-10 for 24 hours 
induced modest gene expression changes (Figure 4.7), in comparison to the 
magnitude of gene expression changes induced by another cytokine which can 
modulate macrophage function, IFNγ (Figure 4.8). This gene expression response was 
concordant with known functions of IL-10, such as modulation of apoptotic pathways 
(Balcewicz-Sablinska et al., 1999, 1998; Eslick et al., 2004; Rojas et al., 1999; Zhou et 
al., 2001). Many gene expression changes identified have also been reported by other 
investigators as effects of IL-10 on macrophages or monocytes, such as induction of 
SOCS3, IL7R, CD163, C1S, IL1B and CCL18 (Antoniv et al., 2005; Teles et al., 2013; 
Williams et al., 2002). Many of these genes encode for proteins with functions which 
are not classically immunosuppressive or anti-inflammatory, and which have functions 
other than mediating inhibition of transcriptional responses, which is suggested to the 
main mechanism of IL-10/STAT-3 induced AIR factors (Hutchins et al., 2012; Murray, 
2006, 2005). This demonstrates that IL-10 signalling in macrophages can modulate 
function, as well as having directly suppressive effects on pro-inflammatory responses. 
For example, the induction of signalling molecules such as SOCS3 and JAK3 could 
modulate subsequent responses to innate immune stimuli and cytokines, IL1B and 
C1S are potentially involved in inflammation, and CCL18 is chemotactic for Th2 cells 
(Griffith et al., 2014).  
As this gene expression profile represents the outcome 24 hours post-IL-10 
signalling, it may include both genes induced directly by IL-10 via STAT3 signalling, 
and secondary waves of response coordinated via indirect pathways, particularly as it 
is suggested that STAT3 mainly acts to induce the expression of transcription factors 
(Hutchins et al., 2012). That it might include both responses is supported by the 
observation that it includes previously identified secondary STAT3 effectors, such 
BCL3 and BATF (Hutchins et al., 2012), but also clearly includes many genes with 
divergent functions. Additionally, TFBS enrichment analysis only identifies STAT3 
binding sites in a subset of the genes (Figure 4.7b). 
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The effects of IL-10 pre-treatment on the MDM response to IFNγ was measured, 
to assess whether IL-10 could modulate this key interaction in the cell-mediated 
immune response. No significant impact of IL-10 pretreatment was apparent (Figure 
4.8). This is consistent with some published reports, including in the mouse model of 
Mtb, wherein it has been shown that macrophage-derived IL-10 modulates the immune 
response to Mtb by pathways which do not involve the Th1 response (Schreiber et al., 
2009). However, there is a prevalent concept within the field that IL-10 can negatively 
regulate protective IFNγ responses and that this is a pathway by which it could 
compromise protection in TB infection (O’Garra et al., 2013). This may still occur 
indirectly, due to IL-10 regulation of the innate response leading to less Th1 
polarisation (Fiorentino et al., 1991, 1991). It is also possible that post hoc signalling by 
IL-10 might modulate the IFNγ response. The former scenario is supported by 
subsequent experiments assessing the effect of IL-10 blockade on leukocyte 
recruitment, in which IL-10 neutralisation potentiates T cell recruitment, suggesting that 
IL-10 normally acts to inhibit macrophage/T cell interactions.  
However, this experiment strongly indicates that IL-10 does not directly suppress 
the macrophage response to IFNγ, and this is supported by the observation that IL-10 
does not induce expression of the major intracellular negative regulatory of IFNγ 
signalling, SOCS1 (Carey et al., 2012). In fact, IL-10 negatively regulates SOCS1 in a 
subsequent experiment assessing the effects of IL-10 via its blockade (Figure 4.11). 
The main negative regulator induced by IL-10 in these experiments is SOCS3 (Figure 
4.7, Figure 4.12), the main function of which is in negative regulation of innate 
inflammatory IL-6 signalling (Carey et al., 2012). These divergent effects of IL-10 on 
regulatory pathways controlling either adaptive or inflammatory signalling may indicate 
that its main direct function in human macrophages is to regulate the innate response, 
via which it may then exert indirect effects on adaptive immunity. 
Assessment of the role of IL-10 in the innate immune response was further 
extended by specifically investigating its role in inflammation, by blockade of autocrine 
IL-10 signalling during zymosan stimulation of MDMs (Figure 4.9–Figure 4.14). Some 
of the genes shown to be induced by IL-10 in resting MDMs are also highlighted here, 
such as SOCS3, C1S and S100 proteins, showing that in the context of inflammation, 
IL-10 still induces particular phenotypic changes in macrophages, as well as exerting 
suppressive effects. Its suppressive role is strongly evident in this context: IL-10 
negatively regulated approximately 20% of the MDM response to zymosan, consistent 
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with the reported magnitude of its role in regulating the LPS response in murine 
BMDMs (Lang et al., 2002b). It is also clear from this experiment, similarly to the 
previous investigation of the murine LPS response, that the regulatory effects of IL-10 
on gene expression are greater in magnitude in the context of innate activation of 
macrophages than in resting macrophages, supporting the concept that the major role 
of IL-10 is to modulate inflammation. 
Many of the genes affected by IL-10 neutralisation in this experiment may have 
roles in cell-autonomous macrophage functions, highlighting potential dysregulated 
macrophage phenotypes which might result from HIV-1 mediated IL-10 attenuation in 
the innate immune response. These include the previously discussed dysregulation of 
SOCS proteins. Expression of SOCS1, which regulates IFNγ signalling, was induced 
as a result of IL-10 blockade, while the IL-6 signalling regulator SOCS3 was 
suppressed (Figure 4.11, Figure 4.12; Carey et al., 2012). If corroborated in HIV-1 
infected MDMs, this suggests that IL-10 attenuation might cause hyper-responsiveness 
to inflammatory IL-6 signalling and hypo-responsiveness to adaptive IFNγ signalling. 
Assessing responses of HIV-1 infected MDMs to these cytokines may be informative, 
as well as testing the response of HIV-1 infected MDMs to type I IFNs or co-infecting 
viruses, as these latter pathways were highlighted by exploration of the component of 
the innate immune response which was not regulated by IL-10. Finally, the role of IL-10 
in modulating apoptosis was emphasized in these experiments, and as a result 
assessments of dysregulation of apoptosis in HIV-1 infected MDMs are clearly merited. 
As well as indicating macrophage-autonomous functions which are modulated by 
IL-10 neutralisation and hence also potentially by HIV-1 attenuation of IL-10, this 
experiment also identifies many factors secreted by MDMs which are dysregulated as 
a result of IL-10 blockade, including the genes encoding for IL-12 p40, M-CSF, GM-
CSF and a number of chemokines. This suggests that autocrine IL-10 signalling in 
macrophages can indirectly regulate the function of other cells via these factors, thus 
identifying candidate pathways by which the IL-10 attenuation phenotype might impact 
on the downstream immune response. One such pathway, regulation of chemotaxis, is 
discussed subsequently. Other strong candidates for investigation including assessing 
the effect of HIV-1 infected macrophages on T cell polarisation, as IL-12, the major 
inducer of Th1 polarisation, is dysregulated. Exploring the effects of these cells on 
monocyte differentiation is also merited, due to the demonstrated dysregulation of M-
CSF and GM-CSF.  
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The effects of innate immune IL-10 deficiency on chemotaxis were investigated 
by testing recruitment of leukocytes to an inflammatory focus, via modelling this 
interaction in a transwell experiment (Figure 4.15). Conditioned media from zymosan-
stimulated MDMs was shown to induce T cell migration, and IL-10 neutralisation was 
capable of significantly increasing this (Figure 4.15c). This could potentially be due to 
absence of negative regulation by IL-10 of the T cell chemotactic factor CCL22 (Figure 
4.11; Griffith et al., 2014). Assessment of whether HIV-1-mediated IL-10 attenuation 
produces the same phenotype is warranted, as if HIV-1 uses macrophage IL-10 
deficiency to potentiate T cell recruitment in inflammation, this would support the 
concept that HIV-1 produces this phenotype in order to maximise its own propagation. 
The previous investigation of dysregulated responses in HIV-1/Mtb co-infected 
macrophages did not identify CCL22 dyregulation, but did demonstrate exaggerated 
production of the T cell chemotactic factor CCL20 (Griffith et al., 2014; Tomlinson et al., 
2014), also supporting further investigation of this phenotype. Blockade of different 
chemokines with neutralising antibodies within this experimental setup may also help 
identify the specific mechanisms by which IL-10, and possibly HIV-1, lead to 
downstream modulation of leukocyte recruitment. 
These alterations in cellular recruitment due to IL-10 deficiency also have the 
potential to change the quality of the inflammation generated; for example by leading to 
polarised T cell phenotypes. As such, further work defining the phenotype of these 
recruited T cells is merited: firstly, whether they are CD4+ or CD8+, and secondly, 
whether there is differential polarisation within the CD4+ population: CCL22, discussed 
above, is postulated to be associated with specific recruitment of Th2 cells (Griffith et 
al., 2014).   
In these experiments, monocyte recruitment was found to be abrogated in the 
presence of conditioned media from zymosan-stimulated MDMs (Figure 4.15d), and 
as such the effect of IL-10 neutralisation on modulating their recruitment could not be 
assessed. This absence of migration may be due to increased monocyte adhesion in 
the upper chamber of the transwell setup, as monocyte adhesion can be induced by 
various inflammatory mediators that are likely to be generated by zymosan stimulation 
of MDMs (Gerszten et al., 1999; Imhof and Aurrand-Lions, 2004; Jiang et al., 1992). 
In summary, the phenotype of IL-10 attenuation may have substantial 
consequences for both viral replication and for the host immune response. 
Inflammation represents a valuable opportunity for the virus to maximise its own 
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replication, both within macrophages and by inducing recruitment of new target cells for 
infection. Suppressing innate immune IL-10 production allows HIV-1 to potentiate its 
own replication in the context of inflammation. As IL-10 has a multitude of modulatory 
and suppressive effects, this host-virus interaction may impact on the immune 
response in a number of ways. Further exploring the functions of macrophage-
produced IL-10 and dysregulated responses of HIV-1 infected macrophages may 
provide insight into the immunopathology of HIV-1 associated co-infections, and the 
role of macrophages in these. 
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Chapter 5. Results 3. Derivation of transcriptional 
modules reflecting macrophage heterogeneity 
5.1 Background 
Macrophages are tissue-resident sentinel cells which are also involved in regulation 
and repair processes, and so must continuously respond to changes in the 
homeostasis of their environment (Wynn et al., 2013), via a wide variety of potential 
inputs. Each of these inputs requires the macrophage to alter its function appropriately, 
and therefore functional plasticity and subsequent phenotypic heterogeneity are central 
tenets of macrophage biology (Lawrence and Natoli, 2011). This plasticity is assumed 
to be primarily controlled at the transcriptional level, wherein the extracellular mediators 
inducing macrophage phenotypic adaptation activate intracellular signalling cascades 
via receptor ligation, converging on transcriptional outputs which reprogram the 
function of the cell (Lawrence and Natoli, 2011; Natoli and Monticelli, 2014). Hence, 
genome-wide transcriptional profiling, has been widely employed to characterise the 
molecular detail of macrophage activation states (Beyer et al., 2012; Lacey et al., 2012; 
Martinez et al., 2006; Nau et al., 2002; Xue et al., 2014).  
As macrophages are critical co-ordinators of the immune response in the tissue 
microenvironment, most evidently in the context of CMI, assessment of their phenotype 
can potentially provide insight into the overarching phenotype of an immune response. 
I aimed to use the functional heterogeneity of macrophage phenotypes as a window for 
assessing immune responses in vivo, through investigating macrophage plasticity in 
human MDMs by transcriptional profiling, and subsequently using these datasets to 
analyse in vivo-derived gene expression profiles. To make this link between 
macrophage transcriptomes and in vivo gene expression profiles, I chose to use MDM 
gene expression data to develop a modular strategy for transcriptional analysis.  
Modular analysis of gene expression data is a method by which the expression of a 
set of genes that define a particular functional response, cell type or pathway is 
quantified as a single variable for comparative assessments (reviewed fully in 
Introduction section 1.6.3). For example, to measure IFNγ activity, the expression of 
all genes induced by IFNγ is integrated to quantify as a single IFNγ score. There are 
several clear advantages provided by modular transcriptomic analyses. Firstly, in 
identifying a particular biological process of interest, assaying a set of genes as 
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opposed to a single gene is likely to provide superior specificity; a single gene is more 
likely to act as a false positive than is a combined set of genes. Secondly, the power 
available to assess the bioactivity of a particular stimulus is increased by measuring a 
larger set of genes as a proxy, as it does not rely on the ability to measure any single 
particular molecule. Finally, in assessing gene expression profiles derived from 
complex in vivo samples, which are likely to contain multiple signatures of parallel 
functional processes, modular analysis may be a particularly valuable method for 
deconvoluting genome-wide data into its component, functionally informative parts.  
Two principal methods of generating modules currently exist. Firstly, data-driven 
modules, an unsupervised method in which co-clustering networks of transcript 
correlations are built and used to identify a repertoire of modules each of which is 
made up of co-correlated genes. Modules can then be assigned particular functional or 
cellular labels by post hoc assessments (Chaussabel and Baldwin, 2014). The second 
method can be described as hypothesis-driven, in which the modular activity that the 
investigator wishes to assess is defined a priori – for example, the activity of a 
particular cytokine or the phenotype of a specific cell – and a gene set is constructed 
for this module from bioinformatics sources or experimentally generated transcriptomic 
data (Subramanian et al., 2005). Multiple strategies have also been developed to 
quantify enrichment of module expression in transcriptomic datasets. These include 
simple methods, in which the mean or median expression value of the module gene set 
is calculated in the sample of interest, which is then used as a module score which can 
be used for between-group comparisons (Chaussabel and Baldwin, 2014). More 
complex techniques for assessing enrichment involve statistical algorithms such as 
GSEA (Mootha et al., 2003; Subramanian et al., 2005). A gold standard for module 
enrichment scoring is yet to emerge (Hung et al., 2012). The most appropriate analysis 
method to use is likely to depend on the distribution of the dataset to be assessed 
(Alavi-Majd et al., 2014), and use of multiple methods to widely explore datasets and 
confirm enrichment may be most appropriate (Glazko and Emmert-Streib, 2009). 
I aimed to use macrophage heterogeneity, a powerful gauge of the function of the 
immune response, to develop hypothesis-driven modules for stimuli of interest, in order 
to facilitate downstream analyses of in vivo-derived gene expression profiles. In order 
to do this, I aimed to explore macrophage plasticity via transcriptional profiling, to 
develop and optimise gene expression profiles from these data, and to identify 
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appropriate methods for assessing enrichment of these modules in downstream 
applications. The specific objectives of this investigation were as follows: 
(a) To use transcriptional profiling to characterise MDM responses to signature 
cytokines produced by different T cell subsets: IFNγ, or TNFα (Th1), IL-4 
and IL-13 combined (Th2) or TGFβ and IL-10 combined (Treg), to explore 
adaptive immune modulation of macrophage plasticity in different types of 
polarised immune response. 
(b) To use this dataset to generate hypothesis-driven modules, which are 
optimised for detection of stimulus-specific effects in gene expression 
datasets. 
(c) To use the optimised modular generation pipeline to produce modules for 
other stimuli of interest, from appropriate MDM transcriptomic datasets: 
differential IFN responses, immuno-regulatory IL-10 responses, and specific 
innate immune stimuli. 
(d) To identify an appropriate method for quantifying enrichment of these 
modules in in vivo-derived gene expression profiles. 
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5.2 Results 
5.2.1 MDM transcriptional responses to cytokines associated with differentially 
polarised T cell responses 
Whole genome transcriptional profiling of unstimulated MDMs revealed gene 
expression levels above that of the genome-wide median for the receptors for all 
signature cytokines associated with differentially polarised T cell responses (Figure 
5.1a). TGFβ receptor type 1 (TGFBR1) expression was lower than that of the other 
receptors, but still above the background level of detectable expression (Figure 5.1a). 
Interestingly, TGFβ receptor type 2 (TGFBR2) which was highly expressed,  can 
function as a homodimeric receptor (Derynck and Feng, 1997). These data suggest 
that our model of MDM express the full complement of receptors necessary to respond 
to the canonical T cell cytokines. 
To assess macrophage responses to cytokines, human MDMs were stimulated 
with IFN γ, TNFα, IL-4 & IL-13 combined or TGFβ & IL-10 combined, all at 10ng/ml for 
24 hours, and genome-wide transcriptional profiling was performed by microarray. 
Significant transcriptional expression changes in comparison to unstimulated MDMs 
were identified, and are shown as frequency distributions of increased and decreased 
fold changes in gene expression (Figure 5.1b). All four conditions were associated 
with hundreds of up- and down-regulatory changes in gene expression, with IFNγ 
being associated with the greatest magnitude and numbers of changes (Figure 5.1b). 
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 (a) Gene expression matrix for cytokine receptor genes in unstimulated MDMs from five healthy 
donors. Data is presented as normalised microarray expression values, where 6.5 is the lowest 
detectable expression, 18 is the highest and 8 is the median. GAPDH is shown as a reference 
housekeeping gene. (b) Human MDMs were stimulated with recombinant cytokines for 24 hours 
at 10ng/ml. RNA was collected and transcriptional profiling performed by microarray. Significant 
gene expression changes (≥two-fold, P<0.05) from unstimulated MDMs were identified by t-test 
with a Welch’s approximation. All ≥two-fold increases and decreases in gene expression are 
displayed as frequency distributions of numbers of changes induced in each condition. Gene 
lists are filtered to remove any duplicate genes which might be present due to representation of 
the same gene by multiple probes on the microarray. Results represent mean gene expression 
values for at least three individual healthy donor MDMs for each condition.  
 
Figure 5.1: Transcriptional responses of MDMs to cytokines produced by differentially 
polarised T cell responses. 
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5.2.2 Functional investigation of MDM transcriptional responses to cytokines 
associated with differentially polarised T cell responses 
I explored the transcriptional changes induced by each cytokine using a 
bioinformatics approach. Firstly, in order to investigate the potential regulation of each 
up-regulated or down-regulated gene list, TFBS enrichment analysis was performed 
using oPOSSUM-3 (Kwon et al., 2012; http://opossum.cisreg.ca). Diverse arrays of 
transcription factors were enriched in these gene lists, representing potentially complex 
programs of cytokine-induced or cytokine-suppressed transcriptional changes (Figure 
5.2–5.5). These included transcription factors known to be activated by these 
cytokines, such as NFκB in TNFα-induced genes (Figure 5.3) and STAT1 in IFNγ-
suppressed genes (Figure 5.2a). The latter observation may reflect direct 
transcriptional suppression mediated by STAT1, as has been reported in the murine 
system (Begitt et al., 2014). 
Exploration of the functional characteristics of the gene lists was performed via 
pathway enrichment analysis using the web tool InnateDB, a manually curated 
knowledge database for the innate immune response, which integrates interaction & 
pathway information from several public databases (Breuer et al., 2013; 
http://www.innatedb.com; Figure 5.2–5.5). The results of this analysis were visualised 
as networks of enriched pathways and associated genes. All gene lists were enriched 
for multiple pathways. Some of these were confirmatory with regards to the assumed 
effects of the cytokines. IFN signalling pathways were enriched in IFNγ-up-regulated 
genes (Figure 5.2b). Inflammatory pathways, such as complement activation, were 
enriched in genes down-regulated by the regulatory cytokines TGFβ and IL-10 (Figure 
5.5c). Common themes of cytokine-mediated MDM activation were also evident. 
Chemokine activity was enriched in genes up-regulated by TNFα, IL-4 and IL-13, or 
TGFβ and IL-10 (Figure 5.3–5.5). Arachidonic acid metabolism was enriched in genes 
down-regulated by TNFα, or by IL-13 and IL-13 (Figure 5.3, 5.4). 
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Figure 5.2: MDM transcriptional response to IFNγ. 
Human MDMs were stimulated with recombinant IFNγ for 24 hours at 10ng/ml. RNA was 
collected and transcriptional profiling performed by microarray. Significant gene expression 
changes (P<0.05) from unstimulated MDMs were identified by t-test with a Welch’s 
approximation. (a) Lists of genes up-regulated or down-regulated (≥two-fold) by IFNγ were 
subjected to TFBS enrichment analysis using oPOSSUM-3. Significance of the frequency of 
TFBS occurrence in gene lists compared to background was assessed by the Z-score statistic, 
with a score greater than 10 used as a significance threshold. (b, c) Network visualisations of 
InnateDB pathway enrichment analysis for genes up-regulated (b) or down-regulated (c) by 
IFNγ. Enrichment assessment was performed using a hypergeometric algorithm and filtered to 
Reactome-curated pathways with a significance level of P<0.05 (Benjamini-Hochberg 
correction-adjusted. Gene nodes are in red and pathway nodes are in blue. Node size is 
determined by the number of connections.  
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Figure 5.3: MDM transcriptional response to TNFα. 
Human MDMs were stimulated with recombinant TNFα for 24 hours at 10ng/ml. RNA was 
collected and transcriptional profiling performed by microarray. Significant gene expression 
changes (P<0.05) from unstimulated MDMs were identified by t-test with a Welch’s 
approximation. (a) Lists of genes up-regulated or down-regulated (≥twofold) by TNFα were 
subjected to TFBS enrichment analysis using oPOSSUM-3. Significance of the frequency of 
TFBS occurrence in gene lists compared to background was assessed by the Z-score statistic, 
with a score greater than 10 used as a significance threshold. (b, c) Network visualisations of 
InnateDB pathway enrichment analysis for genes up-regulated (b) or down-regulated (c) by 
TNFα. Enrichment assessment was performed using a hypergeometric algorithm and filtered to 
Reactome-curated pathways with a significance level of P<0.05 (Benjamini-Hochberg 
correction-adjusted. Gene nodes are in red and pathway nodes are in blue. Node size is 
determined by the number of connections.  
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Figure 5.4: MDM transcriptional response to IL-4 and IL-13. 
Human MDMs were stimulated with recombinant IL-4 and IL-13 for 24 hours at 10ng/ml. RNA 
was collected and transcriptional profiling performed by microarray. Significant gene expression 
changes (P<0.05) from unstimulated MDMs were identified by t-test with a Welch’s 
approximation. (a) Lists of genes up-regulated or down-regulated (≥twofold) by IL-4 and IL-13 
were subjected to TFBS enrichment analysis using oPOSSUM-3. Significance of the frequency 
of TFBS occurrence in gene lists compared to background was assessed by the Z-score 
statistic, with a score greater than 10 used as a significance threshold. (b, c) Network 
visualisations of InnateDB pathway enrichment analysis for genes up-regulated (b) or down-
regulated (c) by IL-4 and IL-13. Enrichment assessment was performed using a hypergeometric 
algorithm and filtered to Reactome-curated pathways with a significance level of P<0.05 
(Benjamini-Hochberg correction-adjusted. Gene nodes are in red and pathway nodes are in 
blue. Node size is determined by the number of connections.  
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Figure 5.5: MDM transcriptional response to TGFβ and IL-10. 
 Human MDMs were stimulated with recombinant TGFβ and IL-10 for 24 hours at 10ng/ml. RNA 
was collected and transcriptional profiling performed by microarray. Significant gene expression 
changes (P<0.05) from unstimulated MDMs were identified by t-test with a Welch’s 
approximation. (a) Lists of genes up-regulated or down-regulated (≥twofold) by TGFβ and IL-10 
were subjected to TFBS enrichment analysis using oPOSSUM-3. Significance of the frequency 
of TFBS occurrence in gene lists compared to background was assessed by the Z-score 
statistic, with a score greater than 10 used as a significance threshold. (b, c) Network 
visualisations of InnateDB pathway enrichment analysis for genes up-regulated (b) or down-
regulated (c) by TGFβ and IL-10. Enrichment assessment was performed using a 
hypergeometric algorithm and filtered to Reactome-curated pathways with a significance level of 
P<0.05 (Benjamini-Hochberg correction-adjusted. Gene nodes are in red and pathway nodes 
are in blue. Node size is determined by the number of connections.  
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5.2.3 Exploring the stimulus specificity of MDM transcriptional responses 
PCA is an unsupervised exploratory statistical method which can be used to 
assess variance across a large data set in such a way that retains more information 
than simple hierarchical clustering, described in Introduction section 1.6.2.  
PCA was used to explore the transcriptional responses of MDMs to different T 
cell subset-derived cytokines. The outcome of the PCA is shown in Figure 5.6(a), and 
demonstrates that the dataset is highly multidimensional, with 80% of the variance 
explained by seven PCs. A matrix of the PC scores for these components for each 
stimulated MDM condition is shown in Figure 5.6(b). Negative and positive signs in PC 
scores do not represent any inherent increase or decrease in gene expression, but are 
arbitrarily assigned in order to centre each PC on zero. Visualisation of PC scores in 
geometric space is shown for PC1 and PC2, or PC3 and PC4, in Figure 5.6(c). 
Assessment of these PCA plots and the PC score matrix shows that most PC 
directions are associated with more than one condition (displayed in network form in 
Figure 5.6d). This analysis demonstrates that the transcriptional programs induced by 
these cytokines in MDMs have many overlapping features, although a subset of 
responses to each stimulus may in fact be unique and specific, e.g. the positive 
direction of PC3 for IL-4 and IL-13; the positive direction of PC2 for TNFα; and the 
negative direction of PC3 for TGFβ and IL-10. 
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Figure 5.6: Exploring the stimulus-specificity of MDM transcriptional responses to 
cytokines using principal component analysis. 
Principal component analysis (PCA) of gene expression data from MDMs stimulated with IFNγ, 
TNFα, IL-4 and IL-13 or TGFβ and IL-10. (a) Plot demonstrating the variance (determined by 
eigenvalues) attributable to each principal component (PC), autonomously (blue) or 
cumulatively (red). The dashed box shows selection of components which describe 
approximately 80% of the variance in the dataset, for which principal component scores (PC 
scores) for each MDM condition are shown in the matrix in (b). Values shown are the median of 
at least three independent MDM transcriptomes for each condition. (c) PC score plots for PC1 
and PC2, or PC3 and PC4. Each symbol represents a separate MDM transcriptome. (d) 
Network map of relationships of different PC directionss to stimulation conditions. PC directions 
which are uniquely associated with one stimulus are shown in red. 
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5.2.4 Identifying appropriate measurements of module expression and 
enrichment 
I explored the transcriptional responses of MDMs to cytokines associated with 
particular polarised T cell responses and showed that these cytokines induced many 
gene expression changes in MDMs (Figure 5.1), which were associated with particular 
functional outcomes (Figure 5.2–5.5), including responses which were either shared 
between stimuli or were stimulus-specific (Figure 5.6). I then used these gene 
expression data sets to develop a pipeline for generating gene expression modules 
optimised for detecting stimulus-specific transcriptional responses, for subsequent use 
in detecting the effects of these stimuli in in vivo gene expression datasets. I aimed to 
derive modules of optimal specificity, which were powered to detect the specific activity 
of a particular stimulus, while also having adequate sensitivity to detect this activity in a 
potentially noisy in vivo setting. I also aimed to ensure that the modules contained 
enough genes to retain the advantages of using a gene list strategy (discussed in 
section 5.1).  
In order to derive and optimise modules, I first identified an appropriate 
measurement of module expression in a gene expression dataset, as using such a 
measurement would be critical in assessing module specificity. Three measurements 
of central tendency of module gene list expression were considered for this purpose: 
the mean, the median and the geometric mean. These will respectively assume that 
the data in question is parametric, is non-parametric (which is likely for complex gene 
expression data), or that the different parameters contributing to the data may have 
different distributions (which is also likely, as expression of different genes may vary 
over different ranges). 
For this exercise, I used a preliminary module in which high a priori confidence 
was held, due to the potent functional effects of the stimulus in question: an IFNγ 
module, made up of genes significantly (P<0.05) up-regulated by ≥twofold by IFNγ. 
The mean, median and geometric mean expression for this module were assessed in 
unstimulated MDMs and cytokine-stimulated MDMs, as a test group of gene 
expression datasets. All three measurements proved to be discriminatory with regard 
to differential modular expression: the IFNγ module was only highly expressed in IFNγ-
stimulated MDMs (Figure 5.7a–c). There were no clear major differences between the 
three measurements in their quantitative or discriminatory capacities, as they produced 
similar overall expression patterns (Figure 5.7a–c). However, it was considered that 
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the geometric mean was the most appropriate measurement of central tendency due to 
the nature of the data, so this measurement was carried forward for further use. 
Methods for assessing enrichment of modular expression, as quantified by 
geometric mean, were then tested, to establish a system for assigning “module 
enrichment scores” to different samples for comparative analyses. Firstly, enrichment 
with regard to the genome-wide gene expression level was measured, wherein the 
geometric mean of genome-wide expression was calculated and used as the 
denominator in a ratio for normalisation to produce module scores (Figure 5.7d). In 
this method, if the module enrichment score is >0, this indicates that the expression of 
the module is above the genome-wide geometric mean, as the scale used in these 
assessments is a log2 scale, wherein a ratio of 0 indicates equivalence and a ratio of 1 
indicates a twofold difference. This assessment is suitable for measuring enrichment, 
as it can be assumed that the expression of a randomly selected set of genes would 
approximate to the genome-wide geometric mean; thus expression above this level for 
a module gene set shows that the expression of that module is non-random and 
enriched. It can also control for any variation in genome-wide gene expression 
between samples. In this dataset, this appeared to be an appropriate method for 
scoring enrichment, as IFNγ-stimulated MDMs had the highest enrichment scores of all 
MDMs tested (Figure 5.7d). 
Although this is a powerful method for assessing enrichment, the most 
interesting and relevant differences biologically are likely to be those quantified in 
comparison to control samples. In these test datasets, the unstimulated MDMs were 
the appropriate control, and so a second set of module enrichment scores was 
calculated, wherein the denominator was the median of the measured module 
expression values (geometric means) for the control group of unstimulated MDMs 
(Figure 5.7e). This again appeared to be an appropriate method for scoring 
enrichment, as the highest scores produced were for IFNγ-stimulated MDMs (Figure 
5.7e). It is also possible to perform statistical testing of module expression when 
control data are available, by comparison of module expression values between the 
group of interest and the control group. Therefore, in future assessments of module 
enrichment, I aimed to use normalisation to control data where it was available, as this 
is the most biologically relevant comparison. Where control data is not available, 
comparison with the genome-wide geometric mean, as described above, is an 
appropriate alternative. 
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Figure 5.7: Methods of quantifying module expression and module enrichment. 
To identify an appropriate measurement of module gene set expression, a test exercise was 
carried out. Expression of an IFNγ module was assessed in unstimulated and cytokine-
stimulated MDMs. Three measures of central tendency were assessed: mean (a), median (b), 
and geometric mean (c). For all measurements, the IFNγ module was most highly expressed in 
IFNγ-stimulated MDMs. Geometric mean was selected as the most appropriate measurement. 
Using geometric mean module expression, two methods for quantifying module enrichment 
were assessed. (d) Enrichment scores were calculated as module expression normalised by a 
ratio to the geometric mean expression for the entire genome. (e) Enrichment scores were 
calculated as module expression normalised by a ratio to the median value for module 
expression in a control sample group: in this case, unstimulated MDMs. Each symbol shows a 
separate MDM transcriptome. Lines and error bars indicate median and range. 
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5.2.5 Developing modules from T cell subset-derived-cytokine-stimulated 
MDMs 
After selecting appropriate methods for measuring module expression and 
enrichment, I then developed a pipeline for deriving optimally specific modules using 
the cytokine-stimulated MDM datasets discussed in sections 5.2.1–5.2.3. The gene 
lists derived in the analysis presented in Figure 5.1, of genes significantly (P<0.05) up-
regulated by ≥two-fold by each stimulus, were used as the initial modules, shown in 
Table 5.1. I aimed to ensure that these modules had adequate sensitivity for detecting 
the effects of these stimuli in potentially noisy in vivo settings, by selecting a twofold 
change cut-off and hence only including genes which are highly up-regulated by the 
cytokines.  
I then went on to assess the specificity of these modules via two approaches: 
firstly identifying any cross-over in the module gene lists via Venn diagrams, and 
secondly measuring the module enrichment scores in all cytokine-stimulated MDMs, 
with the hypothesis that an optimally specific module should only be highly expressed 
in MDMs stimulated with the module-specific stimulus. These assessments are 
presented as matrices, wherein rows represent modules and columns represent MDM 
transcriptomes for the conditions indicated. The two module enrichment scores 
described in section 5.2.5 and Figure 5.7, by either normalisation to the genome-wide 
geometric mean or the median control geometric mean, were used. 
The specificity of this set of modules was not optimal (Figure 5.8). For example, 
high expression of the TNFα module was evident in IFNγ-stimulated MDMs and 
TGFβ/IL-10 stimulated MDMs (Figure 5.8a). A Venn diagram demonstrated that there 
was considerable cross-over between module gene lists (Figure 5.8c). 
I hypothesised that further restricting the modules to genes up-regulated by 
≥four-fold by each stimulus might improve specificity. The derivation of these modules 
is shown in Table 5.2 and the specificity assessment (performed as for the twofold 
change modules) is shown in Figure 5.9. Some specificity issues were still evident with 
these modules, with cross-enrichment of modules observed in differential conditions. 
Additionally, some cross-over between the module gene lists was still identified by 
Venn diagram (Figure 5.9c).  
I performed a final filtering step to further improve specificity, in which any gene 
which was up-regulated more than twofold by any other stimulus was removed from 
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the fourfold change gene lists (Table 5.3), to produce completely unique gene lists. 
Module specificity was further improved by this filter (Figure 5.10), evident in the 
minimal enrichment detected for all modules in MDMs not stimulated with the module-
specific cytokine, and approximately eight-fold higher enrichment scores in the 
specifically stimulated MDMs in comparison to controls. These modules were 
employed for downstream analyses, and the pipeline used for their development was 
used to derive modules for other stimuli of interest (sections 5.2.6–5.2.8). 
 
 
   
Stimulus
T-test, p<0.05 
filter
2FC filter
IFNγ 1693 315
TNFα 1460 157
IL-4/IL-13 1435 190
TGFβ/IL-10 1084 161
 
Table 5.1: Development of T cell-subset-derived-cytokine modules – twofold 
change modules. 
Numbers in each column represent the number of genes selected by that stage of 
filtering. 2FC, twofold change. 
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Figure 5.8: Assessing specificity of T cell-subset-derived-cytokine modules – twofold 
change modules. 
Matrices are presented showing module enrichment scores in the MDM transcriptomes used for 
module derivation, as an assessment of module specificity. Modules are in rows and MDM 
transcriptomes are in columns. Ctrl indicates unstimulated MDMs. All values presented are the 
medians of module enrichment scores in at least three independent MDM datasets for each 
condition. (a) Matrix of module expression presented as the geometric mean of the expression 
values for the genes making up the module, normalised to the genome-wide geometric mean 
expression for the same sample. Max on the colour scale is the maximum value for this dataset. 
(b) Matrix of module expression presented as the geometric mean of the expression values for 
the genes making up the module, normalised to the same measure of modular expression in the 
control samples. Max on the colour scale is the maximum value for this dataset. (c) Venn 
diagram depicting the shared genes between the four module gene lists. Numbers represent the 
number of twofold change-induced genes shared between/unique to module gene lists. 
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Stimulus
T-test, p<0.05 
filter
2FC filter 4FC filter
IFNγ 1693 315 93
TNFα 1460 157 34
IL-4/IL-13 1435 190 51
TGFβ/IL-10 1084 161 42
 
Table 5.2: Development of T cell-subset-derived-cytokine driven modules  
– fourfold change modules. 
 Numbers in each column represent the number of genes selected by that stage of 
filtering. 2FC, twofold change; 4FC, fourfold change. 
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Figure 5.9: Assessing specificity of T cell-subset-derived-cytokine modules – fourfold 
change modules. 
 Matrices are presented showing module enrichment scores in the MDM transcriptomes used for 
module derivation, as an assessment of module specificity. Modules are in rows and MDM 
transcriptomes are in columns. Ctrl indicates unstimulated MDMs. All values presented are the 
medians of module enrichment scores in at least three independent MDM datasets for each 
condition. (a) Matrix of module expression presented as the geometric mean of the expression 
values for the genes making up the module, normalised to the genome-wide geometric mean 
expression for the same sample. Max on the colour scale is the maximum value for this dataset. 
(b) Matrix of module expression presented as the geometric mean of the expression values for 
the genes making up the module, normalised to the same measure of modular expression in the 
control samples. Max on the colour scale is the maximum value for this dataset. (c) Venn 
diagram depicting the shared genes between the four module gene lists. Numbers represent the 
number of twofold change-induced genes shared between/unique to module gene lists. 
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Stimulus
T-test, p<0.05 
filter
2FC filter 4FC filter Specificity filter
IFNγ 1693 315 93 65
TNFα 1460 157 34 16
IL-4/IL-13 1435 190 51 32
TGFβ/IL-10 1084 161 42 27
 
Table 5.3: Development of T cell-subset-derived-cytokine driven modules  
– specific fourfold change modules. 
 
Numbers in each column represent the number of genes selected by that stage of 
filtering. The specificity filter represents the removal of any gene which features in 
the 2FC gene list for more than one condition. 2FC, twofold change; 4FC, fourfold 
change. 
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Figure 5.10: Assessing specificity of T cell-subset-derived-cytokine modules – unique 
fourfold change modules. 
Matrices are presented showing module enrichment scores in the MDM transcriptomes used for 
module derivation, as an assessment of module specificity. Modules are in rows and MDM 
transcriptomes are in columns. Ctrl indicates unstimulated MDMs. All values presented are the 
medians of module enrichment scores in at least three independent MDM datasets for each 
condition. (a) Matrix of module expression presented as the geometric mean of the expression 
values for the genes making up the module, normalised to the genome-wide geometric mean 
expression for the same sample. Max on the colour scale is the maximum value for this dataset. 
(b) Matrix of module expression presented as the geometric mean of the expression values for 
the genes making up the module, normalised to the same measure of modular expression in the 
control samples. Max on the colour scale is the maximum value for this dataset. 
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5.2.6 Development of differential IFN pathway modules 
Type I and type II IFNs induce complex programs of gene expression which 
share many features, but are known to be functionally distinct (Schneider et al., 2014). 
Recently there has been interest in the impacts that these differential functional effects 
might have on anti-mycobacterial immunity (Teles et al., 2013). I developed modules 
for measuring the specific activity of type I or type II IFNs using the pipeline developed 
in section 5.2.5. The gene expression dataset available for this purpose was derived 
from MDMs stimulated for 4 hours with either IFNβ (type I IFN), or IFNγ (type II IFN)  
(Tsang et al., 2009). Derivation of these modules is presented in Table 5.4. Although 
assessment of the crossover between the two-fold and four-fold change gene lists for 
both IFNs showed considerable overlap (Figure 5.11), an arguably adequate degree of 
specificity was achieved (Figure 5.12), wherein each IFN module was enriched by 
≥twofold in its matched IFN-stimulated MDM dataset in comparison to the non-matched 
dataset. 
As an additional quality control step, post hoc bioinformatic verification of 
module gene list function was carried out using InnateDB pathway analysis. This 
suggested that adequate specificity had been achieved, as each module gene list was 
highly enriched for its respective IFN signalling pathway (Table 5.5). 
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Table 5.4: Development of IFN pathway modules  
– specific fourfold change modules. 
Numbers in each column represent the number of genes selected by that stage of 
filtering. The specificity filter represents the removal of any gene which features in the 
2FC gene list for more than one condition. 2FC, twofold change; 4FC, fourfold change. 
 
Figure 5.11: Venn diagrams of cross-over between IFN-induced gene lists. 
Stimulus
T-test, p<0.05 
filter
2FC filter 4FC filter Specificity filter
Type I IFN 3524 630 181 108
Type II IFN 1373 226 71 24
Venn diagrams depicting shared genes between the IFN-induced gene lists. Numbers 
represent the number of genes shared between/unique to gene lists.  
(a) Two-fold change gene lists. (b) Four-fold change gene lists. 
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Figure 5.12: Assessing specificity of IFN pathway modules – specific fourfold change 
modules. 
Matrices are presented showing module enrichment scores in the MDM transcriptomes used for 
module derivation, as an assessment of module specificity. Modules are in rows and MDM 
transcriptomes are in columns. Ctrl indicates unstimulated MDMs. All values presented are the 
medians of module enrichment scores in at least three independent MDM datasets for each 
condition. (a) Matrix of module expression presented as the geometric mean of the expression 
values for the genes making up the module, normalised to the genome-wide geometric mean 
expression for the same sample. Max on the colour scale is the maximum value for this dataset. 
(b) Matrix of module expression presented as the geometric mean of the expression values for 
the genes making up the module, normalised to the same measure of modular expression in the 
control samples. Max on the colour scale is the maximum value for this dataset. 
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Table 5.5: Bioinformatic verification of IFN pathway modules. 
 
 
InnateDB pathway enrichment analysis (Breuer et al., 2013; http://www.innatedb.com) 
for module gene lists. Enrichment assessment was performed using a hypergeometric 
algorithm and filtered to pathways with a significance level of P<0.05 (Benjamini-
Hochberg correction-adjusted). The three most highly enriched pathways, their sources 
and corrected P values for enrichment significance are shown for each module. 
Module Pathway Name Source Name
Pathway P  value 
(corrected)
Type I IFN Interferon alpha/beta signaling REACTOME 1.90E-08
Scavenging of Heme from Plasma REACTOME 2.75E-06
Nicotinate Nicotinamide metabolism INOH 9.76E-04
Type II IFN Chemokine signaling pathway KEGG 2.70E-06
Interferon gamma signaling REACTOME 9.72E-06
IL23-mediated signaling events PID NCI 1.40E-04
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5.2.7  Development of IL-10 modules 
Gene expression profiling had demonstrated a detectable but limited 
transcriptional response in MDMs to specific stimulation with IL-10 for 24 hours 
(Chapter 4, section 4.2.3). I developed a module from this dataset using a less 
stringent pipeline than the one described in section 5.2.5. A two-fold change filter was 
used, as few genes were up-regulated by more than four-fold by IL-10, and a specificity 
filtration step with comparisons to gene lists from other stimuli was not employed. This 
strategy was used in order to develop a module which was highly sensitive for 
detecting the subtle autonomous effects of IL-10, even if some specificity was 
compromised as a result. A module of 47 genes was derived (Table 5.6).  
An alternative IL-10 module was also developed from an independent dataset: 
gene expression data from MDMs stimulated for 24 hours with an inflammatory 
stimulus (zymosan) in the presence of neutralising antibodies to IL-10 and the IL-10 
receptor (i.e. an inflammatory scenario in which IL-10 activity is known to be deficient) 
(Chapter 4, section 4.2.5). In this case, the module gene list was generated by testing 
for significant gene expression differences between MDMs stimulated with zymosan 
and MDMs stimulated with zymosan in the presence of IL-10 neutralisation. A two-fold 
change filter was then applied, to select genes for which expression was decreased in 
IL-10 neutralisation, i.e. those which are usually positively regulated by IL-10. This 
yielded a module of 49 genes (Table 5.6). Comparison of this gene list with the 
directly-induced IL-10 module revealed some overlap (Figure 5.13), lending 
confidence to the hypothesis that these genes are regulated by IL-10.  
Module gene list specificity was assessed by Venn diagram comparison with 
the T cell-subset-derived cytokine modules (excepting the TGFβ/IL-10 combined 
module, with which overlap would be expected). Both IL-10 modules had minimal 
overlap with these gene lists (Figure 5.14a, b). A formal assessment of specificity 
demonstrated that the IL-10 module was highly enriched in IL-10 stimulated MDMs, 
with a reasonably high degree of specificity, but that the zymosan/IL-10 neutralisation 
module was not enriched as highly or specifically (Figure 5.14c, d). I performed 
bioinformatic verification of these modules by oPOSSUM TFBS enrichment analysis 
(Figure 5.15). Significant enrichment of binding sites for STAT3, the downstream 
mediator of IL-10 signalling, was found in the IL-10 module gene list (Williams et al., 
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2004; Figure 5.15a). STAT3 binding sites were also identified in the majority of genes 
in the zymosan/IL-10 neutralisation module, but this enrichment was not significant 
(Figure 5.15b). 
Due to the low sensitivity and specificity of the zymosan/IL-10 neutralisation 
module in the initial set of analyses, I performed further evaluations of these modules. 
Enrichment scores for both modules were significantly higher in IL-10 stimulated MDMs 
than in MDMs stimulated with other cytokines (Figure 5.16a, b). Correlation and 
covariance of the two module scores were assessed across all cytokine-stimulated 
MDMs. They were found to strongly correlate (r2=0.82) and have significant covariance 
(P<0.0001), but the zymosan/IL-10 neutralisation module scores were much lower for 
each sample (slope = 0.58; Figure 5.16c). This suggested that the zymosan/IL-10 
neutralisation module could specifically detect the effect of IL-10, but that it was less 
sensitive than the IL-10 module.  
I hypothesised that the zymosan/IL-10 neutralisation module might be more 
sensitive to detect the effects of IL-10 in the context of an inflammatory stimulus, as it 
was generated from such a condition. Correlation and covariance of module scores 
were assessed between the two modules in innate immune-stimulated MDMs, and 
were found to strongly correlate (r2=0.93) and have significant covariance (P<0.0001), 
with a slope of close to 1 (Figure 5.16d). Both modules were most highly enriched in 
MDMs stimulated with Mtb, which has been shown to be most potent inducer of IL-10 
of the four stimuli tested (Tomlinson et al., 2014; Figure 5.16d). A formal specificity 
assessment of modular enrichment in innate immune-stimulated MDMs also 
demonstrated that the zymosan/IL-10 neutralisation module was highly enriched in 
these datasets, and in particular in Mtb-stimulated MDMs (Figure 5.17). These 
analyses suggest that the zymosan/IL-10 neutralisation module is most sensitive for 
detecting the effect of IL-10 in an inflammatory context. Therefore, it may have utility in 
assessing IL-10 function in inflammatory in vivo samples. 
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Stimulus
T-test, p<0.05 
filter
2FC filter
IL-10 274 47
Zymosan + IL-10 
neutralisation
374 49
 
Table 5.6: Development of IL-10 modules  
– twofold change modules. 
 
 
 
 
Venn diagrams depicting shared genes between the IL-10 module gene lists. Numbers 
represent the numbers of genes shared between/unique to gene lists. Zym/IL-10n; 
zymosan + IL-10 neutralisation 
  
 
 
Numbers in each column represent the number of genes selected by that stage of 
filtering. 2FC, twofold change. 
Figure 5.13: Venn diagram of cross-over between IL-10 module gene lists. 
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Figure 5.14: Assessing specificity of IL-10 modules – twofold change modules. 
(a, b) Venn diagrams depicting shared genes between the IL-10 module gene lists and other 
cytokine-induced modules; (a) IL-10; (b) zymosan + IL-10 neutralisation. Numbers represent the 
numbers of genes shared between/unique to gene lists. (c) Matrix of module expression 
presented as the geometric mean of the expression values for the genes making up the 
module, normalised to the genome-wide geometric mean expression for the same sample. Max 
on the colour scale is the maximum value for this dataset. (d) Matrix of module expression 
presented as the geometric mean of the expression values for the genes making up the 
module, normalised to the same measure of modular expression in the control samples. Max on 
the colour scale is the maximum value for this dataset. 
  
 
 
Chapter 5. Results 
 
 
239 
 
Figure 5.15: Bioinformatic verification of IL-10 modules by TFBS enrichment analysis. 
 
Module gene lists were subjected to TFBS enrichment analysis using oPOSSUM-3 (Kwon et al., 
2012; http://opossum.cisreg.ca). Significance of the frequency of TFBS occurrence in gene lists 
compared to background was assessed by the Z-score statistic, with a score greater than 10 
used as a significance threshold. Results of this analysis are shown for the IL-10 module (a) 
and the zymosan/IL-10 neutralisation module (b). All significantly enriched TFBSs in the 
sequence region 5000bp upstream/downstream of each gene are shown. The X axis lists the 
number of genes enriched for a TFBS, and the Y axis displays significance by Z score.  
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Figure 5.16: Further investigations of specificity and comparability of IL-10 modules. 
(a) Comparison of the geometric mean of module expression in the dataset of interest 
normalised to the geometric mean of module expression in control MDMs (module score) of the 
IL-10 module in IL-10 stimulated MDMs versus all other cytokine-stimulated MDMs. * represents 
P<0.05, Mann-Whitney test. (b) Comparison of the zymosan/IL-10 neutralisation module scores 
in IL-10 stimulated MDMs versus all other cytokine-stimulated MDMs. * represents P<0.05, 
Mann-Whitney test. (c) Comparison of IL-10 module scores versus zymosan + IL-10 
neutralisation module scores in IL-10 stimulated MDMs (red symbols) and other cytokine-
stimulated MDMs (black). (d) Comparison of IL-10 module scores versus zymosan + IL-10 
neutralisation module scores in the indicated innate immune stimulated MDMs. Dashed lines 
represent linear regressions and descriptive statistics for correlation (r2) and covariance (slope) 
are presented within the plots. All slopes presented were significantly non-zero (P<0.05). Fitting 
and statistical analyses were performed using GraphPad Prism 6.0.  
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Figure 5.17: Assessing enrichment of IL-10 modules in innate immune-stimulated MDMs. 
Matrices are presented showing module enrichment scores in the MDM transcriptomes used for 
module derivation, as an assessment of module specificity. Modules are in rows and MDM 
transcriptomes are in columns. Ctrl indicates unstimulated MDMs. All values presented are the 
medians of module enrichment scores in at least three independent MDM datasets for each 
condition. (a) Matrix of module expression presented as the geometric mean of the expression 
values for the genes making up the module, normalised to the genome-wide geometric mean 
expression for the same sample. Max on the colour scale is the maximum value for this dataset. 
(b) Matrix of module expression presented as the geometric mean of the expression values for 
the genes making up the module, normalised to the same measure of modular expression in the 
control samples. Max on the colour scale is the maximum value for this dataset. 
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5.2.8 Development of innate immune stimulus-driven modules 
Using the module development pipeline outlined in section 5.2.5, I developed 
modules specific to the effects of a selection of innate immune stimuli, with the aim of 
being able to assess specific stimulation of inflammatory pathways within in vivo gene 
expression samples. These were derived from transcriptomic datasets generated in 
previous investigations, in which MDMs were stimulated for 4 hours with different 
innate immune stimuli or pathogens: LPS, a TLR4 ligand; PCSK, a TLR2 ligand; Mtb; 
or S. pneumoniae (Spn) (Noursadeghi et al., 2009; Tomlinson et al., In press, 2014). 
The derivation pipeline for these modules is shown in Table 5.7.  
Cross-over between the two-fold-change and four-fold-change induced gene 
lists for these stimuli was assessed by Venn diagram and was found to be 
considerable (Figure 5.18). Specificity assessments demonstrated that these modules 
were most highly expressed in their matched MDM datasets (Figure 5.19). However, 
some lack of specificity was demonstrated: for example, expression of the PCSK 
module was enriched in LPS-stimulated MDMs, and cross-enrichment of the PCSK 
and Mtb modules was observed in their respective MDM datasets. It is probable that 
these stimuli activate conserved innate signalling pathways, and so the differential 
transcriptomes of innate stimuli may be fairly limited. Further improvements in 
specificity may, therefore, be difficult to achieve. With regard to the cross-enrichment of 
Mtb and PCSK modules, it should be noted that Mtb is known to stimulate TLR-2 
(Means et al., 1999; Reiling et al., 2002), and this cross-enrichment may be expected. 
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Table 5.7: Development of innate immune stimulus-driven modules  
– specific fourfold change modules. 
 
 
 
 
Numbers in each column represent the number of genes selected by that stage of 
filtering. The specificity filter represents the removal of any gene which features in 
the 2FC gene list for more than one condition. 2FC, twofold change; 4FC, fourfold 
change. 
 
Figure 5.18: Venn diagrams of cross-over between innate immune stimulus-
induced gene lists. 
 
Venn diagrams depicting shared genes between the innate immune stimulus-induced 
gene lists. Numbers represent the numbers of genes shared between/unique to gene 
lists. (a) Two-fold change gene lists. (b) Four-fold change gene lists. 
Stimulus
T-test, p<0.05 
filter
2FC filter 4FC filter Specificity filter
LPS 3341 556 121 39
PCSK 3158 628 108 12
Mtb 2645 292 103 19
Spn 3140 403 67 19
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Figure 5.19: Assessing specificity of innate immune stimulus-driven modules – specific 
fourfold change modules. 
Matrices are presented showing module enrichment scores in the MDM transcriptomes used for 
module derivation, as an assessment of module specificity. Modules are in rows and MDM 
transcriptomes are in columns. Ctrl indicates unstimulated MDMs. All values presented are the 
medians of module enrichment scores in at least three independent MDM datasets for each 
condition. (a) Matrix of module expression presented as the geometric mean of the expression 
values for the genes making up the module, normalised to the genome-wide geometric mean 
expression for the same sample. Max on the colour scale is the maximum value for this dataset. 
(b) Matrix of module expression presented as the geometric mean of the expression values for 
the genes making up the module, normalised to the same measure of modular expression in the 
control samples. Max on the colour scale is the maximum value for this dataset. 
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5.2.9 Assessing modular enrichment in in vivo gene expression datasets 
As an initial test exercise to evaluate the ability of the modules developed in 
sections 5.2.5–5.2.8 to detect immune biological activities in in vivo samples, I 
analysed module enrichment scores in gene expression profiles from tuberculin skin 
test (TST) biopsies obtained from healthy volunteers (Tomlinson et al., 2011).  As 
these gene expression profiles had already been investigated via bioinformatic and 
comparative methods, this meant that the function of these modules could be tested in 
a context where some a prior hypotheses existed. For example, enrichment for IFNγ or 
type II IFN signalling was expected, as was differential modular enrichment between 
positive and negative TST biopsies, or between biopsies collected at 6 hours and 48 
hours post-TST.  
I calculated module enrichment scores using the module geometric mean 
expression normalised to the genome-wide geometric mean expression, as an 
appropriate control dataset for normalisation was not available in this dataset. Each set 
of modules developed proved to be quantitative and discriminatory in this dataset 
(Figure 5.20). The IFNγ module was the most highly expressed in the 48 hour positive 
TSTs in comparison to the other cytokine modules, but was not highly expressed in the 
6 hour TST biopsies (Figure 5.20a), which is consistent with findings from 
bioinformatic assessments of this data (Tomlinson et al., 2011). This was also 
confirmed when using the specific IFN modules, wherein the type II IFN module was 
more highly enriched in 48 hour TST biopsies than the type I IFN module (Figure 
5.20b). The differential enrichment measured for the IFN modules also suggested that 
they were able to discriminate between these two closely related immune responses. 
The IL-10 modules were also enriched in the TST samples, consistent with recognized 
IL-10 responses in anti-mycobacterial immune responses (Figure 5.20c; Redford et al., 
2011). Additionally, the two different IL-10 modules were enriched to a similar degree 
in this dataset, supporting the hypothesis that the zymosan/IL-10 neutralisation module 
is able to detect IL-10 activity in the context of inflammation, such as in the TST. Finally, 
the highest enrichment for the innate immune stimulus modules was for the Mtb-
specific or PCSK (TLR-2)-specific modules, suggesting that specific anti-mycobacterial 
innate responses could be measured in the TST using these modules. 
Many published methods exist for quantifying modular enrichment in gene 
expression datasets (Ackermann and Strimmer, 2009). These include simple methods 
such as the one used here, in which a measure of central tendency of the expression 
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values of the module is used as a single measurement of module expression. More 
complex methods are also used, such as the GSEA algorithm, which has been widely 
used for previous modular analysis exercises (Mootha et al., 2003; Subramanian et al., 
2005). This method is designed to detect differences in module enrichment between 
two groups of gene expression samples, as it involves ranking all genes in a dataset in 
order of their difference between the compared two groups. I tested GSEA as an 
alternative method of module enrichment scoring in the TST dataset, using the T cell 
subset cytokine-driven modules (Figure 5.21). GSEA produces a normalised 
enrichment score (NES) for each module, and a recommended statistic used to assess 
the significance of the NES, which is the false detection rate (FDR) q-value.  
The quantitative power of GSEA was assessed by comparison of the 48 hour 
TST samples with the 6 hour TST samples (Figure 5.21a, b). This detected 
enrichment of the IFNγ and TNFα modules in the positive TST samples (Figure 5.21a), 
but assigned a marginally higher NES to the TNFα module than the IFNγ module, 
although the geometric mean scoring method used shown the IFNγ module to be 
expressed at a considerably higher (>two-fold) level (Figure 5.20a). The IL-4/IL-13 and 
TGFβ/IL-10 modules were not scored as significantly enriched in this comparison 
(Figure 5.21a), although the previous assessment had indicated some enrichment of 
the latter in the same samples (Figure 5.20a). No modules were assessed as enriched 
in the negative TST samples (Figure 5.21b), although again, some had been assessed 
as enriched using the alternative method (Figure 5.20a). These observations 
suggested that GSEA might be less sensitive and quantitative for assessment of 
modular enrichment than using a geometric mean-derived module score. 
The discriminatory power of GSEA was assessed by comparisons between the 
48 hour positive TSTs and the 48 hour negative TSTs. Significant enrichment of the 
TNFα module in the 48 hour positive TST in comparison to the 48 hour negative TST 
was identified (Figure 5.21c), suggesting that this method might have some utility for 
discriminating differential enrichment between groups of samples. 
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Figure 5.20: Testing module enrichment in in vivo gene expression datasets. 
A test dataset of in vivo gene expression profiles, generated from TST biopsies obtained from 
healthy volunteers, was used to evaluate module enrichment in in vivo samples. Module 
enrichment scores were calculated as module expression normalised by a ratio to the 
geometric mean expression for the entire genome. (a) Module enrichment score in the 
indicated TST groups for T cell subset-derived cytokine modules. (b) Module enrichment score 
in the indicated TST groups for specific IFN modules. (c) Module enrichment score in the 
indicated TST groups for IL-10 modules. (d) Module enrichment score in the indicated TST 
groups for innate immune stimulus modules. Symbols and error bars represent median −/+ 
range for at least 4 samples in each group. 
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Figure 5.21: Using gene set enrichment analysis to quantitate modular expression 
and enrichment in in vivo gene expression samples. 
Modular enrichment analysis between groups of TST biopsies performed using the gene set 
enrichment analysis (GSEA) algorithm. The normalised enrichment scores (NES) are shown on 
the X axes and measurement of statistical significance (FDR q-value) is shown on the Y axis. 
The dashed line indicates the threshold of statistical significance recommended for use for this 
algorithm. (a) Comparison of 48 hour positive biopsies with 6h positive biopsies. (b) 
Comparison of 48 hour negative biopsies with 6h negative biopsies. (c, d) Comparison of 48 
hour positive biopsies with 48h negative biopsies; three modules were assessed as enriched in 
the positive group (c) and one module was assessed as enriched in the negative group (d). 
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5.3 Chapter discussion 
5.3.1 Insights into macrophage plasticity from transcriptional profiling 
Macrophage plasticity, which is thought to be primarily controlled at the 
transcriptional level, is central to the function of these key sentinel cells of the immune 
system. I aimed to use gene expression profiling of human MDMs to understand this 
plasticity. I then aimed to utilise the multidimensional power of this data for evaluating 
immune responses in vivo, by deriving gene expression modules from MDMs 
stimulated with different factors of interest for use in assessing in vivo transcriptomic 
datasets. 
Human MDMs were shown to express cell-surface receptors for cytokines 
associated with differentially polarised T cell responses (Figure 5.1a), for IFNγ, TNFα, 
IL-4, IL-13, TGFβ and IL-10. Stimulation of MDMs with these cytokines induced 
hundreds of gene expression changes (Figure 5.1b). This illustrated the potent role of 
transcriptional reprogramming in cytokine-driven macrophage activation, and confirmed 
that human macrophages can be functionally modulated by polarised T cell responses 
beyond the Th1 and CMI paradigm, as previously suggested (Mosser and Edwards, 
2008). One potential caveat of this approach is that using cytokines in combination (IL-
4 and IL-13, and TGFβ and IL-10) means that the unique effects of these cytokines 
cannot be teased out; however, while not using an absolutely reductionist approach 
means that some direct mechanistic insight may be lost, this method may better 
simulate polarised inflammatory responses in vivo where multiple cytokines are likely to 
be acting in tandem. 
TFBS analysis of the cytokine-regulated gene lists revealed enrichment for sets 
of transcription factors which may be downstream of signalling by these cytokines. This 
included enrichment for some factors previously shown to be associated with these 
stimuli, such as NFκB in TNFα up-regulated genes (Aggarwal, 2003; Figure 5.3a). 
Strikingly, many of the canonical transcription factors which are activated by these 
cytokines were not shown to be enriched in the up-regulated gene lists. For example, 
STAT1 TFBS were not enriched in the IFNγ-induced genes (Platanias, 2005), STAT6 
was not enriched in the IL-4-induced genes (Takeda et al., 1996) and SMADs were not 
enriched in the TGFβ-induced genes (Derynck and Feng, 1997; Figure 5.2a, 5.4a, 
5.5a). However, as these gene expression profiles represent the MDM transcriptome 
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after 24 hours after cytokine stimulation, it is possible that the primary transcriptional 
responses mediated by these signature transcription factors were no longer evident.  
Pathway enrichment analysis of cytokine-regulated gene lists provided insight 
into the functional outcomes of cytokine signalling in macrophages. Some specific 
effects of the cytokines were confirmed, such as IFN signalling pathway enrichment in 
the IFNγ-stimulated MDMs (Figure 5.2b). Novel pathways downstream of these 
cytokines were also identified. For example, TGFβ and IL-10 induced expression of 
genes enriched for integrin pathways, vascular wall interactions, fibrin formation and 
hypoxia-inducible factor 1α (HIF1α)-regulated gene expression. This included 
expression of the potent angiogenic factor vascular endothelial growth factor A 
(VEGFA; Nagy et al., 2007; Figure 5.5d). This might reflect the role of macrophages in 
structural aspects of inflammatory resolution induced by these regulatory cytokines. 
Further experiments are required to evaluate whether these in silico analyses are 
associated with significant functional effects. 
Common themes of macrophage transcriptional responses to cytokines were 
identified in the bioinformatic assessment of these gene lists, such as chemokine 
activity and integrin interactions (Figure 5.2–5.5). The multidimensional relationships 
between the gene expression programmes were evaluated using the exploratory 
statistical technique of PCA. This demonstrated that the data was highly multi-
dimensional, and that many patterns of variation in gene expression were shared 
between the different stimulation conditions (Figure 5.6). This analysis alludes to the 
multi-dimensional spectral nature of macrophage activation programmes, as described 
in previous reports (Xue et al., 2014). Further analysis of the PCA results, focussing in 
particular on the genes which are most associated with various PC deviations, may 
assist in identifying novel functional hubs of macrophage activation. 
5.3.2 Development of gene expression modules for analysis of microarray data 
I aimed to utilize macrophage transcriptional heterogeneity for evaluation of 
immune responses in vivo, by developing gene expression modules from MDM gene 
expression datasets. The data-driven module generation method has provided 
valuable insights in a number of previous studies (Berry et al., 2010; Li et al., 2014; 
Obermoser et al., 2013; Xue et al., 2014), but as it is inherently reliant on the structure 
of the input data, the range of modules generated may not include those relating to 
pathways of interest if they are not variably expressed in the datasets used. This then 
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precludes assessment of those pathways in downstream analyses. As a major aim of 
the exercise in constructing modules was the ability to assess pathways and 
phenotypes of interest in a range of potential downstream contexts, I chose to use the 
hypothesis-driven method of module generation, in which the function that the user 
wishes to assess is defined a priori.   
Module gene lists for this purpose can be derived from bioinformatic databases, 
published data or publicly accessible array data repositories, but in this context I chose 
to derive these modules using in-house-generated rather than independent datasets. 
This was to maximise confidence that the baseline cellular phenotype in the datasets 
was consistent, so that any differential effects seen were specifically due to the 
stimulation conditions used rather than any extraneous contextual differences. This 
does not preclude using published datasets to derive modules for comparative and 
verification purposes, which may in fact add value to such an exercise and can be used 
for validation. As this is a supervised method, there is a considerable degree of user 
determination in setting parameters for extracting a gene list from a dataset, pertaining 
to statistical or fold-change thresholds, correlation analyses and specificity filters. 
Consensus for a method of deriving such a module has not yet emerged (Bild and 
Febbo, 2005). 
I first evaluated how module expression should be quantified in a dataset of 
interest, and how enrichment of this expression should be measured for comparisons 
to other datasets. Three measurements of central tendency of modular gene list 
expression values were tested: mean, median and geometric mean. Each provided 
broadly similar approximations of module expression (Figure 5.7a–c). Although 
selection of one above the other may therefore be arbitrary, geometric mean was felt to 
provide the most accurate measurement of central tendency in terms of the nature of 
the data, so this was used for further assessments. Two strategies for quantifying 
enrichment of expression were then tested: using either the geometric mean of the 
genome-wide gene expression or the module expression in a control sample as a 
denominator for producing an enrichment score (Figure 5.7d, e). Both methods 
produced discriminatory measurements of enrichment. However, the latter strategy has 
the advantage of allowing statistical testing of modular enrichment, i.e. in comparison 
to control data. This illustrates the importance of identifying or obtaining appropriate 
control datasets for such analyses, as it eliminates the inherent assumptions present in 
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the genome-wide normalisation method with regards to the baseline expression of a 
module. 
I then used the gene expression profiles of MDMs stimulated with different T 
cell subset-derived cytokines to develop a pipeline for module generation. Firstly, 
significant gene expression differences from unstimulated MDMs were identified by t-
tests with a Welch approximation. As an FDR algorithm was not used, it may be 
suggested that high rate of false positive identification will occur. However, as the 
subsequent steps in the pipeline involve applying fold-change filters to select for gene 
expression changes which are within a biologically plausible range of interest, any false 
positives (which are unlikely to exceed these thresholds if they are background noise) 
should be eliminated.  
Two-fold change and four-fold change filters were applied to these gene lists to 
derive modules (Table 5.1, 5.2) which were then subjected to tests of specificity 
(Figure 5.8, 5.9). Although these modules were highly sensitive in detecting the effects 
of the stimulus of interest (suggesting that the t-test and fold-change approach used 
was competent for identifying the effects of these stimuli), their specificity was poor, as 
modular enrichment could be detected in some non-stimulus-specific contexts. The fact 
that non-specificity becomes an issue is not surprising when the PCA of the source 
data is considered (Figure 5.6), as the macrophage transcriptional responses to 
cytokines clearly share many overlapping features. 
I therefore applied an additional filter to improve specificity, in which any gene 
up-regulated by more than two-fold by any of the other cytokines tested was eliminated 
from the four-fold change gene lists (Table 5.3). This improved module specificity 
(Figure 5.10), and so this pipeline was used to develop further modules for specific 
IFN pathways and innate immune stimuli. Although this is an arguably rigorous strategy 
to select the highly specific effects of a stimulus, to construct a stimulus-specific 
module, it is possible that there may still be confounders present. For example, genes 
which are just below the two-fold threshold of induction by one stimulus will not be 
filtered out of other gene lists, and thus may contribute to some residual non-specificity. 
However, as gene expression measurements are essentially continuous variables, 
which vary in multiple contexts, developing completely stimulus-specific modules of 
sufficient gene numbers for usage may not be possible. Overall, there is a trade-off to 
be made between developing highly stimulus-specific modules, and developing 
modules which are sensitive to detect activation of a pathway of interest. Aiming to be 
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entirely reductionist, and eliminating any gene from a module which is potentially 
regulated by another stimulus, may prevent valuable insights being made into 
inherently noisy biological systems in vivo. As long as modules are adequately tested 
and validated, and used appropriately in conjunction with other analysis methods, then 
low-level risk of non-specificity such as described above, may be acceptable. 
Modules for detecting the function of IL-10 were derived using a less stringent 
pipeline than the other cytokine modules, using a two-fold change threshold and no 
specificity filter. The autonomous effects of IL-10 in up-regulating gene expression 
appear to be subtle, perhaps reflecting its immunomodulatory rather than 
immunostimulatory function. As such, IL-10 induced insufficient numbers of genes by 
more than four-fold to use the initial strategy. To maximise confidence using this less 
stringent approach, two IL-10 modules were developed from different gene expression 
datasets in parallel, and their specificity to detect the activity of IL-10 was extensively 
validated (Figure 5.14, Figure 5.16), which suggested that they would still have 
reasonable utility in this regard. 
5.3.3 Measuring enrichment of gene expression modules in gene expression 
profiles from in vivo samples 
Lastly, I validated whether the modules developed could detect enrichment of 
the immune response pathways of interest in in vivo samples, using a previously 
published dataset of TST biopsies (Tomlinson et al., 2011). This analysis suggested 
that the modules were quantitative and discriminatory in detecting the effects of the 
stimuli of interest in an in vivo setting. The enrichment results produced corroborated 
published analyses of this data, and also provided evidence for activity of factors such 
as IFNγ, TNFα, IL-10 and type I IFN at the site of inflammation in in vivo human anti-
mycobacterial immune responses.  
These enrichment scores were based on measuring the geometric mean of 
module expression. For comparative purposes, I tested the GSEA algorithm as a more 
complex method of assessing modular enrichment. This produced different results to a 
certain extent, which seemed to be less quantitative and sensitive for detecting module 
expression than the geometric mean-based analyses (Figure 5.21). Some 
discriminatory capacity was demonstrated in comparing highly expressed modules in 
similar samples (Figure 5.21c). An inherent limitation of the GSEA algorithm is that it 
does not produce a range of module enrichment scores for a group of tested samples, 
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but alternatively produces an average enrichment value for the entire group. This 
means that the heterogeneity of a given dataset cannot be assessed (Chaussabel and 
Baldwin, 2014). It also only allows comparative assessments of enrichment between 
two samples, which may also limit its utility.  
Overall, using the geometric mean of the module gene list to measure 
expression and enrichment appeared to be a sufficiently sensitive, discriminatory and 
quantitative strategy, and may be especially so when appropriate comparative control 
data is available, wherein statistical testing can be performed (as discussed above in 
section 5.3.2). GSEA may have some utility as an adjunctive strategy for comparing 
expression of modules between highly similar groups of samples. Reviews of module 
enrichment assessment strategies have suggested that the most appropriate analysis 
method to use depends on the distribution of the dataset to be assessed (Alavi-Majd et 
al., 2014), or that use of multiple methods to widely explore datasets and confirm 
enrichment may be most appropriate (Glazko and Emmert-Streib, 2009). Thus, using 
both geometric mean expression and GSEA may maximise confidence in the results of 
modular analysis exercises. 
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Chapter 6. Results 4. Modulation of anti-
mycobacterial cell-mediated immunity by HIV-1 in 
vivo assessed in a human challenge model 
6.1 Background 
6.1.1 Cell-mediated immunity, HIV-1 and tuberculosis 
CMI is the process by which T cells and macrophages functionally collaborate 
to kill and control intracellular pathogens (Kaufmann, 1999; Wing and Remington, 
1977). HIV-1 impacts on many functions of the immune system, which is evident in the 
depletion of the circulating CD4+ T cell pool, chronic immune activation and 
compromise of the gut-associated lymphoid tissues (Levy, 2009), among other 
phenomena (reviewed in Introduction section 1.3.6). CMI in particular may be at risk 
of modulation by HIV-1, as the virus directly infects both CD4+ T cells (Spear et al., 
1990) and macrophages (Noursadeghi et al., 2006b).  
Mtb, which also replicates within macrophages, is the prototypic example of a 
pathogen that is thought to be controlled by CMI (Dannenberg, 1989), and the human 
TB granuloma can be described as a mature focus of CMI, wherein macrophages and 
T cells are spatially and functionally coordinated in order to exert this control (Ulrichs 
and Kaufmann, 2006). The major functional axes of CMI, such as IFNγ, IL-12 and 
STAT1 signalling, are known from human genetic studies to be essential for control of 
mycobacterial infections (Altare et al., 1998a; Dorman and Holland, 1998; Dupuis et al., 
2001; Newport et al., 1996). Recent work in non-human primates has shown that 
host/pathogen interactions in individual granulomata are critical in determining the 
course of TB disease (Lin et al., 2014), indicating the importance of an effective 
localised CMI response in Mtb containment. 
The effects of HIV-1 on CMI may therefore have major consequences for 
immune control of Mtb. In vivo, HIV-1 co-infection has profound effects on TB infection; 
it is associated with substantial increases in the incidence and mortality of active TB 
(Corbett et al., 2006), and with differences in disease presentation such as 
disseminated infections (Schutz et al., 2010) and immune reconstitution inflammatory 
syndromes (IRIS; Lawn et al., 2008). CD4+ T cell depletion by HIV-1 is assumed to 
contribute to these changes in TB natural history (Geldmacher et al., 2012). However, 
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TB risk is increased in all HIV-1+ patients including those without substantial CD4+ T 
cell loss (Gupta et al., 2012; Sonnenberg et al., 2005), and so other HIV-1-associated 
immune dysfunction may also contribute. Investigating how HIV-1 modulates anti-
mycobacterial CMI in vivo may aid our understanding of TB pathogenesis in HIV-1/TB 
co-infection. 
6.1.2 Using the tuberculin skin test as an in vivo challenge model to study CMI 
in HIV infection 
I sought to describe the effects of HIV-1 on CMI responses to mycobacteria in 
vivo. Previous studies of active TB in vivo have identified phenotypes in the peripheral 
blood (Antonelli et al., 2010; Berry et al., 2010), which has provided insight into the 
systemic immune response, but does not characterise the function of CMI at the site of 
inflammation. Others have explored samples obtained from the site of disease 
(Matthews et al., 2012; Mwandumba et al., 2008); this latter approach affords a 
valuable opportunity to study CMI in situ, but might be prone to confounding by time of 
sampling and disease heterogeneity. To study CMI at the site of inflammation in vivo 
using a controlled approach, I employed the tuberculin skin test (TST) as a 
standardised challenge model, which as a DTH reaction is a classic in vivo model of 
anti-mycobacterial CMI (Scheynius et al., 1982).  
The TST is performed via an intradermal injection of tuberculin, also known as 
purified protein derivative (PPD), which is a sterilized precipitated filtrate of Mtb 
cultures (Magnusson and Bentzon, 1958). This elicits a localised inflammatory reaction, 
manifest as erythema and induration, over 24–48 hours in mycobacterial antigen-
sensitized individuals. HIV-1 infection is known to be associated with increased 
incidence of TST anergy, i.e. clinical TST non-responsiveness as measured by 
induration (Markowitz et al., 1993), including in individuals who are epidemiologically 
highly likely to have been exposed to mycobacteria (Rangaka et al., 2007). TST anergy 
has been shown to correlate with HIV-1 disease progression (Graham et al., 1992), 
although some reports suggest that compromised skin DTH in HIV-1 infection may not 
correlate with disease markers (Okulicz et al., 2012). 
The TST has previously been used to investigate CMI in situ via histological 
methods. This demonstrated a cellular infiltrate composed of CD4+ T cells, CD8+ T 
cells and APCs (Poulter et al., 1982; Scheynius et al., 1982), showed the presence of 
cytokines at the inflammatory site (Chu et al., 1992; Fullmer et al., 1987), and outlined 
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the contribution of different APC subsets to the reaction (Bond et al., 2012). The effects 
of HIV-1 have also previously been investigated using TST histology, in studies 
showing that DC recruitment to the TST is correlated to the magnitude of T cell 
recruitment in HIV-1+ individuals (Liang et al., 2013), and that the make-up of cellular 
infiltrates in TSTs in these individuals may be altered compared to HIV-1 negative 
(HIV-1−) individuals (Sarrazin et al., 2009). 
I aimed to use the TST as a challenge model to understand the effects of HIV-1 
on anti-mycobacterial CMI in vivo with molecular resolution, by genome-wide 
transcriptional profiling of RNA collected from TST biopsies. This approach was 
previously validated in healthy individuals, in which TST transcriptional profiling was 
used to distinguish molecular signatures of polarised T cell and innate immune 
responses in the positive TST. Furthermore, this method was used to demonstrate 
immune responses in TST negative (TST−) individuals, which were present but 
quantitatively less than in TST positive (TST+) individuals  – demonstrating that the 
transcriptomic approach added value, and may be more sensitive than clinical and 
histological assessments (Tomlinson et al., 2011). It also demonstrated that CMI 
responses in this setting showed no major systematic confounding by ethnicity 
(Tomlinson et al., 2011). I have now used TST gene expression profiling to 
characterise anti-mycobacterial CMI at the site of inflammation in patients with active 
TB and HIV-1 co-infection, and have identified diverse ways in which HIV-1 
dysregulates this immune response in vivo. 
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6.2 Study outline 
Patients with active TB, with or without HIV-1 co-infection, were recruited from 
clinical sites in London (UK) and Cape Town (South Africa) within the first month of TB 
chemotherapy. This patient cohort and time point was chosen in order to minimise 
inter-subject variability in mycobacterial exposure, as patients without active TB may 
have latent or undiagnosed TB, particularly in a high transmission setting in Cape 
Town, and distinguishing these groups clinically may not be possible. HIV-1 status was 
confirmed by routine clinical testing. Microbiological TB diagnosis was confirmed by 
smear, culture or GeneXpert MTB/RIF in >90% of enrolled patients, with the remainder 
of TB diagnoses being made on a clinical basis (see Appendix II for case by case 
clinical details). The study design and sample collection protocol is outlined in Figure 
6.1(a), and inclusion and exclusion criteria are shown in Table 6.1. 
TSTs were performed by intradermal injection of 2U PPD into the proximal third 
of the volar aspect of the forearm. A subset of patients received saline injections as a 
control cohort. TSTs were assessed at 48 hours and two 3mm punch skin biopsies 
were collected from the marked injection site (Figure 6.1b). The biopsies were 
collected into either RNAlater reagent for RNA isolation, or 4% neutral buffered 
formalin for adjunctive histological analysis. A positive TST was defined clinically as an 
induration of ≥10mm at 48 hours, which is indicated to be an appropriate cut-off for this 
cohort (Cobelens et al., 2006). All TSTs, TST assessments and biopsies were 
performed by experienced TB clinical research staff. Blood samples for clinical 
measurements, PBMC, RNA and DNA were also collected from all individuals before 
TSTs were performed, as outlined in Figure 6.1(a). A time-point of 48 hours was 
chosen for assessments, as in the previous proof-of-concept study, both innate and 
adaptive components of the immune response were evident at this time-point in both 
TST+ and TST– individuals, and differences between groups were also evident. Thus, 
using this time-point should allow assessment of the overall CMI response in the 
different groups of interest. 
The study was approved by the research ethics committees of all sites and 
institutions involved, and informed written consent was obtained from all participants. 
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Inclusion criteria Exclusion criteria
Active TB confirmed by microbiological 
and/or clinical diagnosis
Neoplastic disease
Within the first 4 weeks of anti-TB therapy
AIDS defining disease other than tuberculosis or 
KSHV infection
> 16 years of age Hepatitis B/C co-infection 
Immunomodulatory therapy (e.g. interferon) 
Immunization within preceding 2 weeks
Existing paradoxical reaction to anti-tuberculosis 
treatment
Previous keloid formation
Table 6.1: Inclusion and exclusion criteria. 
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Figure 6.1: TST human challenge model study design. 
(a) Flowchart outlining the study design. (b) Diagram demonstrating collection of 
skin biopsies; the injection site was marked with permanent marker, and two 
biopsies were collected directly adjacent to this mark, of which one was used for 
expression profiling and one for complementary histological assessments. 
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6.3 Cohort description 
Characteristics of the recruited cohort are shown in Table 6.2. Fifty patients 
with active TB were recruited. Forty-two received TSTs and eight received control 
saline injections (see Appendix II for case-by-case demographic and clinical 
information table).  
HIV-1− patients were recruited from Cape Town and London. The Cape Town 
cohort were predominantly black African and had pulmonary TB, while the London 
cohort were a mix of ethnicities and had extra-pulmonary disease. This may reflect the 
distinct epidemiological settings of the two groups: a high transmission setting with 
predominantly primary infection in Cape Town (Verver et al., 2004), and a low 
transmission setting with predominantly reactivation of latent disease in London 
(Kruijshaar and Abubakar, 2009). The Cape Town cohort included two patients with 
MDR TB. All HIV-1− patients were TST+, and median induration did not differ between 
London and Cape Town cohorts (Table 6.2). The London and Cape Town HIV-1− 
cohorts were combined as a single group for all subsequent analyses. 
 All HIV-1+ patients were recruited in Cape Town. In comparison to the 
equivalent HIV-1− Cape Town cohort, this group of patients included more females and 
had a higher incidence of extra-pulmonary disease, as might be expected for a HIV-1+ 
South African cohort (Abdool Karim et al., 2009; Schutz et al., 2010). Consistent with 
previous reports, HIV-1 infection was associated with a higher incidence of clinically 
anergic TSTs (Table 6.2; Markowitz et al., 1993; Rangaka et al., 2007). HIV-1+ patients 
were divided into three groups for subsequent analyses: those who were TST− 
(anergic), TST+, or classified as undergoing an unmasking IRIS, which was defined in 
this instance as presentation with active TB within 2–8 weeks of commencing ARVs, 
consistent with published case definitions of this condition (Haddow et al., 2009; 
Meintjes et al., 2008a). All patients in the IRIS group were TST+. Of note, these 
patients had some of the greatest induration reactions of all HIV-1+ TST+ patients. 
The TST− HIV-1+ group of patients had a lower median CD4+ count than TST+ 
HIV-1+ patients (28 vs. 214; Table 6.2). More TST+ patients were on ARVs than TST− 
patients (55.56% vs. 35.71%; Table 6.2), and median length of ARV use was also 
higher (123 weeks vs. 0.7 weeks; Table 6.2). I specifically evaluated the correlation 
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between HIV-1 disease markers and TST induration. Within the HIV-1+ cohort, 
induration was significantly but weakly positively correlated with CD4+ count (Figure 
6.2a), although the CD4+ count ranges in TST+ and TST− patients overlapped (Table 
6.2), suggesting that there is not a direct linear relationship between these variables. 
HIV-1 viral loads, where available, did not correlate with TST induration (Figure 6.2b). 
These findings are consistent with previous reports, in demonstrating that HIV-1 
seropositivity is associated with a high incidence of TST anergy, and that although this 
does correlate with CD4+ count, anergy is still observed among patients with CD4+ 
counts ≥200 CD4+ cells mm-3, and positive TSTs are observed among patients with 
CD4+ counts ≤200 CD4+ cells mm-3 (Markowitz et al., 1993; Selwyn et al., 1992). 
 The group of patients who received saline control injections was made up of 
three HIV-1− patients and five HIV-1+ patients. The characteristics of this group were 
comparable to the groups which received TSTs (Table 6.2). 
To assess TB antigen reactivity directly in T cells, IFNγ release assays (IGRAs) 
were used, in which peripheral blood mononuclear cells are mixed with TB-specific 
antigens and IFNγ release is measured. The QuantiFERON-TB Gold In-Tube test was 
used in this instance. This test uses the Mtb antigens ESAT-6, CFP-10 and TB7.7, 
which are mixed with whole blood ex vivo. IFNγ release is measured after 24 hours by 
ELISA, and compared to baseline IFNγ levels, and release induced by a positive 
control mitogen, to determine whether the test is positive, negative or indeterminate. 
QuantiFERON tests were performed on all patients recruited from sites in Cape Town. 
HIV-1+ individuals had a high incidence of negative or indeterminate QuantiFERON 
results, despite being Mtb antigen-exposed as a result of having active TB (Figure 
6.2c). Positive tests were more frequent in groups with higher CD4+ counts when 
patients were stratified as such (Figure 6.2d) as previously reported (Leidl et al., 
2010).  
TST and IGRA responses were compared by correlating induration with TB antigen-
elicited IFNγ release, and weak positive correlations were observed for both HIV-1− 
and HIV-1+ groups (Figure 6.2e). Some TST+ individuals had negative or indeterminate 
QuantiFERON results, and vice versa, particularly in the HIV-1+ group; this discordance 
is consistent with previous reports (Luetkemeyer et al., 2007; Rangaka et al., 2007). 
In addition to the five groups of patients recruited in this cohort, subsequent 
analyses also made comparisons with gene expression profiles from TSTs obtained 
Chapter 6. Results 
 
 
263 
from healthy individuals in a previous study (Tomlinson et al., 2011). The definitions of 
all groups which were analysed are presented in Table 6.3.  
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Table 6.2: Demographic and clinical characteristics of the study cohort. 
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(a) Correlation of TST induration with CD4+ cell counts for HIV-1+ individuals. Linear regression 
showed a weak but significant positive correlation. (b) Correlation of TST induration with viral 
loads (where available) for HIV-1+ individuals. Linear regression was was non-significant. (c) 
QuantiFERON (IGRA) test responses. (d) QuantiFERON test positivity (% of indicated group) in 
HIV-1+ patients stratified by CD4+ cell count. (e) Correlation of induration with IFNγ release 
elicited by TB antigens in QuantiFERON tests, in HIV-1− and HIV-1+ patients. Weak but 
significant positive correlations were observed for both groups. The dashed horizontal line 
indicates the level required for a positive result; subjects below this line had negative or 
indeterminate results. IU, international units. Red/blue lines indicate medians or linear 
regressions for all plots. 
Figure 6.2: TST responses and IGRAs. 
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Group n TB disease status HIV-1 status
TST 
response
Notes Source
A 16 Active TB Negative Positive This study
B 14 Active TB Positive Anergic
Termed TST anergic as opposed to 
TST negative, as patients have 
confirmed active TB so should 
have Mtb antigen memory, but do 
not react.
This study
C 9 Active TB Positive Positive This study
D 3 Active TB Positive Positive
Unmasking IRIS patients; 
presentation with active TB within 
2–8 weeks of commencing ARV 
therapy.
This study
E 5
Healthy (latent TB, or 
previous exposure to 
mycobacteria)
Negative Positive
Tomlinson 
et al. (2011)
F 5 Healthy  (uninfected) Negative Negative
Termed TST negative, as no TST 
response in healthy individuals with 
no clear risk factor for anergy 
suggests no Mtb exposure.
Tomlinson 
et al. (2011)
G (Saline) 8 Active TB
Negative (3) / 
Positive (5)
N/A This study
Table 6.3: Study group definitions for subsequent analyses. 
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6.4 Histological assessments 
Histological assessments of inflammation were made using biopsies from this 
recruited cohort (groups A, B, C, D, G, Table 6.3). Hematoxylin and eosin (H&E) 
stained sections were scored by a histopathologist blinded to concomitant clinical 
information and TST/saline status. Inflammation was scored from 0 (no inflammation) 
to 3. Figure 6.3(a) shows the relationship between histological inflammation score and 
clinical induration in each group, which demonstrates that although histological 
inflammation was detected in some clinically negative TSTs or saline control samples, 
there was mainly concordance between TST positivity and higher histological 
inflammation scores. No difference in median histological inflammation score was 
found between positive TSTs from HIV-1− patients or HIV-1+ patients. 
Where present, the cellular composition of the inflammatory infiltrate in the TST 
biopsies was assessed. This was largely composed of lymphocytes and histiocytes 
(APCs), which were reported to make up the majority of the cellular influx in all cases, 
consistent with previous studies (Poulter et al., 1982; Scheynius et al., 1982). The 
median ratio of lymphocytes to histiocytes was higher in positive TSTs from HIV-1− 
patients in comparison to HIV-1+ patients, although this difference was not statistically 
significant (Figure 6.3b; Mann-Whitney test, P=0.1049). The distribution of the 
inflammatory infiltrate was also assessed, and found to have a predominantly 
perivascular distribution in all groups, which is again consistent with previous reports 
assessing TST reactions at this time-point (Figure 6.3c; Gibbs et al., 1984).  
Representative images of H&E stains from each group for each inflammatory score 
(where applicable) are shown in Figure 6.4. 
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 Biopsies were formalin fixed, paraffin embedded, sectioned and stained with H&E to 
delineate the inflammatory infilitrate. All quantitative assessments were performed by 
an assessor blinded to clinical information. (a) Inflammatory infilitrate grading on a 0 
(no inflammation) to 3 scale. Each symbol represents an individual TST. (b) 
Composition of cellular infilitrate, where present, as assessed by a 
lymphocyte:histiocyte ratio. Each symbol represents an individual TST. Red lines 
indicates medians per group. (c) Distribution of cellular infilitrate, where present, as 
assessed by a perivascular:other distribution ratio. Each symbol represents an 
individual TST. Red lines indicates medians per group.  
Figure 6.3: Histological assessment of TST and saline biopsies. 
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Figure 6.4: Representative H&E stains of TST and saline biopsies. 
Representative images from each group for each inflammatory score (indicated by the 
left-hand column of numbers). Paraffin embedding of biopsies was performed by Groote 
Schuur Hospital (Cape Town) Department of Pathology. Sectioning and H&E staining 
were performed by the University College London Hospital (UCLH) histopathology 
department. With thanks, histopathology assessments and scoring were performed by 
Dr Alan Ramsay, UCLH Department of Pathology. 
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6.5 Gene expression profiling of TSTs 
6.5.1 Saline injection gene expression profiles 
Biopsies were collected from the site of saline control injections performed on 
eight active TB patients, in order to establish a baseline from which induction of gene 
expression in TSTs could be investigated (group G, Table 6.3). Three patients were 
HIV-1− and five were HIV-1+. Before gene expression profiles from these biopsies were 
used as a pooled group, the characteristics of the samples in the HIV-1− and HIV-1+ 
groups were compared, to assess whether any systematic differences existed that 
could confound their use as a common baseline.  
No difference between the groups was found upon histological inflammation 
scoring of biopsies (Figure 6.5a). Hierarchical clustering of gene expression profiles 
also did not discriminate HIV-1− and HIV-1+ samples (Figure 6.5b). Specific 
assessment of significant differences between the groups in genome-wide gene 
expression identified only 11 genes for which median expression differed by two-fold 
between the HIV-1− and HIV-1+ saline groups, all of which were expressed more highly 
in HIV-1− samples (Figure 6.5c).  
PCA was used to explore the multidimensional relationships of variance within 
the entire dataset. The two highest PCs showed clustering of saline biopsies, with 
again no distinction observed between HIV-1− and HIV-1+ saline biopsies (Figure 6.6). 
The clustering analyses and the minimal level of between-group differences in 
gene expression indicated that there was no systematic difference between the groups 
of saline biopsies. They were subsequently used as a common baseline for all gene 
expression analyses.  
Chapter 6. Results 
 
 
271 
 
Figure 6.5: Comparing HIV-1− and HIV-1+ saline control samples. 
(a) Histological inflammation scoring of HIV-1− and HIV-1+ saline injection biopsies. There was 
no significant difference in scores between the two groups (Mann-Whitney test). Red lines 
indicate medians. (b) Hierarchical clustering of gene expression profiles from HIV-1− and HIV-1+ 
saline injection biopsies using a Euclidean distance metric, average linkage clustering and 
optimised sample leaf order. (c) Heatmap of saline biopsy gene expression of 11 genes for 
which median expression was significantly different (Wilcoxon rank test, P<0.05) by at least 
two-fold between HIV-1− and HIV-1+ saline injection biopsies. Data is presented as normalised 
microarray expression values. 
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Figure 6.6: Principal component analysis of TST and saline biopsy gene 
expression profiles. 
Principal component analysis was performed on genome-wide expression profiles from 
TST or saline biopsies from the indicated groups. Principal component (PC) scores for 
the two highest PCs, PC1 and PC2, are shown. Each symbol represents a distinct 
biopsy gene expression profile. 
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6.5.2 The TST in HIV-1− patients with active TB induces innate & adaptive-
associated gene expression with evidence for cell recruitment and 
immunoregulatory processes 
The TST transcriptional response in active TB was characterised by comparing 
gene expression profiles of TST biopsies from HIV-1− active TB patients to saline 
controls (groups A and G in Table 6.3). Statistically significantly increased expression 
of 1725 genes was found in the TST (Figure 6.7a). Transcription factor binding site 
(TFBS) enrichment analysis of this gene list using oPOSSUM-3 (Kwon et al., 2012; 
http://opossum.cisreg.ca) indicated that these genes were regulated by multiple 
immune response signalling pathways (Figure 6.7b). These included innate immune 
NFκB and IRF2 signalling, adaptive immune STAT1 signalling and regulatory cytokine 
signalling via STAT3.  
The functional characteristics of the TST gene expression profile were explored 
by InnateDB pathway enrichment analysis (Breuer et al., 2013; 
http://www.innatedb.com; Figure 6.7c). This showed enrichment for innate pathways 
such as phagocytosis and type I IFN signalling, and adaptive pathways such as type II 
IFN signalling and T cell receptor (TCR) signalling. Pathways involved in the interface 
between innate and adaptive immunity were also enriched, such as antigen 
presentation and immunoregulatory interactions, as were pathways involved in cellular 
recruitment to inflammatory foci, such as chemokine activity and integrin activation. 
These bioinformatic analyses were complemented by assessing the TST using 
independently derived gene expression modules (see Chapter 5 & Appendix I for 
further description) constructed to detect specific cell types (Figure 6.8a; with thanks to 
Dr Gabriele Pollara; see Appendix I for description), or specific cytokine- or innate 
stimulus-induced functional signatures (generated in Chapter 5; Figure 6.8b and 6.6c 
respectively). Statistically significant enrichment in comparison to the saline control 
baseline was observed for all cell types, but B cell, macrophage and DC-specific 
modules were only very modestly enriched above salines (Figure 6.8a). The modest 
increase observed in enrichment in the macrophage-specific module, despite evidence 
of many histiocytes on histology, may be because these histiocytes are infilitrating 
monocytes which have not yet completely differentiated into MDMs; the monocyte-
specific signature enrichment corroborates this hypothesis. 
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The IFNγ, TNFα, IL-4/IL-13 and TGFβ/IL-10 modules generated in Chapter 5 
from stimulated MDMs can be compared quantitatively, as the gene sets for each had 
similar overall module expression values in MDMS stimulated with the relevant 
cytokines; suggesting that no module is biased towards more highly-expressed genes 
(see pg. 228). The most highly significantly enriched cytokine module was specific for 
IFNγ activity, followed by TNFα – cytokines known to be critical in CMI and anti-
mycobacterial responses. Significant but lesser enrichment was observed for activity of 
the Th2 cytokines IL-4 and IL-13, and the regulatory cytokines TGFβ and IL-10 (Figure 
6.8b). Innate stimulus modules specific to PCSK (a TLR-2 ligand) or Mtb were 
significantly enriched in TSTs, while those specific to another pathogen, Spn or LPS (a 
TLR-4 ligand), were not enriched above saline controls (Figure 6.8c) - suggesting that 
the inflammation generated in the TST exhibits specificity for Mtb-induced innate 
inflammatory respnses. 
 These analyses demonstrated that molecular assessment of the TST in active 
TB, via bioinformatic and modular characterisation of gene expression profiles, can 
provide qualitative and quantitative insights into multiple components of the CMI 
response in site of inflammation samples from patients with active TB.  
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Figure 6.7: TST gene expression profiling in HIV-1− patients with active TB. 
 (a) Frequency distribution of genes for which median expression was significantly increased 
(Wilcoxon rank test, P<0.05) by at least two-fold in HIV-1− TSTs compared to saline controls. 
(b) oPOSSUM transcription factor binding site (TFBS) enrichment analysis of 5000bp 
upstream/downstream of the 1725 genes presented in (a). The X axis lists the number of genes 
enriched for a TFBS, and the Y axis displays significance by Z score. (c) Network visualisation 
of InnateDB (Reactome) pathway enrichment analysis of the 1725 genes. The 12 enriched 
pathways with the highest numbers of genes identified are shown, all of which were significantly 
enriched in this gene set (corrected P<0.05). Red nodes, pathways; blue nodes, genes; node 
size is correlated to number of network connections.  
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Modular analysis of TST gene expression profiles from HIV-1− TST+ (active TB) samples. 
Module score represents the geometric mean expression of the module gene set in each TST 
gene expression profile, normalised to the saline control baseline, which is the median of the 
geometric mean module expression in all saline samples. Symbols represent group median 
module score and error bars represent interquartile range. The statistical significance of 
modular enrichment above the saline baseline was assessed using a Mann-Whitney test for 
differences in module expression between all TSTs and all salines (P<0.05). (a) All modules 
were significantly enriched above salines. (b) All modules were significantly enriched above 
salines. (c) PCSK and Mtb modules were significantly enriched above salines. 
Figure 6.8: Modular analysis of the TST in HIV-1− patients with active TB. 
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6.5.3 The molecular detail of the TST response is not systematically altered by 
active TB disease 
Active TB infection is associated with significant changes to the peripheral 
blood transcriptome (Berry et al., 2010). To assess if active TB also altered or 
confounded the TST response, I compared TST+ gene expression profiles from HIV-1− 
patients with active TB to TST+ gene expression profiles from healthy individuals 
generated in an earlier study (Tomlinson et al., 2011; groups A and E in Table 6.3). 
Previous analysis of the healthy individual TST+ gene expression profiles showed 
similar global functional enrichment results to the active TB profiles (Figure 6.7), such 
as T cell activation, chemokine activity and innate immune pathways (Tomlinson et al., 
2011). 
Comparison of genes which were increased in expression in either TST+ group 
showed a substantial degree of overlap (Figure 6.9a). Directly comparing the 
expression of all these genes showed a significant positive covariance and correlation 
between active TB patients and healthy individuals (Figure 6.9b). I identified 
statistically significant differences in gene expression of more than two-fold between 
the groups (Figure 6.9b). 356 genes were increased in healthy individuals in 
comparison to active TB patients, and 156 genes were increased in active TB patients 
in comparison to healthy individuals (in total, <25% of the integrated gene set). The 25 
most highly increased genes in active TB patients are shown in Figure 6.9c, and 
include immune response factors such as the antimicrobial peptides DEFB4A and PI3, 
and the matrix metalloproteinase MMP1. Pathway enrichment analysis of the gene list 
increased in active TB showed enrichment for Src signalling, integrin activation, 
vascular wall interactions and complement pathway activation (Figure 6.9c). Fewer 
pathways were enriched in the gene list increased in healthy individuals, and reflected 
mRNA processing and splicing (data not shown). 
Modular enrichment analysis of the gene expression profiles showed similar 
enrichment in the two groups for all modules tested (Figure 6.10a, b, c), except for the 
T cell-specific module, which was statistically significantly more highly enriched in 
healthy individual TST+ profiles (Figure 6.10a).  
Overall, these gene expression analyses suggested that substantial 
components of the TST response in active TB are shared with the TST response in 
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healthy individuals, and so employing the TST as a challenge model in active TB 
patients is not likely to be systematically confounded by attendant active disease. In 
fact, as active disease is associated with some functionally enriched alterations in gene 
expression, this may add value to an exercise in investigating inflammation in active TB 
specifically. 
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       Figure 6.9: Comparing active TB and healthy individual TST+ gene expression profiles. 
 (a) Venn diagram of the overlap between genes significantly induced in active TB TST+ vs. 
healthy individual TST+ samples (both in comparison to saline controls). (b) XY plot comparing 
median expression of all genes induced in either active TB or healthy TST+ samples. Linear 
regression showed a significant positive correlation and covariance between the two groups. 
Highlighted genes are significantly (P<0.05, Wilcoxon rank test) expressed ≥two-fold in one 
group compared to the other. Data are normalised microarray expression values. (c) Matrix 
showing the top 25 genes with significantly increased expression in active TB patient TSTs 
compared to healthy individuals. Data are normalised microarray expression values. (d) 
Network visualisation of InnateDB (Reactome) pathway enrichment analysis of genes 
upregulated in active TB TST+ profiles compared to healthy individuals. All significantly 
(corrected P<0.05) enriched pathways are shown. Red nodes, pathways; blue nodes, genes; 
node size is correlated to number of network connections.  
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Figure 6.10: Modular analysis of TST+ gene expression profiles from HIV− active TB 
patients and healthy individuals.  
Modular analysis of TST gene expression profiles from HIV-1− TST+ (active TB) and HIV-1− 
TST+ (healthy individual) samples. Module score represents the geometric mean expression of 
the module gene set in each TST gene expression profile, normalised to the saline control 
baseline, which is the median of the geometric mean module expression in all saline samples. 
Symbols represent group median module score and error bars represent interquartile range. 
The statistical significance of modular enrichment above the saline baseline was assessed 
using a Mann-Whitney test for differences in module expression between all TSTs and all 
salines (P<0.05). Mann-Whitney tests were also used to test for significant differences in 
module score between groups (* indicates P<0.05 between indicated groups). (a) All cell type 
modules were significantly enriched above salines. The T cell module score was significantly 
increased in healthy individuals. (b) All cytokine modules were significantly enriched above 
salines. (c) PCSK and Mtb modules were significantly enriched above salines. 
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6.5.4 Relative preservation of type I IFN responses in anergic TSTs from HIV-1+ 
active TB patients 
In HIV-1+ patients with anergic TST responses, biopsies collected from the 
marked TST injection site at 48 hours were assessed for differences in gene 
expression in comparison to saline controls (groups B and G in Table 6.3). Expression 
of 98 genes was statistically significantly increased in these samples despite the 
absence of a clinical reaction (Figure 6.11a), almost all of which were also increased in 
expression in the HIV-1− TST+ samples (Figure 6.11b). Directly comparing the 
expression of all genes induced in either group showed a significant positive 
correlation, but with a substantially reduced covariance (Figure 6.11c), demonstrating 
significantly attenuated enrichment of TST-associated gene expression in in HIV-1 
anergy. This detectable but attenuated anergic TST response was further evident when 
comparing induction of gene expression in each group above saline (Figure 6.11d). 
Importantly, this analysis suggests that the detectable response is not purely made up 
of genes which are the most highly expressed in TST+ samples, but are instead 
distributed across the spectrum of gene expression levels. 
Pathway enrichment analysis of the HIV-1+ anergic response gene list 
demonstrated enrichment for both type I and type II IFN signalling, with the most 
significant enrichment detected for the former (Figure 6.12a). Directly comparing how 
many genes from the Reactome biological pathway database 
(http://www.reactome.org/) IFN pathway gene lists were expressed in each group 
showed a change in bias from type II IFNs towards type I IFNs in HIV-1+ anergic 
samples (Figure 6.12b). TFBS enrichment analysis of the anergic response gene list 
also reflected the relative dominance of innate type I IFN activity in these samples, with 
highly significant enrichment detected for IRF2 and NFκB TFBS (Figure 6.12c).  
To further characterise IFN activity in these samples, and in particular to 
distinguish type I and type II signatures which have substantial functional overlap, 
modular enrichment analysis was performed using modules specific to type I and type 
II IFNs developed in Chapter 5, section 5.2.6 (Figure 6.13a). Both modules were 
statistically significantly enriched above saline in all TSTs. Type II IFN activity was 
significantly more highly enriched in comparison to type I IFN in all TST+ samples, 
regardless of HIV-1 status. In the HIV-1+ anergic TSTs, both modules were less highly 
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enriched than in TST+ samples. However, a differential pattern of enrichment was 
observed: type I and type II IFN activity were enriched to a similar degree, indicating 
relative preservation of the type I IFN response in these samples. The resulting 
alteration in balance between the two IFN pathways was evident when the type I and 
type II module scores were expressed as a ratio. Significantly increased type I IFN/type 
II IFN ratios were observed in HIV-1+ anergic TST biopsies, in comparison to either 
HIV-1– or HIV-1+ TST+ samples (Figure 6.13b). 
Assessment of the panel of cell type, cytokine and innate stimulus-specific 
modules in HIV-1+ anergic TSTs showed that enrichment of all modules was either 
absent or substantially attenuated in comparison to HIV-1– TST+ biopsies (Figure 
6.13c, d, e). Detectable responses above the saline baseline included IFNγ cytokine 
activity (Figure 6.13d), consistent with some type II IFN activity identified in the specific 
IFN analysis. TLR-2 specific responses induced by PCSK were also detectable (Figure 
6.13e). 
These results indicated that immune responses were evident at the site of 
mycobacterial challenge in clinically anergic TSTs from HIV-1+ active TB patients, and 
that these were characterised by a relatively preserved type I IFN response. 
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Figure 6.11: Gene expression profiling of anergic TSTs from HIV-1+ active TB 
patients.  
(a) Frequency distribution of 98 genes for which median expression was significantly 
increased by at least two-fold in HIV-1+ anergic TSTs compared to saline controls. (b) 
Venn diagram demonstrating the overlap between genes significantly induced in active 
TB HIV-1− TST+ vs. HIV-1+ anergic samples (both in comparison to saline controls). (c) 
XY plot comparing median expression of all genes induced in either HIV-1− TST+ or 
HIV-1+ anergic samples. Linear regression showed a significant positive correlation 
between the two groups, but with a slope of substantially <1, suggesting reduced 
expression in HIV-1+ anergic samples. Data presented are normalised microarray 
expression values. (d) XY plot comparing median fold-change induction compared to 
saline controls of all genes induced in either HIV-1− TST+ or HIV-1+ anergic samples. 
The 98 significantly induced genes in the latter are highlighted in red. 
Chapter 6. Results 
 
 
284 
Figure 6.12: Bioinformatic analyses of the HIV-1+ anergic TST response shows 
enrichment for IFN signalling pathways. 
(a) Network visualisation of InnateDB (Reactome) pathway enrichment analysis of the 98 
induced genes. The 12 enriched pathways with the highest numbers of genes identified are 
shown, all of which were significantly enriched in this gene set (corrected P<0.05). Red nodes, 
pathways; blue nodes, genes; node size and labelling are correlated to the number of network 
connections. (b) Comparison of numbers of genes from Reactome IFN pathways expressed in 
HIV-1- TST+ and HIV-1+ anergic samples. (c) oPOSSUM TFBS enrichment analysis of 5000bp 
upstream/downstream of the induced 98 genes. The X axis lists the number of genes enriched 
for a TFBS, and the Y axis displays significance by Z score. 
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Figure 6.13: Modular analysis of the HIV-1+ anergic TST response demonstrates relative 
preservation of the type I IFN response. 
 Modular analysis of TST gene expression profiles from HIV-1− TST+ and HIV-1+ TST− samples. 
Module score represents the geometric mean expression of the module gene set in each TST 
gene expression profile, normalised to the saline control baseline, which is the median of the 
geometric mean module expression in all saline samples. Symbols represent group median 
module score and error bars represent interquartile range. The statistical significance of 
modular enrichment above the saline baseline was assessed using a Mann-Whitney test for 
differences in module expression between all TSTs and all salines (P<0.05). Mann-Whitney 
tests were also used to test for significant differences in module score between groups (* 
indicates P<0.05 between indicated groups). (a) Modular analysis of gene expression profiles 
using modules specific to type I and type II IFNs. All modules were significantly enriched above 
salines in all groups, but significant differences between type I and type II IFN expression were 
only observed for positive TSTs. (b) Ratio of type I IFN to type II IFN module scores. (c) All cell 
type modules were significantly enriched above salines in TST+ samples, but none were 
significantly enriched in anergic TSTs. (d) All cytokine modules were significantly enriched 
above salines in TST+ samples, but only the IFNγ module was significantly enriched in anergic 
TSTs. (e) PCSK and Mtb modules were significantly enriched above salines in TST+ samples, 
but only the PCSK module was significantly enriched in anergic TSTs. 
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6.5.5 HIV-1+ TST anergy is molecularly distinct from healthy individual TST 
negativity 
A previous investigation showed that healthy individual TST− biopsies contained 
detectable immune responses, which were qualitatively similar but quantitatively less 
than those in TST+ samples (Tomlinson et al., 2011). I evaluated the differences 
between HIV-1+ anergic TSTs and TST− samples from healthy volunteers. This showed 
that the HIV-1+ anergic TST response was manifestly limited in comparison to healthy 
individual TST− samples (Figure 6.14a, b). This analysis also highlighted that a subset 
of the HIV-1+ anergic response was less highly expressed in the HIV-1− TST− biopsies. 
Twenty-eight genes which were increased in the HIV-1+ anergic group were not 
statistically significantly increased in expression in HIV-1− TST− samples in comparison 
to saline controls (Figure 6.14a, b, c). This list included multiple IFN response genes 
(Figure 6.14d).  
These TSTs were also assessed via modular analysis. Statistically significant 
enrichment of most cytokine and cell type modules, as well as LPS and PCSK innate 
stimulus modules, was found in the HIV-1− TST− samples in comparison to salines 
(Figure 6.15a, b, c). As described above (Figure 6.13), only IFNγ and PCSK modules 
were significantly enriched in anergic TSTs, and the expression of these modules was 
much lower than in HIV-1− TST− samples (Figure 6.15a, b, c). This indicates that 
substantial cellular infiltration, cytokine activity and innate inflammation occur at the site 
of a negative TST in a healthy individual, but that these processes are absent in the 
context of HIV-1+ anergy. 
These assessments show that HIV-1+ TST anergy in active TB patients is 
molecularly distinct from TST negativity in a healthy individual. This indicates that 
anergy is mechanistically different from TST negativity, and may involve a specific type 
I IFN response not detected in healthy individuals, in the absence of any other evident 
inflammation or cellular infiltration. 
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(a) Venn diagram demonstrating the overlap between genes significantly induced in healthy 
individual HIV-1− TST− vs. active TB HIV-1+ anergic biopsies (both in comparison to saline 
controls). (b) XY plot comparing median expression of all genes induced in either healthy 
individual HIV-1− TST− or active TB HIV-1+ anergic biopsies. Linear regression showed a 
significant positive correlation between the two groups, but limited covariance with a slope of 
substantially <1, suggesting reduced gene expression in HIV-1+ anergic biopsies. Genes which 
are significantly upregulated in either group are highlighted in blue and red. (c) XY plot 
comparing median fold-change induction compared to saline controls of all genes induced in 
either healthy individual HIV-1− TST− or active TB HIV-1+ anergic biopsies. (d) Heatmap 
showing expression of genes which are significantly increased in expression in HIV-1+ anergic 
TST biopsies but not in healthy individual HIV-1− TST− biopsies. All data presented are 
normalised microarray expression values.  
Figure 6.14: Comparison of HIV-1+ anergic TST samples from active TB patients with HIV-
1− TST− samples from healthy individuals. 
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Figure 6.15: Modular analysis of gene expression profiles from HIV-1+ active TB patient 
anergic TSTs and healthy individual negative TSTs. 
Modular analysis of TST gene expression profiles from HIV-1− TST− and HIV-1+ TST− samples. 
Module score represents the geometric mean expression of the module gene set in each TST 
gene expression profile, normalised to the saline control baseline, which is the median of the 
geometric mean module expression in all saline samples. Symbols represent group median 
module score and error bars represent interquartile range. The statistical significance of 
modular enrichment above the saline baseline was assessed using a Mann-Whitney test for 
differences in module expression between all TSTs and all salines (P<0.05). Mann-Whitney 
tests were also used to test for significant differences in module score between groups. (a) All 
cell type modules were significantly enriched above salines in TST negative samples, but none 
were significantly enriched in anergic TSTs. (b) All cytokine modules except TNFα were 
significantly enriched above salines in TST negative samples, but only the IFNγ module was 
significantly enriched in anergic TSTs. (c) LPS and PCSK modules were significantly enriched 
above salines in TST negative samples, but only the PCSK module was significantly enriched in 
anergic TSTs. 
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6.5.6 TST gene expression is broadly conserved in HIV-1+ TST+ individuals but 
the immunoregulatory IL-10 response is specifically attenuated 
I next investigated the TST+ response in HIV-1+ active TB patients (group C in 
Table 6.3). Significant ≥two-fold increases in expression of 1291 genes were observed 
above saline controls (Figure 6.16a), and this response was broadly concordant with 
the response in HIV-1− patients (Figure 6.16b, c). Specific comparison with the HIV-1− 
TST+ response identified 44 genes which were statistically significantly attenuated in 
expression by ≥two-fold in HIV-1+ TSTs (Figure 6.16c). TFBS enrichment analysis was 
used to assess the attenuated genes (Figure 6.16d). This showed enrichment for 
several factors: innate TFs such as RelA; STAT1, which is downstream of IFNγ 
signalling; and STAT3, which is downstream of signalling by the anti-inflammatory 
cytokine IL-10 (L. Williams et al., 2004).  
I used modular analysis, as in previous sections, to specifically investigate if the 
activities of these pathways were altered in HIV-1+TST+ samples. Innate stimulus 
(downstream of RelA) and IFNγ (downstream of STAT1) module enrichment were 
preserved, as was enrichment of the module measuring activity of TGFβ and IL-10 in 
combination (Figure 6.17b, c). No differences were found in module expression in 
HIV-1+ samples using the overall panel of modules, except for significantly reduced 
enrichment of the T cell-specific module (Figure 6.17a), as might be expected for a 
group of patients with a diminished peripheral CD4+ T cell pool. 
To measure the specific activity of IL-10, I used two IL-10-specific functional 
modules described in Chapter 5 section 5.2.7. IL-10 modular enrichment was 
significantly attenuated in HIV-1+ TSTs (Figure 6.18a). As the enrichment for all other 
cytokine-induced modules tested was preserved, this suggested a specific deficit in IL-
10. An independently published IL-10 module was used to confirm this finding (Teles et 
al., 2013). Enrichment for this module was much lower than that of my IL-10 modules 
(Figure 6.18b), which may reflect that the published module was generated from IL-10-
stimulated PBMC rather than MDMs; the latter may be a more accurate model of a 
tissue-resident cell IL-10 response. Nonetheless, attenuation of IL-10 modular 
enrichment was also observed using this PBMC module (Figure 6.18b). 
To further confirm this observation, a discrete assessment of modular 
enrichment was made using the gene set enrichment analysis (GSEA) algorithm 
(Subramanian et al., 2005). This algorithm is optimised for detecting differences in 
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module enrichment between two groups, as it involves ranking all genes in a dataset in 
order of their difference between the two groups to be compared. In a GSEA 
comparison of HIV-1− and HIV-1+ TST+ samples, significant relative enrichment of one 
IL-10 functional module was demonstrated in the HIV-1− group (Figure 6.18c), further 
confirming IL-10 functional deficiency at the site of inflammation in the HIV-1+ TST+ 
active TB patients.  
As it has been shown that IL-10 responses to Mtb are attenuated in vitro in HIV-
1 infected macrophages (Tomlinson et al., 2014; Chapter 3), this identification of 
functional deficiency of IL-10 activity in the HIV-1+ TST response may represent an in 
vivo correlate of the in vitro observation. This suggests that an important 
immunoregulatory component of CMI to mycobacteria is deficient at the site of 
inflammation in HIV-1+ patients with active TB. 
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Figure 6.16: Gene expression profiling of positive TSTs from HIV-1+ active TB patients. 
 
(a) Frequency distribution of 1291 genes for which median expression was significantly 
increased by at least two-fold in HIV-1+ TST+ samples compared to saline controls. (b) Venn 
diagram demonstrating the overlap between genes significantly induced in active TB HIV-1− 
TST+ vs. HIV-1+ TST+ samples (both in comparison to saline controls). (c) XY plot comparing 
median expression of all genes induced in either HIV-1− TST+ or HIV-1+ TST+ biopsies. Linear 
regression showed a significant positive correlation between the two groups, with a slope of 
approximately 1, demonstrating broad conservation of the TST+ response in HIV-1+ active TB 
patients. Forty-four genes for which expression is significantly reduced by ≥ two-fold in HIV-1+  
TSTs are highlighted.  Data presented are normalised microarray expression values. (d) 
oPOSSUM TFBS enrichment analysis of 10000bp upstream/downstream of the 44 attenuated  
genes. The X axis lists the number of genes enriched for a TFBS, and the Y axis displays 
significance by Z score. 
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Figure 6.17: Modular analysis of gene expression profiles from HIV-1+ active TB 
patient positive TSTs. 
 Modular analysis of TST gene expression profiles from HIV-1
− TST+ and HIV-1+ TST+ samples. 
Module score represents the geometric mean expression of the module gene set in each TST 
gene expression profile, normalised to the saline control baseline, which is the median of the 
geometric mean module expression in all saline samples. Symbols represent group median 
module score and error bars represent interquartile range. The statistical significance of 
modular enrichment above the saline baseline was assessed using a Mann-Whitney test for 
differences in module expression between all TSTs and all salines (P<0.05). Mann-Whitney 
tests were also used to test for significant differences in module score between groups (* 
indicates P<0.05 between indicated groups). (a) All cell type modules were significantly 
enriched above salines in both groups. The T cell module was significantly more highly 
expressed in HIV-1− TST+ samples. (b) All cytokine modules were significantly enriched above 
salines in both groups. (c) PCSK and Mtb modules were significantly enriched above salines in 
both groups. 
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Figure 6.18: Attenuation of the IL-10 response in positive TSTs from HIV-1+ active TB 
patients. 
 Modular analysis of TST gene expression profiles from HIV-1
− TST+ and HIV-1+ TST+ samples. 
(a, b) Module score represents the geometric mean expression of the module gene set in each 
TST gene expression profile, normalised to the saline control baseline, which is the median of 
the geometric mean module expression in all saline samples. Symbols represent group median 
module score and error bars represent interquartile range. The statistical significance of 
modular enrichment above the saline baseline was assessed using a Mann-Whitney test for 
differences in module expression between all TSTs and all salines (P<0.05). Mann-Whitney 
tests were also used to test for significant differences in module score between groups (* 
indicates P<0.05 between indicated groups). (a) Expression of two IL-10 functional modules 
was significantly attenuated in HIV-1+ TST+ samples: an IL-10 inducible module (IL-10), a 
module made up of genes suppressed when IL-10 is neutralised in the context of zymosan-
induced inflammation (zymosan/IL-10n). (b) Expression of an independently published IL-10 
inducible module (Teles et al., 2013) was also attenuated in HIV-1+ TST+ samples. (c) Modular 
enrichment analysis of HIV-1− TST+ biopsies compared to HIV-1+ TST+ samples performed 
using the GSEA algorithm. The dashed line indicates the threshold of statistical significance 
recommended for use for this algorithm. Although a number of modules were scored as 
enriched in HIV-1− TST+ samples compared to HIV-1+ TST+ samples, only the zymosan/IL-10 n 
module was significantly enriched, and consequently assessed to be relatively attenuated in the 
HIV-1+ TSTs. 
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6.5.7 HIV-1+ unmasking IRIS patients display accentuated Th2 responses in the 
TST 
Within the HIV-1+ active TB patient cohort, three patients were classified as 
undergoing an unmasking IRIS (group D in Table 6.3). Unmasking IRIS was defined as 
presentation with active TB within 2−8 weeks of commencing ARVs, consistent with 
published definitions (Haddow et al., 2009; Meintjes et al., 2008a). The 
immunopathology of unmasking IRIS remains incompletely understood (Lai et al., 
2013), and so I used the TST samples collected from these patients as an opportunity 
to gain insights into anti-mycobacterial responses at the site of inflammation in IRIS. 
All patients in this group had clinically positive TSTs (Table 6.2), and high 
histological inflammation scores (Figure 6.3a, Figure 6.4). IRIS TSTs showed 
statistically significant increases in expression of 2780 genes compared to saline 
controls (Figure 6.19a), representing an expanded response in comparison to HIV-1− 
TST+ samples (Figure 6.19b). A direct comparison of all genes increased in IRIS or in 
HIV-1− TST+ samples demonstrated that the responses were broadly concordant with 
significant correlation and covariance, but that 52 genes were statistically significantly 
increased ≥two-fold in expression in the IRIS group (Figure 6.19c). This gene list 
contained factors involved in driving Th2 immune responses, such as IL-13, IRF4, 
CCL26, CCL17 and CCL1 (Corren, 2013; Y. Gao et al., 2013; Gonzalo et al., 2007; 
Imai et al., 1999; Provost et al., 2013), and pathway enrichment analysis of this gene 
list showed overrepresentation for Th2 pathways such as IL-4 signalling and asthma 
(Figure 6.19d).  
Upregulation of the Th2 response in IRIS patient TSTs was confirmed by 
modular analysis, which showed significantly increased enrichment for activity of the 
Th2 cytokines IL-4 and IL-13 in comparison to HIV-1− TST+ samples (Figure 6.20a). All 
other cytokine-driven modules were similarly enriched between the groups, suggesting 
that Th1 responses driven by IFNγ or T-regulatory responses driven by TGFβ and IL-
10 were not accentuated in the IRIS TSTs (Figure 6.20b). Additionally, T cell modular 
activity was not significantly enriched in IRIS TSTs above HIV-1− TST+ samples 
(Figure 6.20c). Together, these observations suggest that the increase in Th2 activity 
in IRIS TSTs is not due to an overall broader T cell response than non-IRIS TSTs, but 
that a specific bias exists within a T cell response of similar magnitude. Activity of all 
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other modules tested was similar, with the exception of a significant but modest 
increase in DC module enrichment (Figure 6.20a, c); this could potentially also be 
involved in Th2 biasing, as a specific role for DCs in initiating this arm of immunity has 
recently been reported (Y. Gao et al., 2013). The Th2 bias in IRIS TSTs compared to 
HIV-1− TST+ samples was further confirmed in a separate modular assessment using 
the GSEA algorithm. This showed significant enrichment of the IL-4/IL-13 module in the 
IRIS samples (Figure 6.20d). 
Th2-type inflammation was also evident in histological assessments of these 
samples. Upon H&E staining, infiltration of eosinophils, which are implicated in Th2 
responses  (Rothenberg and Hogan, 2006), was identified in all biopsy samples in the 
IRIS group, while it was only observed in 11% and 22% of the HIV-1−TST+ and HIV-
1+TST+ groups respectively. Representative images of eosinophils present in IRIS 
biopsy sample H&E stains are shown in Figure 6.21.  
Both gene expression and histological assessments at the site of inflammation 
in IRIS patients demonstrated a Th2 bias in the context of an otherwise typical TST+ 
response. This may provide insight into the nature of the immunopathology which 
exacerbates TB disease in these patients. 
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Figure 6.19: Gene expression profiling of positive TSTs from unmasking TB-IRIS 
patients. 
 (a) Frequency distribution of 2780 genes for which median expression was significantly 
increased by at least two-fold in HIV-1+ TST+ IRIS patient biopsies compared to saline controls. 
(b) Venn diagram demonstrating the overlap between genes significantly induced in active TB 
HIV-1− TST+ vs. HIV-1+ TST+ IRIS biopsies (both in comparison to saline controls). (c) XY plot 
comparing median expression of all genes induced in either HIV-1− TST+ or HIV-1+ TST+ IRIS 
biopsies. Linear regression showed a significant positive correlation between the two groups. 
Fifty-two genes for which expression is significantly increased by ≥ two-fold in IRIS biopsies are 
highlighted.  Data presented are normalised microarray expression values. (d) Network 
visualisation of InnateDB (all curated databases) pathway enrichment analysis of the 52 genes 
for which expression was increased. All significantly enriched pathways in this gene set are 
shown (corrected P<0.05). Red nodes, pathways; blue nodes, genes; node size is correlated to 
number of network connections. 
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Figure 6.20: Modular analysis of gene expression profiles from unmasking TB-IRIS 
patients identifies increased Th2 responses. 
Modular analysis of TST gene expression profiles from HIV-1− TST+ and HIV-1+ TST+ (IRIS) 
samples. Module score represents the geometric mean expression of the module gene set in 
each TST gene expression profile, normalised to the saline control baseline, which is the 
median of the geometric mean module expression in all saline samples. Symbols represent 
group median module score and error bars represent interquartile range. The statistical 
significance of modular enrichment above the saline baseline was assessed using a Mann-
Whitney test for differences in module expression between all TSTs and all salines (P<0.05). 
Mann-Whitney tests were also used to test for significant differences in module score between 
groups (* indicates P<0.05 between indicated groups). (a) All cell type modules were 
significantly enriched above salines in both groups. The DC module was significantly more 
highly expressed in HIV-1+ TST+ (IRIS) samples. (b) All cytokine modules were significantly 
enriched above salines in both groups. The IL-4/IL-13 module was significantly more highly 
expressed in HIV-1+ TST+ (IRIS) samples  (c) PCSK and Mtb modules were significantly 
enriched above salines in both groups. (d) Modular enrichment analysis of HIV-1+ TST+ (IRIS) 
samples compared to HIV-1− TST+ samples performed using the GSEA algorithm. The dashed 
line indicates the threshold of statistical significance recommended for use for this algorithm. 
Although a number of modules were scored as enriched in HIV-1+ TST+ (IRIS) samples 
compared to HIV-1− TST+ samples, only the IL-4/IL-13 module was assessed as significantly 
enriched. 
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Figure 6.21: Eosinophilic infiltration in TST biopsies from IRIS patients. 
Representative images of eosinophils from IRIS patient TST biopsy H&E stains. Each image is 
from a separate patient biopsy. Eosinophils, multinucleated cells staining highly positively for 
eosin (pink/purple), are indicated by white arrows. 
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6.5.8 Evidence for HIV-1 viral activity at the site of TST inflammation 
Gene expression profiles of HIV-1+ active TB patient TSTs showed that HIV-1 
was associated with multiple pathways of dysregulation compared to HIV-1− TST 
responses. I was interested to determine whether HIV-1 was detectable at the TST 
site, as if so this might indicate that these phenotypes were a direct result of viral 
activity in the inflammatory milieu. This might include intracellular viral reservoirs in 
patients on ARVs, as the phenotypes described were not exclusive to patients with 
uncontrolled viral loads (VLs). 
qRT-PCR for the HIV-1 LTR, a highly conserved viral sequence, was performed 
on TST RNA samples. This was detectable in a subset of TSTs (Figure 6.22a), which 
may either represent virus present in the TST tissue, or virus derived from blood 
contamination of the biopsy. In the latter scenario, it might be expected that HIV-1 LTR 
transcript would correlate with blood VL. A significant but weak positive correlation was 
found between the two measures (Figure 6.22b), although some patients with elevated 
VLs had undetectable TST virus, and one patient with a suppressed VL had a low level 
of TST viral transcript detectable. It is difficult to draw any conclusions from this data, 
as the weak correlation between TST LTR and VL is indicative that the LTR detectable 
may be derived from contaminating blood; further assessments are merited which 
would be less confounded by this issue, such as histological staining for HIV-1 
proteins. 
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Figure 6.22: Investigating the presence of HIV-1 at the TST site. 
qRT-PCR for the HIV-1 LTR demonstrates detectable HIV-1 transcript, expressed as 
HIV-1 LTR cycle threshold (ct) in which a lower value indicates higher levels of 
transcript, in a subset of biopsies, which showed a significant but weak positive 
correlation with peripheral blood HIV-1 viral load.  
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6.5.9 Molecular profiles of HIV-1 CMI dysregulation which are evident in the TST 
are not evident in the peripheral blood 
Gene expression profiling of the immune response to TB in vivo has previously 
evaluated the peripheral blood, and insights into systemic immune activity have been 
gained via this method (Berry et al., 2010; Bloom et al., 2013, 2012; Cliff et al., 2013; 
Maertzdorf et al., 2012; Ottenhoff et al., 2012). I sought to assess whether the HIV-1-
dysregulated phenotypes found in the TST were also evident in the peripheral blood. 
Cytokine-specific module expression was measured in peripheral blood gene 
expression profiles from samples which were collected contemporaneously with TST 
injection in the same patient cohort. Although all modules tested were statistically 
significantly enriched in TST+ biopsy samples compared to saline controls, only a 
subset of modules were more highly expressed in active TB patient peripheral blood 
compared to healthy volunteer blood: IFNγ and type II IFN modules, and the IL-10 
module (Figure 6.23a−c). This is hypothesised to reflect systemic immune activity 
resulting from active TB. 
Some modules were differentially expressed in HIV-1+ active TB peripheral blood 
compared to HIV-1− patients. There was evidence for increased IFN signalling in HIV-1 
infection, as the IFNγ, type I IFN and type II IFN modules were all significantly 
increased in expression in HIV-1+ peripheral blood in comparison to HIV-1− patients 
(Figure 6.23a, b). HIV-1+ patients with anergic TSTs also had significant increased 
expression of the TNFα module, and significantly decreased expression of the 
TGFβ/IL-10 module (Figure 6.23a). These observations may be due to systemic 
immune activation in HIV-1+ patients. Importantly, none of the phenotypes associated 
with HIV-1 infection in the TST were observed in the peripheral blood. Although type I 
IFN activity was increased in HIV-1+ patients, this was not specific to those with anergy 
(Figure 6.23b). Attenuation of IL-10 was not evident (Figure 6.23c). No IL-4/IL-13 
(Th2) module expression was observed in any samples, including the IRIS patients 
((Figure 6.23a). This suggests that these phenotypes are specific to the site of 
inflammation and are not evident in systemic immune activity as measured in the 
peripheral blood transcriptome.  
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Figure 6.23: Modular analysis of peripheral blood transcriptional profiles from HIV-1− and 
HIV-1+ active TB patients and healthy volunteers. 
Modular analysis of peripheral blood gene expression profiles. Module score represents the 
geometric mean expression of the module gene set in each TST gene expression profile, 
normalised to the geometric mean expression of the entire genome. Symbols represent group 
median module score and error bars represent interquartile range. Mann-Whitney tests were 
also used to test for significant differences in module score between groups (* indicates P<0.05 
between indicated groups). (a) The IFNγ module was significantly increased in expression in 
active TB patients compared to healthy volunteers, and significantly increased in expression in 
HIV-1+ patients compared to HIV-1− patients. The TNFα module was significantly increased in 
HIV-1+ patients with anergic TSTs compared to HIV-1− patients and healthy volunteers. The 
TGFβ/IL-10 module was significantly decreased in HIV-1+ patients with anergic TSTs compared 
to HIV-1− patients and healthy volunteers. (b) The type I IFN module was significantly increased 
in expression in HIV-1+ patients compared to HIV-1− patients and healthy volunteers. The type II 
IFN module was significantly increased in expression in active TB patients compared to healthy 
volunteers, and significantly increased in expression in HIV-1+ patients compared to HIV-1− 
patients. (c) The IL-10 module was significantly increased in expression in active TB patients 
compared to healthy volunteers. 
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6.6 Chapter discussion 
I have employed genome-wide transcriptional profiling of TST biopsy samples to 
gain insights into the function of CMI at the molecular level in vivo, and the pathways 
by which HIV-1 modulates this response. The TST+ response was broadly consistent in 
active TB and in healthy individuals, but with some specific pathways upregulated 
which may represent active disease processes. Clinically negative TSTs were found to 
contain detectable responses, which were phenotypically divergent: healthy individual 
TST negativity displayed many features of the TST+ response, while HIV-1+ anergy 
showed a manifestly limited response with relative preservation of the type I IFN 
response. Positive TSTs from HIV-1+ active TB patients had broad conservation of the 
TST response but with specific attenuation of activity of the anti-inflammatory cytokine 
IL-10. Finally, a Th2 response bias was identified in TSTs from HIV-1+ unmasking IRIS 
patients. 
Clinical TST responses in this cohort were broadly as expected. The frequency 
and disease correlates of anergic responses in HIV-1+ individuals were consistent with 
previous reports in similar cohorts (Rangaka et al., 2007). Poor concordance was 
found between IGRA results and TST responses, which was again consistent with 
previous studies (Luetkemeyer et al., 2007; Rangaka et al., 2007). This observation 
highlights the potential value of studying anti-mycobacterial responses in a tissue 
setting, as the responses of peripheral blood cells are unlikely to be closely 
comparable. This is also shown by modular assessment of peripheral blood 
transcriptional profiles from these patients, in which the HIV-1-dysregulated 
phenotypes described in the TST were not evident by modular analysis. 
Gene expression profiling of HIV-1− TST+ samples from active TB patients 
confirmed the value of this approach in dissecting the CMI response at a systems level 
in vivo, consistent with the previous investigation in healthy volunteers (Tomlinson et 
al., 2011). A modular analysis strategy was used to gain further insights into the CMI 
response. Signatures of infiltration by a range of cell types were identified, and limited 
Th2 and T-regulatory responses were detected in the context of a dominant Th1 
response. Importantly, Mtb-specific innate responses were enriched in comparison to 
those specific to other pathogens, confirming the utility of the TST as a model to study 
specific Mtb-induced inflammation.  
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Comparison of TST+ samples from active TB patients with those from healthy 
individuals also lent confidence to utilising the TST as a challenge model in active TB 
patients, as it was not systematically confounded by active disease. However, the 
molecular resolution of the transcriptional approach allowed identification of a subset of 
genes with increased expression in active TB TSTs. Some of these have been 
implicated in TB pathogenesis, such as the matrix metalloproteinase MMP1 (Elkington 
et al., 2011) and anti-microbial peptides including a beta-defensin (Rivas-Santiago et 
al., 2006). This gene list was also enriched for inflammatory pathways such as integrin 
and complement activation. These observations suggest that although the TST 
response is broadly conserved in active TB, it may be used to gain disease-specific 
insights. Further such insights were gained from modular analysis showing decreased 
enrichment for the T cell-specific module, perhaps reflecting the relative lymphopenia 
which is observed in active TB patients (Beck et al., 1985).  
Anergic TST responses, i.e. those in which patients fail to react to PPD despite 
having active TB and so presumably having Mtb antigenic memory, were found in 54% 
of the HIV-1+ patients in this cohort, and similarly to previous reports (Cobelens et al., 
2006), I found TST responsiveness to be an “all-or-nothing” phenomenon: i.e. 
responses were clearly positive (≥10mm induration) or completely negative, with no 
intermediate “weak” TST responses. This clinical observation presents the hypothesis 
that TST anergy in these individuals is due to a specific failure to generate any 
inflammation whatsoever, rather than being a diminishment in the inflammatory 
response due to immunosuppression. Gene expression profiling of HIV-1+ anergic 
TSTs lent considerable support to this hypothesis. Comparison with TST+ samples 
from HIV-1− active TB patients showed a detectable but strikingly limited response in 
the anergic TSTs. This differed from observations in healthy individual TST− samples, 
which despite being clinically identical to anergic responses contained a much broader 
gene expression response. Further comparisons between HIV-1+ anergic TSTs and 
healthy individual negative TSTs confirmed that TST anergy was molecularly distinct 
from TST negativity. Anergic TSTs had little evidence of cellular infilitration or 
inflammatory activity, both of which were demonstrated in the healthy TST− individuals. 
Further evaluations showed that the limited response in the HIV-1+ anergic TSTs was 
dominated by a relatively preserved type I IFN response. This response was also 
present in its entirety in TST+ samples. This confirms that type 1 IFN responses are 
evident at the tissue level in human anti-mycobacterial responses, consistent with 
previous reports derived from analysis of peripheral blood (Berry et al., 2010). 
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Interestingly, these can be invoked by PPD alone, which suggests that mycobacterial 
components without live bacterial replication are sufficient to induce a type I IFN 
response in vivo.  
Observation of this type I IFN response in the absence of other inflammation in 
HIV-1+ anergic TSTs raises two questions: firstly, what cells or mechanisms are 
generating this response, and secondly, what consequences might this phenotype 
have for TB pathogenesis in these individuals? As there appears to be an absence of 
any cellular influx in these samples, I hypothesise that the response is being generated 
by tissue-resident sentinel cells such as macrophages. In terms of the consequences 
for TB pathogenesis, there has recently been considerable interest and supportive 
assessment of the hypothesis that type I IFN is immunosuppressive and compromises 
control in tuberculosis and other mycobacterial infections (Manca et al., 2001; Mayer-
Barber et al., 2011; Redford et al., 2014; Stanley et al., 2007; Teles et al., 2013). This 
suggests that this presence of this response in itself might be functionally implicated in 
the anergic failure to generate inflammation. At the site of disease, failure to generate 
an effective CMI response in HIV-1+ individuals may lead to poor granulomatous 
organisation and uncontrolled bacillary replication (Lawn et al., 2002).  This phenotype 
may be analogous to lepromatous lesions in leprosy, in which the failure of host 
immunity leads to uncontrolled bacillary replication and disease - a process which has 
been shown to be driven by type I IFN (Teles et al., 2013). My identification of type I 
IFN responses at the site of CMI anergy in HIV-1+ individuals thus presents a novel 
hypothesis for the mechanism of anergy and associated poor clinical outcomes in 
these patients (Moreno et al., 1993), and lends further support to the notion that type I 
IFNs compromise control of mycobacteria in vivo. 
Assessment of the site of inflammation in HIV-1+ TST+ active TB patients showed 
broadly typical TST responses in these individuals, with a specific deficiency in activity 
of the immunoregulatory cytokine IL-10. As it has been shown that human MDMs 
infected with HIV-1 in vitro display attenuated IL-10 responses to Mtb as a direct result 
of viral infection (Tomlinson et al., 2014, Chapter 3), this observation suggests that this 
phenomenon may also occur in vivo. A clear hypothesis for the mechanism of this 
phenotype within the TST is suggested by my experimental data - that IL-10 responses 
are inhibited in either tissue-resident macrophages or recruited monocyte-derived 
macrophages which are infected with HIV-1. Both my cellular module assessments and 
a previous report (Liang et al., 2013) indicate that recruitment of monocytes/APCs to 
Chapter 6. Results 
 
 
306 
the TST is non-defective in HIV-1+ individuals, meaning the latter scenario is plausible. 
However, if this is a specifically macrophage-driven phenomenon, 48 hours is likely to 
be an insufficient timeframe for differentiation of infiltrating monocytes into 
macrophages. Additionally, the burden of HIV-1 infection within the circulating 
monocyte population is thought to be extremely low (Spear et al., 1990). However, 
multiple reports have demonstrated HIV-1 infection in tissue macrophages in vivo, and 
so attenuated IL-10 responses generated by these cells as a mechanism for this 
phenotype is plausible (Cao et al., 1992; Jambo et al., 2014; Jarry et al., 1990; Koenig 
et al., 1986).  
The potential consequences of attenuated IL-10 responses for TB pathogenesis 
in vivo in HIV-1+ individuals are numerous. Previous in vitro data highlighted that 
deficiency in the innate immunoregulatory functions of IL-10 may lead to exacerbated 
pro-inflammatory responses, which have the potential to increase immunopathology 
and tissue damage (Tomlinson et al., 2014; Chapter 4). IL-10 also plays key roles in 
regulating apoptosis and promoting resolution of inflammation (Eslick et al., 2004; 
Ogawa et al., 2008; Zhou et al., 2001), and dysregulation of these processes could 
have consequences for the effective containment of Mtb within a protective fibrotic 
granuloma structure (Lin et al., 2014). 
Finally, in HIV-1+ active TB patients classified as undergoing an unmasking IRIS, 
I used gene expression profiling to identify a Th2 bias in the context of otherwise 
conserved CMI responses in the TST. Although this observation was made in a small 
patient cohort, it was statistically consistent and confirmed via both modular analysis of 
gene expression profiles and histopathological assessments.. Previous investigations 
of immunopathological mechanisms in IRIS have associated expanded polyfunctional 
T cell populations and hypercytokinaemia with the syndrome (Mahnke et al., 2012; 
Meintjes et al., 2008b; Tadokera et al., 2011), but I am aware of no previous reports 
specifically suggesting a role for Th2 responses. Some reports exist describing a 
systemic Th2 bias in HIV-1+ individuals including in patients on HAART (Hagiwara et al., 
1996; Meroni et al., 1996; Sindhu et al., 2006), which may contribute. Th2 responses 
represent an entirely distinct mode of immunity to the Th1 response which is classically 
protective in TB (Anthony et al., 2007; Jenkins et al., 2011; Voehringer et al., 2004), 
and so it may be suggested that this is a non-protective bias detected at the site of 
inflammation in IRIS. In support of this, corticosteroids have been shown to be effective 
in treating TB IRIS (Meintjes et al., 2012), and these agents are also widely used 
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clinically to treat Th2-associated conditions such as asthma. However, further 
confirmation of whether this phenotype exists in vivo in a wider cohort of patients is 
necessary before its potential consequences can be properly delineated. 
Identification of these three dysregulated phenotypes at the site of anti-
mycobacterial inflammation in HIV-1+ active TB patients posed the question of whether 
virus could be detected in the TST samples, which might suggest that these 
phenotypes were due to some direct effects of the virus in the inflammatory context. 
Although viral transcript was detected in a subset of TST samples, it could not be 
definitively concluded that this was not due to bloodborne virus from contaminating 
blood. As such, there remains a lack of conclusive evidence as to whether HIV-1 is 
directly causing these phenotypes at the site of inflammation, or whether they are a 
result of some systemic effects of HIV-1 infection. Further assessments of whether 
HIV-1 infected cells are present in the TST reaction site are merited, for example by 
immunohistochemical staining of HIV-1 proteins, or by fluorescence in situ 
hybridisation for HIV-1 RNA, as has recently been successfully used to quantify 
infection in AMs ex vivo (Jambo et al., 2014). 
To further investigate the phenotypes identified here, it may be informative to 
assess TST inflammation in similar patient cohorts at earlier and later time-points post-
TST, as further temporal resolution might elucidate the mechanisms driving these 
phenotypes and characterise their consequences. For example, identifying at what 
stage post-TST the type I IFN response develops in HIV-1+ anergy might be illustrative 
as to what cells generate this response and by what mechanism. Evaluation of TST 
inflammation in HIV-1+ TST+ samples at later time-points may assist in exploring the 
functional outcomes of IL-10 deficiency in terms of inflammation and resolution. Finally, 
confirmation of these phenotypes in samples from the site of TB disease is warranted, 
although methods for this which are sufficiently controlled to allow detailed cross-group 
comparisons need to be identified.  
By using the TST as an in vivo human challenge model, I have identified multiple 
pathways through which HIV-1 may exert detrimental modulatory effects on anti-
mycobacterial CMI. How does elucidating these phenotypes aid our ability to effectively 
combat active TB in HIV-1+ individuals? Understanding the divergent nature of TB 
disease in this heterogeneous high-risk group may potentially aid diagnosis and 
treatment, particularly as strategies for targeted immunotherapeutics in human TB 
begin to be elucidated (Mayer-Barber et al., 2014; Tobin et al., 2012).  Understanding 
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the fundamentals of immunopathogenesis in active TB, including in the context of HIV-
1 co-infection, is essential if such strategies are to be widely employed successfully, 
and characterising anti-mycobacterial CMI in vivo is an important step forward in this 
regard.
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Chapter 7. Discussion 
7.1.1 Modulation of CMI by HIV-1 
HIV-1 pathogenesis is characterised by immune and inflammatory dysfunction. 
The two key components of the CMI response, CD4+ T cells and macrophages, are 
direct targets for infection by HIV-1. The effects that the virus has on these cells, as 
well as its other pleiotropic effects on immunity, has the potential to disrupt the function 
of this arm of the immune response. I have investigated how HIV-1 modulates CMI, 
firstly by using an in vitro model of human MDMs, and secondly by using an in vivo 
human challenge model, the TST. 
7.1.2 Dysregulation of IL-10 responses by HIV-1 
I have shown that HIV-1 infection of human MDMs in vitro inhibits production of 
the immunomodulatory cytokine IL-10 in response to innate immune stimulation, and 
that this is a consequence of integration by HIV-1 and expression of viral components. 
Importantly, IL-10 attenuation was also observed in vivo, in positive TST reactions from 
HIV-1+ active TB patients. This suggests that this phenomenon is a novel host-virus 
interaction which may have physiologically significant consequences. Further 
confirmation of its role in vivo, elucidation of the mechanism which causes it and 
delineation of its consequences are priorities for further investigation. These will be 
necessary in evaluating any potential for targeting this phenotype therapeutically in 
HIV-1 associated co-infections. 
The in vitro experiments presented here showed that IL-10 attenuation was 
context-specific and, of the cells tested, occurred only in monocyte-derived 
macrophages differentiated with M-CSF. This phenotype was confirmed in vivo in the 
TST via bioinformatic and modular evaluations of gene expression data, but although 
transcriptional profiling can provide highly multidimensional insights into immune 
responses, it does not facilitate direct identification of the cellular basis of a phenotype. 
Moreover, appropriate markers to evaluate IL-10 attenuation in paired histological 
samples were not available. Identification of the cell types in vivo wherein HIV-1 
attenuates IL-10 responses therefore remains a priority. The most useful insights may 
be gained by studying mononuclear phagocytic cells from HIV-1+ patients, and most 
importantly tissue-resident macrophages. It has recently been confirmed that alveolar 
macrophages (AMs) are infected with HIV-1 in vivo (Jambo et al., 2014), and so a key 
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investigation may be to obtain AMs from HIV-1+ patients and evaluate their ability to 
mount IL-10 responses to Mtb and other clinically important pathogens.  
Investigating site-of-disease samples may also be informative: it should be 
noted that substantially lower IL-10 levels in comparison to HIV-1− individuals have 
been measured in cerebrospinal fluid from TB meningitis cases (Simmons et al., 2006). 
Further investigations could utilise pleural fluid, BAL or other accessible site-of-disease 
samples to further confirm this phenotype. Systemically attenuated IL-10 levels in HIV-
1+ patients have not been reported; conversely, raised systemic IL-10 has been 
identified in HIV-1 infection (Arias et al., 2010; Brockman et al., 2009). However, this 
may be part of the generally raised cytokine levels which are associated with HIV-1 
infection (Kedzierska and Crowe, 2001), and thus non-intuitively be originally due to a 
deficiency of early-response IL-10, causing a defective anti-inflammatory response and 
thus heightened inflammation. The model suggested by my in vitro data points to 
tissue-resident cells generating this phenotype early in the innate immune response, so 
it is conceivable that it will not be evident at steady state in the peripheral blood. This is 
also evidenced by assessment of peripheral blood transcriptional profiles from active 
TB patients, wherein expression of an IL-10 module was detected, but was not affected 
by HIV-1 co-infection. 
As well as evaluating the presence of IL-10 attenuation by HIV-1 in vivo, further 
investigation of the mechanism of this phenotype is merited. I have shown that 
integration by HIV-1 is necessary for IL-10 attenuation, and have begun to delineate 
which viral proteins are involved. Further virological experiments should demonstrate 
which components of the virus are necessary and sufficient for this phenotype. This 
may also provide insight into the host pathways which are affected, but to this end I 
have identified a strong candidate in the PI3K pathway, and assessments of its 
function in HIV-1 infected MDMs may also assist in elucidating the mechanism of IL-10 
attenuation. The experiments presented here indicate that HIV-1 inhibits IL-10 
expression by modulating conserved innate immune signalling pathways involved in IL-
10 induction, and so systems-level assessment of the activation of these pathways 
using phosphoproteomics may also be informative.  
Identifying the consequences of attenuated IL-10 responses may inform our 
understanding of the immunopathogenesis of HIV-1 disease and associated co-
infections. I have demonstrated that IL-10 attenuation potentiates HIV-1 replication in 
an inflammatory setting. Induction of HIV-1 replication by inflammatory pathways is 
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consistent with previous in vitro reports (Garrait et al., 1997; Hoshino et al., 2002; Poli 
et al., 1994, 1990; Ranjbar et al., 2009) and in vivo observations in TB disease (Collins 
et al., 2002; Nakata et al., 1997; Toossi et al., 2001a; Toossi et al., 2001b). As previous 
investigations have shown that IL-10 attenuation is associated with exacerbated pro-
inflammatory responses (Tomlinson et al., 2014), this strongly supports the hypothesis 
that HIV-1 may attenuate IL-10 to promote its own replication in an inflammatory 
microenvironment, by eliminating IL-10-mediated immunosuppression. I have also 
shown that IL-10 neutralisation in the innate inflammatory response leads to increased 
recruitment of T cells, indicating a further pathway by which HIV-1 might promote its 
own propagation by inhibiting IL-10, via inducing recruitment of potential host cells. 
Investigating whether HIV-1 itself alters recruitment of T cells to inflammatory foci via 
IL-10 attenuation, and investigation of the relationship between this phenotype and 
cell-to-cell transfer of virus, may help confirm these hypotheses with regard to viral 
propagation.  
To gain insight into the consequences of IL-10 attenuation for the function of 
the immune system, I carried out a series of experiments to investigate the role of IL-10 
in modulating macrophage function. These experiments showed that IL-10 has a range 
of modulatory effects in the innate immune response, as opposed to being a purely 
immunosuppressive factor, and highlighted some key IL-10-regulated pathways which 
merit further investigation in the context of HIV-1 infection of macrophages. These 
included cell recruitment to inflammatory foci, as discussed above, and regulation of 
pro-inflammatory cytokine production, as previously investigated (Tomlinson et al., 
2014). Exploration of two further pathways may also be informative.  
Firstly, IL-10 regulates the production of secreted factors which control cell 
differentiation and polarisation. These include M-CSF and GM-CSF, which may 
regulate monocyte differentiation, and IL-12 p40, which regulates Th1 cell 
differentiation. Confirmation of whether attenuation of IL-10 by HIV-1 leads to 
dysregulation of these cell differentiation pathways may characterise effects of the 
virus on these key cells of cell-mediated immunity. Monocytes/macrophages and Th1 
cells are the major constituents of the site of TB disease, the granuloma. Elucidating 
how HIV-1 modulates the phenotype of these cells, and hence the phenotype of the 
granuloma, may assist in identifying how HIV-1 exacerbates TB pathology during co-
infection (Diedrich and Flynn, 2011; Lawn et al., 2002). To this end, evaluating the 
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outcomes of IL-10 attenuation and associated phenotypes using developed in vitro 
models of granulomata may be informative (Puissegur et al., 2004). 
A second pathway regulated by IL-10 was apoptosis, consistent with previous 
reports describing IL-10 as an anti-apoptotic factor (Eslick et al., 2004; Zhou et al., 
2001). Modulation of this function via HIV-1 attenuation could potentially contribute to 
macrophage cell death; this again could severely impact on granuloma function, and 
hence exacerbate TB disease in HIV-1+ individuals. Increased cell death in situ has 
been observed in the pleural fluid of HIV-1+ pleural TB patients in comparison to HIV-1− 
patients, particularly among mononuclear phagocytes (Hirsch et al., 2001), as has 
increased necrosis in pleural granulomata in HIV-1+ patients (Bezuidenhout et al., 
2009). These observations suggest that exploration of the effects of HIV-1 on cell 
death in vitro is warranted, and any role of IL-10 in this.  
As well as further exploring the consequences of IL-10 attenuation using in vitro 
models, the fact that this phenotype is evident in the TST challenge model provides a 
valuable in vivo opportunity to study its consequences. Characterising the TST 
response at later time-points in HIV-1− and HIV-1+ TST+ samples, for example at 1 
week post-TST, may elucidate whether functional deficiency of IL-10 impairs resolution 
of inflammation – a described function of IL-10 (Aggarwal et al., 2014; Tabas, 2010). It 
may also be possible to utilize recently developed animal models of HIV-1 infection for 
further in vivo investigations, such as humanized mice (Calderon et al., 2013; Marsden 
et al., 2012; Sun et al., 2007) or macaque models of HIV-1/Mtb co-infection (Diedrich et 
al., 2010; Mattila et al., 2011).  
7.1.3 Other axes of CMI dysregulation by HIV-1 
In addition to identifying IL-10 attenuation by HIV-1 in an in vivo inflammatory 
setting, I used the TST human challenge model to identify two further phenotypes of 
HIV-1 dysregulation of CMI responses. Firstly, in HIV-1+ patients with anergic TST 
responses, I showed that there was relative preservation of the type I IFN response in 
the absence of any other effective inflammation, and that this phenotype was 
molecularly distinct from negative TST responses in healthy individuals. This 
observation may help elucidate the mechanism of anti-mycobacterial anergy in HIV-1+ 
individuals, particularly in the light of recent reports that type I IFN responses are 
damaging and immunosuppressive in mycobacterial disease (Mayer-Barber et al., 
2014; Teles et al., 2013). To consider the effect this phenotype might have on TB 
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immunopathology, comparisons may be drawn with reports that the site of TB disease 
in severely immunosuppressed HIV-1+ individuals is characterised by a paucity of CMI 
response (analogous to anergy) and a preponderance of replicating bacilli (de Noronha 
et al., 2008; Lawn et al., 2002; Nambuya et al., 1988). This suggests that anergy could 
promote TB disease via uncontrolled mycobacterial replication. Confirmation of 
whether type I IFN responses exist at disease sites, in a similar fashion to the TST 
model, may implicate them in this mechanism, along with in vitro evaluations of 
whether type I IFN can suppress CMI responses and mycobacterial killing. 
Consideration of how HIV-1 might mechanistically cause this anergic phenotype is also 
merited. 
A second phenotype identified using the TST challenge model was that of 
exaggerated Th2 responses detectable at the site of CMI in HIV-1+ patients classified 
as undergoing an unmasking IRIS. Further confirmation of this phenotype using the 
same model in further IRIS patients is warranted, as this finding was made in a limited 
cohort of patients. Additionally, it will be valuable to explore whether it is evident at the 
site of TB disease, if appropriate sampling opportunities are available. A mechanism is 
not clear for how HIV-1 would cause exaggerated Th2 responses, or how these would 
lead to exacerbated presentations of active TB in IRIS patients. If this phenotype is 
further confirmed in vivo, this may therefore be another potential avenue for 
investigation. 
7.1.4 The impact of HIV-1 on TB disease 
Two major models have emerged recently which have enhanced our 
understanding of the development and pathogenesis of mycobacterial disease. Firstly, 
the “Goldilocks effect”, in which either too little or too much inflammation can 
compromise protection and lead to immunopathogenesis. This is supported by 
evidence from the M. marinum zebrafish model, in which the magnitude of TNFα 
production can determine disease outcome (Roca and Ramakrishnan, 2013; Tobin et 
al., 2012), and from studies of human and mouse mycobacterial infections, in which a 
balance between inflammatory IL-1 or adaptive IFNγ responses and 
immunosuppressive type I IFN responses has been shown to be critical in 
mycobacterial control (Mayer-Barber et al., 2014; Teles et al., 2013). Secondly, 
although it has long been assumed that the function of the granuloma is central to Mtb 
control (Davis and Ramakrishnan, 2009), recent studies have demonstrated that the 
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dynamic and heterogeneous host/pathogen interactions which take place at the level of 
the single granuloma are critical in determining the clinical outcome of TB infection, 
particularly with regard to the granuloma stability and the degree of bacillary killing 
which occur in each lesion (Lin et al., 2014). Integrating these two models defines our 
current understanding of Mtb control and pathogenesis, in which the quantity and 
quality of inflammation at each site of infection has the potential to determine the 
systematic outcome of disease, via effects on bacterial killing and local tissue integrity.  
By considering how the modulatory effects of HIV-1 on CMI described in this 
thesis might impact on this model, ways by which I have shown HIV-1 may 
compromise Mtb control are summarised (Figure 7.1). Dysregulation of IL-10 
responses, in granulomata containing HIV-1-infected mononuclear phagocytes, may 
generate a nidus of exaggerated inflammation, which has the potential to compromise 
granuloma integrity, exacerbate symptoms and lead to excessive cell death. The 
exaggerated Th2 responses seen in IRIS patients may similarly contribute to 
exaggerated inappropriate inflammatory phenotypes which compromise granuloma 
function. Conversely, HIV-1 anergy at the site of disease, in which type I IFNs may 
potentially be implicated, may lead to active disease via the failure to generate an 
effective CMI response and subsequent uncontrolled bacillary replication. These 
stochastic events caused by HIV-1, which alter the functionality of individual 
granulomata, may convert sites of Mtb control to sites of uncontrolled replication and 
inflammation, and hence lead to development of clinical TB disease. Further work is 
required to confirm these proposed interactions and to delineate their mechanisms. 
A body of previous data describes how the IL-10 response in TB is damaging, 
and compromises control of the pathogen by suppressing effective immune responses 
(Redford et al., 2011). Additionally, it is proposed that some of the immunosuppressive 
effects of type I IFN are in fact mediated by induction of IL-10 (Mayer-Barber et al., 
2011; Teles et al., 2013). These findings are in conflict with the model presented here, 
as I propose that IL-10 deficiency is a pathway by which HIV-1 increases risk of TB 
disease. However, it should be pointed out that these observations have mainly been 
made out with the context of HIV-1 infection. The pleiotropic effects of HIV-1 on 
immunity may alter the outcomes of IL-10 deficiency. Additionally, another “Goldilocks 
effect” may be in evidence, wherein too much or too little IL-10 can lead to aberrant 
immune processes, and IL-10 attenuation by HIV-1 leads to the latter scenario.  
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TB disease clearly has an altered phenotype in HIV-1+ individuals, wherein 
profound loss of control of the pathogen is evident in disseminated disease and 
mycobacteraemia (Domoua et al., 1995; Elliott et al., 1993; Gilks et al., 1990; von Reyn 
et al., 2011), as well as in altered inflammatory phenotypes such as IRIS (Lawn et al., 
2008). Modulation of CMI by HIV-1, which I have shown may include IL-10 attenuation, 
is likely to contribute to these processes. Further molecular characterisation of aberrant 
immune phenotypes in human tuberculosis in vivo, in HIV-1+ individuals and in other 
contexts, is necessary to fully elucidate the contribution of risk factors, genetics and 
immunology to this phenotypically heterogeneous disease. 
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Figure 7.1: HIV-1 modulation of the CMI response to Mtb may contribute to 
granuloma instability. 
Stable granulomata are hypothesised to be a site of an effective CMI response co-
ordinated by macrophages, giant cells and T cells, in which mycobacteria and 
associated necrotic processes are contained by these cell types and recruited fibrotic 
processes (Ulrichs and Kaufmann, 2006). Progression to granuloma instability, in 
which there is uncontrolled mycobacterial replication and increased necrosis, is 
postulated to increase the risk of clinical TB disease (Lin et al., 2014). This schematic 
summarises the contribution of different inflammatory processes to granuloma 
deterioration, and wherein the effects of HIV-1 on CMI described in this thesis may 
contribute to this. 
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7.1.5 Potential for restoring functional CMI in HIV-1 infection 
HIV-1 infected macrophages may represent a long-lived reservoir of viral 
infection (Gendelman et al., 1989; Groot et al., 2008). This indicates that HIV-1 
modulation of CMI which results from macrophage infection may persist in the context 
of ART, hence potentially providing insight into immune and inflammatory dysfunction 
post-ARVs, such as IRIS. ARVs are highly effective in reducing mortality in HIV-1+ 
patients (The HIV-CAUSAL Collaboration, 2010). In treating aspects of disease which 
persist despite their use (Palella et al., 2006) - or in the case of IRIS, because of it – 
understanding how HIV-1 modulates CMI may suggest potential therapeutics targeting 
immune processes dysregulated by the virus. These may also be therapeutic options in 
the context of ARV treatment failure. The mechanism of IL-10 attenuation, if elucidated, 
may be one such target. Exaggerated Th2 responses in IRIS, if confirmed to be 
pathogenic, are a clear opportunity for intervention due to the range of effective 
therapies available for treating Th2-mediated diseases such as allergy and asthma. In 
fact, as there is some evidence for using corticosteroids in the treatment of IRIS 
(Meintjes et al., 2012), it is possible that this pathway is already being targeted 
therapeutically. 
7.1.6 Insights into the normal function of the cell-mediated immune system 
Understanding pathological processes can provide insights into normal physiology, 
and the effects of HIV-1 on CMI described in this thesis provide some insights into the 
basic biology of this system. While investigating a mechanism by which HIV-1 might 
inhibit IL-10 but not pro-inflammatory cytokine production, a specific role was identified 
for the PI3K pathway in regulating IL-10 and not pro-inflammatory cytokine production. 
This may be a critical mechanism by which the host mounts appropriate immune 
responses to pathogenic and non-pathogenic microbes, as reported in the murine 
system (Ivanov and Roy, 2013), and as such further investigation is merited of how this 
pathway functions in human macrophages. 
I have also specifically evaluated some functions of the cell-mediated immune 
system out with the context of HIV-1 infection. I used transcriptional profiling to explore 
how IL-10 regulates macrophage-mediated immune responses, showing that it might 
exert its most potent effects in modulating the innate response, while not inhibiting 
macrophage responses to IFNγ. This is in conflict with a prevalent concept in the field 
that IL-10 can inhibit protective IFNγ responses (O’Garra et al., 2013). Although a large 
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body of work exists describing the functions of IL-10, this highlights that many aspects 
of the biology of this immunomodulatory cytokine remain uncharacterised or 
controversial. Further work to clarify its precise functions is merited, particularly as it 
has been postulated to be a therapeutic target (O’Garra et al., 2008) 
 I also used transcriptional profiling to explore macrophage plasticity in the context 
of differentially polarised T cell responses, and showed that cytokines associated with 
Th1, Th2 and Treg responses could all produce large magnitudes of transcriptional 
changes in human MDMs. This corroborates recent reports demonstrating the broad 
diversity of macrophage activation states (Xue et al., 2014). One important limitation of 
these investigations is that they rely on the hypothesis that the transcriptome is an 
accurate barometer of cell state, when in fact there may be dissociation between the 
transcriptome and the functional proteome (Germain et al., 2011). Future systems 
biology approaches to understanding macrophage diversity, and furthermore, to 
understand immune responses in vivo, may be enhanced by integrating transcriptomic 
and proteomic approaches. 
7.1.7 Summary of findings and further work 
In this thesis, I have used in vitro and in vivo models to explore the effects of 
HIV-1 on the CMI response, and to gain insights into the normal function of this arm of 
the immune system. Using an in vitro MDM model, I have characterised a phenotype 
wherein HIV-1 attenuates innate immune production of the immunomodulatory cytokine 
IL-10. In work exploring the mechanism of this phenotype, I have determined that it is 
highly context-specific and likely to be due to a function of the viral accessory proteins. 
I have also identified that the PI3K pathway is involved in specifically regulating IL-10 
production in human MDMs, suggesting that it might be a target for HIV-1 in mediating 
IL-10 attenuation. I have shown that HIV-1 may attenuate IL-10 in order to maximise its 
own replication in the advantageous inflammatory microenvironment, and have 
identified potential consequences of this phenotype for the immune response by 
studying the normal functions of IL-10 in regulating macrophage biology and innate 
immune responses. 
By using transcriptional profiling to explore macrophage plasticity, I have 
developed methods for assessing the activity of different axes of the immune response 
in in vivo gene expression profiles. I have applied these while evaluating the effect of 
HIV-1 on CMI in vivo using a human challenge model, the TST, in active TB patients. 
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Using this model, I have gained insights into the function of CMI at the site of 
inflammation in vivo with molecular resolution, and have identified three dysregulated 
phenotypes associated with HIV-1 infection: IL-10 attenuation (corroborating my in vitro 
findings), a role for type I IFNs in anergy, and exaggerated Th2 responses in IRIS 
patients. 
My findings suggest a range of potential future investigations. Further in vitro 
work to identify the mechanism of IL-10 attenuation by HIV-1 may identify a novel host-
virus interaction. Further characterisation of the downstream consequences of this 
phenotype in vitro, in terms of its effects on cell differentiation, recruitment and 
apoptosis, will highlight its potentially physiologically relevant consequences. To this 
end, using macrophage/T cell co-culture systems or in vitro granuloma models may 
allow assessment of the effects of HIV-1 on CMI beyond the function of macrophages. 
Using systems biology approaches to assess a human challenge model of CMI 
in vivo provided valuable insights into how HIV-1 dysregulates responses to 
mycobacteria. Further use of such approaches, both in expanding this challenge model 
to further timepoints and contexts, and in assessing samples obtained from the site of 
disease, will help to further confirm and explore these phenotypes. Such an approach 
may identify opportunities for using immunotherapeutics to mitigate the potent 
dysregulatory effects of HIV-1 on CMI, most importantly in the context of TB. 
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Chapter 8. Appendix I: Modules 
Gene lists for modules developed in Chapter 5 and/or used in Chapter 6 are 
presented in this appendix. Modules 1–12 are those developed in Chapter 5. 
Modules 13–19 were developed by Dr Gabriele Pollara (University College London). 
The strategy for deriving these modules is described as follows: 
A semi-supervised bioinformatic approach was used to identify cell-type defining 
modules. A gene expression matrix of many cell types was derived from publicly 
available transcriptional profiling data repositories. For each cell type of interest, gene 
probes representing 3 putative markers that conventionally identify such cells were 
identified from the published literature. A correlation script in R identified the degree of 
co-correlation in gene expression between each marker probe and all other gene 
probes present in the expression matrix. The 1% of probes that were most co-
correlated with the expression of each marker were identified, and modules were then 
derived from those highly co-correlated probes that were common to all 3 markers for 
each cell type. 
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(1) IFNγ module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_23_P18452 NM_002416 CXCL9 A_24_P12690 NM_194294 IDO2
A_23_P112026 NM_002164 IDO1 A_23_P18604 NM_015907 LAP3
A_23_P81898 NM_006398 UBD A_33_P3424217 NM_001243962 HLA-DQB1
A_24_P303091 NM_001565 CXCL10 A_24_P687326 NR_024366 LINC00256A
A_23_P1962 NM_004585 RARRES3 A_23_P76529 NM_000889 ITGB7
A_23_P7827 NM_001010919 FAM26F A_33_P3402615 NM_201649 SLC6A9
A_32_P44394 NM_004833 AIM2 A_33_P3393821 NM_001733 C1R
A_33_P3259393 NM_178232 HAPLN3 A_23_P65651 NM_004184 WARS
A_23_P39840 NM_006634 VAMP5 A_23_P116942 NM_002286 LAG3
A_23_P72737 NM_003641 IFITM1 A_33_P3376971 NM_024111 CHAC1
A_19_P00812190 NA Q5D1D6 A_23_P105794 NM_033255 EPSTI1
A_24_P48204 NM_003004 SECTM1 A_23_P349966 NM_152913 TMEM130
A_23_P32404 NM_002201 ISG20 A_33_P3401826 NM_207315 CMPK2
A_23_P139123 NM_000062 SERPING1 A_24_P387875 NM_002241 KCNJ10
A_33_P3407880 NM_144590 ANKRD22 A_24_P323148 NM_182573 LYPD5
A_23_P42353 NM_016135 ETV7 A_23_P400378 NM_001077191 GPBAR1
A_24_P270460 NM_005532 IFI27 A_24_P7594 NM_030641 APOL6
A_24_P28722 NM_080657 RSAD2 A_24_P245815 NM_020437 ASPHD2
A_24_P274270 NM_139266 STAT1 A_33_P3369058 NM_198578 LRRK2
A_23_P121253 NM_003810 TNFSF10 A_33_P3299279 NM_001014279 C5orf39
A_32_P356316 NM_002119 HLA-DOA A_33_P3396139 NM_005214 CTLA4
A_23_P45871 NM_006820 IFI44L A_23_P258493 NM_005573 LMNB1
A_32_P171061 NM_005170 ASCL2 A_23_P41470 NM_017631 DDX60
A_33_P3276615 NM_030643 APOL4 A_33_P3413905 NM_024866 ADM2
A_32_P209960 NM_000246 CIITA A_32_P108254 NM_017565 FAM20A
A_23_P85693 NM_004120 GBP2 A_23_P17663 NM_002462 MX1
A_23_P64721 NM_006018 HCAR3 A_24_P274831 NM_153236 GIMAP7
A_23_P370682 NM_138456 BATF2 A_23_P9883 NM_001079821 NLRP3
A_33_P3284933 NM_145659 IL27 A_24_P340128 NM_178129 P2RY8
A_24_P557479 NM_017523 XAF1 A_33_P3271635 NM_002121 HLA-DPB1
A_23_P210690 NM_021158 TRIB3 A_23_P42588 NM_018384 GIMAP5
A_23_P156687 NM_001710 CFB A_23_P6535 NM_138433 KLHDC7B
A_32_P453321 NM_001145636 C1orf228  
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(2) TNFα module 
 
 
 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_23_P119478 NM_005755 EBI3
A_33_P3398912 NM_017585 SLC2A6
A_33_P3303810 NM_005558 LAD1
A_33_P3227899 NR_015361 LOC440896
A_32_P87013 NM_000584 IL8
A_23_P76901 NM_015549 PLEKHG3
A_33_P3242623 NM_014331 SLC7A11
A_23_P106002 NM_020529 NFKBIA
A_23_P98350 NM_001165 BIRC3
A_23_P214222 NM_002356 MARCKS
A_33_P3226395 NR_024420 LOC389634
A_24_P56689 NM_003456 ZNF205
A_33_P3255131 NM_001100915 KCTD19
A_24_P941217 NA SGPP2
A_23_P256948 NM_005098 MSC
A_23_P119042 NM_005601 NKG7
Appendix I 
 
 
324 
(3) IL-4/IL-13 module 
 
 
Agilent Probe ID
RefSeq Accession 
number
Gene 
Symbol
A_23_P215484 NM_006072 CCL26
A_23_P55373 NM_001140 ALOX15
A_24_P125335 NM_005408 CCL13
A_23_P86470 NM_003956 CH25H
A_23_P254507 NM_139211 HOPX
A_23_P157795 NM_003798 CTNNAL1
A_23_P153390 NM_198492 CLEC4G
A_24_P73577 NM_170697 ALDH1A2
A_24_P313418 NM_002990 CCL22
A_32_P217750 NM_002183 IL3RA
A_23_P27795 NM_021102 SPINT2
A_33_P3258392 NM_001955 EDN1
A_24_P49190 NM_181655 C17orf58
A_33_P3354935 NM_172212 CSF1
A_23_P164773 NM_002002 FCER2
A_23_P139418 NM_198516 GALNTL4
A_23_P19624 NM_001718 BMP6
A_23_P339818 NM_183376 ARRDC4
A_33_P3245908 NM_001010863 C10orf128
A_33_P3422124 NM_181310 IL22RA2
A_23_P88626 NM_001150 ANPEP
A_23_P394986 NM_153836 CREG2
A_32_P86763 NM_004613 TGM2
A_33_P3287348 NM_004067 CHN2
A_24_P203056 NM_020993 BCL7A
A_23_P215956 NM_002467 MYC
A_23_P147711 NM_000906 NPR1
A_33_P3379775 NA TLE1
A_23_P55749 NM_015719 COL5A3
A_23_P121499 NM_006005 WFS1
A_33_P3423979 NM_001166109 PALLD
A_23_P400716 NM_001010846 SHE
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(4) TGFβ/IL-10 module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol
A_23_P131676 NM_020311 CXCR7
A_23_P144959 NM_004385 VCAN
A_23_P78543 NM_005498 AP1M2
A_23_P166408 NM_020530 OSM
A_23_P434809 NM_002964 S100A8
A_24_P413126 NM_020182 PMEPA1
A_23_P28815 NM_000782 CYP24A1
A_32_P65616 NM_000948 PRL
A_24_P118196 NM_001080393 GXYLT2
A_23_P79978 NM_020689 SLC24A3
A_23_P57709 NM_013363 PCOLCE2
A_24_P299685 NM_198389 PDPN
A_33_P3358099 NM_181449 CD300E
A_23_P21485 NM_017933 PID1
A_23_P87049 NM_003105 SORL1
A_24_P330518 NM_001218 CA12
A_23_P154037 NM_001159 AOX1
A_23_P404494 NM_002185 IL7R
A_33_P3236177 NM_001145 ANG
A_23_P79518 NM_000576 IL1B
A_19_P00318323 NR_015410 LINC00340
A_23_P99253 NM_004664 LIN7A
A_23_P33723 NM_004244 CD163
A_19_P00320881 NR_040025 LOC100505474
A_23_P134935 NM_001394 DUSP4
A_23_P136978 NM_014467 SRPX2
A_24_P277367 NM_002994 CXCL5  
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(5) IL-10 module 
 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_24_P59667 NM_000215 JAK3 A_23_P4662 NM_005178 BCL3
A_23_P207058 NM_003955 SOCS3 A_23_P98350 NM_001165 BIRC3
A_23_P55270 NM_002988 CCL18 A_23_P134176 NM_001024465 SOD2
A_23_P404494 NM_002185 IL7R A_33_P3329013 NM_001050 SSTR2
A_23_P38795 NM_002029 FPR1 A_23_P94552 NM_013390 TMEM2
A_23_P434809 NM_002964 S100A8 A_32_P47754 NA SLC2A14
A_32_P108254 NM_017565 FAM20A A_23_P2492 NM_001734 C1S
A_23_P63209 NM_181755 HSD11B1 A_23_P19226 NM_013352 DSE
A_23_P12082 NM_001025199 CHI3L2 A_23_P74001 NM_005621 S100A12
A_23_P62647 NM_003037 SLAMF1 A_23_P102731 NM_175839 SMOX
A_23_P33723 NM_004244 CD163 A_24_P122921 NM_138621 BCL2L11
A_23_P63390 NM_001017986 FCGR1B A_24_P261259 NM_004566 PFKFB3
A_23_P94338 NM_006209 ENPP2 A_23_P386478 NM_024873 TNIP3
A_23_P77493 NM_006086 TUBB3 A_24_P329795 NM_007021 C10orf10
A_33_P3381671 NA LOC731424 A_32_P24585 NM_001017995 SH3PXD2B
A_23_P110473 NM_004536 NAIP A_23_P55649 NM_001462 FPR2
A_23_P79518 NM_000576 IL1B A_23_P112482 NM_004925 AQP3
A_33_P3413840 NM_001205019 GK A_23_P23048 NM_002965 S100A9
A_33_P3375934 NM_005746 NAMPT A_33_P3298587 NM_014963 SBNO2
A_23_P61371 NM_198282 TMEM173 A_23_P52647 NM_006795 EHD1
A_23_P128974 NM_006399 BATF A_33_P3408918 NM_030754 SAA2
A_23_P62115 NM_003254 TIMP1 A_23_P74609 NM_015714 G0S2
A_24_P141214 NM_198194 STOM A_23_P200728 NM_000569 FCGR3A
A_23_P28485 NM_012198 GCA
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(6) Zymosan/IL-10 neutralisation module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_23_P434809 NM_002964 S100A8 A_23_P145965 NM_003596 TPST1
A_23_P38795 NM_002029 FPR1 A_23_P127288 NM_000417 IL2RA
A_23_P74001 NM_005621 S100A12 A_33_P3338121 NM_001017402 LAMB3
A_33_P3408918 NM_030754 SAA2 A_23_P211445 NM_016733 LIMK2
A_24_P335092 NM_000331 SAA1 A_33_P3420035 NM_181489 ZNF445
A_23_P123853 NM_006274 CCL19 A_23_P72117 NM_006714 SMPDL3A
A_23_P386478 NM_024873 TNIP3 A_33_P3242543 NM_000240 MAOA
A_23_P41424 NM_022154 SLC39A8 A_23_P156687 NM_001710 CFB
A_23_P119042 NM_005601 NKG7 A_24_P141214 NM_198194 STOM
A_23_P77493 NM_006086 TUBB3 A_19_P00318323 NR_015410 LINC00340
A_23_P206920 NM_001040114 MYH11 A_33_P3352578 NM_080387 CLEC4D
A_24_P133905 NM_005064 CCL23 A_33_P3412975 NM_175875 SIX5
A_24_P59667 NM_000215 JAK3 A_33_P3413840 NM_001205019 GK
A_23_P61371 NM_198282 TMEM173 A_33_P3350074 NM_001126121 SLC25A19
A_23_P12082 NM_001025199 CHI3L2 A_24_P299685 NM_198389 PDPN
A_32_P108254 NM_017565 FAM20A A_23_P309701 NM_002828 PTPN2
A_23_P208182 NM_033130 SIGLEC10 A_23_P2492 NM_001734 C1S
A_23_P150979 NM_058173 MUCL1 A_23_P64650 NM_005726 TSFM
A_33_P3253394 NM_002287 LAIR1 A_33_P3384432 NM_001178138 TFDP2
A_23_P128974 NM_006399 BATF A_23_P256641 NM_012282 KCNE1L
A_24_P277367 NM_002994 CXCL5 A_33_P3215803 NM_001974 EMR1
A_23_P207058 NM_003955 SOCS3 A_23_P59045 NM_021052 HIST1H2AE
A_23_P127584 NM_006169 NNMT A_23_P7827 NM_001010919 FAM26F
A_33_P3421351 NA TRAF3IP3 A_24_P322474 NM_006202 PDE4A
A_33_P3358601 NM_001170820 IFITM10
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(7) Type I IFN module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_23_P24004 NM_001547 IFIT2 A_23_P66948 NM_022751 FAM59A
A_23_P52266 NM_001548 IFIT1 A_23_P97700 NM_006472 TXNIP
A_23_P139786 NM_003733 OASL A_23_P104318 NM_019058 DDIT4
A_32_P9543 NM_145699 APOBEC3A A_24_P236251 NM_003836 DLK1
A_23_P132159 NM_017414 USP18 A_24_P23034 NM_021035 ZNFX1
A_32_P54553 XM_036729 USP41 A_23_P408285 NM_153026 PRICKLE1
A_23_P53137 NM_000559 HBG1 A_23_P116942 NM_002286 LAG3
A_23_P121106 NM_003865 HESX1 A_24_P68079 NM_014831 TRANK1
A_24_P66027 NM_004900 APOBEC3B A_24_P183664 NM_014817 TRIL
A_23_P23074 NM_006417 IFI44 A_23_P160025 NM_005531 IFI16
A_23_P150609 NM_000612 IGF2 A_23_P75220 NM_031212 SLC25A28
A_23_P127948 NM_001124 ADM A_23_P45087 NM_016220 ZNF107
A_23_P166686 NM_016201 AMOTL2 A_23_P252928 NM_005367 MAGEA12
A_23_P60146 NM_006207 PDGFRL A_23_P94338 NM_006209 ENPP2
A_23_P87879 NM_001781 CD69 A_23_P423331 NM_032536 NTNG2
A_23_P321501 NM_182908 DHRS2 A_32_P108156 NR_001458 MIR155HG
A_23_P59547 NM_001002010 NT5C3 A_23_P34628 NM_001514 GTF2B
A_23_P312851 NM_006928 PMEL A_23_P65442 NM_006084 IRF9
A_23_P6263 NM_002463 MX2 A_23_P48414 NM_003914 CCNA1
A_23_P20122 NM_024625 ZC3HAV1 A_23_P26457 NM_000517 HBA2
A_23_P66798 NM_002276 KRT19 A_24_P148717 NM_001295 CCR1
A_23_P52761 NM_002423 MMP7 A_24_P258051 NM_032844 MASTL
A_24_P277657 NM_006877 GMPR A_23_P21838 NM_033133 CNP
A_23_P29773 NM_014398 LAMP3 A_23_P256504 NM_001633 AMBP
A_23_P72737 NM_003641 IFITM1 A_23_P84596 NM_016459 MZB1
A_23_P64828 NM_002534 OAS1 A_23_P127584 NM_006169 NNMT
A_24_P42136 NM_000224 KRT18 A_23_P62227 NM_025159 CXorf21
A_23_P200001 NM_144573 NEXN A_23_P115261 NM_000029 AGT
A_23_P123672 NM_014290 TDRD7 A_23_P398566 NM_173200 NR4A3
A_23_P328740 NR_026875 NEURL3 A_23_P23266 NA BLZF1
A_23_P155514 NM_001622 AHSG A_23_P257834 NM_000477 ALB
A_32_P231617 NM_014220 TM4SF1 A_32_P120895 NM_153374 LYSMD2
A_23_P86470 NM_003956 CH25H A_32_P157945 NM_004415 DSP
A_23_P153372 NM_032855 HSH2D A_23_P61398 NM_001001852 PIM3
A_23_P154488 NM_033109 PNPT1 A_23_P118722 NM_001671 ASGR1
A_24_P7594 NM_030641 APOL6 A_23_P89755 NM_016271 RNF138
A_24_P175187 NM_017654 SAMD9 A_32_P36235 NM_004907 IER2
A_24_P261259 NM_004566 PFKFB3 A_23_P151710 NM_000956 PTGER2
A_23_P38346 NM_024119 DHX58 A_23_P252106 NM_003821 RIPK2
A_23_P304171 NM_001145642 KIAA0226 A_32_P151800 NM_207418 FAM72D
A_23_P165624 NM_007115 TNFAIP6 A_23_P111132 NM_005345 HSPA1A
A_23_P121011 NM_033027 CSRNP1 A_23_P109881 NM_002218 ITIH4
A_24_P239076 NM_020070 IGLL1 A_23_P203191 NM_000039 APOA1
A_23_P200829 NM_015326 SRGAP2 A_23_P157299 NM_001129 AEBP1
A_24_P228796 NM_021123 GAGE7 A_23_P89941 NM_001800 CDKN2D
A_23_P29922 NM_003265 TLR3 A_24_P214598 NM_152542 PPM1K
A_23_P15727 NM_021939 FKBP10 A_24_P274831 NM_153236 GIMAP7
A_24_P12435 NM_181782 NCOA7 A_24_P209455 NM_018326 GIMAP4
A_23_P59138 NM_002701 POU5F1 A_24_P896205 XR_132630 LOC645722
A_23_P215634 NM_001013398 IGFBP3 A_23_P337753 NM_138402 SP140L
A_24_P576174 NM_018403 DCP1A A_23_P254741 NM_003102 SOD3
A_23_P42718 NM_004289 NFE2L3 A_23_P374149 NM_015050 FTSJD2
A_23_P143845 NM_015508 TIPARP A_23_P37375 NM_004755 RPS6KA5
A_24_P228130 NM_001001437 CCL3L3
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(8) Type II IFN module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol
A_23_P18452 NM_002416 CXCL9
A_23_P81898 NM_006398 UBD
A_32_P209960 NM_000246 CIITA
A_23_P1962 NM_004585 RARRES3
A_24_P165864 NM_014879 P2RY14
A_24_P304071 NM_001547 IFIT2
A_23_P89431 NM_002982 CCL2
A_23_P125278 NM_005409 CXCL11
A_23_P207058 NM_003955 SOCS3
A_24_P125335 NM_005408 CCL13
A_23_P63390 NM_001017986 FCGR1B
A_23_P128974 NM_006399 BATF
A_24_P416997 NM_145641 APOL3
A_24_P59667 NM_000215 JAK3
A_23_P211445 NM_016733 LIMK2
A_23_P40453 NM_001236 CBR3
A_23_P38795 NM_002029 FPR1
A_23_P55270 NM_002988 CCL18
A_24_P941167 NM_030641 APOL6
A_23_P74278 NM_001037341 PDE4B
A_23_P153320 NM_000201 ICAM1
A_32_P56249 NR_038996 LOC100131733
A_23_P141555 NM_013351 TBX21
A_24_P322353 NM_024430 PSTPIP2  
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(9) LPS module 
 
Agilent Probe ID
RefSeq Accession 
number
Gene Symbol
A_23_P253791 NM_004345 CAMP
A_23_P349966 NM_152913 TMEM130
A_23_P15727 NM_021939 FKBP10
A_23_P253602 NM_001721 BMX
A_23_P215634 NM_001013398 IGFBP3
A_23_P136683 NM_001243961 HLA-DQB1
A_24_P42136 NM_000224 KRT18
A_23_P78248 NM_015515 KRT23
A_23_P58266 NM_005980 S100P
A_24_P236251 NM_003836 DLK1
A_23_P46429 NM_001554 CYR61
A_23_P206760 NM_005143 HP
A_24_P201153 NM_201629 TJP2
A_32_P206839 NR_037631 LOC100288911
A_23_P252928 NM_005367 MAGEA12
A_24_P216361 NM_206956 PRAME
A_24_P941217 NA SGPP2
A_23_P112982 NM_018711 SVOP
A_23_P59138 NM_002701 POU5F1
A_23_P319423 NM_003740 KCNK5
A_23_P254507 NM_139211 HOPX
A_23_P166297 NM_207627 ABCG1
A_23_P85783 NM_006623 PHGDH
A_23_P212508 NM_001063 TF
A_23_P257971 NM_001353 AKR1C1
A_23_P19517 NM_002224 ITPR3
A_23_P144916 NM_005110 GFPT2
A_23_P84596 NM_016459 MZB1
A_23_P30567 NM_001882 CRHBP
A_23_P256572 NM_000324 RHAG
A_32_P526255 NM_001145717 PNPLA1
A_23_P257834 NM_000477 ALB
A_23_P112482 NM_004925 AQP3
A_23_P2920 NM_001085 SERPINA3
A_23_P138541 NM_003739 AKR1C3
A_23_P157793 NM_001216 CA9
A_32_P141682 NM_001145127 EVPLL
A_23_P146456 NM_001333 CTSL2
A_23_P69586 NM_005245 FAT1
A_23_P50919 NM_006216 SERPINE2  
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(10) PCSK module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol
A_23_P82868 NM_000930 PLAT
A_23_P29773 NM_014398 LAMP3
A_23_P62647 NM_003037 SLAMF1
A_23_P112026 NM_002164 IDO1
A_23_P160720 NM_018664 BATF3
A_23_P51487 NM_018284 GBP3
A_23_P135271 NM_001497 B4GALT1
A_24_P126628 NM_015257 TMEM194A
A_24_P63522 NM_002130 HMGCS1
A_23_P207367 NM_003152 STAT5A
A_23_P94754 NM_005118 TNFSF15
A_24_P911676 NM_003107 SOX4  
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(11) Mtb module 
 
(12) Spn module 
 
Agilent Probe ID
RefSeq Accession 
number
Gene Symbol
A_24_P252945 NM_032966 CXCR5
A_24_P399230 NM_175575 WFIKKN2
A_23_P407112 NM_145263 SPATA18
A_23_P52986 NM_152718 VWCE
A_23_P206359 NM_004360 CDH1
A_23_P218807 NM_017590 ZC3H7B
A_32_P52153 NR_038453 LOC728978
A_24_P404458 NM_170678 ITGB1BP3
A_23_P126103 NM_001902 CTH
A_23_P167983 NA HIST1H2AC
A_24_P165423 NM_052960 RBP7
A_23_P309381 NM_001040874 HIST2H2AA4
A_23_P254944 NM_000853 GSTT1
A_24_P319374 NM_005814 GPA33
A_23_P16523 NM_004864 GDF15
A_23_P59045 NM_021052 HIST1H2AE
A_23_P428184 NM_021065 HIST1H2AD
A_24_P152649 NR_033748 LOC644189
A_24_P68631 NM_175065 HIST2H2AB
Agilent Probe ID
RefSeq Accession 
number
Gene Symbol
A_23_P207456 NM_005623 CCL8
A_24_P133905 NM_005064 CCL23
A_23_P52207 NM_012342 BAMBI
A_24_P788878 NM_001007595 C2CD4B
A_23_P89431 NM_002982 CCL2
A_24_P277367 NM_002994 CXCL5
A_23_P25155 NM_020370 GPR84
A_23_P128808 NM_013345 GPR132
A_23_P78037 NM_006273 CCL7
A_24_P8371 NM_001124758 SPNS2
A_23_P25674 NM_001823 CKB
A_24_P280497 NM_001142641 FBRSL1
A_23_P329261 NM_000891 KCNJ2
A_23_P126735 NM_000572 IL10
A_23_P24004 NM_001547 IFIT2
A_23_P339818 NM_183376 ARRDC4
A_32_P9543 NM_145699 APOBEC3A
A_23_P108751 NM_001039492 FHL2
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(13) T cell module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_23_P10025 NM_006159 NELL2
A_23_P103361 NM_005356 LCK
A_23_P114299 NM_001504 CXCR3
A_23_P128993 NM_033423 GZMH
A_23_P1473 NM_005041 PRF1
A_23_P161280 SPOCK2
A_23_P28334 NM_003853 IL18RAP
A_23_P302018 NM_003328 TXK
A_23_P306941 NM_153615 RGL4
A_23_P340019 NM_178844 NLRC3
A_23_P34676 NM_198053 CD247
A_23_P37685 TMEM204
A_23_P44155 NM_198196 CD96
A_23_P8297 SCML4
A_23_P8424 PVRIG
A_23_P98173 PTPRCAP
A_24_P291278 LAX1
A_24_P673968 TTC22
A_24_P854492 NR_003491 MIAT  
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(14) Macrophage module 
 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol
A_23_P140591 ABHD2 A_23_P114414 NM_001031855 LONRF3
A_23_P256205 NM_014945 ABLIM3 A_23_P112004 NM_012472 LRRC6
A_23_P21758 ADAM28 A_23_P388670 NM_000895 LTA4H
A_23_P320304 AKR7L A_23_P70688 NM_004271 LY86
A_23_P83098 NM_000689 ALDH1A1 A_23_P250379 MAN2B2
A_23_P105184 ARAP1 A_23_P212061 MME
A_24_P378202 ARL11 A_24_P184445 NM_002429 MMP19
A_23_P379864 ASRGL1 A_23_P171296 NM_002436 MPP1
A_23_P380614 NM_006045 ATP9A A_23_P148737 NM_004997 MYBPH
A_23_P104996 NM_004183 BEST1 A_23_P360240 NM_138768 MYEOV
A_23_P7325 NM_004334 BST1 A_23_P143817 NM_053025 MYLK
A_23_P76983 NM_025057 C14orf45 A_24_P339664 NM_020170 NCLN
A_23_P163467 NM_207380 C15orf52 A_23_P381431 NPL
A_23_P368484 NM_207387 C17orf76 A_23_P88381 NM_001005743 NUMB
A_23_P142055 C19orf38 A_23_P372848 NM_002558 P2RX1
A_23_P153562 NM_001736 C5AR1 A_23_P24903 NM_176072 P2RY2
A_24_P283189 CD14 A_24_P243749 NM_002612 PDK4
A_23_P33723 NM_004244 CD163 A_23_P21485 NM_017933 PID1
A_23_P209055 NM_001771 CD22 A_24_P40165 PIGT
A_23_P26771 NM_006678 CD300C A_23_P151506 NM_016445 PLEK2
A_23_P15369 NM_174892 CD300LB A_23_P6355 POM121L1P
A_24_P279307 CD300LF A_23_P103011 NM_004914 RAB36
A_23_P364437 NM_022124 CDH23 A_32_P393316 NM_001098531 RAPGEF3
A_23_P137665 NM_001276 CHI3L1 A_32_P377577 SCAF1
A_23_P105571 NM_020244 CHPT1 A_32_P74391 SIRPD
A_23_P383986 NM_015892 CHST15 A_24_P76831 SLC11A1
A_23_P128470 NM_138337 CLEC12A A_23_P325562 NM_006671 SLC1A7
A_24_P180654 CREB3L2 A_23_P388900 NM_018420 SLC22A15
A_23_P217258 CYBB A_24_P208345 NM_033102 SLC45A3
A_23_P119266 NM_001375 DNASE2 A_32_P109653 SNCA
A_23_P133506 DOK3 A_23_P7642 SPARC
A_23_P79251 NM_014600 EHD3 A_23_P121533 NM_012445 SPON2
A_23_P11764 EIF2C1 A_23_P94736 NM_175039 ST6GALNAC4
A_23_P165848 EMILIN1 A_24_P122337 NM_080737 SYTL4
A_23_P63390 NM_001017986 FCGR1B A_23_P75369 TCIRG1
A_23_P126298 FCGR3B A_23_P76402 TCTN1
A_23_P67847 NM_024572 GALNT14 A_23_P10873 NM_003263 TLR1
A_23_P8640 NM_001039966 GPER A_24_P17677 TLR6
A_23_P160226 NM_001039464 HEATR8 A_24_P728604 TMEM114
A_23_P210330 NM_014181 HSPC159 A_23_P121196 NM_024334 TMEM43
A_24_P318656 NM_000212 ITGB3 A_23_P24784 NM_003282 TNNI2
A_23_P501232 KCNAB2 A_23_P145965 NM_003596 TPST1
A_24_P346762 NM_025182 KIAA1539 A_24_P239811 NM_183008 UBXN11
A_23_P125117 KLHDC8B A_23_P201551 NM_006113 VAV3
A_23_P86283 NM_006762 LAPTM5 A_24_P337700 VNN1
A_23_P89187 NM_006148 LASP1 A_23_P217269 NM_007268 VSIG4
A_24_P348989 NM_006863 LILRA1 A_23_P105562 NM_000552 VWF
A_23_P142205 NM_006866 LILRA2 A_23_P215132 NM_014149 WDR91
A_23_P107847 LILRA5 A_23_P161156 NM_182755 ZNF438
A_32_P95147 LOC100506190 A_24_P376787 NM_032752 ZNF496
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(15) DC module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol
A_23_P500400 NM_080284 ABCA6 A_23_P166376 GGT5
A_23_P202327 ADAM12 A_23_P167005 NM_014373 GPR160
A_23_P115011 NM_019032 ADAMTSL4 A_23_P154245 GPR35
A_23_P55373 NM_001140 ALOX15 A_24_P356601 NM_006460 HEXIM1
A_23_P86570 NM_004034 ANXA7 A_24_P354800 HLA-DOA
A_24_P31275 NM_001678 ATP1B2 A_24_P243528 HLA-DPA1
A_23_P49539 NM_001080519 BAHCC1 A_24_P288836 NR_001435 HLA-DPB2
A_24_P203056 NM_020993 BCL7A A_24_P239676 HLA-DQB1
A_23_P24097 C10orf128 A_24_P402222 HLA-DRB3
A_23_P155477 NM_016210 C3orf18 A_23_P99906 NM_199330 HOMER2
A_23_P345710 NM_152531 C3orf21 A_24_P305067 HOXB4
A_23_P58390 NM_152400 C4orf32 A_23_P126757 NM_023015 INTS3
A_24_P123516 C5orf20 A_23_P50591 NM_004823 KCNK6
A_23_P39898 CALCRL A_23_P402157 KCTD17
A_32_P4985 NM_015215 CAMTA1 A_23_P309619 NM_001145206 KIAA1671
A_23_P26965 CCL13 A_32_P226646 XR_109259 LOC100129781
A_23_P26325 NM_002987 CCL17 A_23_P145336 LOC100510687
A_24_P12065 NM_004354 CCNG2 A_23_P34452 NM_000427 LOR
A_23_P402670 NM_001763 CD1A A_23_P83857 MAOA
A_23_P351844 NM_001764 CD1B A_23_P85008 MAOB
A_23_P51767 CD1C A_23_P67042 NM_017947 MOCOS
A_23_P201160 CD1E A_23_P37205 NDRG2
A_23_P41217 NM_138806 CD200R1 A_24_P129277 NM_006092 NOD1
A_23_P70095 NM_001025158 CD74 A_23_P147711 NM_000906 NPR1
A_23_P113613 NM_022842 CDCP1 A_23_P212779 PARM1
A_23_P83976 NM_145036 CEP112 A_24_P27373 PLDN
A_23_P7212 NM_000204 CFI A_23_P150807 PPFIBP2
A_23_P86470 NM_003956 CH25H A_24_P296772 PPP1R14A
A_23_P338603 NM_001011667 CHCHD7 A_24_P162911 PRKD3
A_23_P33384 CIITA A_32_P30345 RAB30
A_23_P57784 NM_021101 CLDN1 A_23_P50946 NM_005855 RAMP1
A_23_P141508 CLEC10A A_24_P36890 NM_002885 RAP1GAP
A_24_P360993 CLEC1A A_23_P425073 NM_002898 RBMS2
A_23_P153390 NM_198492 CLEC4G A_23_P113245 RBPJ
A_23_P157795 NM_003798 CTNNAL1 A_23_P256297 RRP1B
A_32_P104000 NM_173475 DCUN1D3 A_32_P227870 SLC30A4
A_23_P20337 DPYSL2 A_23_P129433 NM_004594 SLC9A5
A_23_P54291 NM_017434 DUOX1 A_23_P156907 NM_018013 SOBP
A_24_P44453 DUOXA1 A_23_P27795 NM_021102 SPINT2
A_23_P3237 ELL3 A_23_P121061 STAC
A_23_P94338 NM_006209 ENPP2 A_24_P99046 NM_015000 STK38L
A_24_P28578 EPS15 A_23_P149529 NM_002353 TACSTD2
A_24_P205045 NM_015576 ERC2 A_23_P301372 NM_153365 TAPT1
A_24_P170983 NM_194312 ESPNL A_23_P24751 NM_173810 TTC9C
A_23_P395609 FAM110B A_23_P256445 VCPIP1
A_23_P308150 NM_152424 FAM123B A_23_P218108 WDFY2
A_23_P103765 NM_002001 FCER1A A_24_P179504 NM_144668 WDR66
A_23_P164773 NM_002002 FCER2 A_23_P211926 WNT5A
A_32_P164246 NM_033260 FOXQ1 A_23_P53588 NM_030775 WNT5B
A_23_P139418 NM_198516 GALNTL4 A_23_P210608 NM_006526 ZNF217
A_23_P146922 NM_000820 GAS6 A_23_P16652 NM_152791 ZNF555
A_23_P129144 NM_001018100 GCOM1
Appendix I 
 
 
336 
(16) B cell module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol
A_23_P251686 ADRBK2 A_23_P320739 NM_002397 MEF2C
A_23_P373464 NM_002285 AFF3 A_23_P116371 MS4A1
A_23_P110151 ARHGAP24 A_23_P140434 NM_018728 MYO5C
A_23_P10232 NM_017935 BANK1 A_23_P90130 NM_004851 NAPSA
A_23_P97394 NM_003567 BCAR3 A_23_P90125 NAPSB
A_23_P218584 BCL11A A_23_P42746 NM_000265 NCF1
A_23_P139500 NM_030762 BHLHE41 A_23_P30655 NM_004556 NFKBIE
A_23_P53763 NM_025113 C13orf18 A_23_P365614 NM_004557 NOTCH4
A_23_P152858 NM_018405 C17orf79 A_23_P53663 NM_002583 PAWR
A_23_P158470 C3orf54 A_23_P206532 NM_001031835 PHKB
A_23_P134477 NM_032350 C7orf50 A_23_P253321 NM_006228 PNOC
A_23_P422851 NM_138375 CABLES1 A_23_P408285 NM_153026 PRICKLE1
A_23_P500741 NM_005187 CBFA2T3 A_23_P130194 NM_006907 PYCR1
A_23_P113572 NM_001770 CD19 A_23_P97517 RALGPS2
A_23_P74575 CD1D A_23_P12363 NM_005012 ROR1
A_23_P351286 CD22 A_23_P169629 NM_005412 SHMT2
A_23_P107735 NM_001783 CD79A A_23_P76969 NM_015556 SIPA1L1
A_23_P70670 NM_004233 CD83 A_23_P160159 NM_003039 SLC2A5
A_23_P259189 NM_013943 CLIC4 A_23_P130735 NM_014037 SLC6A16
A_23_P214208 NM_033181 CNR1 A_23_P209962 NM_024624 SMC6
A_23_P40108 NM_001853 COL9A3 A_23_P7697 NM_003100 SNX2
A_23_P360804 NM_020939 CPNE5 A_23_P203920 NM_005086 SSPN
A_23_P14774 NM_004390 CTSH A_23_P47282 NM_021978 ST14
A_23_P3237 ELL3 A_23_P116533 SWAP70
A_23_P201211 NM_031281 FCRL5 A_23_P163697 NM_016524 SYT17
A_23_P67847 NM_024572 GALNT14 A_23_P357717 NM_021966 TCL1A
A_23_P153897 NM_052847 GNG7 A_23_P53276 NM_003920 TIMELESS
A_23_P134734 GOLSYN A_23_P33420 TLR10
A_23_P30736 NM_002120 HLA-DOB A_23_P85240 NM_016562 TLR7
A_23_P30900 HLA-DQA1 A_23_P24716 NM_017870 TMEM132A
A_23_P25194 NM_003806 HRK A_23_P91764 NM_052945 TNFRSF13C
A_23_P158817 IGHG1 A_23_P132536 NM_001042646 TRAK1
A_23_P167168 NM_144646 IGJ A_23_P168229 NM_030810 TXNDC5
A_23_P117582 NM_130469 JDP2 A_23_P132956 NM_004181 UCHL1
A_23_P366453 NM_152688 KHDRBS2 A_23_P168306 NM_003931 WASF1
A_23_P217528 NM_007250 KLF8 A_23_P134601 NM_057168 WNT16
A_23_P70688 NM_004271 LY86 A_23_P159027 NM_015461 ZNF521
A_23_P5281 LYL1 A_23_P169978 NM_020747 ZNF608
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(17) NK cell module 
 
Agilent Probe ID
RefSeq Accession 
number
Gene Symbol
A_23_P128281 NM_007333 KLRC3
A_23_P348257 NM_014840 NUAK1
A_23_P259611 NM_016616 TXNDC3
A_23_P151046 NM_002259 KLRC1
A_23_P70359 NR_024277 NCRNA00241
A_23_P393777 NM_000953 PTGDR
A_23_P50678 NM_139355 MATK
A_23_P85453 NM_016382 CD244
A_23_P334218 NM_145647 WDR67
A_23_P1473 NM_005041 PRF1
A_23_P257895 NM_138957 MAPK1
A_23_P254507 NM_139211 HOPX
A_23_P219197 NM_134427 RGS3
A_23_P423331 NM_032536 NTNG2
A_23_P317683 NM_003274 TRAPPC10
A_23_P141394 NM_017983 WIPI1
A_23_P141429 NM_016428 ABI3
A_23_P28334 NM_003853 IL18RAP
A_23_P50799 NM_013939 OR10H2
A_23_P53081 NM_020896 OSBPL5
A_23_P152727 NM_014798 PLEKHM1
A_23_P142447 NM_012335 MYO1F
A_23_P28263 NM_021198 CTDSP1
A_23_P23443 NM_024329 EFHD2
A_23_P414913 NM_022343 GLIPR2
A_23_P121533 NM_012445 SPON2
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(18) Monocyte module 
 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_23_P143120 NM_003183 ADAM17 A_23_P214222 NM_002356 MARCKS
A_23_P257971 NM_001353 AKR1C1 A_24_P278126 NM_002485 NBN
A_23_P259071 NM_001657 AREG A_23_P106002 NM_020529 NFKBIA
A_23_P68970 NM_014570 ARFGAP3 A_24_P214754 NR3C1
A_23_P97871 ARID5B A_24_P124624 NM_002543 OLR1
A_23_P211047 NM_206866 BACH1 A_23_P71570 OSR2
A_23_P207564 NM_002984 CCL4 A_23_P95755 PFKFB3
A_23_P138760 NM_013246 CLCF1 A_23_P61398 NM_001001852 PIM3
A_23_P7144 NM_001511 CXCL1 A_32_P89310 NM_001080475 PLEKHM3
A_24_P257416 NM_002089 CXCL2 A_23_P30254 NM_006622 PLK2
A_24_P251764 CXCL3 A_23_P90172 NM_014330 PPP1R15A
A_24_P217520 EREG A_24_P77008 PTGS2
A_24_P382661 ETS2 A_23_P121064 NM_002852 PTX3
A_32_P96000 NM_001004341 ETV3L A_23_P88849 RRAD
A_24_P4816 NM_031412 GABARAPL1 A_23_P4561 SERPINB8
A_24_P100387 GK A_23_P30687 SERPINB9
A_23_P105442 GRASP A_24_P359191 NM_003043 SLC6A6
A_23_P19619 NM_002114 HIVEP1 A_23_P131846 NM_005985 SNAI1
A_23_P86330 NM_016545 IER5 A_24_P935819 SOD2
A_23_P72096 NM_000575 IL1A A_23_P156788 NM_003764 STX11
A_23_P79518 NM_000576 IL1B A_23_P74129 TMEM50A
A_23_P71037 NM_000600 IL6 A_24_P157926 NM_006290 TNFAIP3
A_32_P87013 NM_000584 IL8 A_23_P165624 NM_007115 TNFAIP6
A_23_P80635 IRAK2 A_24_P5856 TNFSF9
A_23_P162300 NM_007199 IRAK3 A_24_P89891 NM_005658 TRAF1
A_32_P74409 NM_001145033 LOC387763 A_23_P167595 NM_003337 UBE2B
A_32_P219581 LOC440934 A_23_P215096 UBE2H
A_23_P35035 LPAR3 A_23_P371155 WTAP
A_23_P78209 NM_002359 MAFG A_23_P326160 ZC3H12A
A_23_P23947 NM_005204 MAP3K8
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(19) Neutrophil module 
 
Agilent Probe ID
RefSeq 
Accession 
number
Gene Symbol Agilent Probe ID
RefSeq 
Accession 
number
Gene 
Symbol
A_23_P250294 NM_016006 ABHD5 A_23_P79398 IL1R2
A_23_P206945 ACOX1 A_23_P209995 IL1RN
A_23_P110212 NM_001995 ACSL1 A_23_P17655 KCNJ15
A_23_P127948 NM_001124 ADM A_23_P43380 KIAA1539
A_23_P106362 NM_020980 AQP9 A_23_P217447 LAMP2
A_24_P336577 NM_019099 C1orf183 A_23_P30547 NM_005565 LCP2
A_23_P259506 NM_032412 C5orf32 A_23_P163380 NM_006441 MTHFS
A_23_P130515 NM_001815 CEACAM3 A_23_P305060 NAMPT
A_23_P152234 NM_144673 CMTM2 A_23_P106463 NM_002537 OAZ2
A_23_P77401 NM_018340 CPPED1 A_24_P97342 NM_021935 PROK2
A_23_P157117 NM_182898 CREB5 A_24_P250922 NM_000963 PTGS2
A_23_P126218 CSF3R A_23_P137470 NM_020808 SIPA1L2
A_23_P7144 NM_001511 CXCL1 A_23_P29083 SLC19A1
A_23_P155057 NM_013385 CYTH4 A_23_P216004 SLC25A37
A_23_P321201 NM_015213 DENND5A A_23_P134176 NM_001024465 SOD2
A_23_P53198 NM_032564 DGAT2 A_24_P351906 STEAP4
A_23_P364580 DOCK4 A_23_P394216 TECPR2
A_23_P39925 DYSF A_23_P60306 TLR4
A_24_P154080 NM_001397 ECE1 A_23_P421423 NM_006291 TNFAIP2
A_23_P208768 NM_002000 FCAR A_23_P165624 NM_007115 TNFAIP6
A_23_P214603 NM_005803 FLOT1 A_23_P119102 NM_003370 VASP
A_23_P55649 NM_001462 FPR2 A_23_P122724 NM_004665 VNN2
A_23_P96556 GK A_23_P214935 VNN3
A_23_P61637 NM_002108 HAL
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Chapter 9. Appendix II: TST study case list 
Anonymised demographic and clinical data for all active TB patients recruited into 
the TST study (Chapter 6) are presented in this Appendix. For the healthy volunteers, 
the relevant data can be found in the original publication (Tomlinson et al., 2011). 
Abbreviations used in tables: UIN, unique identification number; LDN, London; 
CPT, Cape Town; M, male; F, female; LN, lymph node; LLL, left lower lobe; MDR, 
multi-drug resistant; ARV, anti-retrovirals; Y, yes; N, no; CXR; chest x-ray; dx, 
diagnosis; TST, tuberculin skin test; N/A, not applicable. 
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